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In 2008 (most recent data) 0.5% of the 304,059,724 people in the United States 
developed an invasive form of cancer. Breast cancer (inc. 184,450 , † 40,930), colon 
and rectum cancer (inc. 148,810, † 49,960), lung cancer (inc. 215,000, † 161,840), 
and prostate cancer (inc.186,320, †28,660) appear to be the most common forms. 
Of the 1,437,180 people who developed cancer, around 21,810 got brain and/or 
other central nervous system tumors with a corresponding death rate of 13,070; 
which is more than half of the incidence in that year. When studying these numbers, 
one can see that apart from central nervous tumors, lung cancer too has a relatively 
high death rate. However, one should take into consideration that lung cancer often 
occurs at a higher age than brain cancer cases.1 
In 2008 in The Netherlands an incidence of 90,182 (0.5%) of invasive cancer cases 
was reported on a population of 16,446,000 people in total.  The most common type 
of cancer was breast cancer, with an incidence of 13,121 and a death rate of 3357. 
Similar to the US the other most common types of cancers were lung cancer 
(11,507, † 10,339), prostate cancer (10,512, † 2,476), and colon cancer (19,654, † 
12,202). Cancer of the central nervous system had an incidence of 1156 and a death 
rate of 992.2 As one can see, the numbers in The Netherlands reflect those of the 
United States.2,3,1 The conclusion that can be drawn from these numbers is that in 
order to prevent death extensive research is needed for early diagnosis and 
treatment of invasive cancer in general. A particular high focus is necessary for the 




Cancer is simply stated by the transformation of a healthy cell into a malignant 
cancer cell. This malignant transformation can be predisposed by genetic factors, but 
Table 1.: Cancer incidence and death rates for the USA and The Netherlands (2008). 
USA Incidence Death % Death The Netherlands Incidence Death % Death 
Breast  184,450 40,930 22.19030 Breast  13,121 3,357 25.58494 
Colon 148,810 49,960 33.57301 Colon 19,654 12,202 62.08405 
Lung 215,000 161,840 75.27442 Lung 11,507 10,339 89.84966 
Prostate 186,320 28,660 15.38214 Prostate 10,512 2,476 23.55403 
CNS 21,810 13,070 59.92664 CNS 1,156 992 85.81315 
Abbreviations: USA, United States of America; CNS, Central Nervous System. 
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environmental influences mostly underlie the process of cancer. When 
environmental factors are the cause, think of certain chemicals, radiation or 
biological causes such as bacteria and viruses. It is important to take a closer look at 
the development of cancer cells, namely, which genes are involved? We can 
separate at least four groups of genes involved in this malignant transformation: 
oncogenes, tumor suppressor genes, DNA repair genes, and the gene encoding 
telomerase. The first oncogenes were discovered ironically with the help of viruses. It 
was rationalized that if a virus could be held responsible for the onset of cancer, then 
the genome of that virus should contain the responsible sequences for that onset. 
Furthermore, in the 70’s Bishop and Varmus discovered that normal human cells too 
could have these similar gene sequences without the process of any malignancy. 
Nevertheless, these genes were as a matter of fact involved in the regulation of cell 
growth and differentiation and could therefore be defined as pro-oncogenes. 
Sometimes, numerous copies of those oncogenes occur in a cancer cell such as the 
c-erb-B2 gene which is repeated in a certain type of breast cancer or N-myc which 
can have an important role in the development of the neuroblastoma. Other 
processes associated with these oncogenes are chromosomal translocation, point 
mutations and viral infection, with the latter due to the incorporation of a virus into the 
human genome.  
Tumor suppressor genes can be held responsible for the onset of a cancer cell when 
the expression of these genes is suppressed in response to different stimuli, for 
example a point mutation or a genetic cause; hence cell growth is no longer limited. 
DNA repair genes are not directly responsible for cancer formation, however, since 
they are the care takers of the DNA, their absence or inadequate function will lead to 
instability in the genome and thus leading to a higher chance of cancer formation. A 
lot of research on telomerase expression resulted recently in the discovery that 
telomerase is present in almost all carcinoma cells; therefore, telomerase could have 
a great diagnostic and maybe even therapeutic value.4  
The transcription factor Nuclear Factor kappa B (NF-kB), will be discussed shortly to 
give a quick impression of the complexity and interaction chains involved in the onset 
of cancer. The NF-kB complex in the cytoplasma of the cell is usually bound to the 
IkB family making it impossible for NF-kB to travel to the cell nucleus and bind to the 
DNA for further action. Many different signals, such as growth factor and hormones, 
can result in the activation of IkB kinase responsible for phosphorylation of IkB and 
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thereby releasing NF-kB dimers. These dimers are then translocated to the nucleus 
where they bind to the kB location in the promoter or enhancer region of the target 
genes controlling the expression of this gene. When NF-kB is activated, the 
transcription of many genes is induced. Moreover, NF-kB seems to be a key 
mediator in inflammation, tumor onset and growth and the formation of blood 
vessels. NF-kB activation is also known to be associated with numerous types of 
cancer.5 This example should give us an understanding of how important it is to 
reveal the function of these molecular factors in cancer and by further exploring 
some of these processes. This is exactly where the field of molecular imaging has 
been indispensible. By revealing these biological processes step by step, each 
discovery is a step closer to better cancer diagnostics and treatment.  
One can also think about the biological processes of metastatic cells, which involve 
numerous genes and proteins. The journey of metastasis is nonetheless not easy for 
a cancer cell. The estimation is that around 0.01% of the tumor cells will be able to 
depart from the original site, survive the blood stream, attach to a suitable tissue and 
manipulate normal cells for the malignant transformation. However, once a cancer 
cell is able to metastasize, the new colonies are more resistant to the standard 
treatment than the original tumor due to their genetic alternations.  
To overcome this problem research focuses on different theories of metastasis. One 
can see cancer for example as an inflammatory disease that uses immune cells for 
its spread and therefore the metastasis can be limited by the inhibition of the immune 
system. Or one can see metastasis as an embryonic process and the traveling 
cancer cells are in fact cancer stem cells that use the properties of a stem cell to 
migrate.  
Recently, individual tumor cells were detected in the blood stream of patients with 
early-stage cancer, suggesting that the onset of metastasis might even take place in 
the beginning of the cancer formation. This would open the doors for early-stage 
cancer detection by simple blood assays. 
Nevertheless, the facts that some tumor cells need years to spread whereas others 
go out immediately and that metastatic tumor cells look different in every organ, 
remain a barrier for early detection and treatment. Besides, what if the cancer cells 
that are not killed by the chemotherapeutic obtain mutations, which transform them 






Gliomas account for 31% of all tumors in the Central Nervous System (CNS) and for 
78% of all CNS malignancies (www.Cbtrus.org). Malignant gliomas are classified as 
astrocytoma, oligodendroglioma, or oligo-astrocytoma and histologically graded as 
WHO grade II, III (anaplastic) or IV.7 Grade II tumors are associated with a survival 
time of 5 to 15 years, while grade III gliomas often predict a survival time of less than 
3 years. Glioblastoma Multiforme (GBM, or astrocytoma grade IV) is the most 
malignant of all glial tumors and has an extreme poor prognosis, with an average 5 
years survival of only 3.3% and the majority of patients dying within a year. Without 
treatment median survival is 4-6 months.8 The characteristics of this malignancy 
include uncontrolled cellular proliferation, invasiveness with both long root like 
processes and single invasive cells, areas of necrosis, and extensive angiogenesis.9, 
10 Furthermore, the GBM cells are resistant to apoptosis, and possess multiple 
genetic alterations.11 Primary GBM occurs de novo, without a pre-existing less 
malignant precursor lesion, and comprises over 90% of the GBM cases. Secondary 
GBM occurs through progression of a low grade astrocytoma or anaplastic 
astrocytoma and generally occurs in younger patients.12 
 
The current standard of care treatment for GBM consists of surgical macroscopic 
debulking of the tumor mass, followed by both radiation and chemotherapy.13, 14 
Progression free survival in the first 6 months appears to be directly related to the 
amount of tumor mass removed, with a more extensive resection corresponding to a 
better outcome (41 vs. 21%).15, 16  Combined treatment with radiation and 
temozolomide further increases median survival to 12-14 months, which is 
significantly better than the results achieved with radiation alone (median survival: 9 
months).8, 15, 17 However, regardless of treatment most patients die within a year from 
new secondary tumor foci forming within 2 cm of the resected area.18, 19 
 
 
2.1 Factors complicating GBM treatment   
 
Evidently, GBM is difficult to treat. Average survival increased with months instead of 
years, while researchers worldwide are working hard to find a cure. The aggressive 
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behavior of GBM tumor cells is caused by an array of tools that are specifically 
designed to escape eradication. The distinct tumor heterogeneity, the ability to 
escape the cellular immune response, the resistance to therapy, the interaction 
between the tumor cells and the microenvironment, and the inability of treatment to 
reach all tumor cells make GBM such a challenge to treat. 
 
2.1.1 Tumor heterogeneity 
 
One of the hallmarks of GBM is its heterogeneity. Cells differ in morphology, 
behavior and genetics20 and consequently it is very difficult to grade the tumors, 
measure response to therapy and understand the mechanisms of resistance. Not 
one GBM tumor is similar to another. Primary and secondary GBM appear 
morphologically the same, but genetically, differences are profound.21 It is thus 
unlikely that one standard therapy aimed to cure all tumors diagnosed as GBM can 
be developed.   
 
Necrosis is one of the features of GBM and is thought to play an important role in the 
development of the heterogeneity of the cell population. First, hypoxia is likely to 
appear in tumor regions where metabolic demands exceed the supply or as a result 
of thrombolytic events that are often seen in glioma patients. As a result, migratory 
genes are triggered and cells start to move away from the hypoxic site, whereas 
necrosis ensues in the hypoxic center. A lining of palisade cells develops around this 
necrotic core, expressing an abundance of angiogenic and growth factors and 
thereby facilitating angiogenesis and tumor proliferation.22, 23 At the same time, a 
clonal selection takes place selecting highly malignant tumor cells that are resistant 
to apoptosis by inactivation of p53.24 The selection of more highly malignant cells 
may then again lead to a higher metabolic demand, causing a vicious cycle of 
hypoxia, necrosis, selection and proliferation; resulting in a very heterogeneous 
population of cells, which are highly resistant to conventional therapy. Therefore, 







2.1.2 Tumor invasion in the microenvironment 
 
Gliomas are known for their tendency to infiltrate the surrounding brain parenchyma, 
which makes it very difficult to rely on locally applied treatment, like surgery. After 
initial surgery, tumor reoccurrence usually takes place within 2 cm of the original 
tumor site, suggesting that at the time of surgery individual cells already invaded the 
surrounding brain tissue. This is one of the major challenges in GBM treatment and 
makes a better understanding of both tumor cell biology and tumor 
microenvironment highly desired.  
 
Tumor invasion is a very intricate process involving a combination of the ability to 
migrate (cell motility) and the ability to modulate the extracellular matrix (ECM). 
These abilities are present in both low and high grade gliomas, suggesting they are 
acquired early in tumorigenesis.9 Preferential patterns of migration can be discerned, 
including migration along the white matter tracts, around neurons in the gray matter 
(a phenomenon known as perineural satellitosis), perivascular growth and subpial 
spread.9 These patterns suggest the existence of some sort of tropism or a restricted 
ability of GBM to invade specific regions between certain cell combinations and also 
show that interactions with the tumor microenvironment play an important role in the 
process of invasion.25 
To facilitate invasion, GBM cells display a wide array of tools. First, a variety of 
proteases such as cysteines, serines and matrix metalloproteinases (MMP’s) is 
secreted by the tumor cells to degrade the ECM in order to allow migration, and to 
remodel the ECM in a way that facilitates tumor growth.26 Expression of these 
proteases increases with tumor grade. Further, an increase of integrin receptors can 
be observed, facilitating the interaction of the cells with the ECM molecules and 
thereby modifying the cell cytoskeleton towards locomotion. Kinases such as the 
cytosolic Focal Adhesion Kinase (FAK) are activated by epidermal growth factor 
receptor (EGFR) which in turn activates downstream pathways involved in 
proliferation, survival and migration.27, 28 Growth factors as fibroblast growth factor 
(FGF), epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), 
platelet derived epidermal growth factor (PDEGF) and their receptors are 
upregulated and promote both proliferation and migration. EGFRvIII mutation is often 
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found in GBM and is known to upregulate expression of genes responsible for MMP 
and collagen production, thereby further facilitating invasion.29  
 
The final tool GBM cells display in their attempt to remodel the ECM into an optimal 
niche for growth and development is the creation of a zone of local immune 
suppression. Immunosuppression is facilitated by cell-to-cell contact and by the 
secretion of various cytokines. This strategy leads to T cell activation inhibition and 
the initiation of T cell apoptosis, and thereby prevents the immunesystem form 
actively attacking the tumor cells.30  
 
2.1.3 Angiogenesis in GBM 
 
In order to adapt to hypoxic conditions once the tumor mass increases, GBM cells 
release pro inflammatory agents. Also, GBM cells have the ability to 
transdifferentiate in tumor derived endothelial cells (TDEC).31 These TDEC are 
capable of forming vascular structures within the tumor, reestablishing oxygen and 
nutrient flow and making GBM one of the most vascularized tumors. However, anti-
angiogenesis treatment with anti-VEGF receptor inhibition does not seem to affect 
the TDEC’s. 
  
2.1.4 Blood Brain Barrier 
 
Since extra-neural spread of GBM is very rare, the most convenient method of 
treatment would be local in the CNS. However, the delivery of therapeutics is 
challenging due to a natural filtering mechanism, the blood-brain-barrier. Most 
chemotherapeutics are unable to cross this barrier, or are cleared very rapidly out of 
the brain extracellular space. The integrity of the blood-brain-barrier varies per region 
and this affects the locally available drug concentration.32 GBM cells are capable of 
pumping out drugs after uptake, by means of P-glycoprotein and other pumps.33 The 
high intratumoral pressure further complicates delivery of therapeutic agents. 
Damage to healthy brain tissue, due to the limited intracranial space, is another point 





2.1.5 Cancer Stem Cells 
 
The “old” stochastic model on tumor growth proclaims that all cells in a tumor are 
biologically equivalent and are able to initiate or drive tumor formation, due to 
accumulation of mutations.34, 35 In contrast, the Cancer Stem Cell  (CSC) theory 
suggests that a rare population of tumor cells is responsible for tumor growth, 
resistance and recurrence.36 These cells are named Cancer Stem Cells because of 
their “normal stem cell” like properties; they share important characteristics with stem 
cells, including their ability of limitless self-renewal and differentiation.37 They are 
capable of generating a diverse population of cells, both tumorigenic and non-
tumorigenic, present in tumors. They seem to exclusively drive tumor growth and to 
give rise to a diverse progeny.38 Once implanted in immunogenic mice, CSC are 
capable of generating a photocopy of the original malignancy of which they were 




Figure 1. Model of cancer theories. The CSC theory suggests a strong hierarchal pattern 
within the tumor. Cancer stem cells are the only cells capable of self-renewal and 
proliferation. They initiate and drive tumor growth. The stochastic model describes tumor 
20 
 
growth as a random process. Accumulation of genetic alterations and mutations drives tumor 
growth and all cells can contribute to this process. Red: CSC. Yellow: transient amplifying 
cells. These cells are slowly maturing and lose their ability of self-renewal along the way. 
Green: fully differentiated tumor cells that are no longer capable of self-renewal. Image 
adapted from www.eurostemcell.org 
 
The CSC theory implies that indiscriminate killing of all cancer cells may be an 
inefficient and ineffective way to treat cancer, since it is not targeted to eliminate the 
few CSC that actually drive the cancer. In this scenario the treatment will kill the 
proliferating “innocent” cell population, and since these cells consists of the majority 
of the tumor, treatment will seem effective. However, CSC are known to be very 
resistant to chemo- or radiotherapy due to their stem cell-like properties and their 
relative quiescence, and will remain at the tumor site (unless surgically removed), 
eventually causing a relapse (Figure 2).33, 40, 41 Selective targeting of CSC might be a 




Figure 2 The effect of two different therapeutic approaches on CSC. If standard therapy is 
used, CSC will escape elimination and start the process of tumor initiation and proliferation 
all over again. Tumor relapse seems inevitable. If however, tumor therapy is aimed at CSC 
directly, CSC will die and the remaining tumor bulk, with no tumorigenic capacities of its own, 
will shrink and disappear, and no recurrence will occur. Image adapted from Lui et al. 
Cancer Research, 2011.  
 
In GBM, glioma stem cells (GSC) have shown similarities to normal stem cells and 
progenitor cells, expressing the markers CD133 and Nestin.37 This leads to concern 
of toxicity when using these markers to design drugs targeted to GSCs. Since glioma 
stem cells produce vascular endothelial growth factor (VEGF), promoting 
21 
 
angiogenesis, and since they appear to need a vascular niche for optimal 
functioning,42-44 the use of anti-angiogenic therapy to inhibit glioma CSC functioning 
might be a better strategic approach. There is ongoing discussion over the exact role 
of CSC and their characteristics,45 but nonetheless CSC are believed to play an 
important role in GBM tumor initiation, progression and angiogenesis, making GBM 
so complicated to treat. 
 
2.1.6 Genetic alterations and resistance to apoptosis 
 
Resistance to apoptosis of GBM cells is very common. Genetic alterations that 
upregulate oncogenes and inactivate tumor-suppressor genes (including 
retinoblastoma protein (RB) and p53) are found in the majority of GBM cells.46, 47 
This, combined with the natural selection of highly malignant clones, and the stem 
cell-like properties of a subgroup of the GBM cells, make that GBM cells are highly 
resistant to apoptosis.33 In addition, GBM cells express a variety of molecules 
affecting both intrinsic and extrinsic apoptotic pathways. They secrete soluble decoy 
death receptors aimed at the natural defense mechanisms and often the Bcl2 family 
of anti-apoptotic genes is upregulated. Crosstalk between the anti apoptotic 
pathways further contributes to the difficulty of finding an effective treatment. 
 
 
3. WHAT ARE THE CURRENT STRATEGIES FOR TREATING GBM? 
 
3.1 Current treatment 
 
The National Comprehensive Cancer Network states that standard treatment of 
GBM consists of maximal surgical removal of the tumor mass, 6 weeks 
postoperative radiotherapy, and concomitant systemic chemotherapy with 
temozolomide followed by 6 months of adjuvant treatment with temozolomide 
(NCCN guidelines version 2.2011: CNS Cancers, www.nccn.org).48, 49 Advances in 
both surgical and imaging techniques permit safer and more extensive removal of 
the tumor, but due to the highly invasive nature of GBM surgery is not intended to be 
curative. The prognosis after recurrence is very poor, and recommendations for 
adjuvant treatment strategies are ill defined. Current options include surgery with or 
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without camustine wafer placement (if the recurrence is local), radiotherapy, 
chemotherapy, anti-angiogenic agents (monoclonal antibody bevacizumab), or 
experimental therapies (www.nccn.org). Surgery seems to prolong survival up to a 
limited degree. The benefits of repeated radiotherapy remain unclear.50-52 Due to 
toxicity to normal cells, high enough doses can’t be delivered. Resistance to 
chemotherapy can be overcome by changes in dose regimen and by combining 
temozolomide with the cyclo-oxygenase 2 (COX-2) inhibitor rofecoxib, leading to an 
anti angiogenic effect.52 Interestingly enough, not all anti-angiogenic agents seem to 
enhance the efficacy of temozolomide treatment. Combined temozolomide and 
bevacizumab regimens resulted in inferior outcomes than seen after treatment with 
bevacizumab or temozolomide monotherapy.53 This may be partially explained by 
many patients with CNS tumors however require dexamethasone or anti epileptic 
drugs, which in combination with temozolomide or other anti cancer agents, may 
lead to drug-drug interactions with a reduced efficacy and an increase of side 
effects.54 
 
Genotyping for personalized medicine is slowly starting to influence treatment 
options. 60% of GBM tumors with chromosomal 1p loss respond to a chemotherapy 
regimen of PVC (procarbazine, CCNU and vincristine) combined with temozolomide, 
while ‘regular’ GBM tumors are not sensitive to this specific regimen. GBMs with 
EGFR amplification rarely respond to chemotherapy at all. O6- methylguanine DNA 
transferrase or MGMT, a DNA repair enzyme that protects cells from damage 
caused by ionizing radiation and alkylating agents, is another powerful molecular 
predictor.55, 56 The MGMT promotor is methylated in 40 to 45% of GBMs, which 
means that cells are unable to properly repair DNA damage.57, 58 MGMT methylation 
is currently the strongest predictor of outcome and benefit of temozolomide 
treatment.59 Simple genotyping assays screening patients for chromosomal 1p loss, 
EGFRIII mutation and MGMT promotor methylation can therefore not only increase 
quality of life (only exposing those patients to treatment that have a high chance of 
good response), but can further result in higher survival rates, since no time is 
wasted on the ‘wrong’ type of therapy.    
 
Since GBMs are highly vascularized tumors, anti angiogenesis strategies have 
received a great deal of attention. VEGF expression levels correlate with tumor 
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malignancy levels and many angiogenic factors are secreted (VEGF, PDGF, 
fibroblast growth factor 2 (FGF2), Hepatocyte Growth Factor).60 Monoclonal 
antibodies directed against VEGF or its receptor (e.g. Bevacizumab) are FDA 
approved and currently in use, although treatment did not prove to be more effective 
than standard therapy (www.nccn.org)61 However, quality of life seemed to 
improve.62, 63 Side effects related to toxicity, resistance, and progression to a more 
invasive type of tumor are reported. Other strategies including small molecule 
inhibitors (Cediranib) designed to inhibit VEGFR2 Tyrosine Kinase activity, or soluble 
decoy receptors identical to VEGFR1 (Aflibercept) are currently under investigation 
in clinical trials.64, 65  
 
3.2 New foci of research 
 
Due to the limited success of therapies discussed above, new foci of research have 
emerged. As discussed earlier, GBM tumors are highly heterogeneous, display all 
kinds of anti-apoptotic escape routes, suppress the immune system, invade the 
surrounding parenchyma with unmatched aggressiveness and possess a whole 
array of tools to rearrange the extra tumoral environment to their advantage. 
Integrins, the cell surface receptors responsible for cell adhesion to the ECM, are 
known to play a crucial role in the recruitment of the ECM by activating intracellular 
pathways responsible for cell survival, migration, and angiogenesis in both GBM 
cells and cells in their direct environment (fibroblasts, vascular endothelial cells, 
bone marrow derived cells).66 Further, interaction between GBM cells and ECM 
molecules results in modification of the GBM cytoskeleton and locomotion. In a 
Phase II clinical trial, Cilengitide, a synthetic cyclic peptide that blocks the binding of 
integrin to its receptors, showed moderately positive results.67 This drug is also being 
tested in combination with other anti cancer agents (www.clinicaltrials.gov). 
 
Other targeted therapies aimed at disrupting the interactions between GBM and 
ECM include receptor tyrosine kinase inhibitors (blocking the activation of 
intracellular pathways associated with cell proliferation and migration) and small non-
coding RNA’s, which are used to inhibit cell to cell signal transduction and activation 
of stem cell pathways. The latter approach is believed to directly target cancer stem 
cells and, since this population is thought to be the driving source of tumor 
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proliferation and metastasis, should result in less aggressive behavior of the tumor 
as a whole. Unfortunately, so far the results of these strategies have been poor, with 
no survival benefit in GBM patients. 
 
The fact that many of the single agent targeted therapies seem to fail is most likely 
attributable to the complexity of the interactions between GBM and ECM and to the 
crosstalk between the different intra- and extra cellular pathways, allowing tumor 
cells to overcome interventions and to escape cell death over and over again. The 
relatively low number of patients diagnosed with GBM makes recruitment for clinical 
trials and testing of new agents even more problematic. Further advances in surgery, 
genomics, proteomics, genetics and imaging modalities will be needed to get more 
insight in GBM tumor biology and to find diagnostics, predictive biomarkers, and 
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1. GENE THERAPY 
 
Gene therapy (GT) is based on the idea to use nucleic acid (DNA or RNA) as a 
pharmaceutical agent to treat disease.1,2 This idea came to life as soon as Watson 
and Clark unraveled the mysteries of DNA in the 1950’s. In 1972 Friedman and 
Roblin published a paper in Science titled “Gene Therapy for Human Genetic 
Disease?” formulating the first concrete concept of the field.6 It would take another 
20 years before the FDA approved the use of gene therapy in the United States, but 
then in 1992 Ashanti da Silva, a four years old girl, became the first person in history 
to receive gene therapy.7 She suffered from X-linked SCID, a single genetic defect 
resulting in immune deficiencies. Treatment was successful, however the effects 
were temporally. Since then, over 2000 clinical trials with gene therapy have been 
conducted (www.clinicaltrials.gov) and now this field seems to hold one of the 
promises of modern medicine.   
 
In contrast to drug-based therapies, that are administered exogenously and 
repeatedly, gene therapy aims to heal from within. DNA recombination techniques 
allow pieces of DNA (or RNA) to be created from scratch, resulting in genes with 
desirable characteristics. These newly created genes can be incorporated in the 
genome of the cells of choice, where they’ll start producing the tools for the intended 
intervention. Since integration in the host genome will theoretically result in long-term 
expression of the therapeutic gene, there’s no need for repeated administration. 
Virtually any type of intervention can be programmed into DNA, allowing the cell’s 
original genes to be inactivated or upregulated, nonfunctioning genes to be replaced, 
and genes with desirable characteristics to be introduced.  
 
1.1 Viral vectors  
 
Viral vectors are the vehicles of choice for transgene delivery in the gene therapy 
field. Viruses are characterized by their ability to introduce their genetic material into 
host cells as part of their replication cycle, while to a certain extent avoiding immuno-
surveillance. When the host cells are attacked by the virus, introduction of the viral 
genetic material takes place. As soon as this newly introduced information is 
translated, hijacking of the host replication machinery is initiated. The host cell will 
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carry out the instructions of the viral genetic material, creating more and more virus 
to invade surrounding cells. This way, viruses are capable of surrendering large 
populations of cells.  
 
In gene therapy several types of viruses are redesigned in such a manner that, 
instead of their own genetic material, they carry therapeutic genes into the host cells. 
Each type of virus has its own characteristics (Table 1), making it suited for different 
appliances. For the projects in this thesis, we mainly worked with adeno-associated 
viruses (AAV) and Lentivirus. 
 
Adeno-associated virus (AAV) is the virus of choice for the treatment of many 
neurological disorders. Several serotypes exists (2,4,5,7,8), with 2 being the one 
most often used in the brain, due to its preference for neuronal cells.8 AAV is 
capable of infecting both dividing and non-dividing cells and long time stable gene 
expression is achieved. Wild type AAV is known to integrate its DNA on a specific 
locus on chromosome 19, but this specificity is lost with the different serotypes, 
which usually maintain their DNA in a linear configuration in the cytoplasm 
(episomaly).9 AAV is associated with very low toxicity and does not seem to evoke 
an immune response. Due to all these features, it is currently used in clinical trials for 
neurological disorders. A disadvantage of AAV is its low genomic capacity. A 
maximum of 5 kb can be packaged into AAV vectors, which makes it often 
impossible to deliver both a transgene and its reporter.10  
  
Lentivirus (HIV-based) is a subgroup of the retroviridae family. It can deliver 
significant amounts of DNA and is capable of integrating its DNA permanently into 
the host genome, resulting in long-term stable gene expression.11 This might lead to 
a risk of oncogenic mutagenesis when integration happens at the site of e.g. a tumor 
suppressor gene.12 This is the reason that lentiviruses are primarily used for in vitro 
systems or in animal models after ex vivo infection. Some clinical trials are testing 







Table 1 Characteristics of the most commonly used viral vectors for gene therapy. Image 
www.genetherapy.net1.3 Gene therapy for GBM 
 
1.2 Gene therapy and cancer 
 
Gene therapy against cancer is based on the delivery of cytotoxic genes to the tumor 
cells to achieve cell death directly, or by delivering “replacement genes” to overcome 
the resistance to therapeutics that is seen in many cancer types.1,14 The most 
studied direct cytotoxic transgene in GBM is the Herpes Simplex Type 1 Thymidine 
Kinase (TK).15 This gene enables the conversion of the prodrug ganciclovir into the 
highly toxic deoxyguanosine triphosphate, resulting in early chain termination of 
nascent DNA strands. The advantage of this approach is that only cells expressing 
the TK gene will convert ganciclovir (intracellular) into its lethal counterpart, while 
regular cells will remain unharmed. A modest increase in survival is reported in 
several studies. Another commonly used transgene if the E. Coli cytosine deaminase 
(CD) which converts 5-fluorocytine (5-FC) into its toxic variant 5-fluorouracil (5-FU).16 
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After successful introduction of the gene and administration of 5-FC, extensive cell 
death could be observed. Unlike TK, the CD therapeutic strategy has the advantage 
of excellent bystander effect since the 5-FU can travel from cell-to-cell via gap 
junctions. 
 
Instead of introducing drug-activating genes into cells, it is also possible to deliver 
genes coding for immunotoxins. An example of such an approach is an AAV 
encoding transgenes for PE (pseudomonas exotoxin).17 Expression of the PE gene 
leads to disruption of the cellular protein translation and causes cell death. To 
prevent elimination of normal non-tumor cells, the PE toxin is linked to human IL 
13RĮ2, a variant of the IL13 receptor that is overexpressed by 50-80% of GBM cells, 
but not by normal cells.  This approach is still in an experimental phase18, but tumor 
regression and long-term survival was observed in ~70% of the animals.  
 
Despite some success stories, gene therapy is not living up to its full promise yet. It 
appears to be very difficult to achieve a high enough percentage of transduced cells, 
limiting the effectiveness of the therapy.19 GBM cells prove to be particular difficult to 
transduce, due to the characteristic intra-tumoral heterogeneity and high intracranial 
pressure. Bystander effect of the transgene, in which the neighboring non-
transduced cells are also killed, is needed to ensure effective therapy. Another 
problem is caused by the short-lived nature of this approach. Whereas theoretically 
integration of DNA in the host genome will result in long-term expression, this seems 
to be problematic to achieve in real life.  After initial transduction, loss of transgene 
expression can be observed over time. Due to problems with integration of viral 
vector DNA into the genome and rapidly dividing cells, no permanent expression can 
be acquired so that patients require multiple rounds of gene therapy. Other concerns 
for viral therapy include toxicity of the gene or its vector to normal tissue, the host 
immune-response, tissue targeting, gene control, virus safety and the chance of 
inducing tumors by insertional mutagenesis. As of today, it is still impossible to 
exactly pinpoint the spot in the DNA where the new gene is to be integrated. 
Chances are the new gene integrates at the wrong place along the DNA strand, 





As mentioned above one of the challenges of using gene therapy in GBM is the 
achievement of a high enough yield of viral expression. Most approaches are 
focused on direct intratumoral injection of the virus to achieve expression of the 
therapeutic protein by the tumor cells themselves. Besides the fact that it is very 
difficult to establish consistent transduction of this heterogeneous cell population, 
another problem arises. Once the virus delivers its therapeutic gene to the tumor 
cells, production of the desired anti tumor proteins begins. Anti tumor proteins are 
designed to be highly lethal in order to be as effective in eliminating tumor growth as 
possible. However, since the tumor cells express the drug themselves, the 
therapeutic reservoir is rapidly depleted once the drug gets effective and the cells 
start dying, allowing for the escape of residual cells. To overcome this problem, 
Maguire et al designed a different approach in which not the tumor cells but the 
surrounding healthy brain parenchyma was engineered to express and anti-cancer 
agent, creating a ‘zone of resistance.’20 Using an AAV8 vector expressing interferon 
beta (INFȕ) to transduce the normal brain, tumor growth in orthotopic xenograft 
models was completely prevented, even in the contralateral hemisphere and 
complete eradication of established tumors was achieved. These results open new 
possibilities for a more effective treatment of GBM with gene therapy. 
 
All the above strategies are aimed at the elimination of tumor cells. This is however 
not the only way gene therapy can be of use in GBM. A very important role is 
reserved for its attribution to the knowledge of GBM tumor biology. Combining gene 
therapy and molecular imaging has lead to major discoveries in tumor signaling 
pathways, behavior, response to therapy and the role of the microenvironment, 
allowing the development of more effective treatment options.  
 
1.3 An alternative approach: Liposomes  
 
To enhance the diagnostics and treatment of many disorders, including cancer, one 
should think of disease-specific-targeting strategies. Most conventional 
chemotherapeutics lack the ability to deliver the therapeutic content specifically to 
the target tissues, which results in toxicity to healthy structures and often inadequate 
levels of therapeutic agents at the targeted tissue. Furthermore, gene therapy by use 
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of viral vectors is not yet at the level where we can 100% specifically target a specific 
group of cells. Liposomes might provide an interesting alternative for selective target 
delivery of therapeutics. Since many liposomes are currently widely used for 
pharmaceutical therapy and thereby approved for clinical purposes, they are of great 
interest for further exploration and applications. 
 
About 45 years ago, Alec Bangham observed that phospholipids form closed 
bilayered structures when put in aqueous solutions, which were named liposomes. In 
short, liposomes are spherical, self-closed structures formed by one or several 
concentric lipid bilayers with an aqueous phase inside and between the lipid 
bilayers.21 A real breakthrough occurred around 20 years ago when several 
liposomal drugs were approved and thereby many biomedical products and 
technologies were developed. The ideal liposome has 1. a size of around 80-120 nm 
to minimalize phagocytosis of the liposome particles in the blood 22, 2. a coat of for 
example PEG to slow down liposome recognition by the immune system and the 
resulting clearance of liposomes 21, and 3. target specificity such as 
immunoliposomes, foliate-mediated targeted liposomes, transferrin-mediated 
liposomes or biotin-streptavidin liposomes. Furthermore, liposomes are often PH-
sensitive for efficient release of their contents inside the acidic endosome of the cell 
or the liposomes can be thermo-sensitive for ultra sound release of their therapeutic 
content. 23,24 
 
Besides the use of liposomes for therapy, they are also suitable for the delivery of 
imaging agents, which can be detected with most of the imaging modalities 
described in the next paragraph. For gamma-scintigraphy and MRI, the liposomes 
require respectively a sufficient quantity of radionuclide or paramagnetic metal. CT-
contrast agents also can be incorporated into either the inner water compartment of 
the liposomes or in the liposomal membrane, as well as the incorporation of gas 
bubbles, which are sound reflectors, for the use of ultra sound. 21,25 The use of MRI 
for liposomal therapy and delivery of imaging agents has a great advantage due to 
its non-invasive character, the lack of radiation and its high spatial resolution. On the 
other hand, the sensitivity of MRI can often be disappointing, which fortunately can 
be overcome by a good contrast agent. Liposomes are known to be useful carriers of 





Figure 1: Liposome cell interaction. A) Drug loaded liposomes can specifically (a) or non-
specifically (b) absorb onto the cell surface. Liposomes can also fuse with the membrane (c) 
and release their contents into the cytoplasm, or can be destabilized by certain cell 
membrane components when absorbed on the surface (d) so that the released drug can 
enter the cell via micropinocytosis. Liposomes can undergo the direct or transfer-protein 
mediated exchange of lipid components with the cell membrane (e) or be subjected to 
specific or non-specific endocytosis (f). in case of endocytosis, a liposome can be delivered 
by the endosome into the lysosome (g), or, en route to the lysosome the liposome can 
provoke endosome destabilization (h), which results in drug liberation into the cell cytoplasm. 
B) Liposome modified with viral components (a) and loaded with a drug can specifically 
interact with cells (b), provoke endocytosis, and via the interaction of viral components with 
the inner membrane of the endosome (c), allow for drug efflux into the  cell cytoplasm (d). 21 
 
 
2. MOLECULAR IMAGING 
 
Molecular Imaging (MI), defined by the Center of Molecular Imaging Innovation and 
Translation as ‘the visualization, characterization, and measurement of biological 
processes at the molecular and cellular levels in humans and other living systems,’ 
was developed in the early 21st century and has since rapidly evolved as a useful 
tool in the biomedical research field.26 MI has provided the opportunity to visualize 
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and monitor biological processes at both cellular and subcellular level without 
disturbing the living organism itself, thereby allowing the in vivo monitoring of specific 
molecular and cellular processes as gene expression, multiple simultaneous 
molecular events, progression or regression of cancer, and drug- and gene 
therapy.27  
 
Currently disease is seen as the development of anatomic changes or physiologic 
changes, but unquestionably molecular changes underlie these developments. 
Direct imaging of these molecular changes will allow for detection of the disease in a 
much earlier stage. Further, the effects of the chosen treatment can be monitored.28 
Molecular Imaging is especially getting more and more essential in the cancer field. 
Our assessment of tumor type and diagnosis, prognostic markers, gene expressions, 
behavioral predictions, location, infiltration and response to therapy, e.g. our 
complete anti-tumor toolbox almost entirely relies on the (combined) use of various 
imaging modalities. Since Molecular Imaging allows for real time in vivo monitoring, 
understanding of the complicated and dynamic intra-tumoral processes becomes 
possible. Biological processes can be studied in their own physiologically authentic 
environment, instead of in laboratory-designed models. This is in huge contrast with 
the ex vivo techniques such as histology that we had to rely on before. Only a single 
static point in time could be measured, showing the end effects of molecular 
alterations, but not how and why those alterations took place. This ‘how’ and ‘why’ 
can now be visualized with molecular imaging and this knowledge can be directly 
applied to new treatment strategies.  
 
In order to successfully visualize these biological processes in vivo, specific and 
sensitive molecular imaging probes are needed. These probes are molecules such 
as radiolabeled ligands, substrates, antibodies or cytokines, which can be used to 
differentiate between the different molecular events. Often it is useful to create 
inactive probes that require a substrate-enzyme interaction or the unquenching of a 
fluorophor to become active. Molecular Imaging consists of a wide array of these 
probes to produce imaging signals. Nuclear medicine relies on the decay of 
radioactive molecules (tracers), while sound (ultrasound), magnetism (MRI) and light 
(optical techniques; fluorescence and bioluminescence) are other key players (Table 
2).29 The required common characteristics of all these techniques is the availability of 
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a stable, non toxic high affinity probe or reporter, their ability to overcome 
physiological barriers (blood-brain-barrier), the use of amplification techniques to 
increase the signal to noise ratio, and the availability of high resolution fast imaging 
modalities.28  
Whereas techniques such as positron emission tomography (PET), single photon 
emission computed tomography (SPECT), computed tomography (CT), magnetic 
resonance imaging (MRI), and ultrasound are widely used in the clinical setting, they 
all have different shortcoming for pre-clinical small animal imaging. On the other 
hand, optical imaging including bioluminescence imaging (BLI) and fluorescence 
imaging (FLI) are valuable for pre-clinical small animal imaging.30 Application of 
multimodality imaging using probes which can be imaged with a combination of 
either one of the above techniques results in fast validation in animal models (e.g. 
BLI) and translation into the clinic (e.g. MRI/PET).31 
 
2.1 Overview of different imaging modalities 
 
To gain insight into the different modalities used in molecular imaging and to obtain 
better understanding of the following chapters, a brief overview of the most 
commonly used imaging modalities will be provided. 
 
Nuclear Imaging.  Nuclear medicine gained recognition as a medical specialty in the 
50’s. 32,33 This specialism makes use of radiation to image biological processes for 
medical purposes. To explain the different modalities that are often used in nuclear 
medicine, one should first know the concept of a gamma camera. A gamma 
camera, also known scintigraphy or an Anger camera, counts the gamma photons 
absorbed by the crystal of the camera. When a gamma photon radiates from the 
patient (originating from an administered pharmaceutical) and reaches the camera, 
an electron is released from the iodine in the crystal of the camera, which upon 
finding its minimal energy state produces a faint flash of light. Thereby a 2-
dimensional image is created. Both PET and SPECT scanners are based on the 
principle of a gamma camera. A PET scanner can detect gamma photons that are 
the result of a hit between a positron, emitted by the molecular probe administered, 
and an electron. The molecular probe consists of a decaying nucleotide such as 
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Carbon-11, Fluorine-18, Oxygen-15, or Iodine-124. A PET scanner can thereby 
reconstruct an image of the positron-emitting radionucleotide tagged to a specific 
molecule, which is recognized by enzymes or prone to binding to receptors, to 
visualize for example the expression of a therapeutic gene of interest. 34,35,36,37 The 
PET technique is widely used to visualize molecular processes and a majority of 
these are related to tumor cell growth.38 Whereas PET uses the collision of positrons 
and electrons, SPECT tracks the position of gamma radiation directly by a rotation 
process around the body. Therefore, SPECT acquires information of the 
concentration of gamma emitting radionuclide, such as Technetium-99m, Indium-111 
and Iodine-131, instead of a volumetric distribution that can be acquired by PET. 
Since PET uses this indirect radiation for a real-time image in time and space it is 
more sensitive than SPECT. SPECT on the other hand is significantly less 
expensive.27  PET and SPECT are both used in the clinic and for small animal 
imaging. 
 
X-ray and CT imaging. An X-ray is an image of electromagnetic radiation sent 
through the body and recorded on a film. Dense structures will appear as white on 
the image by blocking most of the radiation, whereas black displays the opposite 
namely air.  X-ray images are commonly used for the evaluation of anatomical 
structures and are easy and relatively cheap to acquire.39,40  CT, also known as CAT 
scanning (Computerized Axial Tomography) uses the same X-ray absorption as 
simple X-rays but it acquires different type of images by rotating the source and the 
detector around the body, resulting in multiple serial images and volumetric data.27,41 
CT is applied both in the clinical settings and for small animal research, although the 
utility of the CT technique for molecular imaging remains controversial mainly 
because of the difficulty in designing adequate contrast agents and probes for this 
modality.28,42  
 
Ultrasound (US). This technique of high-frequency sound waves transmitted 
through tissues and then reflected back and detected, is often used to observe 
perfusion and anatomical characteristics.  
Currently, contrast agents detectable by US and useful for molecular imaging are 
tested in animals. These contrast agents consists of microbubbles to which proteins 
and antibodies can be attached. When these microbubbles are linked to a 
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therapeutic agent the ultrasound can be used to release this therapeutic agent at the 
specific disease site, leading to therapy. 43,44,26  
 
Magnetic resonance imaging. MRI stands for high resolution imaging without 
ionizing radiation.  When a temporary radiofrequency pulse is given to the hydrogen 
atoms in the body, whose spins are aligned because of a strong magnetic field, they 
temporarily change their alignment of spinning and get into an excited state, creating 
a pulse of radio wave the moment they switch back to ground state. These radio 
waves are detected and quantified. The major advantage of MRI is that it is suitable 
for high-resolution tissue images and contrast agents that can even enhance the 
signal, such as paramagnetic gadolinium, are available making MRI an important 
imaging modality. 27,45 Nevertheless, certain drawbacks remain for the use of MRI 
including longer image acquisition time, often large amounts of contrast agent 46, 
difficulty in delivery of those contrast agents, and poor sensitivity due to lack of 
accumulation of the contrast agent at the targeted site. 45 In order to make MRI more 
suited for molecular imaging, it is unnecessary to explain the importance of exploring 








Figure 2: Imaging Modalities, adapted from  47,48,49,50,51,52,53.  A) Nuclear medicine, from left 
to right: Gamma scintigraphy, PET and SPECT scan. B) From top to bottom: MRI, CT and X-






Table 2 Characteristics of the main techniques used in Molecular Imaging. Copyright 
Center for Molecular Imaging Innovation and Translation 
 
 
2.2 Optical Imaging 
 
Optical imaging is specific type of molecular imaging. The basis of optical imaging 
techniques consists of photons travelling through tissue and interacting with tissue 
components.29  Genes encoding fluorescent proteins or luciferases can be 
engineered, transferred into host cells and/or living animals and their light output can 
be measured with sensitive cameras. Optical imaging is highly sensitive for contrast 
agents and reporter molecules in vivo, meaning that even small signals can be 
detected. Further, it proved to be an excellent tool for use in vitro and in small animal 
models. It is inexpensive, highly sensitive, and the procedure is not very time 
consuming. The only disadvantage of optical imaging is the limited transmission of 
light through animal tissues, resulting in a decreased signal quantitation. 
Fluorescence imaging and Bioluminescence imaging are the two optical imaging 
techniques used in this thesis.  
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2.2.1 Fluorescence Imaging 
 
Fluorescence refers to the property of certain molecules to absorb light at a 
particular wavelength and to emit light of a longer wavelength after a brief interval 
known as the fluorescence lifetime.29 The most commonly used fluorescent reporter 
is the green fluorescent protein (GFP). GFP is a 27 kDa protein derived from the 
jellyfish Aquorea Victoria and it emits green light upon illumination with ultraviolet 
light.54 The GFP gene is easily introduced to virtually any cell type and is extensively 
used as a reporter of expression or as a biosensor. When fused to other proteins, it 
becomes possible to monitor specific cell compartments, protein trafficking and all 
kind of cellular dynamic processes.55 Since GFP expression is not harmful to cells, it 
has become a very powerful tool for fluorescence microscopy to observe cellular 
processes over time. Using mutagenesis at the chromophore region of the GFP 
gene, several variants were engineered.56 With the creation of BFP (blue), YFP 
(yellow) and CFP (cyan), each using a different excitation and emission wavelength, 
simultaneous measurements became possible. In 2008 the discovery of GFP was 
awarded the Nobel Prize for Chemistry.  
 
So far, the use of fluorescence has mostly been in in vitro setting due to its emission 
peak in the 500 nm wavelength (green light) leading to poor tissue penetration. In 
vivo, only 1-2 mm depth can be detected, and often surgical exposure is needed 
before visualization of the reporter is possible. Further, an external light source is 
needed for excitation, leading to high background signals due to tissue auto-
fluorescence. Current research focuses on overcoming these limitations. Proteins 
that emit light in the far-red region of the spectrum or that show brighter light 
emission might improve the in vivo use of fluorescence. Due to a spectrum shift 
towards a wavelength longer than 600-610 nm, signals from red fluorescent (RFP) 
can be detected for several millimeters to centimeters in tissues, without the 
attenuation that occurs with other fluorescent proteins.57,58,59,60,61,62 Recently new 
imaging technologies have made it possible to acquire 3D fluorescence images, 
resulting in further improvement of sensitivity.63 This and several other developments 
in the fluorescence imaging field cleared the road for the use of this technique in the 
clinic. At the moment FLI is near to serving as a highly useful tool for breast imaging 
as well as for intraoperative guidance.45,64  
46 
 
2.2.2 Bioluminescence imaging 
 
Bioluminescence Imaging (BLI) is a technique based on converting chemical energy 
into visible light in living animals. For centuries seamen and fishermen had seen 
lights in the waters and realized that these lights were emitted by organisms living in 
the water; this phenomenon was called bioluminescence. Only about 45 years ago, 
these organisms began to be characterized.65,66,67 It was discovered that their light 
reaction depends on a luciferase (an enzyme), and its substrate (called a luciferin); 
coupling of enzyme and substrate causes a chemical conversion of the substrate 
resulting in light emission as is depicted in figure 3.68 All known luciferases use 
molecular oxygen to catalyze this reaction, and some luciferases require the 
presence of co-factors such as ATP and Mg2+ for activity. Since no external light 
source is needed, BLI has virtually no background. Luciferases comprise a wide 
range of enzymes; usually they are found in lower organisms such as insects, fungi, 
bacteria and marine crustaceans, but no shared sequence homology exists.68 
Luciferase have proved to be very useful reporters in mammalian cells, since they 
are easily introduced in virtually all cell types by means of viral vectors, and they can 
provide real time, non-invasive measurements of in situ biological events, thereby 
giving a complete picture of the kinetics of an entire process.68-70 With the current 
techniques, as few as a 10 cells expressing a luciferase can be detected in deep 








Figure 3. The Bioluminescent reactions of Firefly luciferase (Fluc), Renilla reniformis (Rluc) 
and Gaussia luciferase (Gluc). The chemical structure, the chemical reaction and the peak 
light emission (Ȝ max) are depicted for each luciferase. Adapted from Badr and Tannous, 
Trends in Biotechnology, 2011.  
 
American Firefly Luciferase, or Fluc, is derived from the light emitting organ of the 
Phrotinus Pyralis and is one the most commonly used luciferases. This 62 kDa 
protein has a very high quantum yield (>88%) and emits green light (562 nm peak 
with a broad shoulder) upon oxidation of its substrate D-luciferin (Figure 4). The 
presence of ATP and Mg2+ is required for this reaction to take place. Fluc is 
expressed in the cytoplasm and therefore is cell-associated. Fluc displays a glow-
type light emission kinetics with a half-life of 10 minutes, making it one of the best 
luciferases available to yield stable light output.71-73  
 
The luciferase from the sea pansy Renilla Reniformis (Rluc) is another commonly 
used reporter. Rluc is a 34kDa protein, which uses coelenterazine as a substrate, 
and emits blue light with a peak at 480 nm (Figure 4). No ATP is needed for Rluc 
activity, however the enzymatic turnover and quantum yield of this reaction is only 
6% making it not very suited as a reporter.74  
 
The luciferase from the marine copepod Gaussia Princeps (Gluc) is the smallest 
luciferase (19.9 kDa) known. Similar to Rluc, Gluc uses coelenterazine for its 
chemical reaction, resulting in blue light emission with a peak at 480 nm. Gluc is over 
2000-fold more sensitive than either Fluc or Rluc when expressed in mammalian 
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cells culture and therefore has become the reporter of choice.68 While most 
luciferases are retained in the cell, Gaussia Luciferase is unique as its cDNA 
possesses a natural signal sequence and therefore is secreted upon expression in 
mammalian cells. While this causes a certain loss of signal at the site of origin, it 
does allow Gluc to report both from the cells themselves as well as their 
environment. Therefore, the Tannous Lab developed Gluc as a blood reporter. Since 
Gluc is naturally secreted, the level of Gluc in the blood correlates with the specific 
biological process (cell number, viral transduction, tumor volume, etc).75,76 Despite it 
secretion, Gluc still emits over 200-fold higher signal than Rluc, and is comparable in 
signal intensity to Fluc when imaged in vivo68. A Gluc-variant that is expressed on 
the cell surface was recently designed and showed to be a sensitive reporter for 
tracking T-cells in vivo.77 Gluc is currently the reporter of choice for monitoring of 
different biological phenomena and in different fields including gene expression, 
tumor volume, cell viability in high throughput screening for drug discovery, protein-
protein interactions in BRET.78-84  
 
The luciferase from the Vargula hilgendorfi (Vluc), a marine ostracod, is one of the 
few other naturally secreted luciferases85. In the presence of Vargulin, Vluc emits a 
blue light (462nm). However, the in-availability of the Vluc substrate limited its use. 






Table 3: Different luciferases and their origin, substrate, wavelength and 
emission type.   
Luciferase Origin Substrate Wave length Flash/Glow 
Firefly (Fluc) Photinus pyralis Beetle D-luciferin 562nm Flash 
 American Firefly Mg2+, ATP   
Renilla (Rluc) Renilla reniformis Coelenterazine 480nm Flash 
     
Gaussia (Gluc) Gaussia princeps Coelenterazine 480nm Flash 
     
Vargula hilgendorfii Vargula  hilgendorfii Vargullin  467nm Glow 
(Vluc)     































































































































































































































































































































































































































































































































































































































































































































































































































Aside from light emission characteristics these luciferases have different kinetics of 
light output, sensitivity and enzymatic stability. Rluc and Gluc both display a flash-
type kinetic reaction, in which the emitted light decays to background level within 
minutes. Fluc on the other hand displays a glow type kinetic that decays over a 
longer period of time.68 Further, Fluc has a half-life of 4 hours in contrast to the half-
life of Gluc, which is around 5 days.68 These different characteristics make each 
reporter suitable for a different type of application. Whereas the glow kinetics of Fluc 
is favorable for high throughput screening in vitro, the absence of natural secretion 
makes the real-time monitoring from the same cells impossible. Gluc on the contrary 
is perfect as a secreted reporter, but its flash characteristics make it unsuitable for 
high throughput screening. 
 
For in vivo applications, we can point out a comparable dilemma: Fluc is more 
sensitive due to its emission towards the red side of the spectrum, however, unlike 
Gluc, its activity cannot be monitored in the blood and therefore is not suited for 
monitoring of few circulating cells. Since Fluc and Rluc/Gluc utilize different 
substrates, they can be used together for dual BLI to monitor two different processes 
simultaneously.  
 
2.3 Secreted blood reporters 
 
Traditional enzyme-based reporter systems using cytosolic markers have been 
successfully used in different fields; however, they generally require tissue lysis and 
are therefore not suited for frequent imaging.86 On the other hand, reporter proteins 
which are naturally secreted and can be detected in the cell-free conditioned medium 
in culture or in animal body fluids (blood/urine) were shown to be useful tools for 
non-invasive and real-time monitoring of different biological processes including 
tumor development, growth and response to different therapies, time-course embryo 
development, viral dissemination, gene transfer as well as the fate of genetically 
engineered cells in animal models. 68,87,88 The most commonly used blood reporters 
are the secreted alkaline phosphatase (SEAP), soluble marker peptides derived from 
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human carcinoembryonic antigen and human chorionic gonadotropin, as well as 
Gaussia luciferase. 86 
 
SEAP was the first described blood reporter; Berger et al. 89 used SEAP for 
quantification experiments in cell culture and created a fully active secreted protein 
by introducing a termination codon. Thereafter, this reporter was applied for ex vivo 
analysis of gene transfer in a mouse model. 90 SEAP can be constitutively expressed 
and efficiently released from transfected cells and is the most common reporter to 
monitor biological processes ex vivo. 86 Bettan et al 90 and Cullen and Malim 91 
observed that changes in SEAP levels in medium of Chinese hamster ovary cells are 
directly proportional to changes in intracellular SEAP mRNA and cell number and 
hereby they initiated the widely use of SEAP as a secreted serum reporter. 86,92 Its 
use has been extended to the clinic, where its serum levels have been used to 
monitor systemic and cervical antibodies after vaccination with HPV16/18 AS04-
adjuvant vaccine.92  
Due to its high molecular weight (64kDA) expression level in the blood is low, 
requiring relatively large samples to be measured. Further, most blood samples 
contain naturally occurring serum alkanine phosphatases, which can interfere with 
the SEAP assay.93 
 
Soluble marker peptides are of great use in cancer virotherapy studies since they 
can be introduced into a virus to monitor its spread and elimination in vivo. 
Furthermore, they can even measure the profile of viral gene expression as well as 
the kinetics over time.86,87 An optimal soluble marker peptide should lack biological 
activity, the half-life should be constant in the circulation, it should have a limited 
immunogenicity and a validated assay should be available.87  
Edmonston vaccine strain of measles virus (MV-Edm) has been effectively 
engineered to express different soluble marker peptides, including human 
carcinoembryonic antigen (hCEA) and the ȕ subunit of human chorionic 
gonadotropin (ȕhCG).94,95 Recently strains of this virus have been used to infect and 
destroy cancerous cells without affecting the surrounding tissues. This specificity can 
be explained by an over expression of CD46, a measles virus receptor, on the tumor 
cells. Simultaneously, these strains were modified to express certain soluble marker 
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peptides, such as CEA, and thereby the viral gene expression and replication could 
be monitored in vivo.87 

Recently, Gaussia luciferase has been characterized as a blood reporter. The major 
advantage of using Gluc as a secreted blood reporter is that its ex vivo blood 
analysis can complement in vivo bioluminescence imaging. Thereby Gluc assay has 
the ability to localize the signal in vivo while monitoring the tumor response ex vivo.75 
This multifaceted approach gives Gluc great advantage as a blood reporter. 
Furthermore, Gluc also has a much shorter assay time with increased sensitivity and 
linear range over other secreted blood reporters. 75,68,80 
Gluc has been used extensively as a blood reporter. The Gluc blood assay was for 
instance used to monitor the response to treatment and metastasis of human breast 
cancer in animal models. Besides the good correlation between the primary tumor 
volume and the Gluc level in the blood and urine, more importantly the Gluc assay 
revealed early detection of tumor growth and metastasis in these animal models 
which was not accomplished by typical in vivo imaging techniques.82 
In addition, Gluc can be used for the evaluation of transcriptional regulation 
associated with signaling pathways. These pathways can be dysregulated in many 
human disorders including cancer. 
 
2.4 BLI in cancer: strategic approaches  
 
BLI has shown to be a valuable tool in the understanding of tumor biology and the 
intricate processes associated with tumorigenesis. Its ability to report from the 
subcellular level, to track both proteins and cells, to visualize gene activation and to 
monitor responses to cancer therapies has allowed the development of many new 
research strategies. Its key roles in cancer are summarized below.  
 
Imaging of apoptosis. Apoptosis, or programmed cell death is executed through 
activation of cysteine aspartyl proteases (caspases) and is very often disrupted in 
cancer. This process has recently been monitored by fusing an inactive luciferase 
reporter gene to a caspase cleavage site. An example of such a reporter is the 
caspase 3 – Gluc reporter. Gluc is fused to the estrogen receptor (ER) regulating 
domain and is thereby rendered inactive. Since the two genes are separated by a 
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caspase cleavage site (DEVD), Gluc will be released in the presence of caspase 3, 
resulting in light emission when apoptosis occurs.96-98 
 
Imaging of tumor therapy. BLI allows for the quantitative measurement of tumor 
growth and response to therapy. The amount of luciferase expression correlates 
directly to the amount of tumor cells.99 First, luciferase reporter genes are ex vivo 
introduced in GBM cells for stable expression. Upon transplantation, tumor signal 
can be measured by cooled CCD camera or in the blood using the luciferin 
substrate; making it possible to track growth, metastasis and response to therapy in 
animal models of GBM.100,101 
 
Drug discovery. The screening of drug libraries is a very time consuming process. 
BLI allows for sensitive and relatively quick readout of photon emission. This way 
screening of thousands of compounds can be done in an effective way, using a cell-
based assay. Luciferases are used as cell viability markers and by interpreting their 
light output, molecules with specific toxicity towards cancer cells can be identified.102 
Gluc is especially useful in this setting, since it is secreted. Sampling aliquots of 
conditioned medium over time allows noninvasive evaluation of cell fate in real 
time.103 Luciferases can also be used for the screening of gene-targeted drugs. 
Reporter genes containing a DNA binding sequence of the gene of interest (GOI) 
driving the expression of a luciferase can be introduced. P53, the most studied tumor 
suppressor gene, is an important target for drugs. By using a p53 reporter vector, 
small molecules that affect the transcriptional activation can be identified.  
 
Imaging of (Cancer) Stem Cells. Cancer Stem Cells are thought to play a major role 
in the initiation and progression of GBM. Understanding and tracking of these cells 
could provide new insights in tumor biology. Further, a variety of ‘regular’ stem cells 
(mesenchymal, neural, embryonic, hematogenic) can be used as drug delivery 
vehicles, since they are known to “home” to the tumor site upon iv 
administration.104,105 This way, delivery issues related to the use of viral vectors (low 
transduction percentage, targeting) can be circumvented. An RFP-luciferase-
thymidine kinase reporter protein has been used to label mesenchymal stem cells 
and track them in mice using BLI and PET.106  Other stem cell tracking assays based 
on Gluc have been validated in animal models for several stem cell lines.  
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Imaging of hypoxia and angiogenesis. Hypoxia and angiogenesis are very closely 
related; they are two of the hallmarks of GBM. Upon hypoxic circumstances, different 
growth factors, transcription factors and cytokines are induced (as described in the 
GBM section). The main transcription factor found in a hypoxic state is the hypoxia-
inducing factor (HIF1). HIF1 binds to HRE (HIF responsive element) to maintain 
transcription factor activation. Reporter luciferases coupled to the HRE element are 
designed to allow the visualization of hypoxic areas in the tumor and to help 
developing HIF targeted therapies.107,108 A similar system exists to measure 
angiogenesis. These luciferase reporters are coupled to VEGFR2, allowing 
visualization of areas high in angiogenic activity upon activation of the receptor.109  
 
BLI and gene therapy. Gene therapy is a promising approach in the battle against 
cancer and many other diseases. BLI reporter luciferases allow the evaluation of 
viral tropism, transduction efficiency and replication110,111, providing the tools to 
further optimize this method. Since the efficacy of gene therapy mediated 
approaches is dependent on proper transduction, it is important to validate whether 
or not enough expression has been established. Otherwise, a lack of effect will be 
blamed on the chosen strategy, and a potential successful approach is rendered 
ineffective for the wrong reasons.   
 
2.5 BLI and cancer: hot topics and limitations  
 
The ability of BLI to give insight in both interactions between cells and their 
environment and intracellular processes makes BLI a very important tool in cancer 
research. Furthermore, it can facilitate the identification of cancer treatment by 
validating novel drugs in animal models, bridging the gap between the laboratory and 
the clinic. However, some limitations need to be overcome to further increase the 
value of BLI in (cancer) research. As for this moment, the use of BLI is limited to 
animal models, due to its relatively weak light emission (due to signal quenching and 
scattering through tissue) and potential substrate-associated toxicity). 
 
Light emission and signal quenching. Both Gluc and Rluc emit light in the blue range 
of the spectrum. This causes that part of their light is absorbed by pigmented 
molecules as hemoglobin and melanin and is scattered through tissue, limiting its in 
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vivo sensitivity. Still, sufficient signal can escape these barriers and is detected by a 
cooled CCD camera or in the blood. Current research is focusing on the engineering 
of luciferase variants emitting light in the red region of the spectrum or with an even 
brighter intensity.  
 
Signal Stability. Gluc emits light in a flash type bioluminescence reaction, resulting in 
a peak signal as soon as substrate is added, followed by rapid light decay. This is 
favorable for readings with a CCD camera, since accumulation of signal over time is 
limited, allowing for several reads in a relatively short amount of time. Since Gluc is 
secreted, it is also very suitable as a cell viability marker in drug screens. Aliquots of 
the conditioned medium can be assayed over time, allowing functional analysis of 
drug kinetics. However, due to the rapid light decay, the use of a luminometer with a 
built-in injector is essential for immediate reading of signal once substrate is added, 
one well at a time. Too much time delay will be accompanied by a drop in Gluc 
signal, not caused by efficacy of the drug, but by kinetic instability, potentially 
confounding results. Therefore, a Gluc variant with a more stable light output would 
be highly desirable for use in drug screens. A more stable type of Gluc has recently 
been discovered; however, this luciferase only exhibits its increased stability in the 
presence of the detergent Triton-X100. Interactions between the detergent and the to 
be tested drugs cannot be excluded, limiting the value of the assay.  
 
Measuring interaction. One limitation to current bioluminescence imaging is that 
typically only one luciferase reporter is used to measure one parameter of tumor 
development. As a highly malignant form of brain tumor, GBM progression is a 
complex process involving communication between tumor cells, surrounding 
“normal” cells, and the vasculature.112 Simultaneous measurement of multiple factors 
of tumor growth as well as the tumor’s response to therapeutic agents would be 
extremely helpful in getting insight in the complex interactions of cancer growth. 
Since Fluc and Gluc/Rluc use different substrates, recently a combination of these 
luciferases has been used for dual reporting allowing the simultaneous monitoring of 
two events.113  
 
TRAIL. TRAIL (tumor necrosis factor related apoptosis inducing ligand) is a member 
of the TNF family and is one of the most commonly explored cancer therapeutics, 
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because it binds to death receptors found specifically on tumor cells. Therefore, 
TRAIL is able to cause a widespread apoptotic effect with minimal cytotoxic effects 
on normal tissues.114,115 In preclinical studies, impressive growth inhibition and 
cytotoxicity against malignant tumor cells of various origin was observed, including 
lung, breast, colon, bladder, brain and T cell malignancies.116 However, there also 
appears to be a group of tumors, including GBM, that is resistant to TRAIL-mediated 
apoptosis. Upregulation of the Bcl2 associated Athanoge (BAG3) genes and multiple 
other genes have been described, causing resistance at various points along the 
apoptotic pathway. The second issue in the use of TRAIL for glioma therapy is its 
inability to cross the blood brain barrier. In a recent Gluc-based drug screen of the 
Tannous lab, molecules were identified that sensitized GBM cells for TRAIL. This 
resulted in the selection of Lanatoside C, an FDA approved cardiac glycoside that is 
capable of crossing the blood-brain barrier.103 Lanatoside C on its own was found to 
induce a non-apoptotic necroptosis-like cell death. The combination of the dual cell 
death mechanisms displayed by TRAIL (apoptotic) and Lanatoside C (necroptotic) 
appeared to be very successful and provides a basis for the development of new 
glioma therapy.103 
 
2.6 In vitro Glioma Research and Mycoplasma 
 
Mycoplasma species are the smallest organisms known and thereby not seen by 
microscope.  Mycoplasma are resistant to commonly used antibiotics and therefore 
are frequent contaminants in regular cell culture with an incidence up to 70%.4,117,118 
These contaminants have been shown to affect different pathways in cell culture 
yielding to false interpretation of data. Whether in vitro or in vivo, all molecular 
techniques described above can be severely affected by mycoplasma contamination 
with almost all cellular processes.117,119,120 Logically, these facts underlie the 
importance of detecting and clearing Mycoplasma contamination in all experimental 
research laboratories.  
 
While many different species of mycoplasma have been isolated, only few are 
responsible for 90-95% of mammalian cell contaminations, namely: M. orale, M. 
hyorhinis, M. arginini, M. fermentans, M. hominis or A. laidlawii. The most common 
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form of Mycoplasma is the M. orale, found in the oral cavity of healthy humans and 
accounts for 20-40% of all mycoplasma infections in cell cultures (Table 5).4 With the 
knowledge of this widespread contamination and its disastrous effects, one can 
understand that a detection method which is simple, sensitive, specific and 
inexpensive is needed.  
Currently a wide range of detection methods are being used, of which the classical 
culture assay with the polymerase chain reaction (PCR) is known to be the most 
reliable nonetheless complex and time-consuming approach. PCR is based on the 
amplification of mycoplasma DNA, it has the advantage to distinguish different 
species of Mycoplasma and it provides a sensitive and specific method to quickly 
identify contamination and monitor growing cell cultures. Nevertheless PCR requires 
careful preparation of the sample, attention to polymerase inhibitors in the cell 
cultures and often has false positive contaminants.121 Traditional bacterial culture 
has the advantage of actually observing the colonies in combination with a high 
sensitivity and inexpensiveness. However this assay disqualifies itself by being even 
more time consuming; expertise is required and simply not all common Mycoplasma 
species can be cultured.4 In addition to culture and PCR, other assays have been 
described, such as fluorescent DNA staining, enzyme-linked immunosorbent assays 
and RNA amplification, with each having significant drawbacks. Fluorescence DNA 
staining lacks the ability to reveal all the common species, enzyme-linked 
immunosorbent assays have a low sensitivity and RNA amplification requires a 
rather complex protocol.4,117,121 Currently a simple bioluminescence-based 
mycoplasma detection kit is commercially available, but it has low sensitivity and its 





Table 5: Most common mycoplasma contaminations.  4 
Species Frequency Natural host 
M. orale 20 – 40% Human 
M. hyorhinis 10 – 40% Swine 
M. arginini 20 – 30% Bovine 
M. fermentans 10 – 20% Human 
M. hominis 10 – 20% Human 
A. laidlawii   5 – 20% Bovine 
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3. AIMS AND OUTLINE  
 
The aim of this thesis is to combine the strengths of gene-therapy and BLI for the 
development of novel reporter systems in order to study glioma tumor biology and its 
response to therapeutic compounds. We further tried to optimize the currently 
available BLI luciferases (Gaussia luciferase, Vargula hilgendorfi) and assays (Gluc 
blood assay, Mycoplasma detection assay). We explored a new multimodal targeted 
liposome formulation with increased relaxivity for the treatment and imaging of 
cancer. Finally we combined the newly developed and enhanced reporters to test a 
new therapeutic combination for the treatment of Glioma (TRAIL, Lanatoside C). 
The research as described above is divided into ten chapters (chapter III to XII). 
Sarah Bovenberg takes responsibility for chapter III, IV, V, and XI, and Hannah 
Degeling takes responsibility for chapter VI until X and chapter XII.  

Secreted blood reporters are valuable tools for sensitive and fast detection, 
quantification and noninvasive monitoring of in vivo biological processes.75,80 The 
level of these secreted reporters can be measured over time to generate multiple 
data sets without the need to sacrifice the animal, since only a small amount of blood 
is required.  In Chapter III we enhanced the sensitivity of Gluc as a blood-reporter by 
designing an alternative Gluc blood assay. The enormous advantage of capturing 
Gluc in a blood-based assay instead of by CCD camera is the ability to follow 
intracellular processes in real time. Whereas CCD camera obtained pictures show 
luciferase signal  (and thereby reporter gene activation) at a static point in time, the 
blood assay allows for a dynamic approach, in which a drop of blood can be 
collected every 5 minutes. The CCD camera does not share this characteristic, since 
the procedure is time consuming and the BLI reaction takes place inside the animal. 
Therefore, one has to wait until the previous BLI signal has died out, before a new 
(reliable) measurement can be made.  In the new assay, Gluc is captured from the 
blood by an antibody-mediated reaction before bioluminescence reaction takes 
place. This procedure prevents signal quenching by pigmented molecules like 
hemoglobin, resulting in an over one order in magnitude increase in sensitivity, 




In Chapter V the development of a triple reporter system based on Vargula, Gaussia 
and Firefly luciferases for sequential imaging of three different biological processes 
is described. We applied this system to monitor the effect of the apoptosis-inducing 
ligand sTRAIL (soluble Tumor necrosis factor-Related Apoptosis-Inducing Ligand) on 
GBM tumor cells using an adeno-associated viral AAV vector.  As explained earlier, 
TRAIL is only toxic to cancer cells, since only these cells overexpress TRAIL death 
receptors. Unfortunately, GBM cells seem to be resistant to TRAIL-mediated 
apoptosis. To overcome this limitation, in a drug screen a molecule sensitizing GBM 
cells for TRAIL, called Lanatoside C, was identified. Lanatoside C is a known, FDA 
approved, cardiac glycoside. We designed a triple luciferase reporter system, to 
measure the activation patterns and outcome of combined treatment of TRAIL and 
Lanatoside C in GBM. Since TRAIL cannot cross the blood brain barrier, we 
circumvented this problem by delivering sTRAIL directly to brain tumor environment 
by AAV-mediated gene delivery. By engineering the normal brain to synthesize and 
secrete sTRAIL, it can form a zone of resistance against newly developed glioma, 
which can be treated with lanatoside C therapy. We used Vluc to monitor AAV gene 
delivery of sTRAIL, Gluc to monitor the binding of sTRAIL to the glioma death 
receptor and the consequential activation of downstream events, and Fluc to 
measure tumor response to combined sTRAIL and Lanatoside C treatment. This 
work is the first demonstration of triple in vivo bioluminescence imaging and will have 
broad applicability in different fields. 
 
In Chapter IV we describe the development of a first of its kind multiplex blood 
reporter that allows the ex vivo evaluation of in vivo processes. Since tumorigenesis 
is an intricate and dynamic process and GBM cells in particular are known for their 
ability to escape cell death and change characteristics, we developed the first 
multiplex blood reporter based on secreted alkaline phosphatase (SEAP), Gaussia 
and Vargula luciferases. This multiplex system differs from the triple imaging system 
as described in Chapter V in that here all reporters are secreted. As a result, tumor 
changes can be followed in real time (by simply taking an aliquot of blood), whereas 
the reporter from chapter V does not allow for real time imaging. Since Vargulla has 
not been previously used as a blood reporter, first we characterized it as a secreted 
blood reporter. As a proof of concept the response of three different subsets of 
glioma cells to the chemotherapeutic agent Temozolomide (TMZ) in the same animal 
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was monitored. No signal bleeding or substrate cross reaction was observed, 
proving that these 3 reporters can be used simultaneously in the same animal. This 
new multiplex reporter system can be extended and applied to many different fields 
for simultaneous monitoring of multiple biological parameters in real time.  
 
One of the current limitations of BLI for in vivo imaging applications is the emission of 
light in the blue range of the spectrum. As discussed above, pigmented molecules 
like melanin and hemoglobin absorb the emitted light, while tissue further scatters 
the signal. Therefore, little signal remains to be picked up by CCD camera, 
decreasing the sensitivity of BLI for in vivo applications. Red light on the other hand, 
does not get absorbed, and would therefore be an ideal characteristic for a sensitive 
in vivo BLI reporter. Another issue is the flash type bioluminescence of Gluc when 
used in high throughput drug screens, limiting the numbers of drugs that can be 
screened.103 A Gluc variant that catalyzes a glow-type reaction would be extremely 
helpful in the field of drug discovery allowing for high-throughput approach without 
the risk of confounding results due to kinetic instability (wildtype Gluc) or to 
interactions with detergents such as TritonX-100 (GucM43I). Therefore, in Chapter 
VI we used directed molecular evolution to optimize Gaussia luciferase for high 
throughput applications and in vivo work. We screened for variants with a higher light 
intensity, glow-type luminescence and shift in emission spectrum, resulting in the 
identification of several variants with 10-15nm shifts in emission spectrum and one 
variant with a glow-type of bioluminescence that remained stable for over 10 
minutes.  
 
The exploration for new luciferases hasn’t come to an end yet. So far liFluc has only 
been used for cell-based assays and has only been expressed in bacteria. 
Therefore, in Chapter VII we developed and characterized a codon-optimized 
variant of liFluc for mammalian gene expression and used it for in vivo imaging of 
tumors. 
 
Since glioma research relies heavily on tissue culture, and since almost every single 
intracellular biological processes can be influenced by Mycoplasma contamination –
severely confounding results- the use for Gluc as a Mycoplasma detection sensor 
was explored in Chapter VIII. We developed a simple and cost-effective 
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mycoplasma detection assay using the Gaussia luciferase reporter and showed it to 
be much more sensitive than other bioluminescence-based assays.  
In Chapter IX we describe the step-by-step protocol for Gluc Mycoplasma assay as 
created in Chapter VIII. Further, we point out critical steps and potential pitfalls 
regarding the assay for other users.   
  
In Chapter X, we developed a new type of liposome as a contrast agent for MRI with 
a higher efficiency than the conventional liposome. We showed that this new 
liposome can be used for MRI guided therapeutic delivery to targeted cells due to its 
biotin inclusion and for ultrasound guided release of its contents due to its thermo-
sensitivity. 
 
In Chapter XI and XII we provide an overview of the Glioma research field, placing 
the work developed in this thesis in a broader setting. We review current research 
strategies, both in experimental setting and in the clinic, discuss the translational gap 
that exists between those two worlds and reflected on possible future directions. 
 
In Chapter XIII we both discuss our own work and suggest what following steps 
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Secreted Gaussia Luciferase (Gluc) has been shown to be a useful tool for ex vivo 
monitoring of in vivo biological processes. The Gluc level in the blood was used to 
detect tumor growth, metastasis and response to therapy, gene transfer, circulating 
cells viability, as well as transcription factors activation, complementing in vivo 
bioluminescence imaging. The sensitivity of the Gluc blood assay is limited due to 
the absorption of blue light by pigmented molecules such as hemoglobin resulting in 
quenching of the signal and therefore lower sensitivity. To overcome this problem, 
we designed an alternative microtiter well-based binding assay in which Gluc is 
captured first from blood using a specific antibody followed by the addition of 
coelenterazine and signal acquisition using a luminometer. This assay showed to be 
over one order of magnitude more sensitive in detecting Gluc in the blood as 






Secreted blood reporters are valuable tools for sensitive and fast detection, 
quantification and non-invasive monitoring of in vivo biological processes1-5. The 
level of these secreted reporters can be measured over time to generate multiple 
data sets without the need to sacrifice the animal, since only a small amount of blood 
is required. Gaussia Luciferase (Gluc) has been recently shown to be a promising 
blood reporter for ex vivo monitoring of in vivo biological processes4-6. This small 
luciferase (19.9 kDa) emits a blue flash light (480 nm) upon catalyzing the oxidation 
of its substrate coelenterazine7. Gluc cDNA possesses a signal sequence and 
therefore is naturally secreted in an active form upon expression in mammalian 
cells7. Further, the level of secreted Gluc in blood is linear with respect to cell 
number, growth and proliferation, and therefore can be used as a marker for 
monitoring of biological processes including tumor growth, metastasis and response 
to therapy6,8,9, gene transfer6,9-11, viral infection12, circulating cells viability6, as well 
as transcription factors activation13,14, complementing in vivo bioluminescence 
imaging. Compared to other widely used secreted blood reporters such as the 
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secreted alkaline phosphatase or SEAP, Gluc has several advantages including a 
much shorter assay time, an increased sensitivity and linear range as well as shorter 
half life in circulation allowing multiple measurements within a short period of time 
without accumulation of signal4,5.  
 
One of the major disadvantages of using Gluc as a blood reporter is the absorption 
of its blue light by pigmented molecules such as hemoglobin resulting in quenching 
of the signal and therefore lower sensitivity. To overcome this problem, we designed 
an alternative microtiter well-based assay in which Gluc is captured first from blood 
using a specific antibody followed by the addition of coelenterazine and signal 
acquisition using a luminometer. This optimized microtiter well-based assay showed 
to be over one order of magnitude more sensitive than the typical direct Gluc blood 
assay. This optimized assay is useful for the detection of subtle luciferase levels in 











Figure 1. Gluc is captured from the blood in an antibody-mediated reaction, before 





Animal studies and blood collection. All animal studies were approved by the 
Massachusetts General Hospital Review Board. U87 human glioma cells (ATCC) 
were transduced by a lentivirus vector to stably express Gluc as we previously 
described6. To generate tumors, 1 million of these cells (in 50 l) were mixed with 
equal volume of Matrigel and injected subcutaneously in the flanks of athymic nude 
coat plates with 
anti-Gluc antibody
add diluted blood 










mice. Blood samples were collected from these mice as well as mice with no tumors 
by making a small incision in the tail and directly adding it to an eppendorf tube 
containing EDTA as an anti-coagulant (10 mM final concentration).  
 
Microtiter well-based Gluc assay. High binding microtiter 96 well plates (Thermo 
Fisher Scientific, Rochester, NY) were coated overnight with different amounts of 
polyclonal rabbit anti-Gluc antibody (Nanolight, Pinetop, AZ) or monoclonal mouse 
anti-Gluc (generated through the Massachusetts General Hospital antibody 
production facility15) diluted in 100 mM carbonate buffer pH 9.6 [or phosphate-buffer 
saline (PBS) or 50 mM Tris-HCl, pH 7.8 in the presence of 0.5 g/l NaN3 for 
optimization studies] in a total volume of 50 l (unless otherwise stated). Eighteen to 
twenty four hours later, the plates were washed 2x with 200 mM Tris-HCl pH 7.8 (or 
PBS or 100 mM carbonate pH 9.6 for optimization studies). Blood samples were 
then mixed in 200 mM Tris pH 7.8 to a final volume of 50 l, centrifuged at 200x g, 
and the supernatants were added to the coated wells, incubated for one hour (unless 
otherwise stated) at room temperature with shaking. The plates were then washed 
once with 200 mM Tris-HCl, pH 7.8 (PBS or 100 mM carbonate buffer, pH 9.6) and 
analyzed by injecting 50 l 50 g/ml (unless otherwise stated) coelenterazine diluted 
in PBS (or 200 mM Tris-HCl pH 7.8 in the presence or absence of 5 mM NaCl) and 
acquiring photon counts for 10 sec using a microplate luminometer (Dynex, Chantilly, 
Va).  
 
Direct Gluc blood assay. Five l (unless otherwise stated) of Gluc-containing blood 
or Gluc negative blood were added directly to a 96-well white microtiter plate and the 
Gluc activity was detected by injecting 50 l 50 g/ml (unless otherwise stated) 
coelenterazine and  acquiring photon counts for 10 sec using a microplate 
luminometer as described4. 
 
Statistical Analysis. All experiments were repeated at least 3 times to achieve 
statistical significance. Data are presented as the mean relative light units (RLU) ± 
standard deviation (SD) from 5 different replicates in each experiment. P values 
were calculated using Student's t-test. Reproducibility was assessed by calculating 




RESULTS AND DISCUSSION 
 
We performed several optimization steps for the microtiter well-based Gluc binding 
assay. Two Gluc specific antibodies are available, a polyclonal rabbit anti-Gluc 
antibody and a monoclonal mouse anti-Gluc antibody.  We first compared these two 
antibodies by coating the microtiter plates with 50 l (diluted 1:100 in 50 mM Tris-HCl 
pH 7.8) with either of these antibodies. Twenty-four hours later, plates were washed 
with Tris-HCl buffer and 5 l blood (Gluc positive and negative) were mixed with 45 
l Tris-HCl, centrifuged for 5 min at 200x g and the supernatant was added to each 
well (in triplicates) and incubated for 1 hour at room temperature with shaking. Wells 
were then washed with Tris-HCl buffer and analyzed with 50 l 50 g/ml (diluted in 
PBS) coelenterazine using a luminometer. The polyclonal antibody showed to have 
higher binding capacity of Gluc from the blood and therefore was used for all 
subsequent studies (Fig. 1A).   
 We next checked the optimum amount of polyclonal antibody for coating the 
microtiter plates.  Polyclonal Gluc antibody was serially diluted in 50 mM Tris-HCl, 
pH 7.8 and added to all wells.  Twenty-four hours later, the Gluc assay was 
performed as above. A 1:500 dilution of the antibody yielded the highest Gluc 
binding (Fig. 1B) without any effect on the noise defined as the signal obtained from 
the Gluc negative blood samples (data not shown).  Several buffers were then tested 
for coating the microtiter wells with the Gluc polyclonal antibody including PBS, 50 
mM Tris-HCl pH 7.8 and 100 mM carbonate pH 9.6. The carbonate buffer showed 
the highest signal and the lowest background yielding around 2-fold higher signal-to-
noise ratio (calculated by dividing the signals obtained from Gluc-positive blood to 
Gluc-negative blood) as compared to all other buffers tested (Fig. 1C). Therefore, the 
polyclonal antibody diluted 1:500 in carbonate buffer was used for all subsequent 
studies.  
 We also optimized the assay time for binding Gluc on antibody-coated plates. 
The optimum coating protocol above was used to capture 5 l Gluc-containing blood 
in Tris-HCl buffer for different time points ranging from 5 min to 24 hours.  One hour 
incubation time gave high binding of Gluc, which even increased further by 2-fold 
over 24 hours (Fig. 1D). For simplicity purposes, one hour binding time can be used. 
We also compared the assay volume, in which all assay steps including coating, 
binding and detection were performed, in 50 or 100 l. No statistical significance 
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differences were observed between the two volumes tested and therefore the lowest 





Figure 1. Optimization of the Gluc blood-binding assay. (A) Polyclonal or monoclonal 
anti-Gluc antibody diluted 1:100 in 50 mM Tris-HCl, pH 7.8 were used to coat the microtiter 
plates. Twenty-four hours later, plates were washed and 5 l blood containing Gluc or 
negative blood (mixed with 45 l 200 mM Tris pH 7.8) were added to each well in triplicates, 
incubated for 1 hour, and analyzed after the addition of 50 l 50 g/ml coelenterazine using 
a luminometer. (B-C) Different dilutions of the polyclonal anti-Gluc antibody diluted in 50 mM 
Tris-HCl buffer (B) or the same antibody diluted 1:500 in different buffers (C) were used to 
detect 5 l of blood-containing Gluc as in (A). (D) 5 l blood (mixed with 45 l Tris-HCl 
buffer) were added to the microtiter wells pre-coated with anti-Gluc antibody and incubated 
at different time points. Plates were then washed and analyzed as in (A). (E) Different 
volume of the polyclonal anti-Gluc antibody (diluted 1:500 in carbonate buffer) was used to 
coat the microtiter wells and was used to detect 5 l of blood as in (A). Data presented as 
average ± SD from 3 independent experiments with 5 replicates per experiment. *p<0.001. 
 
After optimizing the assay conditions, we focused on improving the bioluminescent-
detection step. Different volumes and concentrations of coelenterazine, the Gluc 
substrate, were tested using the optimized protocol above. A concentration of 50 
g/ml in a total volume of 50 l was found to give the best signal-to-noise ratio (Fig. 
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2A and B). We then compared different buffers to dilute the coelenterazine for the 
detection of Gluc. We used PBS or 50 mM Tris-HCl in the presence or absence of 
NaCl, since this salt is known to enhance the Gluc reaction. We found that PBS 
resulted in the highest signal-to-noise ratio and therefore was chosen for final 
analysis (Fig. 2C).  
 Previously, we showed that 5 l of blood gives the highest Gluc signal which 
is substantially decreased when using higher volumes due to quenching of the 
bioluminescence signal by hemoglobin and other molecules8. Further, detecting Gluc 
in serum did not show an increased sensitivity due to auto-oxidation of 
coelenterazine yielding higher noise6,8. We confirmed these data using the direct 
Gluc blood assay and compared them to our optimized microtiter plate-based Gluc 
blood assay.  Different volumes of Gluc-containing blood (or Gluc negative blood) 
were analyzed with both assays. As expected, using the direct assay, a linear 
decrease of Gluc signal with increasing amount of blood was observed showing 
quenching of light by hemoglobin. On the other hand, a linear increase in signal 
reaching a plateau at around 40 l was observed with the microtiter plate-based 
binding assay showing that this assay can be used to detect higher blood volume 
(Fig. 2D). The background noise for the binding assay did not change with increasing 
blood volume (average 0.186 RLU). On the other hand, the direct assay showed a 
decrease in background RLUs ranging from 0.136 RLU for 5 l blood to 0.08 RLU for 
80 l blood. More importantly, higher signal-to-noise ratio was obtained with all 
different blood volumes tested yielding around 20-fold higher ratio when assaying 40 
l blood using the microtiter plate binding assay as compared to the typical 5 l 
direct detection of Gluc (Fig. 2D).  
Finally, using the optimized protocol above, we compared the sensitivity of the 
microtiter plate-based binding assay to the typical direct assay for detecting Gluc in 
the blood. Blood was collected from nude mice bearing tumors expressing Gluc, 
serially diluted with Gluc-negative blood and analyzed with both assays. The 
microtiter well-based binding assay showed to be over 16-fold more sensitive in 
detecting Gluc in the blood as compared to the direct standard approach showing 
that our optimized protocol could be used for detection of subtle luciferase levels in 
vivo facilitating non-invasive monitoring of various biological processes (Fig. 2E).  To 
assess reproducibility, we analyzed 3 different dilutions (1:1, 1:10, 1:100) of Gluc-
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containing blood (n=9) using both the binding and direct assays.  We found that the 




Figure 2. Microtiter plate-based binding assay for the detection of Gluc in blood. 
Microtiter wells were coated with 50 l of the polyclonal rabbit anti-Gluc antibody diluted 
1:500 in carbonate buffer. (A-C) Five l blood-containing Gluc or negative blood (mixed with 
45 l 200 mM Tris pH 7.8) were added to each well in triplicates, incubated for 1 hour and 
analyzed with different volumes of 50 g/ml (a) or amounts (b) of coelenterazine diluted in 
PBS or in 50 mM Tris-HCl pH 7.8 in the presence or absence of 5 mM NaCl  (c). (D) 
Different amounts of blood-containing Gluc or negative blood (background noise) were 
mixed with 200 mM Tris pH 7.8 and added to each well in triplicates. One hour later, plates 
were washed and analyzed with 50 l 50 g/ml coelenterazine (diluted in PBS) using a 
luminometer. The same samples were also analyzed using the standard direct Gluc blood 
assay. The signal (RLUs from Gluc-positive cells) over noise (RLUs from Gluc-negative 
cells) ratio with respect to blood volume is showing. (E) Blood-containing Gluc was serially 
diluted with Gluc-free blood and analyzed by both the microtiter plate-based binding assay 
as well as the direct assay. Data presented as average ± SD from 3 independent 






In conclusion, we developed a microtiter plate-based binding assay and showed it 
to be more sensitive in detecting Gluc in the blood as compared to the typical direct 
measurement. This assay is suited for the detection of Gluc in any sample including 
conditioned medium from mammalian cell cultures as well as urine from small 
animals. The optimized assay is very useful for ex vivo monitoring of in vivo 
biological processes where high sensitivity is required such as detecting few 
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Secreted blood reporters are valuable tools for sensitive and fast detection, 
quantification and non-invasive ex vivo monitoring of in vivo biological processes.1 
Currently, the three most commonly used secreted blood reporters are the secreted 
alkanine phosphatase (SEAP)2-5, soluble peptides derived from human 
carcioembryonic antigen (hCEA) and human chorionic gonadotropin (ȕHCG)6-9 and 
Gaussia luciferase (Gluc)10-14. The level of these secreted reporters can be 
measured over time in blood, serum and/or urine to generate multiple data sets 
without the need to sacrifice the animal, since only a small amount of fluid is 
required. In contrast to other tools for monitoring of cellular processes, secreted 
blood reporters are suitable to follow biological parameters along the way, providing 
new insights in the factors contributing to disease development and progression1. 
During the last 20 years, secreted blood reporters have proven their value in a wide 
variety of medical fields, including embryo development, viral dissemination, fate of 
(stem) cells, gene transfer and tumorigenesis and response to therapy.14-16 The 
contribution of secreted blood reporters to understanding of these complicated 
processes would increase even further, if instead of one, multiple parameters could 
be measured simultaneously and over time.  
 
The discovery of new secreted reporters with different substrate specificities, 
emission spectra and/or detection assays will allow the development of multiplex 
assays that are capable in monitoring several processes, given that their separate 
reactions remain distinguishable. Here, we characterized the naturally secreted 
luciferase from the marine ostracod Vargula (Cypridina) hilgendorfi (Vluc)17,18 as a 
blood reporter and multiplexed it with Gluc and SEAP to develop a triple blood 
reporter system to monitor three distinct biological processes. As a proof of concept, 
we successfully monitored the response of three different subsets of glioma cells to 
the chemotherapeutic agent temozolomide19 in the same animal. This multiplex 
system can be extended and applied to many different fields for simultaneous 








We first characterized a codon-optimized Vluc variant for mammalian gene 
expression as a blood reporter. Different amounts of U87 human glioma cells stably 
expressing Vluc and the mcherry red fluorescent protein (RFP) were implanted 
subcutaneously in nude mice. Three days post-implantation, 5 l blood samples (in 
triplicates) were withdrawn, mixed with EDTA (as an anti-coagulant), and assayed 
for Vluc activity using a luminometer after addition of the vargulin substrate. Several 
optimization steps for the detection of Vluc in the blood were first performed using 
different concentrations of the vargulin substrate in blood and serum. We found that 
100 l of 0.25 g/ml vargulin (diluted in PBS) gave the best signal-to-background 
(S/B) ratio (supplementary Fig. 1a). Since hemoglobin in whole blood is known to 
interfere with bioluminescence, we compared the activity of Vluc in blood versus 
serum and observed that serum gave higher S/B ratio at a concentration of 0.2 g/ml 
(supplementary Fig. 1a).  EDTA did not have any effect on the Vluc activity 
(Supplementary Fig. 1b). Using these optimized conditions, we observed that Vluc 
activity in blood is linear with respect to cell number in a range covering at least 3 
orders of magnitudes (Fig. 1a). We then checked the possibility of detecting Vluc in 
urine, similar to Gluc14,13.  We found that Vluc activity in urine was also linear with 
respect to cell number, albeit less sensitive, showing that Vluc is cleared by the 
kidneys (Fig. 1a). We next evaluated the half-life of Vluc in circulation by 
intravenously injecting Vluc-containing conditioned medium of cells in nude mice and 
assaying blood for Vluc activity at different time points. We found that the Vluc half-
life in circulation to be around 3 hours (Fig. 1b).  
 
Since it is of uttermost importance that the chemical reaction of the individual 
reporters used for multiplex application can be distinguished, we determined the 
specificity of each reporter to its substrate in the blood. U87 glioma cells stably 
expressing Gluc, Vluc or SEAP (all under the control of CMV promoter) were 
implanted subcutaneously in different nude mice.  Three days later, 5 l blood was 
assayed for each reporter activity using coelenterazine, vargulin or SEAP substrate. 
Significant signal from blood was obtained only when the proper reporter/substrate 
combination was used, showing no substrate overlap or cross reaction among the 
86 
 
different reporters, and indicating that Gluc, Vluc and SEAP can be used together for 
multiplex applications (Fig. 1c).  
 
 
Figure 1. Triple secreted reporter system. (a) Linearity of Vluc blood reporter with respect to 
cell number. Different U87 glioma cells expressing Vluc were implanted subcutaneously in 
nude mice (n=4/group). One week later, 5 l blood or urine (in triplicates) was assayed for 
Vluc activity using 100 l of the vargulin susbtrate. (b) half-life of Vluc in circulation. 
Conditioned medium from U87 cells expressing Vluc were filtered, and 150 l was i.v. 
injected in nude mice (n=4). At different time points, 5 l blood (in triplicates) was assayed 
for Vluc activity. Specificity of each reporter for its substrate. Mice were injected 
subcutaneously with U87 cells expressing either Gluc, Vluc or SEAP (n=4/group).  One 
week later, 5 l blood or serum (in triplicates) were assayed for Gluc, Vluc, and SEAP 
activity. A significant signal is obtained in blood/serum only with the proper reporter/substrate 
combination. 
 
Finally, we applied the triple reporter system for non-invasive monitoring of three 
different subsets of U87 glioma cells in response to temozolomide (TMZ), the 
chemotherapeutic agent of choice for the treatment of grade IV glioma19. We used 
U87 parent cells as well as two TMZ-resistant subclones of these cells, U87R1 and 
U87R2. U87 parent cells (sensitive to TMZ) were engineered by a lentivirus vector to 
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express Gluc (U87-Gluc), while U87R1 were engineered to express Vluc (U87R1-
Vluc) and U87R2 to express both SEAP and Fluc (U87R2-SEAP/Fluc). Fluc here is 
used for in vivo localization of U87R2 cells with bioluminescence imaging (since 
SEAP cannot be imaged in vivo) while Gluc and Vluc are used to localize U87 and 
U87R1 cells respectively.  First, the triple secreted reporter system was confirmed in 
culture by plating 5,000 of either U87-Gluc, U87R1-Vluc, U87-R2-SEAP/Fluc 
(singleplex) or combination of all three cells (2,000 cells of each line; multiplex) in a 
96-well plate.  Aliquots of the conditioned medium were then assayed for each 
luciferase activity every day over 4 days. Using the singleplex assay, we observed 
that U87-Gluc cells responded very well to TMZ (>50% cell death) while this drug 






Figure 2. Triple secreted reporter system in vitro. U87-Gluc, U87R1-Vluc, U87R2-
SEAP/Fluc cells or a combination of all three cell lines (multiplex) were plated in a 96-well 
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plate and treated with either TMZ (100 nM) or DMSO control.  At different time points, 
aliquots of conditioned medium were assayed for Gluc, Vluc or SEAP reporters. Only U87 
parent cells responded to TMZ (as observed by Gluc assay) but not U87R1 or U87R2 cells 
with both singleplex and multiplex assay. 
 
The multiplex assay showed the exact same phenomena proving that these three 
reporters can be used together for simultaneous monitoring of three distinct 
biological processes over time. We then mixed these three cell lines equally and 
intracranially implanted 75,000 cells (25,000 of each line) in the brain of nude mice.  
One week later (time zero), a sample of blood was withdrawn and a group of mice 
(n=6) was injected with 10 mg/kg TMZ, while the other group was injected with 
DMSO (control). Blood was collected at different time points and 5 l of blood (for 
Gluc) or serum (for Vluc and SEAP) was assayed for each luciferase activity using 
coelenterazine, vargulin or SEAP assay respectively.  As expected, a continuous 
decrease in Gluc level in the blood in response of parent U87 cells to TMZ was 
observed over time in the treated group, while an increase in Gluc signal was 
observed in the control group (Fig. 3). On the other hand, both Vluc and SEAP levels 
increased in serum over time in both treated and control groups showing that U87R1 
and U87R2 cells are resistant to TMZ (Fig. 3).  Before and 10 days post-treatment, 
mice were imaged for Gluc, Vluc and Fluc after injection of coelenterazine, vargulin 
and D-luciferin confirming the blood assays (Fig. 3).  All together, these results show 
that Gluc, Vluc and SEAP can be multiplexed together as blood reporters for non-





Figure 3.  Multiplex blood reporter systems. A mixture of U87-Gluc, U87-Vluc and U87-
SEAP/Fluc cells (25,000 of each cell line) were intracranially injected in the brain of nude 
mice.  One week later, mice were randomized in 2 groups, which received either 10mg/kg 
TMZ or DMSO vehicle (n=6/group). Before and at different time points post-treatment, 5 l 
blood was assayed for Gluc activity. Likewise, 5 l of serum was assayed for Vluc and SEAP 
activity.  Before and at day 10 post-TMZ treatment, signal was localized to tumors by in vivo 
bioluminescence imaging of Gluc, Vluc and Fluc after injection of coelenterazine, vargulin 
and D-luciferin substrates respectively. 
 
In summary, we have developed a multiplexed blood reporter system for 
simultaneous monitoring of multiple biological parameters in the same experimental 
animal.  This system could be applied in many different fields facilitating the 
understanding of disease development and expedites findings of novel therapeutics 





Lentivirus vectors. Lentivirus vectors expressing CMV-SEAP, CMV-Gluc and CMV-
Fluc were previously described14. Codon-optimized Vluc cDNA for mammalian gene 
expression was amplified by polymerase chain reaction (PCR) from pCMV-Vluc 
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(Targeting Systems) and cloned in a similar vector backbone as CMV-SEAP creating 
CMV-Vluc.  Lentivirus vectors were packaged as previously described.14 
 
Cell culture and reagents. U87 human glioma cells were obtained from ATCC. 
U87R1 and U87R2 cells were generated by repeated exposure of U87 cells to low 
doses of TMZ (a kind gift from Dr. Peter Wesseling, VU University Medical Center, 
Cancer Center, Amsterdam, the Netherlands). All cells were grown in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(Sigma, St. Louis, MO, USA), 100 U penicillin, and 0.1 mg streptomycin (Sigma) per 
milliliter, at 37 °C and 5% CO2 in a humidified atmosphere. Temozolomide was 
obtained from Sigma. 
 
Reporter substrates. Coelenterazine was obtained from NanoLight™ Technology 
(Pinetop, AZ) and resuspended at 5 mg/ml in acidified methanol. Vargulin substrate 
was obtained from NanoLight™ Technology and was resuspended at 5 mg/ml in 
acidified methanol. D-luciferin was purchased from Gold Biotechnology® (St. Louis, 
MO) and resuspended at 25 mg/ml in PBS.  SEAP was detected using the the Great 
EscAPe SEAP kit (Clontech) as per manufacturer’s instructions. 
 
In vitro experiments. U87-Gluc, U87R1-Vluc and U87R2-SEAP/Fluc cells were 
plated in a 96 well plate (5000 cells/well) in a total volume of 50 and 24 hours later 
treated with either temozolomide (100 nM) or DMSO vehicle. At different time points, 
10 l aliquot (in triplicates) of cell-free conditioned medium was collected and 
assayed for either Gluc, Vluc or SEAP using either coelenterazine (5 g/ml in PBS), 
vargulin (1 g/ml in PBS) or the Great EscAPe respectively. We refreshed the media 
of cells 6 hours before measurements to avoid accumulation of the reporter. 
 
Animal studies and blood collection. All animal studies were approved by the 
Massachusetts General Hospital Review Board. U87 human glioma cells, U87R1 
and U87R2 were transduced with each lentivirus vector for stable expression by 
adding the vector directly to the cells using 10 transducing units of each vector per 
cell. To generate tumors, different amount of these cells (in 50 l) were mixed with 
equal volume of Matrigel and injected subcutaneously in the flanks of athymic nude 
mice. For brain tumor model, a mixture of these cells (25,000 per cell line, in 2 l 
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Opti-MEM) were intracranially injected in the left midstriatum of nude mice using the 
following coordinates from bregma in mm: anterior-posterior +0.5, medio-lateral +2.0, 
dorso-ventral í2.5. These injections were performed using a Micro 4 Microsyringe 
Pump Controller (World Precision Instruments, Sarasota, FL) attached to a Hamilton 
syringe with a 33-gauge needle (Hamilton, Rena, NV) at a rate of 0.2 L/min. One 
week later, mice were randomized in 2 groups (n=6/group) and treated with either 
10mg/kg temozolomide or DMSO vehicle. Blood samples were collected from these 
mice as well as from mice with no tumors (negative control) by making a small 
incision in the tail and directly adding it to an eppendorf tube containing EDTA as an 
anti-coagulant (10 mM final concentration).  
 
Ex vivo multiplex blood reporter assays. For Gluc assay, activity was measured by 
injecting 100 l 100 M coelenterazine (nanolight, pinetop, AZ) to 5 l of blood and 
acquiring photon counts over 10 seconds using a luminometer (Dynex). The SEAP 
chemiluminescence activity was measured in 5 l serum using the Great EscAPe 
SEAP kit (Clontech) as per manufacturer’s instructions. For Vluc assay, activity was 
measured in 5 l blood or serum after injecting 100 l 0.25 g/ml of vargulin (diluted 
in PBS) and acquiring photon counts using a luminometer. 
 
Triple in vivo imaging. For Fluc imaging, mice were injected i.p. with 200 mg/kg body 
weight of D-luciferin solution and imaging was performed 10 min later. For Gluc 
imaging, mice were injected i.v. (through retro-orbital route) with 5 mg/kg body 
weight of coelenterazine solution diluted in PBS and imaging was performed 
immediately.  For Vluc in vivo imaging, mice were injected i.v. with 4 mg/kg body 
weight (diluted in PBS) and imaging was performed immediately. For sequential 
imaging of all three reporters, we imaged Gluc on day 1, Vluc 4 hrs later and Fluc on 
Day 2 to allow enough time for the signal to reach background levels between 
different imaging sessions. Imaging was performed using an IVIS® Spectrum optical 
imaging system fitted with an XGI-8 Gas Anesthesia System (Caliper Life Sciences, 
Hopkinton, MA).  Bioluminescent images were acquired using the auto-exposure 
function. Data analysis for signal intensities and image comparisons were performed 









Supplementary Figure 1: optimization of Vluc assay. (a) Blood was withdrawn from mive 
bearing subcutaneous U87-Vluc tumors and 5ȝl blood or serum (in triplicates) was assayed 
for Vluc activity using different concentrations of vargulin (in 100 ȝl). (b) conditioned medium 
of U87 cells expressing Vluc or Fluc (control) were assayed for Vluc activity in the presence 
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We developed a triple reporter system based on Vargula, Gaussia and firefly 
luciferases for sequential imaging of three different biological processes. We applied 
this system to monitor the effect of soluble tumor necrosis factor-related apoptosis-
inducing ligand (sTRAIL-delivered using an adeno-associated viral AAV vector), in 
combination with the cardiac glycoside lanatoside C, in different orthotopic glioma 
models. Binding of sTRAIL on tumor cells activated downstream events leading to an 
initial decrease in glioma proliferation, followed by tumor re-growth through resistant 
cells. Co-treatment with lanatoside C sensitized the resistant subpopulation of glioma 
to sTRAIL-induced apoptosis as monitored by the triple reporter system. Since AAV 
vectors, TRAIL, and cardiac glycosides have been used in the clinic separately, this 
therapeutic strategy could be easily adapted to humans. This work is the first 
demonstration of triple in vivo bioluminescence imaging and will have broad 





Bioluminescence imaging (BLI) using luciferase reporters has been indispensible for 
non-invasive monitoring of different biological processes in cancer such as tumor 
volume and transcriptional activation during tumor development/therapy, as well as 
immune cell infiltration into the tumor environment1. The major advantage of using 
BLI compared to endpoint analysis is that it provides real-time, non-invasive 
measurements of in situ biological events, giving a complete “picture” of the kinetics 
of an entire process. Great strides have been made since the seminal study by 
Contag et al. published in 1995 which was the first demonstration of in vivo BLI2. For 
example, as few as 10 cells expressing firefly luciferase can be detected in deep 
tissue in some animal models3. This study followed by the discovery and molecular 
construction of different luciferases with a multitude of properties including secreted 
luciferases4, multi-color light emission spectras for better tissue penetrance in vivo 
and spectral deconvolution5, increased thermostability6, and light output (sensitivity)7. 
One limitation to current bioluminescence imaging is that typically only one and at 
most two luciferase reporters are used to measure one or two parameters8.  As 
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tumor formation is a complex process, concurrent measurement of several 
processes will be important for the development of novel therapeutics and their 
transition to the clinic.   
Tumor necrosis factor apoptosis-inducing ligand (TRAIL) is regarded as a potential 
anti-cancer agent, however, considerable numbers of cancer cells, especially adult 
gliomas, are resistant to apoptosis induction by TRAIL9,10. Another major 
disadvantage of using TRAIL for glioma therapy is its inefficient transport across the 
blood-brain barrier11. Through drug screening, we have identified lanatoside C, an 
FDA approved cardiac glycoside, to sensitizes primary GBM cells to TRAIL-induced 
apoptosis12. Cardiac glycosides including lanatoside C have been recently shown to 
provide neuroprotection against ischemic stroke showing that these drugs penetrate 
the brain efficiently13, 14.   
In this study, we explored the use of adeno-associated viral vector (AAV) to deliver 
soluble TRAIL (sTRAIL) to brain tumors in combination with its sensitizer, lanatoside 
C for glioma therapy. The AAV vector serotype chosen (AAVrh.8) efficiently 
transduces the normal brain (primarily neurons) to synthesize and secrete sTRAIL, 
which in turn binds to death receptors found specifically on glioma cells, and kill them 
upon lanatoside C treatment.  We first developed and optimized triple 
bioluminescence imaging system using three different luciferases, each specific to its 
own substrate, from the marine copepod Gaussia princeps (Gluc-uses 
coelenterazine as a substrate), the American firefly photinus pyralis (Fluc,-D-luciferin 
substrate), and ostracod Vargula (Cypridina) hilgendorfii (Vluc-uses vargulin as a 
substrate). We then applied this system to monitor sequentially (1) AAV gene 
delivery; (2) sTRAIL binding to glioma death receptors and activation of downstream 
events; and (3) tumor response to the combined sTRAIL/lanatoside C therapy. We 
showed that glioma cells are somewhat resistant to sTRAIL monotherapy and the 
combined sTRAIL/lanatoside C therapy yields significant delay in tumor growth. This 
combined therapy could potentially be translated to humans since all its components 
have been used in clinical trials separately. Further, this study is the first 
demonstration of triple in vivo BLI, which would be applicable to many 








Characterization of a codon-optimized Vargula luciferase for mammalian gene 
expression. We first cloned the Vluc cDNA, codon-optimized for mammalian gene 
expression into a lentivirus vector under the control of the CMV promoter (Lenti-
Vluc).  This vector also expresses the mCherry fluorescent protein under an internal 
ribosomal entry site (IRES), used to monitor transduction efficiency. Since Vluc 
cDNA carries a natural signal sequence,15 it is secreted to the conditioned medium 
once expressed in mammalian cells. We first compared the level of Vluc secretion by 
transducing 293T cells with this lentivirus vector and evaluating cell lysates and 
conditioned medium for Vluc activity using the vargulin substrate. We observed that 
the majority of Vluc activity (78%) was contained in the medium fraction showing 
efficient secretion (Fig. 1a).  Next, we checked the light emission kinetics of Vluc 
after substrate addition over 5 minutes. We observed a slow decay in light emission 
with 44% of the initial signal remaining 5 minutes post substrate addition (Fig. 1b).  
To further characterize Vluc as a mammalian cell reporter, we measured the stability 
of the enzyme over time at 37qC.  Conditioned medium from cells expressing Vluc 
was incubated at 37qC in a humidified cell incubator. Aliquots were taken at different 
time points and assayed for Vluc activity. We observed that Vluc levels did not drop 
below initial levels over 12 days indicating high enzyme stability in cells conditioned 
medium (Fig. 1c), similar to that reported for the secreted Gaussia luciferase16.  We 
next evaluated Vluc as a reporter to monitor cell viability and proliferation over time.  
U87 glioma cells transduced with Lenti-Vluc were plated and aliquots of media were 
collected at different time points.  In parallel a commercially available Fluc-based 
viability assay was performed for comparison.  We observed a high correlation 
(r2=0.98) between the Vluc viability assay and the established viability assay (Fig. 




     
Figure 1.  In vitro characterization of Vluc-catalyzed luminescence. (a) A Vluc assay 
was performed on conditioned medium as well as cell lysates from 293T cells transduced 
with a lentivirus vector encoding Vluc to determine the fraction (in RLU) of Vluc being 
secreted. (b) Vluc light emission kinetics was performed by adding vargulin to Vluc-
containing media and acquiring signal over time. (c) Stability of Vluc enzyme was 
determined by assaying an aliquot of Vluc-containing cell-free conditioned medium, 
incubated at 37 0C, at different time points.  (d) Vluc-based viability assay. 105 U87 cells 
expressing Vluc were seeded in a 12-well plate and an aliquot of conditioned medium was 
assayed for Vluc activity over time.  For comparison, a commercially available Fluc-based 
viability assay (CellTiter Glo; Promega) was performed.  
 
 
Optimization of the triple in vivo bioluminescence imaging system. In order to 
validate Vluc as a reporter for in vivo imaging, we first characterized its 
bioluminescence properties in a quantitative tumor model.  Nude mice were injected 
subcutaneously with 2x106 U87 cells stably expressing Vluc (through transduction 
with Lenti-Vluc). Ten days later, mice were injected intravenously (i.v.- through retro-
ocular route) with vargulin (4 mg/kg body weight) and imaged using a cooled charge-
coupled device (CCD) camera at different time points post-vargulin injection. We 
observed the peak luminescent signal immediately upon injection of vargulin, which 



















































minutes (Fig. 2a). Next, we compared i.v. versus intraperitoneal (i.p.) injection of the 
vargulin substrate for Vluc imaging and observed that the peak signal occurred 10 
minutes after i.p. injection (Supplementary Fig. 1), with the i.v. injection yielding an 
8-fold higher photons/min compared to the i.p. injection (Fig. 2b).  Therefore, the i.v. 
injection route was used throughout the study. 
We then evaluated the potential of Vluc to be multiplexed with Gluc and Fluc for 
sequential triple bioluminescence imaging by testing luciferase/substrate specificity 
in vivo.  U87 stably expressing either Vluc, Gluc or Fluc (under control of the CMV 
promoter) were implanted subcutaneously in nude mice at three different sites. Ten 
days later, mice were imaged first for Gluc-mediated bioluminescence imaging by i.v. 
injection of coelenterazine (5 mg/kg body weight) and acquiring photon counts 
immediately. Intense luminescence was detected only from tumors expressing Gluc 
(Fig. 2c). Next, mice were imaged after i.v. injection of vargulin (4 mg/kg body 
weight) and again signal was obtained only from tumor-expressing Vluc. Finally, 
mice were i.p. injected with D-luciferin (150 mg/kg body weight) and imaged 10 min 
later which showed signal only in tumor-expressing Fluc (Fig. 2c). Fluc was imaged 
last since it is known to have glow-type kinetics in mice. These results show that 
each of these luciferases is specific to its own substrate and can be multiplexed 






Figure 2.  Triple in vivo bioluminescence imaging. (a,b) 2x106 U87-Vluc glioma cells 
were implanted subcutaneously in nude mice. Tumor-associated Vluc bioluminescence 
signal was imaged after i.v. injection of vargulin over time (a).  Tumor associated Vluc signal 
after i.v. or i.p. injection of vargulin was measured (b). U87 glioma cells stably expressing 
Gluc, Vluc or Fluc (all under CMV promoter) were injected subcutaneously in nude mice at 
different sites. Ten days later, Sequential imaging of Gluc, Vluc and Fluc was performed 
after injection of coelenterazine, vargulin and D-luciferin, respectively (c). 
 
 
Monitoring of glioma therapy using triple in vivo bioluminescence imaging. We 
used the triple luciferase reporter system to monitor the effect of glioma to a secreted 
soluble variant of the anti-cancer agent TRAIL (sTRAIL17) in combination with its 
sensitizer lanatoside C. We first cloned sTRAIL under control of the constitutively 
active chicken beta-actin (CBA) promoter into an AAV2 ITR-flanked transgene 
cassette and pseudotyped it with an AAVrh.8 capsid (AAV-sTRAIL; Fig. 3a).  As a 
control, we packaged a similar vector expressing GFP driven by the CBA promoter. 
We chose to use AAVrh.8 as we have previously shown that this serotype yields 
excellent transduction efficiency of murine normal brain18.  Injection of AAVrh.8 into 
the tumor using convection-enhanced delivery results in transduction of primarily 
Figure 2
































































neuronal cells surrounding the tumor18. The transduced neurons form a therapeutic 
zone around the tumor by synthesizing and secreting sTRAIL, which in turn will find 
and bind its death receptor present specifically on glioma cells. Co-treatment with 
lanatoside C should allow sensitization of glioma cells to TRAIL’s pro-apoptotic 
effects12.  
To determine the functionality of the AAV-sTRAIL construct, we transduced U87 
cells with 104 genome copy (g.c.)/cell of AAV-sTRAIL vector or AAV-GFP as a 
control.  Three days later, conditioned media from these cells were harvested and 
analyzed for TRAIL using an ELISA kit. We observed a TRAIL concentration of 124 
ng/ml from conditioned medium of AAV-sTRAIL infected cells while it was 
undetectable in the media from AAV-GFP control cells, showing the proper 
expression and secretion of sTRAIL into the conditioned medium of cells. Transfer of 
conditioned media from AAV-sTRAIL transduced cells along with lanatoside C onto 
U87 cells provided robust cell killing as expected (Supplementary Fig. 2).   
We next cloned Vluc cDNA under control of CBA promoter in another AAV2 vector 
pseudotyped with AAVrh.8 capsid (AAV-Vluc; Fig. 3a). Vluc was used as a marker 
for efficient gene transfer.  We then engineered U87 glioma cells to stably express 
Fluc and the mCherry fluorescent protein (U87Fluc) under control of CMV promoter, 
using a lentivirus vector (Fig. 3a). Fluc was used as a marker for tumor volume. 
Since TRAIL is known to activate a series of events including the nuclear factor 
kappa B (NF-NB) pathway, we engineered a lentivirus vector expressing Gluc under 
the control of tandem repeats of NF-NB responsive elements (Fig. 3a)19, and used it 
to transduce the U87Fluc cells generating U87Fluc/NF-Gluc cells.  We initially used 
U87 glioma cells as a model since these cells are partially resistant to the pro-
apoptotic effects of TRAIL20.    
We stereotactically implanted 105 U87Fluc/NF-Gluc cells into the striatum of nude 
mice and allowed tumors to form.  Two weeks later, mice were randomly divided into 
two groups (n=5).  The first group was infused into the same tumor implanted site 
with 1010 g.c. of both AAV-Vluc + AAV-GFP (AAV-Vluc/GFP; serving as a negative 
control for tumor therapy and for imaging of gene delivery) and the second group 
was infused with 1010 g.c. of both AAV-Vluc (to monitor successful transgene 
delivery) and AAV-sTRAIL (anti-tumor therapy; AAV-Vluc/sTRAIL). As a negative 
control for Vluc imaging, a group of mice received similar injection of AAV-GFP 
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alone. Ten days post-vector injection, we monitored AAV gene delivery by injecting 
(i.v.) mice with vargulin substrate and immediately imaging using a CCD camera. 
Evident bioluminescent signal (average radiance of 7.5x105 p/s/cm²/sr +/- 2.3E4) 
was seen at the injection site of all AAV-Vluc injected mice (and not the AAV-GFP 
control) showing successful gene delivery (Fig. 3b). Mice were also imaged at 1, 2, 
and 3 weeks post-vector injection for tumor-associated Fluc-signal, and therefore 
tumor size, after i.p. injection of D-luciferin substrate. We observed that AAV-
mediated sTRAIL expression slowed the tumor growth as compared to control mice.  
For example, at week 1 post-vector injection, Fluc imaging showed an average 
radiance for AAV-Vluc/GFP control mice of 1.03 x 106 photons/s/cm2/sr while it was 
only 2.38 x 104 photons/s/cm2/sr for AAV-Vluc/sTRAIL treated mice (Fig. 3c,d). The 
average bioluminescent signal remained high (1.28 x 106 photons/s/cm2/sr) for AAV-
Vluc/GFP control mice at week 2 and by week 3, 70% of mice were sacrificed due to 
advanced tumor progression (Fig. 3c,d).  In contrast, at two weeks post-vector 
injection, the average signal remained very low (1.8 x 104 photons/s/cm2/sr) for the 
AAV-Vluc/sTRAIL injected group (Fig. 3c,d).  Interestingly, in this group the radiance 
increased by 214-fold between the two and three week post-vector injection 
presumably due to gained-resistance to sTRAIL therapy (Fig. 3c,d).   
TRAIL binding to its death receptors recruits TNFR1-associated death domain 
protein (TRADD) leading to NF-NB activation21, we therefore sought to detect NF-NB 
induction and therefore sTRAIL binding to glioma cells in our model. Mice in both the 
AAV-Vluc/GFP (control) and AAV-Vluc/sTRAIL groups were imaged 3-4 days post-
viral injection for Fluc (tumor size) and for Gluc after retro-orbital injection of 
coelenterazine. Fluc bioluminescence at the tumor location was detectable in both 
groups of mice as expected but visible specific Gluc signal detected only in mice 
injected with AAV-Vluc/sTRAIL and not AAV-Vluc/GFP control animals indicating 
binding of sTRAIL to glioma cells and induction of the downstream NF-NB pathway 
(Fig. 3e). In two separate experiments, we compared the relative NF-NB induction 
between the AAV-Vluc/GFP and AAV-Vluc/sTRAIL groups by normalizing the Gluc 
levels to the tumor size (quantitated by Fluc imaging).  In both experiments, we 
observed a much higher normalized Gluc signal (15-142-fold) in the mice treated 
with AAV-sTRAIL compared to the control group indicating induction of NF-NB (Fig. 
3f). These results were reproduced in three independent experiments and shows 
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Figure 3. Monitoring of TRAIL-mediated cancer gene therapy with triple 
bioluminescence imaging. (a) Schematic diagram for the different AAV (left) and lentivirus 
vector (right) constructs used in this study.  AAV vectors: CMV E, cytomegalovirus enhancer; 
CBA, chicken beta actin promoter; WPRE, woodchuck hepatitis virus posttranscriptional 
regulatory element; pA, bGH poly A signal.  Lentivirus vectors:  Diagrams shown represent 
integrated provirus. CMV IE, cytomegalovirus immediate early promoter; cHS4 INS, chicken 
E globin hypersensitive site 4 insulator sequence; NF, NF-NB inducible promoter. (b-f) 105 
U87Fluc/NF-Gluc glioma cells were implanted intracranially in nude mice. (b) Two weeks 
later, the mice brain were infused at the same tumor injection site with 1010 g.c. of either 
AAV-GFP, AAV-Vluc/GFP or AAV-Vluc/sTRAIL (as noted). Vluc bioluminescence imaging 
was performed 10 days post-vector injection confirming AAV-mediated gene delivery. 
Representative mice from AAV-Vluc/sTRAIL and AAV-GFP are shown. (c) Tumor volume 
was monitored by Fluc bioluminescence imaging at different time points. (d) Quantitation of 
tumor-associated Fluc signal in c. (e) Fluc imaging, a marker for tumor volume, as well as 
Gluc imaging, a marker for TRAIL binding on glioma cells, was performed. (f) Gluc signal 
normalized to Fluc signal in (e) to account for tumor size from two separate experiments is 





We have previously discovered that a cardiac glycoside, lanatoside C (LanC), 
sensitizes glioma cells to recombinant TRAIL, thus overcoming their resistance to 
TRAIL-mediated killing, both in cultured cells and in a subcutaneous model12. We 
then tested the effect of this combined therapy in our orthotopic glioma model using 
AAV vector to deliver sTRAIL.  Nude mice were again implanted into the striatum 
with 105 U87Fluc/NF-Gluc cells as above. Two weeks post-injection (when tumor 
was formed as monitored by Fluc imaging), mice were randomly divided into two 
groups, which received injection of either AAV-Vluc/GFP or AAV-Vluc/sTRAIL. Each 
group was then divided into two subgroups (n=10) which either received i.p. injection 
of DMSO (vehicle) or LanC (7.5 mg/kg body weight). This resulted in the following 
four groups:  (1) AAV-Vluc/GFP, (2) AAV-Vluc/GFP + LanC, (3) AAV-Vluc/sTRAIL, 
(4) AAV-Vluc/sTRAIL+LanC.  Lanatoside C was injected daily for 3 weeks starting 
one-day post-vector injection. Gene transfer as well as TRAIL binding to glioma cells 
was imaged as above, using Vluc and Gluc, which showed similar results to figure 3. 
Tumor volume was imaged over time with Fluc bioluminescence imaging. At two 
weeks post-injection, AAV-Vluc/GFP and AAV-Vluc/GFP + LanC treated mice had 
an average radiances of 1.04 x 106 and 3.6 x 106 photons/s/cm2/sr, respectively (Fig. 
4a,c).  On the other hand, both AAV-Vluc/sTRAIL and AAV-Vluc/sTRAIL+LanC 
treated mice had similar radiances to one another, which were significantly lower 
(>18-fold; p<0.05) than AAV-Vluc/GFP and AAV-Vluc/GFP+LanC control groups 
(Fig. 4a,c).  Between 2 and 3 weeks post-vector injection, all mice in the AAV-
Vluc/GFP and AAV-Vluc/GFP+LanC were sacrificed due to tumor progression 
whereas mice from AAV-Vluc/sTRAIL and AAV-Vluc/sTRAIL+LanC remained alive. 
Imaging of mice in the AAV-Vluc/sTRAIL and AAV-Vluc/sTRAIL+LanC groups at 
week 3 post-vector injection revealed a 6.7-fold lower mean radiance (p<0.05) in the 
combination treated group as compared to AAV-Vluc/sTRAIL alone showing that 






Figure 4. Lanatoside C enhances TRAIL-mediated therapy against intracranial 
gliomas.  Mice bearing U87Fluc/NF-Gluc gliomas received an infusion of AAV-Vluc/GFP or 
AAV-Vluc/sTRAIL. Each group was divided into 2 subgroups, which either received vehicle 
or LanC. Tumor growth was monitored over time by Fluc bioluminescence imaging. (a,b) 
Bioluminescence images from representative mice in each group at week 2 (a) and 3 (b).  (c) 
Quantitation of tumor-associated bioluminescence of the different treatment groups over 
time. (d) Quantitation of Fluc signal in the AAV-Vluc/sTRAIL and AAV-Vluc/sTRAIL+LanC 
groups at week 3. Mice in AAV-Vluc/GFP and AAV-Vluc/GFP+LanC had been sacrificed 
prior to week 3 imaging due to tumor progression. 
 
To check whether lanatoside C could re-sensitize TRAIL-resistant cell population to 
its apoptotic effects, mice bearing established U87Fluc/NF-Gluc were injected with 
AAV-Vluc/sTRAIL as above. Sixteen days post-vector injection, mice were treated 
for 6 consecutive days with LanC. At day 22, Fluc imaging revealed a 17-fold 
decrease in tumor volume confirming sensitization (Fig. 5a).  These mice were then 
left off the drug for 7 days. At day 29, Fluc imaging revealed a 60-fold increase in 
tumor-associated signal indicating that U87 glioma cells regained TRAIL resistance 
in the absence of LanC (Fig. 5a). Placing the mice back on this drug from day 29 to 
day 36 again showed re-sensitization of glioma tumors to TRAIL (Fig. 5a). These 
data suggest that LanC could re-sensitize resistant glioma cells to TRAIL-induced 
cell death. In another group of mice, we allowed the glioma cells to gain resistance to 
TRAIL before treating with one cycle of LanC (given at day 29). U87Fluc/5NF-Gluc 
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were implanted in the brain of mice, injected with AAV-Vluc/sTRAIL or AAV-
Vluc/GFP as above and imaged for tumor-associated Fluc signal over time, which 
showed tumor re-growth. Fluc imaging at day 36 showed a 1.6-fold decrease in Fluc 
signal and therefore sensitization of resistant glioma cells to TRAIL in the AAV-
Vluc/sTRAIL injected group (Fig. 5b). On the other hand, the control group injected 
with AAV-Vluc/GFP+LanC showed a 6.3-fold-increase in tumor volume between day 
29 and 36 (Fig. 5c), proving that the observed anti-tumor effect is due to the 




Figure 5.  Lanatoside C re-sensitizes glioma tumors to TRAIL.  (a) Mice brains bearing 
U87Fluc/NF-Gluc gliomas were infused with AAV-Vluc/sTRAIL.  Sixteen days later, mice 
were treated with two 6-days cycle of LanC with a 7 days period off drug between each 
cycle.  Tumor volume was monitored by Fluc bioluminescence imaging. (b) Similar treatment 
as (a) except mice received only one cycle of LanC treatment 30 days post-vector injection.  
(c) Control experiment in which mice bearing U87Fluc/NF-Gluc gliomas were injected with 
AAV-Vluc/GFP vectors and then subjected to one cycle of LanC treatment.  Tumor volume 
was imaged at the beginning and end of drug treatment. Representative mouse from each 
group is shown under each time point. 
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We next evaluated our AAV-sTRAIL+LanC therapy in an invasive primary glioma 
orthotopic xenograft model using human GBM8 tumor stem-like cells22 stably 
expressing Fluc.  These cells are cultured as neurospheres and we observed that 
they are semi-sensitive to monotherapy of TRAIL and LanC, However, combined 
therapy induces >95% cell death (Supplementary Fig. 3). GBM8-Fluc cells were 
implanted into the striatum of nude mice.  At day 14 post-tumor injection, mice were 
imaged for Fluc signal (tumor volume) and then divided into 4 different groups (n=8), 
such that the mean bioluminescence of each group was similar to one another.  At 
day 22, when imaging showed no significant difference in tumor volume between 
groups (p=0.9955, Supplementary Fig. 4), each group of mice was treated as 
follows: (1) AAV-Vluc/GFP, (2) AAV-Vluc/GFP+LanC, (3) AAV-Vluc/sTRAIL, (4) 
AAV-Vluc/sTRAIL+LanC. Tumor volume was monitored once/week using Fluc BLI 
over 4 weeks. One week post-treatment, the Fluc signal in the AAV-Vluc/GFP and 
AAV-Vluc/GFP+LanC group increased by 8.5-fold and 17-fold, respectively (Fig. 6a).  
In contrast, groups of mice treated with AAV-Vluc/sTRAIL or AAV-
Vluc/sTRAIL+LanC showed a 4-fold and 7.2-fold decrease in Fluc signal, and 
therefore tumor volume, respectively (Fig. 6a). The AAV-Vluc/GFP and AAV-
Vluc/GFP+LanC groups reached a maximum signal between 2 and 3 weeks post-
treatment.  Mice treated with AAV-Vluc/sTRAIL continued to have a lower signal 
compared to the control group, although the signal increased 20-fold between weeks 
1-4 (Fig. 6a).  On the other hand, mice in the co-treatment group which received 
AAV-Vluc/sTRAIL+LanC group only increased 1.6-fold between weeks 1-4 (Fig. 6a).   
Histological analysis of brains from mice in the different treatment groups was 
performed at the time of sacrifice. Mice treated with the control AAV-Vluc/GFP vector 
showed large multi-lobed tumors that were easily visualized by Hematoxylin and 
Eosin (H&E) stain (Fig. 6b).  Large tumors at the injected side were also apparent in 
the control AAV-Vluc/GFP+LanC treated mice (Fig. 6b).  In contrast, mice treated 
with AAV-Vluc/sTRAIL had more diffuse tumor with “ring like” phenotype around the 
site of vector injection (striatum), with secondary tumor masses away from injection 
site, and tumor cell infiltration along the corpus callosum (Fig. 6b,c).  In mice treated 
with both AAV-Vluc/sTRAIL+LanC, no visible tumor masses were observed at the 
site of vector injection showing efficient therapy of the primary tumor mass (Fig. 6b).  
However, tumor cells migration away from the therapeutic zone was also observed 






Figure 6.  Combined AAV-sTRAIL and lanatoside C therapy slows invasive primary 
glioma growth. (a) Mice were stereotactically injected with human GBM8 tumor stem-like 
cells stably expressing Fluc. Three weeks later, mice were divided into 4 different treatment 
groups as noted.  Fluc imaging for tumor size was performed over time.  Arrow indicates the 
start of the treatment.  (b-c) H&E histological analysis of a representative mouse from each 
group at the site of vector injection (b) and distal from the tumor/vector injection site (c) are 
shown. * indicates tumor/vector injection site. Arrows indicate tumor cells migration away 





Luciferases have played a major role in advancing our understanding of biological 
processes. A broader array of biocompatible, non-toxic and efficiently- expressed 
reporters that can be used together with existing luciferases can serve to expand this 
potential. The present study demonstrates for the first time a triple luciferase reporter 
system suitable for in vivo bioluminescence imaging.  We showed that Vargula 
luciferase can be multiplexed together with Gaussia and firefly luciferases for 
sequential monitoring of three distinct biological phenomena.  We also showed that 
this triple bioluminescence imaging yield specific, detectable bioluminescence signal 
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deep within the brain (with intact skull, ~3.5 mm) of mice.  Importantly, we 
successfully employed this reporter system to monitor three different biological 
processes in an orthotopic brain tumor model, thus validating the system for different 
applications. 
Since the cloning and sequencing of Vargula (formerly Cypridina) hilgendorfii (Vluc) 
cDNA in 198915, several reports have demonstrated the usefulness of this enzyme 
for luminescence assays23-26.  However, to our knowledge, no reports have applied it 
for in vivo imaging probably due to the unavailability of its substrate, vargulin, which 
is now commercially available. Vluc cDNA possess a signal sequence and therefore 
is naturally secreted from cells allowing real time, multi-time point analysis from the 
same cells23, 27.  In this study, we characterized a codon-optimized Vluc cDNA for 
mammalian gene expression and showed Vluc to be very stable with no significant 
decline in activity over 12 days in cell-free conditioned media at 37 qC.  Despite the 
fact that the majority of Vluc was found in the conditioned media of mammalian cells, 
the intracellular Vluc level was efficient for in vivo imaging. In applications where 
higher sensitivity is required, a membrane-bound variant of Vluc27 could be used 
which should yield higher cellular activity similar to a recent report for Gaussia 
luciferase28, 29. 
Systems for multi-modal imaging exist which incorporate different technologies such 
as fluorescence, bioluminescence, positron emission tomography (PET), and 
magnetic resonance imaging (MRI)30.  While substantial multi-parameter information 
can be gained by these systems, they have several drawbacks including high cost 
(e.g. MRI), logistical concerns such as short half-life of some PET probes, and broad 
technical expertise. While fluorescent reporter-based imaging as well as luciferases 
emitting at different wavelengths can be used for multi-imaging applications, they 
require expensive and complicated instrumentation with spectral deconvolution for 
visualizing of each biological parameter of interest31,32. Furthermore, fluorescence-
based imaging is limited by a high background due to tissue autofluorescence as 
well as single animal analysis. On the other hand, BLI has low background noise and 
is thus more sensitive for deep tissue imaging applications1. The triple in vivo 
bioluminescence imaging system described here yields multi-parameter information 
distinguished by sequential imaging using different specific substrates, while 
remaining both cost effective and highly sensitive, as well as being user friendly 
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since only a simple CCD camera is required with no need for sophisticated 
instrument hardware/software.  This same system can be extended and applied to 
any field to monitor three distinct biological phenomena, allowing one to obtain 
maximal information in animal models  
TRAIL has been regarded as an anti-cancer agent, however, significant cancer 
types, including gliomas, are resistant to TRAIL-induced cell death9. Mechanisms of 
resistance include downregulation of death receptors33, decoy receptor expression34, 
as well as overexpression of the caspase-8 inhibitor, c-FLIP, due to deregulation of 
the mTOR signaling pathway35. Additionally NF-NB induction by TRAIL has been 
reported as a tumor cell resistance mechanism10,36. Through drug screening, we 
have previously shown that the family of cardiac glycosides, including lanatoside C, 
sensitizes glioma cells to TRAIL-induced cell death partially through upregulation of 
death receptors12,37. Cardiac glycosides have been recently shown to provide 
neuroprotection against ischemic stroke13,14 and therefore penetrate the brain 
efficiently. Another disadvantage of using TRAIL for brain tumor therapy is its 
inability to cross the blood-brain barrier. In this study, we circumvented this problem 
by delivering sTRAIL directly to brain tumor environment by AAV-mediated gene 
delivery. By engineering the normal brain to synthesize and secrete sTRAIL, it can 
form a zone of resistance against newly developed glioma, which can be treated with 
lanatoside C therapy. Since TRAIL, AAV vectors, and lanatoside C have been used 
separately in clinical trials, this therapeutic approach can be potentially translated to 
humans. In addition to the more traditional U87 glioma model in which sTRAIL and 
LanC showed a therapeutic benefit, we tested this therapy against an invasive 
human glioma model, GBM822.  While AAV-sTRAIL showed a therapeutic response 
compared to the controls, mice eventually succumbed to tumor burden. H&E staining 
revealed a ring-like tumor formation around the vector injection site (highest 
concentration of sTRAIL), as well as secondary tumor formation away from injection 
site due to tumor cell migration. On the other hand, the combined AAV-
sTRAIL+LanC group showed significantly lower bioluminescent signal over the 
course of treatment, as compared to AAV-sTRAIL alone, with practically no tumor at 
the injection site as shown by H&E staining. However, tumor cell migration away 
from the injection site was also observed which eventually lead to animal death.  To 
enhance this combined therapy against invasive tumor cells, a multi-injection 
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approach of the vector may be required. Alternatively, systemic injection of an AAV 
vector which can lead to global gene delivery (e.g. AAV9) may allow for widespread 




Cells: U87 human glioblastoma cell line and 293T human kidney fibroblast cells 
were obtained from the American Type Culture Collection (Manassas, VA). Both cell 
lines were cultured in high glucose Dulbecco’s modified Eagle’s medium (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (Sigma, St Louis, MO) 
and 100 U/ml penicillin, 100 ȝg/ml streptomycin (Invitrogen) in a humidified 
atmosphere supplemented with 5% CO2 at 37°C.  GBM8 tumor stem-like cells were 
grown as neurospheres as previously described22.  Briefly, spheres were cultured in 
Neurobasal medium (Invitrogen) supplemented with 3mM L-Glutamine (Mediatech), 
1x B27 supplement (Gibco), 0.5x N2 supplement (Gibco), 2 g/ml heparin (Sigma), 
20 ng/ml recombinant human EGF (R & D systems), 20 ng/ml recombinant human 
FGF2 (Peprotech) and 0.5x penicillin G/streptomycin sulfate/amphotericin B complex 
(Mediatech).   
 
Adeno-associated viral vectors and lentivirus vectors. The AAV-Vluc vector was 
constructed by replacing EGFP in AAV-CBA-EGFP39 with the human codon 
optimized Vluc cDNA (a kind gift from Dr. Rampyari Walia, Targeting Systems, El 
Cajon, CA).  AAV-sTRAIL vector consists of a transgene cassette for soluble, 
secreted TRAIL carrying amino acid (a.a.) 1-150 from human Flt3L, an isoleucine 
zipper domain, and the extracellular domain (a.a. 114-281) of the human TRAIL 
designed based on previously reported h-Flex-zipper-TRAIL17. In all these AAV 
vectors, gene expression is controlled by a hybrid cytomegalovirus enhancer/chicken 
beta actin promoter (CBA). All vectors carry a woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) downstream of the transgene.  AAV 
vector pseudotyped with AAVrh.8 capsids were produced by co-transfection of 293T 
cells using calcium phosphate precipitation of vector plasmid, a mini-adenovirus 
helper plasmid pFǻ6 (from Dr. Weidong Xiao, Univ. Penn. Med. Ctr., Philadelphia, 
PA), and AAVrh.8 helper plasmid pAR8 as described39.  AAV vectors were purified 
and titered, as described39,  yielding typical titers of  1013 g.c. per ml18. For sTRAIL 
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expression in culture, AAV vectors were packaged as AAV2 since this serotype is 
known to transduce cells in culture much more efficiently as compared to AAV2 
genome pseudotyped with AAVrh.8. 
U87 cells stably expressing Fluc and mCherry were generated by transduction of 
these cells with CSCW2-Fluc-ImCherry lentivirus vector at a multiplicity of infection 
of 10 transducing units/cell as described18. These cells were subsequently 
transduced with Lenti-NF-Gluc, a lentivirus vector encoding a Gluc under the control 
of 5 tandem repeats of NF-NB-responsive elements19. These double-transduced U87 
cells are referred to as U87Fluc/NF-Gluc cells.  The lentivirus vector encoding Vluc 
was constructed by replacing the Fluc insert in CSCW2-Fluc-ImCherry with the 
human codon-optimized Vluc cDNA. The lentivirus vector expressing Gluc was 
previously described16. U87 cell lines stably expressing Vluc or Gluc were generated 
in a similar manner to Fluc. GBM8 cells stably expressing Fluc and mCherry were 
generated by transduction of these cells with CSCW2-Fluc-ImCherry as above. 
 
In vivo tumor models. All animal experiments were approved by the Massachusetts 
General Hospital Subcommittee on Research Animal Care following guidelines set 
forth by the National Institutes of Health Guide for the Care and Use of Laboratory 
Animals.  Six-eight weeks athymic nude mice were anesthetized with a mixture of 
Ketamine (100 mg/kg) and Xylazine (5 mg/kg) in 0.9% sterile saline.  For 
subcutaneous tumors, mice were injected with 100 L of a 50:50 mixture of 
Matrigel™ Basement Membrane Matrix (BD Biosciences, Franklin Lakes, NJ) and 1-
2 million U87 cells expressing either Gluc, Vluc or Fluc resuspended in Opti-MEM.  
For the brain tumor model, 105 U87Fluc/5NF-Gluc cells (in 2 L Opti-MEM) were 
intracranially injected in the left midstriatum of nude mice using the following 
coordinates from bregma in mm: anterior-posterior +0.5, medio-lateral +2.0, dorso-
ventral í2.5. These injections were performed using a Micro 4 Microsyringe Pump 
Controller (World Precision Instruments, Sarasota, FL) attached to a Hamilton 
syringe with a 33-gauge needle (Hamilton, Rena, NV) at a rate of 0.2 L/min. For 
implantation of GBM8-Fluc spheres in mice, cells were dissociated with Accutase 
(Innovative Cell Technologies, San Diego, CA) 2 days before injection.  On the day 
of injection the majority of spheres were of medium size of approximately 100 
cells/sphere, which were left intact for implantation.  Approximately 3x105 cells (3000 
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spheres) were injected per mouse in a volume of 3 l at 0.3 l/min using the 
microsyringe pump and a 33-gauge needle as above. 
For AAV vector injection, mice were anesthetized as above and injected 
intracranially using the same coordinates as for tumor injections.  AAV vectors were 
infused at a rate of 0.2 L/min using a Micro 4 Microsyringe Pump Controller 
attached to a Hamilton syringe with a 33-gauge needle.  
 
In vitro and in vivo luciferase imaging. D-luciferin was purchased from Gold 
Biotechnology® (St. Louis, MO) and resuspended at 25 mg/ml in PBS.  For Fluc 
imaging, mice were injected i.p. with 200 mg/kg body weight of D-luciferin and 
imaging was performed 10 min later.  Coelenterazine was obtained from 
NanoLight™ Technology (Pinetop, AZ) and resuspended at 5 mg/ml in acidified 
methanol.  For Gluc imaging, mice were injected i.v. (through retro-orbital sinus) with 
5 mg/kg body weight of coelenterazine solution diluted in PBS and imaging was 
performed immediately.  Vargulin substrate (Cypridina luciferin) was obtained from 
NanoLight™ Technology and was resuspended at 5 mg/ml in acidified methanol or 
from Targeting Systems, sold as a solution.  For Vluc as a marker for cell 
proliferation, and since Vluc was shown to be stable in the conditioned medium, we 
refreshed the media of cells 4 hours before measurements to avoid accumulation of 
the reporter. For Vluc in vivo imaging, mice were injected i.v. (unless otherwise 
noted) with 4 mg/kg body weight (diluted in PBS) and imaging was performed 
immediately. Imaging was performed using an IVIS® Spectrum optical imaging 
system fitted with an XGI-8 Gas Anesthesia System (Caliper Life Sciences, 
Hopkinton, MA).  Bioluminescent images were acquired using the auto-exposure 
function. Data analysis for signal intensities and image comparisons were performed 
using Living Image® software (Caliper Life Sciences).   
 
TRAIL ELISA. The functionality of the AAV-sTRAIL vector was tested by transducing 
U87 cells with 104 g.c./cell with AAV2-sTRAIL or a negative control vector AAV2-
GFP. Three days later, media was harvested from all wells and a Quantikine Human 





 Statistical analysis. Statistical analysis was performed using GraphPad Prism 
version 5.01 software (LaJolla, CA).  For comparisons between two samples, an 
unpaired two-tailed t test was performed.  A p value of < 0.05 was considered to be 
statistically significant.  For analysis between multiple groups, a one-way analysis of 
variance (ANOVA) was performed followed by a Bonferroni’s Multiple Comparison 
Test to compare 2 groups.    
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Gaussia Luciferase (Gluc) has proven to be a powerful mammalian cell reporter for 
monitoring numerous biological processes in immunology, virology, oncology and 
neuroscience. Current limitations of Gluc as a reporter include its emission of blue 
light, which is absorbed by mammalian tissues, limiting its use in vivo, and a flash-
type bioluminescence reaction, making it unsuited for high-throughput applications. 
To overcome these limitations, a library of Gluc variants was generated using 
directed molecular evolution and screened for relative light output, a shift in emission 
spectrum, and glow-type light emission kinetics. Several variants with a 10-15 nm 
shift in their light emission peak were found. Further, a Gluc variant that catalyzes a 
glow-type bioluminescence reaction yielding over 10 minutes of stable light output, 
suited for high-throughput applications, was also identified.  These results indicate 






Bioluminescence imaging (BLI) is currently one of the most valued and widely used 
techniques in basic biomedical research.1-3 Bioluminescence relies on the 
conversion of chemical energy into visible light in culture or in living animals. This 
reaction is dependent on a luciferase enzyme which, in the presence of oxygen, 
causes a biochemical conversion of the luciferin substrate resulting in emission of 
light.1 In the past decade, bioluminescence imaging has become indispensable for 
non-invasive monitoring of biological processes including gene expression,4, 5 
protein-protein interactions,6-8 T-cell and stem cell trafficking,9, 10 tumorigenesis and 
response to therapy,4, 11, 12 and has further been used as a read-out for high-
throughput screening assays in drug discovery.13, 14 Although many luciferases exist, 
only a few are currently in use. As a mammalian cell reporter, luciferase needs to 
meet certain criteria including a distinct emission spectrum ideally with a significant 
red component (for in vivo applications), and a high quantum yield without 
intracellular accumulation of substrate to allow for real-time monitoring of enzyme 
expression1-3. Examples of frequently used luciferases are from the American firefly 
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Photinus Pyralis (Fluc), Renilla reniformis (Rluc), Gaussia princeps (Gluc) and 
Vargula hilgendorfi  (Vluc)1.  Recently, differences between properties of these 
luciferases including specificity to different substrates, spectral emission, or 
bioluminescence half-life, were used to develop multiplex reporter systems by which 
several cellular processes can be monitored simultaneously.15-17 The next step to 
further improve the field of bioluminescence is to generate more stable, brighter and 
variants with different light emission properties suited for different applications.  
 
Gaussia luciferase from the marine copepod Gaussia princeps has many 
advantageous properties over other luciferases including high signal intensity, a 
favorable enzyme stability, and a secretion signal, making it suitable for real time ex 
vivo monitoring of biological processes in medium of cultured cells and blood or urine 
in animals.18-20 Gluc is a monomeric protein composed of 185 aa (19.9 kDa) that 
uses coelenterazine as a substrate. It is the smallest luciferase known with a peak 
light emission at around 470 nm and a broad spectrum extending up to 600 nm.19  
Since Gluc does not require ATP for activity, in contrast to the commonly used Fluc, 
it can be used as a reporter from cells as well as their immediate environment.  
 
Current limitations of Gluc include signal quenching and absorption of its blue light 
by pigmented molecules when used in vivo and its rapid light decay, making the use 
of a luminometer with a built-in injector essential for immediate reading of signal 
once substrate is added, one well at a time. Several successful attempts have been 
made to optimize Gluc as a mammalian cell reporter. To overcome signal quenching 
when measuring Gluc in the blood ex vivo, we have developed an alternative 
microtiter well-based binding assay in which Gluc is captured from the blood before 
coelenterazine is added leading to around 10-fold increased sensitivity18. We have 
also characterized a Gluc mutant, GlucM43I, which catalyzes stable light output in 
the presence of Triton-X 100 detergent, suited for high-throughput applications.21 
Gluc was also shown to potentially contain 2 catalytic domains, the first covering 
amino acids 27-97 and the second domain covering amino acids 98-168.22 Recently, 
Kim and colleagues developed a semi-rational consensus sequence driven 
mutagenesis strategy to synthesize potent mutant Gluc by comparing sequence 
similarities between the chromophore region of Aequorea green fluorescent protein 
(GFP) and coelenterazine.23 Using this rational and hydrophobicity search, they 
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hypothesized that Gluc active site is between amino acids 71-140, the most 
hydrophilic domain. Site-directed mutagenesis of this active core, similar to those 
performed for GFP, lead to efficient alteration of Gluc properties including variants 
with a shift in emission spectrum [Y97W, I90L and Monsta (combination of F89W, 
I90L, H95E and Y97W mutations)], and enhanced light output (I90L). In this study, 
we used directed molecular evolution to create a Gluc library based on the sequence 
of wild type Gluc and screened around 5000 newly generated clones for increased 
activity, a shift in the emission spectrum, and increased light emission stability.  
Several variants were selected and sequenced for their mutations. One of these 
mutants carrying three different mutations (L30S, L40P, M43V; Gluc4) showed a 
glow-type bioluminescence reaction (as compared to flash reaction for wild-type 
Gluc) with stable light output up to 10 minutes without the need of a detergent, suited 





Construction of Gluc library. A library of Gluc variants was created by shuffling 
cDNA fragments using error-prone PCR. First, the humanized codon-optimized 
cDNA sequence encoding Gaussia luciferase19 (Nanolight, Pinetop, AZ)  was 
amplified by PCR (without the Gluc signal sequence) using Taq polymerase (5 
PRIME, Fisher Scientific, Pittsburgh, PA) and two flanking primers, which introduced 
an EcoRI (upstream primer) and XhoI (downstream primer) restriction sites, using 
the following conditions: 1 cycle of 94 °C-2 min; 35 cycles of: 94 °C-30 s, 58 °C-30 s 
and 72 °C-30 s; 1 cycle of 72 °C -7 min. The PCR product was then digested using 
0.3 Units of DNaseI (New England Biolabs, Ipswich, MA) for 10 min at room 
temperature followed by heat inactivation at 75°C for 15 min after the addition of 
EDTA. The digested DNA was separated on a 2% agarose gel by electrophoresis. 
DNA fragments from ~50–150 base pairs were carefully excised using a sterile 
scalpel. The gel slice was placed in 3,500 MWCO dialysis tubing (Fisher Scientific, 
Pittsburgh, PA) and the DNA was eluted into TBE by electrophoresis for 15 min at 
120V. The DNA was then ethanol precipitated and re-suspended in nuclease-free 
water. The PCR fragments were reassembled into the full-sized product using 
Extensor Hi-Fidelity PCR enzyme mix (Thermo Scientific, Portsmouth, NH) without 
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primers using the following conditions: 1 cycle, 94 °C-2 min; 40 cycles of: 94 °C-30 s, 
45 °C-30 s and 68 °C-30 s. One microliter from this reaction then served as a 
template for a second PCR using the same primers as for error prone PCR above 
and the following conditions: 1 cycle, 94 °C-2 min; 25 cycles of: 94 °C-30 s, 58 °C-30 
s and 68 ° C-30 s; 1 cycle, 68 °C-7 min. The PCR product was gel extracted after 
electrophoresis, digested with EcoRI and XhoI and ligated into a similarly digested 
pHGCx expression vector.19 
 
Screening procedure. HMS174 bacterial cells were transformed with the newly 
created Gluc library by electroporation and spread on ampicillin agar plates. The 
next day, different colonies were collected by a Hudson RapidPick colony picker 
(Hudson Robotics, Inc., Springfield, NJ) and grown for 12 hours in 1 ml of LB media 
at 37 0C in deep 96 well plates. The bacterial cell culture media was then used 
directly to screen for emission spectrum shift using the Flexstation III plate reader 
(Molecular Devices, Sunnyvale, CA). Samples of 50 l were transferred to regular 
white 96 well plates and read with 50 l 40 M coelenterazine (CTZN). The 
remaining bacterial media in the deep 96 well plates were mixed with glycerol and 
frozen at -80 0C. The clones showing differential spectrum shift as compared to wild-
type (wt) Gluc were selected, sequenced for mutations, and cloned into a CSCW 
lentivirus mammalian expression backbone under the control of CMV promoter20 
using upstream primers which re-introduced the signal sequence to the cDNA.  293T 
cells (obtained from ATCC) were then transfected with the different Gluc variants 
using calcium phosphate protocol and two days later, the cell-free conditioned 
medium was collected and used for the different bioluminescent assays.  Lentivirus 
vectors were packaged as previously described.18-20 
 
Bioluminescence assays. The emission spectrum for the different Gluc variants 
was confirmed using a Cary Eclipse Fluorescence Spectrophotometer (Varian, Inc., 
Palo Alta, CA) that reads the full spectrum within milliseconds (averaging reading 
time per sample of 5 msec). Emission spectrum analysis was performed using 100 ȝl 
of conditioned medium brought up to 500 ȝl in 1X PBS in a cuvette followed by 
addition of 500 ȝl CTZN (8 ȝg/ml diluted in PBS). The emission slit (nm) was set to 
10-round, under a 400-600 nm emission wavelength window, using the 
bio/chemiluminescence setting. For relative activity comparison, 293T cells were 
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plated in 6-well plates and co-transfected with 0.5 g of different Gluc variants and a 
similar amounts of a plasmid expressing firefly luciferase and mCherry fluorescent 
protein under control of CMV promoter (CSCW-Fluc-ImCherry)20 as above. Forty-
eight hours later, cells were analyzed by fluorescent microscopy for mCherry 
expression for transfection efficiency. Ten microliter aliquots (in 5-plicates) of the 
conditioned medium were assayed for Gluc activity as above. Cells were then lysed 
in 200 ȝl 1xRLB lysis buffer (Promega) and 20 ȝl aliquots of lysates (in triplicates) 
were assayed for Fluc activity using 80 ȝl of FLAR reagent (Targeting Systems, El 
Cajon, CA) and a luminometer (Model MLX, Dynex Technologies) that was set to 
read for 10 sec and integrate the signal for 2 sec.  Fluc reads were used to normalize 
for transfection efficiency between wells. The enzymatic activities of different Gluc 
mutants over multiple coelenterazine injections were determined by reading 10 ȝl 
samples of conditioned medium in a 96 well microtiter plate using the Dynex 
luminometer while multiple injections of 20 ȝl of CTZN (8 ȝg/ml, in PBS) was added 
to the same wells and signal was recorded immediately after each injection; we used 
a 1 sec reading time and 10 different injections of CTZN per well, resulting in a total 
of 10 reads. The kinetic assay was performed by transferring 10 ȝl aliquots of 
conditioned medium (in 5-plicates) to a 96 well white plate, automatically injecting 40 
ȝl 8 ȝg/ml CTZN in PBS (with or without 0.01% Triton) and recording kinetic intervals 
of 14 seconds over 10 min using the Flexstation III instrument (Molecular Devices). 
For validation of Gluc4 for high-throughput applications, 15 ȝl aliquots of conditioned 
medium from cells expressing wt Gluc, GlucM43I or Gluc4 were first transferred to a 
384 well plate (in triplicates) using an automated dispenser (Multidrop Combi, 
Thermo Scientific). In a similar fashion, 45 ȝl 8 ȝg/ml CTZN diluted in PBS was also 
dispensed into each well and the plate was then analyzed using the Flexstation III 
that was set to read for 50 msec/well. In another experiment, U87 human glioma 
cells (ATCC) expressing either Gluc4 or wt Gluc were plated in a 96-well plate.  The 
next day, several wells/plate were marked and treated with 1 mM temozolomide 
(Sigma).  Seventy-two hours later, 10 ȝl aliquot of conditioned medium was 
transferred to a white plate followed by the addition of 45 ȝl 8 ȝg/ml CTZN/well using 
an automated dispenser and acquiring photon counts using the Dynex luminometer 




Cloning multiple mutations. All mutations derived from the screen were located in 
the first catalytic domain of Gluc as described.22 Mutations were then transferred to 
the second catalytic domain by site directed mutagenesis, using PCR to create the 
desired point mutations for GlucL40P, GlucM43V, and GlucL40S variants, resulting 
in Gluc1 (L40S, E111S), Gluc2 (L30S, M43V, I114V), Gluc3 (L40P, E111P) and 
Gluc4 (L40P, M43V, L30S). For each Gluc variant, the desired mutation was 
incorporated using an overlapping PCR strategy. Using the screen derived Gluc 
variant cDNA as a template, two flanking Gluc primers which introduce a 5’ NheI site 
and a 3’ XhoI site were used for direct cloning of the final PCR product into CSCW 
plasmid. Two complementary inner primers were designed with a desired sequence 
mismatch to alter the codon of interest. Three different PCR reactions were 
performed to incorporate the mutation using specific primer sets (Supplementary 
Table 2): PCR 1 used Gluc variant cDNA as template and the forward flanking NheI 
primer combined with the reverse mutagenic primer. PCR 2 using the reverse 
flanking XhoI primer and the forward mutagenic primer.  Specific bands for PCR 1 
and 2 were gel extracted and 2 l of PCR product from PCR 1 and 2 were then used 
as template for overlapping PCR (PCR 3) using the flanking primers.  All PCR 
reactions were performed using Phusion high fidelity polymerase (New England 
Biolabs). Correct incorporation of specific mutations was confirmed using DNA 
sequencing at the Massachusetts General Hospital DNA core facility. The full length 
PCR product was digested with NheI and XhoI and ligated with similarly digested 
CSCW lentivirus plasmid.  The PCR primer sequences used in this study can be 
found in Supplementary Tables 1 and 2.  
 
Statistical Analysis. All experiments were repeated at least 5 times to achieve 
statistical significance. Data are presented as the mean relative light units (RLU) ± 
standard deviation (SD) from 5 different replicates in each experiment. P values 
were calculated using Student’s t-test. Relative reaction kinetics, turnover rates, and 








RESULTS AND DISCUSSION 
 
Recently, through hydrophobicity search and by comparing sequence similarities 
between the chromophore region of Aequorea green fluorescent protein (GFP) and 
coelenterazine, Kim et al suggested that the Gluc active core ranges between amino 
acids 71-140.23 We took an alternative strategy and used directed molecular 
evolution to shuffle Gluc cDNA to find potent Gluc variants. Table 1 shows potential 
Gluc variants and their corresponding mutations derived from our screen.  
 
Table 1. Overview of the different Gluc variants and corresponding mutations. 
 
Interestingly, all these Gluc variants were not part of the active core discovered by 
Kim et al., suggesting that Gluc could have another potential putative core region. 
Importantly, none of these mutations were found in 10 random clones from the 
original Gluc plasmid library showing that our library is fairly diverse (data not 
shown). Another study suggested that Gluc contains two catalytic domains and 
therefore two coelenterazine binding pockets.22 According to this study, all mutations 
derived from our screen are found in the first catalytic domain (amino acids 27-97; 
Fig. 1). We therefore attempted to enhance our mutants by also changing the 
corresponding amino acids in the second catalytic domain (amino acids 98-168) 
creating Gluc1, Gluc2 and Gluc3 variants (Fig. 1 and Table 1). Finally, we attempted 
to amplify our mutants by combining different mutations into a single Gluc cDNA 





Figure 1. Gluc variants and corresponding mutations in the second active domain 
characterized in this study. Shown, the Gluc signal peptide covering amino acids 1-27, 
first active domain covering amino acids 27-97, and second active domain covering amino 
acids 98-168. 
 
Variants were first screened for a shift in emission spectrum using the Flexstation III 
device which is a slow reader requiring several minutes to read the full spectrum. 
Results could therefore be confounded by the kinetic properties of each clone (e.g. 
flash versus glow emission). All our shifted clones were confirmed using a Cary 
Eclipse Fluorescence Spectrophotometer, which reads the full spectrum in 
milliseconds. Upon conformational analysis, we found that GlucL40P, GlucL40S and 
Gluc4 (L30S, L40P, M43V) showed a 10-15 nm shift in light emission peak as 
compared to wild-type (wt) Gluc (Supplementary Fig. 1). Mutating the corresponding 
amino acid in the second active domain (Gluc1, Gluc2 and Gluc3) did not have an 
additional effect on the emission spectrum (data not shown). These results suggest 
that this strategy could be used to find Gluc mutants with different emission spectra 
suited for different applications. 
 
 
  SS        
  MGVKVLFALICIAVAEA 
          
  1) 
Gluc wt  KPTENNEDFNIVAVASNFATTDLDAD  
GlucL40P  KPTENNEDFNIVAVASNFATTDLDAD  
GlucL40S  KPTENNEDFNIVAVASNFATTDLDAD  
GlucL30S,M43V  KPTENNEDFNIVAVASNFATTDLDAD 
Gluc1   KPTENNEDFNIVAVASNFATTDLDAD 
Gluc2  KPTENNEDFNIVAVASNFATTDLDAD 
Gluc3   KPTENNEDFNIVAVASNFATTDLDAD  
Gluc4    KPTENNEDFNIVAVASNFATTDLDAD  
Gluc5    KPTENNEDFNIVAVAKNFATTDLDAD  
 
  27) 




Gluc1  RGKLPGKKLPLEVSKEMEANARKAGCTRGCLICLSHIKCTPKMKKFIPGRCHTYEGDKESAQGGIGEAIVD 
Gluc2  RGKSPGKKLPLEVLKEVEANARKAGCTRGCLICLSHIKCTPKMKKFIPGRCHTYEGDKESAQGGIGEAIVD 
Gluc3  RGKLPGKKLPLEVPKEMEANARKAGCTRGCLICLSHIKCTPKMKKFIPGRCHTYEGDKESAQGGIGEAIVD 
Gluc4      RGKSPGKKLPLEVPKEVEANARKAGCTRGCLICLSHIKCTPKMKKFIPGRCHTYEGDKESAQGGIGEAIVD 
Gluc5   RGKLPGKKLPLEVLKEVEANARKAGCTRGCLICLSHIKCTPKMKKFIPGRCHTYEGDKESAQGGIGEAIVD 
 
  98) 




Gluc1  IPEIPGFKDLEPMSQFIAQVDLCVDCTGCLKGLANVQCSDLLKKWLPQRCATFASKIQGQVDKIKGAGGD 
Gluc2  IPEIPGFKDLEPMEQFVAQVDLCVDCTGCLKGLANVQCSDLLKKWLPQRCATFASKIQGQVDKIKGAGGD 
Gluc3  IPEIPGFKDLEPMPQFIAQVDLCVDCTGCLKGLANVQCSDLLKKWLPQRCATFASKIQGQVDKIKGAGGD 
Gluc4  IPEIPGFKDLEPMEQFIAQVDLCVDCTGCLKGLANVQCSDLLKKWLPQRCATFASKIQGQVDKIKGAGGD 




We then compared the relative activities of different Gluc variants to wt Gluc.  293T 
cells were co-transfected with an expression plasmid for Fluc and each of the Gluc 
variants, or wt Gluc.  Forty-eight hours later, aliquots of conditioned medium were 
assayed for Gluc activity. Cell lysates were assayed for Fluc activity, which was used 
to normalize for transfection efficiency. Gluc5 (S16K, M43V, V159M) showed to have 
around 2-fold enhanced activity as compared to wt Gluc (Fig. 2a). Further, Gluc4 
carrying multiple mutations and all variants with corresponding mutations in the 
second active domain (Gluc1, Gluc2, Gluc3) showed to have 10-100x less activity as 
compared to wt (Fig. 2a). These results suggest that these amino acids in the 
second active domain are important for Gluc activity.   
 
To further characterize these new Gluc variants, we compared their light output to wt 
Gluc after several substrate injection/read intervals to gain insight into enzymatic 
turnover rate of these variants.  GlucL30S/M43V and GlucL40P with similar activity 
to wt Gluc (Fig. 2a) showed increasing activities after each substrate injection, 
reaching a plateau after 2-3 rounds of injections (Fig. 2b). Interestingly, the 
combination of these two variants (Gluc4) showed even higher turnover rate where 
the signal continued to increase even after 6 rounds of substrate addition, proving 
that these mutations are important for this characteristic (Fig. 2b). Gluc3 variant 
containing the corresponding mutation in the second Gluc active domain also 
showed higher activities over multiple injections as compared to wt Gluc (Fig. 2b). 
These properties suggest a higher turnover rate of these Gluc variants.   
 
Next, we determined the bioluminescent reaction kinetics of all Gluc variants. Since 
our laboratory previously reported on a Gluc variant which catalyzes a stable light 
output in the presence of TritonX-100 (GlucM43I),21 we decided to include this 
variant and assay all variants in the presence and absence of this detergent. 
Remarkably, all Gluc variants, with the exception of Gluc5 (S16K, M43V and V159M) 
and GlucM43I, showed higher stable light output as compared to wt Gluc, which 
typically catalyzes a flash-type reaction in the absence of the detergent (Fig. 2c). 
Gluc variants containing corresponding mutations in the second active domain 
[Gluc1 (L40S and E111S); Gluc3 (L40P and E111P)], having lower relative activity, 
showed enhanced light output stability. More importantly, the Gluc4 variant carrying 
multiple mutations which had lower activity and higher turnover rate (Fig. 2a, b) 
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displayed a glow-type reaction with ~20% loss in signal over 10 minutes without the 
need of a detergent (Fig. 2c). All variants including the wt Gluc showed higher stable 
light output in the presence of TritonX-100, however, L40P, L40S, Gluc1, Gluc2, 
Gluc3 and Gluc4 exhibited the highest stability (Fig. 2c). As expected, the addition of 
the detergent decreased the light output of all variants and native Gluc by around 
one log of magnitude21 (data not shown).   
 
 
Figure 2. Characterization of different Gluc variants. 293T cells were transfected with 
different Gluc variants or wt Gluc and 48 hours later, aliquots of the conditioned medium 
were assayed for different properties. (a) Relative activity of each Gluc variant normalized to 
Fluc signal, a marker for transfection efficiency. (b) Enzymatic activity over repeated 
injections of coelenterazine (diluted in PBS) followed by signal acquisition using a plate 
luminometer with a built-in injector. (c) Bioluminescence light emission kinetics for each Gluc 
variant was analyzed by adding coelenterazine (diluted in PBS in the presence or absence 
of TritonX-100) and acquiring photon counts every 14 seconds over a period of 10 minutes 
using a luminometer. 
 
Since Gluc4 showed to have the most stable light output without the need of TritonX-
100, and since detergents could interfere with some assays such as live cell 
analysis, protein assays, or enzymatic activities, we decided to evaluate this variant 
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using Gluc as a cell viability marker.13 Since Gluc is secreted, aliquots of the 
conditioned medium can be assayed over time, allowing functional analysis of drug 
kinetics. In this study, we have used the native Gluc as a viability marker and 
therefore measurements of one well at a time using a luminometer with a built-in 
injector was essential due to the flash-type reaction kinetics of this reporter, limiting 
the numbers of drugs that can be screened.13 A Gluc variant that catalyzes a glow-
type reaction would be extremely helpful in the field of drug discovery allowing for 
high-throughput approach without the risk of confounding results due to kinetic 
instability (wt Gluc) or to interactions with detergents such as TritonX-100 
(GucM43I). 293T Cells were infected with a lentivirus vector carrying the expression 
cassette for wt Gluc, GlucM43I or Gluc4 under the control of CMV promoter. Aliquots 
of conditioned medium from these cells were transferred to a 384 well plate and read 
under high throughput conditions by adding coelenterazine (diluted in PBS) to all 
wells simultaneously and acquiring photon counts for 50 msec/well, resulting in a 
read-time of <1 minute per plate. As expected, the signal from wt Gluc and GlucM43I 
variant decreased over the course of measurements of different columns in the 384-
well plate, with around 50% signal loss between the first and last columns (Fig. 3a,b 
and Supplementary Fig. 2). On the other hand, there was no significant signal loss of 
Gluc4 activity among all columns showing the usefulness of this variant for high-
throughput applications (Fig. 3a,b). During this experiment, we noticed that the 
emission of blue light and the stable light emission of Gluc4 is so sensitive that we 
can simply visualize it by naked eye in the dark. Further, despite the fact that Gluc4 
is 100x less sensitive than wt Gluc, this mutant yields 2 logs of magnitude more light 
output when expressed in mammalian cells under our assay conditions, as 
compared to firefly luciferase, the most commonly used mammalian cell reporter 
(Supplementary Fig. 3a). To confirm that this change in relative activity is not due to 
simply different amounts of protein production/expression or secretion levels, 
conditioned medium as well as lysates from cells expressing Gluc4 or wt Gluc were 
analyzed for Gluc protein level by western blotting using anti-Gluc antibody which 
showed nearly equal Gluc protein levels being produced and secreted 
(Supplementary Fig. 3b)  
 
To further evaluate Gluc4 mutant for high-throughput screening, we plated U87 
glioma cells stably expressing Gluc4 or wt Gluc in 96-well plates in triplicate.  We 
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deliberately added temozolomide, a known chemotherapeutic agent against glioma, 
to 12 selected wells that were marked.  Seventy-two hours later, 10 l aliquots of 
conditioned medium were transferred to a new 96-well plate, to which coelenterazine 
was added to all wells simultaneously using an automated injector, followed by Gluc 
signal acquisition (column by column) using a plate luminometer. The Gluc4 mutant 
showed signal stability across all columns in the plate.  Upon data analysis for 
positive hits defined as >50% decrease in Gluc activity and therefore cell viability, 
Gluc4 revealed 100% of the “true” hits (selected wells to which the drug was added) 
without any false-positives (Fig. 3c,d). On the other hand, the wt Gluc signal 
decreased across all columns; the last column of the plate had >80% lower signal 
compared to the first column.  In this case, wt Gluc revealed 51 false positive hits, 
which is more than half of the screened plate (Fig. 3c,d). These data suggests that 






Figure 3. Gluc4 variant displays a glow-type reaction suited for high-throughput 
applications. (a-b) Aliquots from conditioned medium of cells expressing wt Gluc, or Gluc4 
were dispensed in 3 different 384-well plates in a high-throughput fashion followed by 
addition of coelenterazine (diluted in PBS) to all wells and signal acquisition (50 msec/well) 
using the Flexstation III device. Data presented in (a) as average raw RLUs/column ± SD 
and in (b) as average %RLU/column ± SD in which the first well was set at 100%. (c-d) U87 
human glioma cells expressing Gluc4 or wt Gluc were plated in a 96-well plate and 12 
wells/plate were marked and treated with 1 mM temozolomide. Seventy-two hours later, 10 
l aliquots of conditioned medium were transferred to a new 96-well plate to which 45 l of 
coelenterazine was added to all wells simultaneously and signal was acquired using the 
Dynex luminometer column by column. Raw data is showing in (c) highlighting the “true” hits 
and false-positives using the Gluc4 or wt Gluc. (d) Scatter plot of each plate in which data 
are presented as %RLU where the first well of the first column was set at 100%.   
 
In conclusion, using directed molecular evolution, we identified several Gluc variants 
with a shift in emission spectrum (up to 15 nm) and enhanced light-output stability. 
We showed that mutations in the second active domain of Gluc could have dramatic 
effect on light emission intensity, but have advantages with respect to turnover rate 
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and bioluminescence reaction kinetics. We also discovered a Gluc variant (Gluc4) 
that catalyzes a glow-type reaction with <20% decrease in signal over 10 min, suited 
for high-throughput applications.  Interesting, all these mutations were not part of the 
Gluc active core recently discovered by Kim et al.,23 suggesting another potential 
Gluc putative core domain. Aside from the given useful improvements of the current 
repertoire of available Gluc variants, these clones and their mutations shed new light 
on the structure and biophysical characteristics of Gluc giving insight towards the 
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Luciferases have proven to be useful tools in advancing our understanding of 
biological processes. Having a multitude of bioluminescent reporters with different 
properties is highly desirable. Here, we characterized codon-optimized thermostable 
green- and red-emitting luciferase variants from the Italian firefly Luciola italica for in 
vivo imaging.  Using lentivirus vectors to deliver and stably express these luciferases 
in mammalian cells, we showed that both variants displayed similar levels of activity 
and protein half-lives as well as similar light-emission kinetics. Further, we 
characterized the red-shifted variant for in vivo bioluminescence imaging.  
Intramuscular injection of tumor cells stably expressing this variant into nude mice 
yielded a robust luciferase activity.  Light emission peaked at 10 minutes post-D-
luciferin injection and retained >60% of signal after 1 hr. Similarly, luciferase activity 
from intracranially-injected glioma cells expressing the red-shifted variant was readily 
detected and used as a marker to monitor tumor growth over time. Overall, our 
characterization of these codon-optimized luciferases lays the groundwork for their 





 Bioluminescence imaging (BLI) using luciferase reporters has provided crucial 
information regarding many biological processes including tumorigenesis, bacterial 
pathogenesis, and transcription factor activation1-3.  The major advantage of BLI 
compared to endpoint analysis is that it provides real time, non-invasive analysis of 
in situ biological events, thereby giving a complete “picture” of the kinetics of an 
entire process.  Great strides have been made since the seminal study by Contag et 
al. published in 1995 which was the first demonstration  of  in vivo BLI4. For example, 
as few as 10 cells expressing an optimized American firefly luciferase can be 
detected in mice5.  Additional progress has been made by the discovery and codon 
optimization of the naturally secreted Gaussia princeps luciferase, allowing for 
sensitive detection of in vivo biological processes by simple blood sampling6. The 
discovery of luciferases as well as the genetic engineering of existing luciferases 
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which emit light at longer wavelengths, thus reducing tissue absorption of light, has 
enhanced the sensitivity of in vivo BLI7,8, 9.      
 The luciferase with the most biochemical characterization is from the North 
American firefly Photinus pyralis (Fluc). Fluc catalyzes a two-step reaction in which 
luciferin is first adenylated through an ATP-dependent mechanism.  Next, molecular 
oxygen is used to oxidize the adenylated intermediate yielding oxyluciferin, a 
molecule in an excited energy state.  Upon decay of excited state oxyluciferin, a 
photon of light is emitted10. Due to the high quantum yield of the luminescence 
reaction, Fluc was pursued as a reporter enzyme.  Since its cloning and expression 
in mammalian cells in 198711, Fluc has become the “workhorse” of the molecular 
biology lab as a reporter for gene expression and ATP levels in cells12, 13 as well as 
non-invasive monitoring of in vivo processes using bioluminescence imaging 
technology14. 
Subsequently, other luciferases have been cloned and characterized for 
bioluminescence imaging in an attempt to increase detection sensitivity as well as 
dual parameter measurement. Luciferases which catalyze red-shifted light (emission 
peak >600nm)15 or mutations of existing luciferases to a red-shifted emission 
spectra16 have improved the sensitivity of detection as light absorption by 
mammalian tissues and hemoglobin decreases greatly above 600 nm17.  Renilla 
reniformis luciferase (Rluc) and Gaussia princeps luciferase (Gluc) utilize 
coelenterazine as a substrate, in contrast to Fluc, and therefore sequential imaging 
of Fluc and Gluc or Rluc in vivo can be used to monitor two different biological 
processes18.  Recently, the cDNA encoding the green-emitting luciferase from the 
Italian firefly Luciola italica (liFluc) was cloned by Branchini et al.  which has 64% 
amino acid identity with the luciferase from Photinus pyralis19. This luciferase has 
several advantages over Fluc including thermostability and higher enzyme turnover 
leading to approximately 2-fold higher light output19.  Further, using standard 
mutatagenesis, a red-shifted variant was characterized20.  liFluc has been expressed 
and purified from bacteria and was used for cell based assays20, however, a codon-
optimized variant for mammalian gene expression has not been established for in 
vivo imaging. In the current study, we characterize codon-optimized variants of both 
the green- and red-emitting liFluc for mammalian gene expression and use the 
ladder for in vivo bioluminescence imaging in small animals.   
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MATERIALS AND METHODS 
 
Cell culture and reagents. 293T human kidney fibroblasts cells, U87 human glioma 
cells (both from American Type Culture Collection, Manassas, VA) and Gli36 human 
glioma cells (kindly provided by Dr. Anthony Capanogni, University of California at 
Los Angeles, Los Angeles, CA), were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO), 
100 U/ml penicillin, and 0.1 mg/ml streptomycin (Sigma), referred to as complete 
DMEM. All cells were grown at 37 0C in a 5% CO2 humidified atmosphere. 
Lentivirus vector construction. Human codon optimized cDNA variants of both green 
emitting Luciola italica luciferase (G-liFluc) and red emitting (R-liFluc) were kindly 
provided by Dr. Rampyari Walia (Targeting Systems, El-Cajon, CA).  These cDNAs 
were cloned into a lentivirus vector plasmid, CSCW21. Transgene expression in this 
plasmid is driven by a cytomegalovirus (CMV) promoter with the inclusion of an 
internal ribosomal entry site (IRES) for co-expression of mCherry red fluorescent 
proteins to allow for titering and transduction confirmation6. Both G-liFluc and R-
liFluc coding sequences were PCR-amplified using Pfu polymerase (Agilent 
technologies, Santa Clara, CA) and the following primers:  Forward primer, 5’ 
ATAGCTAGCGATCCATGGAAACAGAAAG3’; reverse  primer, 
5’TACTCGAGACTACCCACCTGCTTGAGGT 3’. The thermalcycler conditions were 
1 cycle of 94ºC for 2 min; 30 cycles of 94 ºC for 45s, 60 ºC for 45s, 72 ºC for 90s; 1 
cycle of 72 ºC for 10 min.  The forward primer was synthesized with an NheI site and 
the reverse with an XhoI restriction site for ligation with similarly-digested CSCW-
ImCherry plasmid. Constructs were named CSCW-GliFluc-ImCherry and CSCW-R-
liFluc-ImCherry. A lentivirus vector encoding the Gaussia luciferase (Gluc) and the 
Cerulean fluorescent protein (CFP) separated by an IRES (CSCW-Gluc-ICFP) was 
described previously22. Lentivirus vectors were produced as described before21 and 
vector titers (transducing units/ml) were determined by performing serial dilutions of 
vector stocks on 293T cells followed by counting the number of mCherry or CFP 
positive 293T cells 3 days later using fluorescence microscopy.   
Lentivirus vector transduction. For side by side comparison of G-liFluc and R-liFluc 
luciferases, Gli36 and U87 human glioma cells were engineered to stably express 
both Gluc and either one of these luciferases. Around 350,000 cells were plated in a 
6 well plate. The Next day, cells were first transduced with the CSCW-Gluc-ICFP 
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lentivirus using a multiplicitiy of infection (MOI) of 50 in the presence of 10 g/mL 
Polybrene in 3 mL.  The plate was centrifuged at 1800 rpm for 1 hr at room 
temperature. Afterwards, cells were cultured overnight. Seventy-two hrs later, the 
same protocol was applied to transduce the same cells with either CSCW-RliFluc-
ImCherry or CSCW-GliFluc-ImCherry. The CFP (a marker for cell number) and 
mCherry (marker for transduction efficiency) fluorescence intensities in both cell lines 
was quantified using a FlexStation® 3 microplate reader (Molecular devices, 
Sunnyvale, CA).   
In vitro Gaussia luciferase assay. 104 cells/well were plated in a 96 well plate. After 
24 h, cells were washed once with 50 L PBS and lysed on the plate in 50 L lysis 
buffer (Targeting systems, El Cajon, CA). From each well, 20 L cell lysates were 
transferred to a standard white opaque 96 wells plate for endpoint luminescence 
measurement using the FlexStation® 3 microplate reader. 50 L 10 M 
coelenterazine in PBS was injected into each well and photon count was measured 
immediately for 500 ms. 
In vitro Luciola italica luciferase assays. A 20 L aliquot from cell lysates was 
transferred to a white opaque 96 well plate. 80 L FLAR-1 Luciferase Assay Kit 
reagent (Targeting systems, El Cajon, CA) was added and total luminescence was 
measured for 500 ms.  
Luciferin dosing studies. 80 L of different D-luciferin concentrations (Gold 
biotechnology, St Louis, MO; diluted in PBS containing 2 mM ATP) ranging from 0.5 
M to 50 mM were added into wells containing 20 L of lysates from Gli36 cells 
expressing either G-liFluc or R-liFluc.  Photon count was acquired for 500 ms using 
the microplate reader. 
Stability of luciferases. 5x105 cells plated in a well of a 6 well plate were lysed in 500 
L of cell lysis buffer. A 65 L aliquot of cell lysates was frozen immediately. Lysates 
were incubated for 30 min, 1h, 2h, 4h and 6h at 37 °C. In triplicate, 20 L aliquots 
from each time point was transferred into an opaque 96 well plate and 80 L FLAR 
reagent was injected per well.  Luminescence was acquired as above. 
Kinetic assays. 20 L aliquots of lysates from Gli36 cells stably expressing G-liFluc 
or R-liFluc (104 cells lysed in 50 L) were mixed with 80 L 830 M D-Luciferin (in 
PBS containing 2 mM ATP). Luminescence was acquired for 500 ms every 20 
seconds for 4 minutes using the microplate reader.  
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Spectral analysis of G-liFluc and R-liFluc light emission. 80 L of FLAR reagent was 
added to 20 L of cell lysates and light emission was measured using the microplate 
reader every 10 nm using the device’s emission monochromator.  
In vivo experiments. All animal experiments were approved by the Massachusetts 
General Hospital Subcommittee on Research Animal Care. Athymic nude mice were 
anesthesized with a mixture of Ketamine (100 mg/kg) and Xylazine (5 mg/kg) in 
0.9% sterile saline. For intramuscular injection (n=4), 3x106 (in 25 L) Gli36 cells 
expressing R-liFluc and Gluc were mixed with equal volume of MatrigelTM (BD 
Biosciences, San Jose, CA) and injected using an insulin syringe.  For the brain 
tumor model, 105 U87 cells expressing R-liFluc and Gluc (in 1 L PBS) were 
intracranially injected in the left midstriatum of nude mice (n=4) using the following 
coordinates from bregma in mm: anterior-posterior +0.5, medio-lateral +2.0, dorso-
ventral í2.5. These injections were performed using a Micro 4 Microsyringe Pump 
Controller (World Precision Instruments, Sarasota, FL) attached to a Hamilton 
syringe with a 33-gauge needle (Hamilton, Rena, NV) at a rate of 0.2 L/min.  
 
In vivo bioluminescence imaging. Bioluminescence images were obtained at different 
time points post-implantation of tumor cells. Mice were anesthesized as above. 
Initially, 20 L blood was drawn from the tail vein of each mouse and mixed with 2 L 
20 mM EDTA which was stored on ice until assayed. Mice were then 
intraperitoneally (i.p.) injected with 150 L of D-luciferin (150 mg/kg body weight).  
Ten min later, photon count was acquired using a cryogenically-cooled CCD camera 
for 1 min as described23. For in vivo light emission kinetics, imaging was performed 
every 5 minutes for 1h, starting immediately upon substrate injection. CMIR-Image 
software, developed by the Center for Molecular Imaging Research at the 
Massachusetts General Hospital, was used to process the data and quantify signal 
intensity. Total bioluminescent signals, representing the sum of 1 minute photon 
counts, are shown in a pseudo-color photon count manner. Images were fused with 
a gray-scale white light image to allow anatomic localization. 
Gluc blood assay. The Gluc-blood assay was performed as described24.  Briefly, 5 
L blood was transferred into a white opaque 96-well plate and 100 L 100 M 
coelenterazine was injected to each well and the total luminescence was acquired 






Expression of codon-optimized variants of the Luciola italica luciferase in 
mammalian cells 
To ascertain the utility of the codon-optimized green- and red-emitting variants of the 
Luciola italica luciferase as mammalian cell reporters, we cloned the cDNA of either 
variant into a lentivirus vector plasmid.  Cells were first transduced with a lentivirus 
vector encoding Gaussia princeps luciferase (Gluc) and the Cyan fluorescent protein 
expressed using an internal ribosomal entry site (IRES) element (Fig. 1A & B). The 
expression of Gluc and CFP is used as an internal control to normalize for cell 
number both in vitro and in vivo as previously described6. These cells were then 
engineered using lentivirus vectors to stably express either the green-emitting G-
liFluc or red-shifted R-liFluc as well as the mCherry Red fluorescent protein 
separated by an IRES element (Fig. 1A). mCherry is used as a marker for 
transduction efficiency for the liFluc construct (Fig 1B). Two weeks post-
transduction, cells were plated in a 96-well plate.  First, the mCherry fluorescence 
intensity was measured using a microplate reader which showed that Gli36 cells had 
1.5-fold higher transduction efficiency with R-liFluc as compared to G-liFluc (Fig. 
1C).  Then, aliquots of lysates from same cells were assayed for Gluc activity to 
normalize for cell number (Fig. 1D).  Finally, the same lysates were analysed for 
liFluc activity. Luciferase activity was 3.6x104 RLU for G-liFluc and 4.4x104 RLU for 
R-liFluc (Fig 1E). When the liFluc values were normalized to transduction efficiency 
(mCherry, Fig. 1C) and cell number (Gluc, Fig 1D), we obtained 2.2x104 RLU for G-
liFluc and 1.2x104 RLU for R-liFluc (Fig. 1F).  This 1.83-fold difference was found to 






Figure 1.  Expression of the codon-optimized Luciola italica luciferase green-emitting 
(G-liFluc) and red-shifted (R-liFluc) variants in mammalian cells. (A) Lentivirus 
expression cassettes used in this study. Gli36 human glioma cells were first transduced with 
a lentivirus vector encoding Gaussia luciferase (Gluc) and CFP (i.) followed by either G-
liFluc (ii.) or R-liFluc (iii.) and mCherry encoding vectors.  (B) Confirmation of successful 
transduction with these vectors using fluorescence microscopy.  Shown are overlays of 
bright field and mCherry fluorescence (i., ii.) and bright field and CFP fluorescence (iii.-iv.).  
Scale bar, 100 m. (C) Transduction efficiency of Gli36 with vectors encoding G-liFluc or R-
liFluc was determined by assaying for mCherry fluorescence using a microplate reader. (D)  
Gluc assay from lysates of same cells using coelenterazine as a substrate. (E) Luciola italica 
luciferase assay on separate aliquot of the same cellular lysates in (D) using D-luciferin as a 
substrate.  (F) Luciola italica luciferase activity normalized for transduction efficiency 
(mCherry levels from C) and cell number (Gluc levels from D).  
 
 
Emission and stability of liFluc variants 
We first confirmed the spectrum of light output from G-liFluc and R-liFluc in 
mammalian cells.  As expected, we obtained an emission spectra with a peak at 550 
nm and 610 nm  for G-liFluc and R-liFluc respectively, which are similar to values 
reported for non-codon optimized variants purified from bacteria20 (Fig. 2A).  Stability 
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assays were then performed for these variants and were compared to the North 
American firefly luciferase (Fluc). Both G-liFluc and R-liFluc showed an increased 
thermostability compared to Fluc (5.3 h and 2 h vs 0.5 h; Fig. 2B).   
 
Dose response of green and red-emitting liFluc to D-luciferin 
To gain insight into the performance of each variant under different substrate 
concentrations, we carried out a dose response analysis of D-luciferin ranging from 1 
M to 50 mM on lysates from Gli36 cells expressing either liFluc. Both G-liFluc and 
R-liFluc displayed a similar dose/activity profile, although at lower doses the G-liFluc 
displayed a substantially higher activity than R-liFluc (Fig. 2C).  For example at a D-
luciferin dose of 5 M, G-liFluc displayed a 5.1-fold higher RLU value than R-liFluc.  
This difference was reduced to 1.27-fold at the 0.5 mM dose (Fig. 2C).  At the higher 






Figure 2.  Characterization of Luciola italica luciferase activity in mammalian cells.  (A) 
Emission spectra of G-liFluc and R-liFluc and the North American firefly luciferase Fluc.  (B) 
Luciola italica luciferase stability at 37qC.  Lysates from cells expressing either G-liFluc, R-
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liFluc or Fluc, were incubated at 37 qC and assayed for luciferase activity at different time 
points.  (C) D-luciferin dose response of G-liFluc, R-liFluc, and Fluc was assayed on lysates 
from B..  (D) light emission kinetics of liFluc variants.  D-luciferin was added to a well 
containing lysates from cells expressing either G-liFluc, R-liFluc or Fluc. Light emission was 
measured every 30 seconds for 5 minutes.   
 
Light emission kinetics for liFluc variants 
 Light emission kinetics after substrate D-luciferin addition was determined for both 
G-liFluc and R-liFLuc in lysates from cells expressing either luciferases. The relative 
light units declined to 50% of starting values at 1 minute for G-liFluc and 46 sec for 
R-liFluc variant (Fig. 2D).  Interestingly, luminescence signal stabilized for R-liFluc at 
2 minutes to 10 minutes post-substrate addition (16% of starting signal) while the 
luminescence continued to decay  for G-liFluc (from 20% to 6%).  
 
In vivo imaging of R-liFluc  
Since light of longer wavelengths is known to have much lower absorption by 
pigmented molecules such as hemoglobin and melanin as well as scattering by 
mammalian tissues, we characterized the red-shifted Luciola italica luciferase R-
liFluc for in vivo deep tissue bioluminescence imaging.  Nude mice were injected into 
the hamstring with 3x106 Gli36 cells expressing R-liFluc.  Forteen-days post-
injection, mice were injected intraperitoneally (i.p.) with 150 mg/kg D-luciferin and 
imaged using a cooled CCD camera.  Light emission was readily detected from 
these muscle tissues (4.03x105 photons/min; Fig. 3A). To determine the optimum 
acquisition time for imaging R-liFluc in deep tissues, we imaged mice immediately 
and at 5 min interval for 1 hr after D-luciferin injection.  Bioluminescence signal was 
detected immediately after injection and peaked at 10 minutes post-substrate 
injection (Fig. 3B).  Signal began to slowly decline at 30 minutes, although never 
dropped below 48% for the 1 hour duration (Fig. 3B).   
 Having confirmed its utility for imaging in muscle tissues, we next tested R-liFluc as 
a reporter to image brain tumors, which requires adequate light to pass through 2.5 
mm of brain tissue as well as ~1mm of skull.  105 U87 glioma cells stably expressing 
R-liFluc-ImCherry and Gluc-ICFP were injected into the striatum of nude mice.  At 
two and three weeks post injection, mice were anesthetized and blood was collected 
and assayed for Gluc activity6, and then mice were i.p. injected with 150 mg/kg D-
luciferin and imaged for R-liFluc 10 min later.  At two weeks post tumor cells 
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implantation, luminescence was detected at an average of 1.23x103 photons/min 
(Fig. 4A).  This signal increase to 8.58x103 photons/min at week 3 post tumor 
injection (Fig. 4A) resulting in a 7-fold increase in signal between the two time points 
proving that R-liFluc can be used as a reporter to monitor biological processes 
including tumor growth over time.  A similar fold increase was observed for Gluc in 
the tumor as assessed by Gluc-blood assay at the same time points (Fig. 4B).   
 
 
      
Figure 3.  Red-emitting Luciola italica luciferase variant for in vivo imaging. 3x106 Gli36 
cells expressing R-liFluc were injected into the hamstring of nude mice.  (A) Two weeks 
later, mice were injected i.p with D-luciferin (150 mg/kg body weight) and imaged 10 min later 
using a cooled CCD camera.  Signal from tumor was quantified using CMIRimage program. 
Data shown are mean ± SD (n=4). (B) Light emission kinetics after injection of D-luciferin.  
Same experiment in (A) was repeated but the luciferase activity was acquired immediately 







Figure 4.  Bioluminescence imaging of brain tumors expressing Red-emitting Luciola 
italica luciferase. A.Luciferase activity from U87 cells stably expressing R-liFluc and Gluc. 
B. The striatum of nude mice were stereotactically injected with 10^5 U87 human glioma 
cells expressing both R-liFluc and Gluc. At 2 and 3 weeks post-tumor implantation, mice 
were intraperitoneally injected with D-luciferin (150mg/kg body weight) and imaged for 
Luciola Italica luciferase activity 10 minutes later using a cooled CCD camera. Intracranial 
brain tumor associated R-liFluc signal (bottom) as quantified using the CMIR-image program 
(top). C. Prior to D-luciferin injection, 5uL blood was collected and assayed for Gluc activity 
after addition of 100uL of 100uM coelenterazine and acquiring photon counts using a 





Luciferases catalyze light producing chemical reaction by oxidizing their substrates, 
luciferin, while emitting photons. This process, known as bioluminescence, is a 
natural phenomenon found in many lower forms of life including fungi, bacteria, 
insects and marine cutaneous. The North American firefly luciferase from Photinus 
pyralis (Fluc) is the best characterized luciferase for luminescence applications and 
has proven invaluable as a biological reporter protein25, 26.  Oxidation of D-luciferin by 
Fluc results in a high quantum yield of light emission leading to a sensitive detection.  
Less than 104 molecules of Fluc protein can be detected using a standard luciferase 
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assay27.  However, the yellow-green color of light emission is suboptimal for in vivo 
imaging. Although there is single report of a red-shifted variant of Fluc with enhanced 
in vivo luminescence properties16, the availability of other luciferases expands the 
potential of advancing our understanding of biological processes. Our results 
broaden the characterization of the Luciola italica luciferase as a promising biological 
reporter in mammalian cells.  Using green and red-emitting codon-optimized, liFluc 
variants, we observed a robust luciferase activity in cultured mammalian cells.  
Additionally, we found that the red-emitting variant was a valuable tool for in vivo 
bioluminescence imaging of tumors in deep tissues. 
 One important characteristic of luciferases for molecular biological 
applications is thermostability. For measurement of luciferase activity in cultured 
cells or tissue homogenates, cells are lysed and the luciferase protein is subject to 
degradation/inactivation by proteases, pH changes, and temperature fluctuations28, 
29.  This has implications for storage conditions of samples post cell lysis.  We found 
that both the G-liFluc and R-liFluc variants had a 10 and 4-fold increase in half-life 
activity compared to Fluc. This may lower the amount of signal decay between 
sample harvest and freezing/assaying, allowing for higher number of samples to be 
processed simultaneously. Interestingly, at a lower substrate dose, the green-
emitting liFluc had a higher activity than R-liFluc, most likely due to a lower KM for the 
green-peaked variant.  This characteristic may be desirable for in vitro assays in the 
case that lower substrate concentrations are used.    
 For a luciferase/luciferin combination to be suited for in vivo imaging, they 
need to overcome certain barriers such as light absorption by pigmented molecules 
(e.g. hemoglobin and melanin) and scattering by deep tissues.  Since most light 
below 600 nm cannot penetrate mammalian tissues, red-emitting luciferases would 
be highly beneficial for in vivo imaging.  The codon-optimized red-emitting liFluc 
characterized here with a peak emission at 610 nm showed to be a robust tool for 
imaging tumor cells injected intramuscularly or in the brain of nude mice.   
 
 Aside from in vivo imaging, having multiple luciferases utilizing the same 
substrate but yielding different emission properties could be highly useful for 
multicolor applications using spectral unmixing9, 30.  Since the codon-optimized green 
and red-emitting liFluc variants have a distinct emission maximum, they can be used 
together to monitor dual biological processes simultaneously. Further, they can be 
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combined with other luciferases utilizing different substrates, such as Gaussia or 
Renilla luciferase, for triple reporter systems20.  
 In conclusion, we have characterized two human codon-optimized Luciola 
italica thermostable variants for bioluminescence applications in mammalian cells 
and showed that the red-emitting variant is useful for deep tissue imaging. These 
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Mycoplasma contamination in mammalian cell cultures is often overlooked yet is a 
serious issue, which can induce a myriad of cellular changes leading to false 
interpretation of experimental results.   Here we present a simple and sensitive 
assay to monitor mycoplasma contamination (mycosensor) based on degradation of 
the Gaussia luciferase reporter in the conditioned medium of cells. This assay 
proved to be more sensitive as compared to a commercially available bioluminescent 
assay in detecting mycoplasma contamination in seven different cell lines. The 
Gaussia luciferase mycosensor assay provides an easy tool to monitor mammalian 





Mycoplasmas, in the class mollicutes, are the smallest free-living organisms known. 
Small size combined with the absence of a rigid cell wall allows them to pass through 
most bacterial filters making them common pathogens in mammalian cell culture. 
Many contaminations go unnoticed, as there are often no overt signs of mycoplasma 
presence.  This is in contrast to fungal or bacterial contamination where changes 
such as media pH, turbidity, odor, and direct microscopic visualization of organisms 
are observed.  Mycoplasma contamination rates have been reported to be between 
15-35% and could be as high as 70%1-3 and are resistant to commonly used 
antibiotics such as Penicillin and Streptomycin.  Several antibiotics which are known 
to kill mycoplasma are mostly effective in the extracellular media with intracellular 
mycoplasmas being somewhat sequestered from drugs1. The effect of mycoplasma 
contamination depends on the particular species of mycoplasma as well as the 
contaminated cell type. Whereas some species may have no apparent effect on cell 
function, many others can produce severe cytopathic changes3. Due to a competition 
with their host cells for medium nutrients, mycoplasma can lead to significant 
changes in cell metabolism, proliferation, gene expression and function, leading to 




The ideal detection method for mycoplasma contamination would be simple to 
perform, sensitive, specific, rapid and inexpensive and can be used to test numerous 
cell cultures simultaneously and on a regular basis. Unfortunately, current 
mycoplasma assays have some but not all of these characteristics. For instance, 
classical microbiology culture assays are lengthy and can be unreliable due to the 
fastidious culture requirements for some species8. Polymerase chain reaction (PCR)-
based detection of mycoplasma-specific nucleic acids is known to be the most 
reliable assay, however it is complex, time consuming and suffers from false positive 
and negative results if performed inadequately9.  Other assays include fluorescent 
DNA staining, enzyme-linked immunosorbent assays and immunoblotting, with each 
having significant drawbacks10-12.  
 
Here, we describe a simple assay to monitor mycoplasma contamination in 
mammalian cell cultures based on degradation of the Gaussia luciferase (Gluc) 
reporter in the conditioned medium.  This assay proved to be more sensitive in 
detecting mycoplasma as compared to a commercially available bioluminescent-





Cell culture. 293T human kidney fibroblast cells, HeLa human cervix 
adenocarcinoma cells and U87 human glioma cells were obtained from American 
Type Culture Collection (Manassas, VA). Gli36 human glioma cells were a kind gift 
from Dr. Anthony Capanogni, UCLA, CA. GBM11/5 and GBM20/3 glioblastoma cells 
were kindly provided from Dr. Xandra Breakefield, Massachusetts General Hospital, 
Boston, MA. MDA-MB-231 were obtained from ATCC. All cells were cultured in high 
glucose Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA) 
supplemented with 10% fetal bovine serum (FBS; Sigma, St Louis, MO) and 100 
U/ml penicillin, 100 ȝg/ml streptomycin (Invitrogen) in a humidified atmosphere 
supplemented with 5% CO2 at 37°C. 293T cells were engineered to stably express 
the naturally secreted Gluc by infecting these cells with a lentivirus vector expressing 
Gluc and GFP under the control of CMV promoter at a multiplicity of infection of 10 
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transducing units/cell in the presence of 10 g/ml Polybrene® (Sigma) as we 
previously described13.  
 
Standard mycoplasma contamination assays. The status of mycoplasma 
contamination of cultured cells was determined by MycoAlert® (Lonza Rockland, 
Rockland, ME) and where indicated by PCR PromoKine Mycoplasma Test KIT I/C 
(PromoCell, Heidelberg, Germany) according to the manufacturer’s standard 
protocol. Mycoplasma contamination of cells was established by transferring media 
from cells which were tested positive by both MycoAlert® and PCR PromoKine to 
clean cells. Cells were intentionally contaminated 3 days prior to use in most 
experiments unless otherwise stated.  Mycoplasma contamination status was 
monitored on a weekly basis for all cells using Lonza MycoAlert®. Cells treated with 
Plasmocin™ (InvivoGen, San Diego, CA) were cultured for 2 weeks in the presence 
of this drug according to the manufacturer’s instructions, followed by 1 week without 
the drug and confirmed to be mycoplasma negative using MycoAlert®.  
 
Recombinant Gluc protein.   Recombinant Gluc protein was purified from bacterial 
extracts using a 6-histidine tag as we previously described14.  Enzyme purity was 
determined using Commassie staining of purified Gluc after being resolved on SDS-
PAGE Gel.  
 
Gluc mycoplasma sensor assay. 1x105 mycoplasma clean or contaminated cells 
were plated in a 24 well plate.  16-24 h later, conditioned medium from cells 
expressing Gluc (previously aliquoted and frozen) or purified Gluc (35 ng/ml) was 
added to the media of these cells. Immediately following mixing Gluc with the media 
on these cells (time 0h) and 24 h later, 50 l aliquots were collected and frozen at -
80 0C. Twenty l of these samples (in duplicates) were than transferred into a black 
96 well microtiter plate (Greiner bio-one, Frickenhausen, Germany) and assayed for 
Gluc activity after the addition of 80 l 20 M coelenterazine (Nanolight, Pinetop, AZ) 
and acquiring photon counts for 10 sec using the Dynex MLX microtiter plate 
luminometer (McKinley Scientific, Sparta, NJ). Gluc stability is calculated as the RLU 
at time point B (e.g. 24 h)/ RLU at time point A (e.g. zero h).  For the cell-free assay 
(Fig. 2a), conditioned media was removed from cells and cell debris removed by a 5-
minute centrifugation at 300 x g.  Cell-free media was then mixed in a 1:1 ratio with 
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Gluc-containing media and aliquots of media were collected at several time points 
before performing the Gluc bioluminescence assay.    
 
Western blot analysis.  Twelve microliter of conditioned medium from mycoplasma 
positive and negative cells containing Gluc were electrophoresed on 4-12 % gradient 
SDS-polyacrylamide gels (NuPAGE Bis-Tris, Invitrogen) and transferred to 
nitrocellulose membranes (Bio-Rad). Blots were stained with Ponceau to verify equal 
protein loading and blocked overnight at 4 0C using 10% non-fat dry milk in TBS-T. 
The membrane was then incubated with polyclonal rabbit anti-Gluc primary antibody 
(Nanolight technology, Pinetop, AZ) diluted 1:2000 in 2% milk/TBS-T for 1h at room 
temperature followed by washing using TBS-T. The blot was incubated with 
horseradish peroxidase (HRP) conjugated secondary anti-rabbit antibody (1:10,000; 
GE Healthcare; Little Chalfontbuckinghamshire, UK). Blots were developed using 
SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL) 
followed by exposure to HyBlot CL autoradiography film (Denville Scientific, South 
Plainfield NJ). 
 
Purified mycoplasma experiments. The following mycoplasma species were 
purchased from Leibniz Institute DSMZ-German Collection of Microorganims and 
Cell Cultures (Braunschweig, Germany):  Acholesplasma laidlawii, Mycoplasma 
arginini, Mycoplasma fermentens, Mycoplasma hominis, Mycoplasma hyorhinis, and 
Mycoplasma orale.  Lyophilized mycoplasma pellets were sterilely rehydrated for 30 
minutes in 500 l of cell culture media.  Next, 50 l was mixed with 3 ml of complete 
cell culture media and transferred to a 10 cm2 tissue culture well containing 3x105 
Gli36 cells. Successful mycoplasma growth was determined by Lonza MycoAlert® at 
10 days post-infection.  Cells were then plated into 24 well plates and mixed with 
Gluc-containing media and Gluc stability was calculated from 0 h and 72 h time 
points.   
   
DNA sequence analysis of mycoplasma in contaminated media.  Conditioned 
cell culture media (1.5 ml) from a contaminated HeLa culture was centrifuged at 
500x g to remove cellular debris and then 15,000x g for 15 minutes to pellet 
mycoplasma. The pellet was resuspended in 100 l of nuclease-free water and 
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mycoplasma DNA was amplified using PromoKine PCR Mycoplasma test kit I/C.  
The PCR reaction was desalted using Qiagen gel extraction columns (Qiagen, 
Valencia, CA) and specific amplification of the mycoplasma-specific PCR product 
was confirmed by agarose gel electrophoresis and ethidium bromide staining. The 
PCR product (~270 b.p.) was ligated into a subcloning plasmid (PCR®4-TOPO®) 
using the TOPO TA Cloning kit for Sequencing (Invitrogen) and transformed into 
electrocompetent DH10B bacteria (Invitrogen). Single bacteria colonies were 
isolated, cultured and plasmid DNA was purified using a QIAprep Miniprep kit 
(Qiagen).  DNA sequencing was performed at the Massachusetts General Hospital 
DNA core facility using M13 forward and M13 reverse primers provided in the TOPO 
TA Cloning kit.  The nucleotide sequence of each clone was compared to the DNA 
database on the National Center for Biotechnology Information website using basic 
local alignment search tool (BLAST®).         
 
 
RESULTS AND DISCUSSION 
 
We incidentally observed that the bioluminescent signal in conditioned media of 
different cell types expressing the naturally secreted Gaussia luciferase (Gluc)15 
varied in stability over time (originally reported to be ~6 days in media13). Further 
analysis using commercially available tests revealed that cells with a decreased 
Gluc-catalyzed bioluminescent signal were contaminated with mycoplasma, while 
those with a more stable signal were mycoplasma-free. To further explore this 
phenomenon, we determined the stability of Gluc activity added to conditioned 
medium of seven different cell types.  Initially, we confirmed that these cell lines were 
mycoplasma-free using both PCR and bioluminescence-based commercially 
available assays (see Experimental Section).  Next, each cell line was divided into 
two groups in which one was maintained in mycoplasma-free environment and the 
other intentionally infected with mycoplasma-contaminated tissue culture media. 
Gluc-containing conditioned medium (from mycoplasma negative cell cultures) were 
added to these cells and the Gluc activity was measured immediately and twenty-
four hours later. A decrease in Gluc signal (2-30 fold; p<0.0005) was observed only 




To investigate the means by which Gluc enzymatic activity declines over time in 
mycoplasma-contaminated cells, we analyzed Gluc protein levels immediately and 
24 h post-transfer of Gluc-containing medium on three mycoplasma-free and positive 
cells by Western blotting. While the level of Gluc protein remained stable in 
conditioned medium from mycoplasma-free cells over 24 hours, Gluc protein was 
undetectable in mycoplasma-contaminated conditioned medium from the same cell 
type (Fig. 1b). Equal loading of media was confirmed by Ponceau staining of 
transferred proteins (Supplementary Fig. 1). These data indicate that the decline in 
Gluc activity over time in mycoplasma-contaminated cells is likely caused by 
protease degradation of Gluc and not another mechanism of enzymatic inhibition.    
 
To extend these findings and develop an assay to detect mycoplasma contamination 
(mycosensor), we purified 6xHistidine-tagged recombinant Gluc from bacteria and 
used it on 293T, U87, and HeLa cells. Recombinant Gluc (35 ng/ml) was added to 
cultured medium of mycoplasma-free and contaminated cells (1x105 cells plated in a 
24 well plate) and the Gluc activity was analyzed immediately and twenty-four hours 
later in an aliquot of the conditioned medium. Again, a significant (8-100 fold; 
p<0.0005) decrease in Gluc activity was observed only in mycoplasma-contaminated 
cells and not in uncontaminated cells confirming that recombinant Gluc can be used 
as a reporter to monitor mycoplasma contamination in mammalian cells (Fig. 1c). 
 
In order to verify that the mycoplasma strain(s) we are using are one of the six most 
commonly (90-95%) found in contaminated mammalian cells1, we performed PCR 
using primers specific to a region of DNA within the 16S rRNA operon coding region 
of these strains on U87, 293T, and HeLa cell lines and analyzed them by agarose 
gel electrophoresis. Specific bands of approximately 250 bp were observed in all 
mycoplasma-contaminated cultures while no bands were observed in negative cells 
(Fig. 1d). To ascertain which mycoplasma strain(s) were in our cultures, the PCR 
products were cloned into a bacterial plasmid and 10 individual clones were 
sequenced and their sequences were compared to entries in the public nucleotide 
database.  Six clones aligned with 100% homology to Acholeplasma laidlawii, three 
clones aligned with sequence data from Mycoplasma bovigenitalium, and one clone 
which had highest sequence identity aligned with Mycoplasma faucium. This 
analysis indicated that our contaminated cell culture contained a mixture of 
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mycoplasma species, with the highest represented clone (A. laidlawii) being a 
common cell culture contaminant.   
 
Figure 1.  Gaussia luciferase (Gluc) reporter as a measure of mycoplasma 
contamination in mammalian cell culture.  (a-b) conditioned medium from cells 
expressing Gluc were added on different mycoplasma clean or contaminated cells (1x105 
cells plated in a 24-well plate) and the Gluc activity was detected immediately (0 h) and 24 h 
later either using a luminometer after addition of coelenterazine (a) or by Western blot 
analysis using anti-Gluc antibody and horse radish peroxidase-conjugated secondary 
antibody (b).  (c) Purified recombinant Gluc (35 ng/ml) was added to mycoplasma positive or 
negative cells and Gluc activity was detected immediately and 24 h later using a 
luminometer. (d) A PCR assay, which specifically detects the most common strains of 
mycoplasma, was performed on all cell lines used. The smaller band (265-278 b.p., arrow 
head) results from the amplification of mycoplasma DNA. The larger band (479 b.p., 
asterisk) is an internal control indicating successful PCR amplification; it is not mycoplasma-
specific.   (e) Mycoplasma positive or negative cells were treated with Plasmocin for two 
weeks or left untreated. Three weeks post-treatment, a subculture of these cells was 
assayed using the Gluc mycoplasma assay. Activity data are presented as the average 
(from 3 independent experiment) of RLU ratios of 24 h over 0 h ± standard deviation 
(*P<0.005).   
 
As the sequencing data revealed that our culture media was contaminated with at 
least three different types of mycoplasma, the decline in Gluc signal observed in the 
mycosensor assay could be due to one or more of these species.  To ascertain that 
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the mycosensor assay is applicable for detection of individual and different 
mycoplasma species, we infected separate wells of uncontaminated Gli36 with three 
species of mycoplasma commonly found in cell culture contaminations (Mycoplasma 
fermentens, Mycoplasma hominis, and Mycoplasma orale). Infected cells were 
incubated with mycoplasma for several days.  The presence of mycoplasma was 
initially confirmed using the MycoAlert® test.   Next, cells were plated and the Gluc 
mycosensor assay was performed.  Calculating Gluc stability from the 0 h and 72 h 
time points revealed that the Gluc mycosensor assay detected all three types of 
mycoplasma (Table I).  The decline in Gluc sensitivity ranged from 14% (M. 





To further confirm that the Gluc degradation was caused by mycoplasma, we treated 
both contaminated and uncontaminated 293T cell cultures with a well described anti-
mycoplasma agent that contains both a macrolide and a quinolone (Plasmocin™). 
We also maintained the original mycoplasma-free or contaminated 293T cells 
without drug treatment. Three weeks later, the MycoAlert® mycoplasma assay was 
performed which showed the successful treatment of these cells (i.e. the treated 
cells tested negative for mycoplasma). The Gluc mycosensor assay was then 
performed as above. As expected, a significant decrease in Gluc activity over 24 h 
was observed in conditioned medium from contaminated/non-treated cells compared 
to mycoplasma-free cells (Fig. 1e; P<0.0001). More importantly, the anti-
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mycoplasma treatment of contaminated cells restored Gluc stability to levels similar 
to mycoplasma-free cells showing that this assay can be used to monitor response 
of mycoplasma to different treatments.  These results also confirm that the Gluc 
decline in these cells is indeed linked to mycoplasma contamination and not other 




Image 1. Setup of the mycoplasma detection assay 
 
As many mycoplasma are found in the extracellular conditioned media, we 
performed the Gluc mycoplasma assay in a simpler cell-free format. Conditioned 
medium was obtained from either mycoplasma-free or mycoplasma-contaminated 
HeLa cells and mixed with purified recombinant Gluc and activity was detected at 
different time points as above. As expected, no decline in Gluc activity was detected 
in medium from mycoplasma-free cells while a 38%, 81%, and 91% decline in Gluc 
activity was observed in medium from mycoplasma contaminated cells at 24 h, 48 h, 




To evaluate the optimum time to perform the Gluc mycoplasma assay, highly-
contaminated and non-contaminated 293T cells were plated in a 24-well plate and 
incubated with recombinant Gluc as above.  Immediately and at different time points, 
the Gluc activity was measured on an aliquot of the conditioned medium. A linear 
decrease in Gluc activity was observed over time showing that highly-mycoplasma 
contaminated cells can be evaluated within one hour of incubation, being most 
sensitive at 24 hours (Fig. 2b).   
 
To determine the linearity of Gluc mycosensor with respect to contaminated cell 
number, different amounts of mycoplasma-contaminated 293T cells were plated and 
analyzed using purified recombinant Gluc as above. Gluc stability was inversely 
proportional to cell number. The highest decline in activity over 24 h was observed 
with the highest concentration of cells (2x105 cells, 50-fold), followed by 1.0x105 cells 
(7-fold) and 5.0 x 104   cells (1.5-fold; Fig. 2c).  No decline was observed at the 
lowest number of plated cells (1.0 x 104).  These data indicate that at least 5.0 x 104 
contaminated cells are required for the Gluc mycoplasma assay under the tested 
conditions. 
   
To compare the sensitivity of our Gluc mycosensor to a commonly used 
commercially available bioluminescent-based assay (Lonza MycoAlert®), we 
performed dilutions of mycoplasma contaminated conditioned medium and added 
them to clean 293T cells.  For a negative control, mycoplasma free 293T cells were 
used. One day post-contamination, equal amounts of cells were plated in a 24 well 
plate and recombinant Gluc was added to their conditioned medium 24 hrs later.  At 
different time points (24, 48 and 72 hours), aliquots of conditioned medium were 
either assayed for Gluc activity or using the commercially available bioluminescent 
assay (Lonza MycoAlert®). For the Gluc-based mycoplasma assay, a significant 
decrease in Gluc activity was observed at all dilutions and all time points when 
compared to the respective negative control sample (Fig. 2d). In contrast, the 
commercially available assay was not able to detect any of the contaminated cells at 
the highest dilution (1:1600) at any of the time points (Fig. 2d, using a cut off of 2 as 
per manufacturer’s instructions).  This assay did detect mycoplasma lower dilutions 
of 1:200 (48h and 72h) and 1:800 (only at 72 h). These results indicate that the Gluc 
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mycoplasma assay is much more sensitive in detecting mycoplasma contamination 





Figure 2.   Gluc mycosensor assay optimization and sensitivity comparison. (a) Cell-
free conditioned medium from mycoplasma free or contaminated HeLa cells were incubated 
with recombinant Gluc (35 ng/ml) and assayed immediatey (0 h) and 24 h, 48 h, and 72 h 
later for Gluc activity using a luminometer. (b) Mycoplasma contaminated and non-
contaminated 293T cells were plated in a 24 well plate and incubated with recombinant Gluc.  
Immediately (time zero) and at different time points, an aliquot of the conditioned medium 
were assayed for Gluc activity. (c) Recombinant Gluc was added to different amounts of 
cells plated in a 24 well plate. Immediately and 24 h later, aliquots of conditioned medium 
were assayed for Gluc activity. (d) Mycoplasma contaminated conditioned medium were 
diluted (1:200, 1:800, 1:1600) and added to clean 293T cells, which were plated the next day 
in a 24 well plate. Twenty-four h later, recombinant Gluc was added to each well. 
Immediately and at different time points, aliquots of conditioned medium were assayed for 
mycoplasma contamination using both the Gluc mycosensor assay and the commercially 
available MycoAlert® bioluminescent-based assay. The left y-axis corresponds to the Gluc 
assay results and the right y-axis corresponds to the commercially available assay results.  
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A cutoff ratio of 2 for mycoplasma contamination using the commercially available assay was 
used as per manufacturer’s instructions.  
 
 
In conclusion, we have developed a facile and sensitive assay for detection of 
mycoplasma contamination in mammalian cell cultures using Gaussia luciferase.  
Either conditioned medium from uncontaminated cells expressing Gluc or purified 
recombinant Gluc (which is commercially available) can be used for mycoplasma 
detection, making this assay simple and cost-effective. While the Gluc mycosensor 
assay detected mycoplasma from three separate types of mycoplasma, it remains to 
be seen if it can detect all strains of mycoplasma commonly found as cell culture 
contaminants.  As recommended by Young et al., screening of mycoplasma should 
be performed using two independent techniques to reduce the rate of false positives 
or false negatives8.  We recommend using the Gluc mycosensor assay for screening 
purposes followed by PCR-based detection (which directly detects mycoplasma 
genomic DNA) for conformational analysis. Since mycoplasma contamination 
degrades Gluc in the conditioned medium of cells, it could lead to false data 
interpretation when using Gluc as a reporter. These observations highlight the need 
for strict and frequent monitoring of mycoplasma contamination of all mammalian cell 
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Mycoplasma contamination in mammalian cell culture is a common problem with 
serious consequences on experimental data, and yet many laboratories fail to 
perform regular testing. In this chapter, we describe a simple and sensitive 
mycoplasma detection assay based on the bioluminescent properties of the Gaussia 
luciferase reporter.  
 
Key words: Mycoplasma contamination, Mycoplasma detection assay, Gluc 




Mycoplasmas are common contaminants of mammalian cell culture; due to their 
small size and the absence of a rigid cell wall, they have the ability to pass through 
most bacterial filters. In contrast to other contaminants such as fungi and bacteria, 
mycoplasma contamination is impossible to detect by eye, since the contamination 
does not influence the color of the cell culture medium, the pH, the turbidity, nor the 
odor. Mycoplasmas are also not visible under the regular light microscopes in cell 
culture laboratories. Furthermore, the fact that mycoplasma can grow both 
intracellular and extracellular greatly contributes to their resistance to several 
antibiotics in the extracellular cell culture medium, such as penicillin and 
streptomycin.1 Due to these issues, mycoplasma contamination rates in mammalian 
cell culture laboratories have been found to be as high as 70%.1-3  
 
Mycoplasma contamination can have a tremendous effect on host cells. For 
instance, mycoplasma can interfere with numerous cellular processes including cell 
metabolism, proliferation, gene expression, and function.2,3,4,5,6,7 Therefore, all cell 
culture laboratories should test cell cultures for mycoplasma contamination on a 
regular basis. The ideal detection method for mycoplasma contamination should be 
simple to perform, sensitive, specific, rapid, inexpensive, and suitable for testing of 




In this chapter, we describe a simple mycoplasma detection assay based on 
degradation of the Gaussia luciferase (Gluc) reporter protein. Typically, in 
conditioned medium of cells under regular culture conditions, Gluc has a half-life of 
>7 days.8 The half-life of Gluc is tremendously decreased in the presence of 
mycoplasma contamination, and therefore the level of decline in Gluc activity 
correlates to mycoplasma infection rate.9  This mycoplasma-specific decrease has 
been confirmed by several assays including Western blot analysis, which showed 
Gluc protein degradation over short period of time (2 - 24 hours) only in the presence 
of mycoplasma contamination. We reasoned that this phenomenon could be used as 
a sensitive and specific biosensor to monitor the mycoplasma contamination in 
mammalian cells (Mycosensor).9   
 
Around 90-95% of all mycoplasma contamination in mammalian cell cultures is 
caused by either M. orale, M. hyorhinis, M. arginini, M. fermentans, M. hominis or A. 
laidlawii.1 The Gluc mycosensor has been confirmed on three of these commonly 
isolated mycoplasma strains including Mycoplasma fermentens, Mycoplasma 
hominis, and Mycoplasma orale. Importantly, this Mycosensor showed to be more 
sensitive in detecting mycoplasma contamination as compared to a commercially 
available bioluminescent-based assay and is amenable to high-throughput 
applications.9 Alternative Mycoplasma detection methods are available including 
mycoplasma DNA amplification by polymerase chain reaction, which is sensitive but 
prone to errors; by traditional bacterial cell culture, which is very time consuming;10 
or by commercially-available kits which have low sensitivity and are costly. The Gluc 
Mycosensor however, is easy to use, sensitive, and especially suited for testing of 
numerous cell quantities simultaneously. Nevertheless, we recommend in all cases 
to combine two different detection methods to achieve and maintain total 




2.1. Gluc Recombinant Protein  
1. Gluc recombinant protein (Nanolight) 
Or, for the preparation of Gluc recombinant protein: 
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2. cDNA encoding Gluc (Nanolight), and N-terminal pelB periplasmic signal 
sequence, and a C-terminal 6-His tag in pET26b (+) vector (Novagen).  
3. HMS174 competent bacterial cells and LB containing 30 ȝg/mL kanamycin.  
4. IPTG Bugbuster Master Mix containing Benzonase (Novagen).  
5. NJ45 ȝm syringe filter nickel charged resin column (Novagen).  
6. Binding buffer: 0.5 M NaCl, 20mM Tris-HCl, 5 mM imidazole, pH 7.9 
7. Wash buffer: 0.5 M NaCl, 20 mM Tris-HCl, 60 mM imidazole, pH 7.9 
8. Elution buffer: 0.5 M NaCl, 20mM Tris-HCl, 1 M imidazole, pH 7.9  
9. Coelenterazine and a luminometer  
10. 3500 MW cut-off dialysis tubing (Fisher Scientific).  
11. Bradford assay. 
12. SDS-PAGE, NuPAGE„¥ 10% Bis-Tris gel and coomassie blue staining 
(Invitrogen).  
 
2.2. Gluc-containing medium 
1. 293T human fibroblast cells.  
2. Lentivirus vector expressing Gluc and the enhanced green fluorescent protein 
(GFP) under the control of CMV promoter  
3. Polybrene. 
 
2.3. Cell culture 
1. High glucose Dulbecco’s modified Eagle’s medium. Supplemented with 10% fetal 
bovine serum, and 100 U/mL penicillin and 100 ȝg/mL streptomycin (see note 1 
and 2). 
2. Incubator with a humidified atmosphere supplemented with 5% CO2 at 37 °C.  
3. 24-well cell culture plates. 
 
2.4. Bioluminescence reaction 
1. A luminometer to measure the bioluminescence activity of Gluc (see note 3). 
2. 20 ȝM coelenterazine (Nanolight). Diluted in phosphate buffer saline (PBS; see 
note 4). 





3.  Methods 
 
Be aware that all materials used for cell culture and the Mycosensor assay should be 
stored and used under sterile conditions to avoid contamination during the Gluc 
incubation period. An overview of the complete Gluc Mycosensor assay protocol is 
presented in Figure 1.  
 
Figure 1. Setup of mycoplasma assay. 
 
3.1. Gluc recombinant protein purification 
In brief, the cDNA encoding Gluc is amplified by PCR using specific primers and 
cloned in-frame between an N-terminal pelB periplasmic signal sequence and a 
C-terminal 6-His tag in pET26b(+) vector using BamHI and XhoI sites. In this 
vector, gene expression is under the control of an isopropyl ȕ-D-1-
thiogalactopyranoside (IPTG)-inducible T7 RNA polymerase promoter. The 
vector is transformed into HMS174 competent bacterial cells and grown overnight 
in 200 mL LB containing 30 ȝg/mL kanamycin. Once the culture reached an 
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OD600 of 0.6, protein expression is induced by adding 20 ȝM IPTG to the culture 
which is grown for 18 h at room temperature. Cells should be pelleted by 
centrifugation for 15 min at 10,000x g and resuspended in 10 mL Bugbuster 
Master Mix containing Benzonase. Insoluble debris is pelleted by another spin. 
The clarified lysate is then filtered through a 45 ȝm syringe filter and loaded onto 
a nickel charged resin column equilibrated with binding buffer. The column should 
be rinsed with 20x volumes of binding buffer followed by 18x volumes of wash 
buffer. His-tagged Gluc is eluted from the column with 1.2 mL of elution buffer 
collecting 200 ȝL fractions. The fraction containing the highest Gluc activity (as 
measured using coelenterazine and a luminometer should be pooled and 
dialyzed against 30 mM Tris-HCl, pH 8.0 overnight using 3500 MW cut-off 
dialysis tubing. Glycerol is added to a final concentration of 10% and protein 
concentration is determined using the Bradford assay. Purity of protein can be 
analyzed by SDS-PAGE under reducing conditions using a NuPAGE„¥ 10% Bis-
Tris gel and coomassie blue staining.  
 
3.2. Gluc-containing medium 
As an alternative to recombinant Gluc, conditioned medium from mycoplasma-
free cells stably expressing Gluc can be aliquoted and stored at -80 0C and can 
be used for the Mycosensor assay. In this chapter, we will take the widely used 
293T human fibroblast cells as an example for the Mycosensor assay. 239T cells 
can be engineered to stably express the naturally secreted Gluc (see note 1) by 
infecting these cells with a lentivirus vector expressing Gluc and the enhanced 
green fluorescent protein (GFP) under the control of CMV promoter at a 
multiplicity of infection of 10 transducing units/cell in the presence of 10 ȝg/mL 
Polybrene. 8  The next day, cells are washed and maintained in regular growth 
medium. GFP can be used as a marker to monitor transduction efficiency and 
therefore Gluc expression. 
 
3.3. Mycosensor assay  
1. Culture the test cells for at least 72 hours under normal culture conditions as 
described above (see note 2). 
2. Plate cells to be tested in triplicates in a 24 well plate at around 30% confluency; 
an ideal amount of 293T cells would be 1x105 cells/well, however, as low as 
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5x104 cells can be used. Cells should be plated in 500 ȝL of growth medium (see 
note 6). In order to save time, it is also possible to simply assay the cell-free 
conditioned medium of the test cells by transferring a small aliquot to the 24 well 
plate instead of re-plating the cells, In this case, the Gluc-containing medium or 
purified Gluc can be added immediately and step 3 can be skipped. One should 
take into consideration that this technique is much less sensitive than the 
standard protocol (see note 7). 
3. The next day, add purified Gluc to a final concentration of 35 ng/mL to 
conditioned medium.  Alternatively, if one chooses to use Gluc-containing 
medium, remove 250 ȝL of medium from cells to be tested and add 250 ȝL of 
Gluc-containing media (see note 8). 
4. Mix by stirring the plate and immediately take a 50 ȝL aliquot from each well; this 
will be used as the time point zero.  Samples can be frozen at -80 0C until further 
analysis (see note 9). 
5. Return the plate to the cell culture incubator.  
6. At 24 hours post-Gluc addition, take another 50 ȝL aliquot from each well and 
freeze at -80 0C. If fast analysis is required, and if mycoplasma contamination is 
high, it is possible to detect a decrease in Gluc activity (and therefore 
mycoplasma contamination) after 4 hours. However, if mycoplasma 
contamination is low, 4 hours will not yield a significant degradation of Gluc and 
longer incubation time is needed. One may choose to perform time analysis by 
storing an aliquot of conditioned medium at different time points. 
7. Do not discard the cells at the 24-hour time point since very low levels of 
mycoplasma can be detected after 48h or 72h, even if test results are negative at 
earlier time points (see note 9). 
8. Assay these aliquots for Gluc activity using coelenterazine and a luminometer 
(see below). 
 
3.4. The Mycosensor bioluminescence assay 
9. Thaw aliquots from the different time points to room temperature (see note 10). 
10. While waiting, dilute coelenterazine in PBS to a final concentration of 20 ȝM and 
incubate for 20-30 minutes in the dark (see note 11). 
11. Transfer 20 ȝL of each aliquot into black 96 well microtiter plate. 
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12. Using a luminometer with a built-in injector, inject 80 ȝL of coelenterazine and 
acquire the signal immediately for 10 seconds (see note 12).  
 
3.5. The Mycosensor assay results 
Mycoplasma contamination is determined by comparing the Gluc signal at time point 
B (e.g., 24h) to the signal at time zero. A significant decrease in Gluc activity 
indicates mycoplasma contamination (see note 13).  Typical results from a positive 






1. Be alert that the cells used to express Gluc, and from which the conditioned 
medium is used for the Mycosensor assay, are not contaminated with 
mycoplasma. We recommend to test these cells on a regular basis with two 
different mycoplasma detection assays such as: MycoAlert® (Lonza Rockland, 
Rockland, ME) and PCR PromoKine Mycoplasma Test KIT I/C (PromoCell, 
Heidelberg, Germany) according to the manufacturer’s standard protocol. 
2. Mycoplasma needs at least 48 – 72 hours to recover from frozen stocks and 
therefore cells should be cultured for at least 3 days after thawing from liquid 
nitrogen before testing for contamination.  
3. Any plate reader with a built-in injector that can adequately measure 
bioluminescence can be used. 
4. Other concentrations of CZN can be used, up to 100 ȝM; however, the 20 ȝM 
concentration of CZN in combination with the luminometer used in our laboratory, 
Figure 2. Gaussia luciferase as a measure of 
mycoplasma contamination in mammalian cell 
culture. Conditioned medium from cells 
expressing Gluc were added on different 
mycoplasma clean or contaminated cells 
(1*10^5 cells plated on 24-well plate) an the 
Gluc activity was detected immediately (0h) and 




and the black microtiter plate will lead to the most optimum Gluc value under our 
assay conditions. 
5. This note is also to some extent applicable to notes 3 and 4; be aware that the 
Gluc signal can reach saturation depending on the amount of Gluc used and the 
sensitivity of the luminometer. In the case that Gluc-containing conditioned 
medium is used for the Mycosensor assay, this problem is more likely to occur. 
The use of black plates could solve this problem as they typically yield up to one 
log lower signal as compared to white plates. As an alternative, one can dilute the 
medium before the assay.   
6.  Keep in mind that plating too many cells will result in overconfluency at 72 hours 
resulting in cell death and therefore the Mycosensor will not be accurate.  
7. As an alternative to testing mycoplasma contamination on plated cells, 
recombinant Gluc can be added directly to an aliquot of conditioned medium from 
cells to be tested; however, this strategy is less sensitive as compared to testing 
the cells themselves. One may choose to do the assay on conditioned medium 
initially and if the results are negative, it can then be confirmed on plated cells. 
8. Be careful when adding Gluc not to disrupt the cells, since some cell types are 
easily detached from the plate leading to false results.  
9. It is of uttermost importance to include a time point zero when performing the 
Mycosensor at a range of time points. It is recommended to take 2 different 
aliquots of conditioned medium at time point zero in case one chooses to run the 
24 hour time point first. If test results are negative, the 48 and 72 hours time point 
can then be assayed and compared to the second aliquot of time point zero. 
10. We observed that aliquots from the same sample but treated in a different 
manner (e.g. frozen versus not-frozen) can show some variation in Gluc signal 
intensity. It is important to treat all aliquots, including the ones from different time 
points, in the same manner.  
11. Coelenterazine purchased should be first reconstituted in acidified methanol (1 
drop of HCL to 10 mL of Methanol) to a final concentration of 5 mg/mL.  Just 
before use, it is diluted in PBS to a final concentration of 20 ȝM. Coelenterazine 
is prone to auto-oxidation and a decrease in bioluminescence signal over time 
can simply be observed due to this artifact. Incubating diluted coelenterazine for 
20 min in the dark stabilizes the signal and will result in a stable bioluminescent 
output.   
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12. A luminometer with built-in injector is required to perform the Mycosensor assay, 
since Gluc catalyzes a flash-type bioluminescence reaction. Therefore, the 
reaction starts with a high signal, followed by a rapid decrease over the course of 
few seconds.11  If a luminometer with built-in injection is not available, one can 
dilute coelenterazine in PBS containing 0.1% Triton X-100.  We showed that this 
detergent yields some stability to the Gluc signal, especially when used in 
combination with GlucM43I mutant.12  Alternatively, stabilization kits are available 
from Targeting Systems or Nanolight (GAR-reagents). The substrate should be 
diluted in the appropriate reagent and can be added manually to the medium and 
assayed using a luminometer. 
13. We recommend testing cells for mycoplasma contamination on a regular basis 
using the Gluc Mycosensor.  Confirm negative results with another type of assay, 
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Liposomes are spherical, self-closed structures formed by lipid bilayers that can 
encapsulate drugs and/or imaging agents in their hydrophilic core or within their 
membrane moiety, making them suitable delivery vehicles. We have synthesized 
and characterized a new targeting, thermosensitive liposome, containing gadolinium-
DOTA lipid bilayer, as a multimodal molecular imaging agent for magnetic resonance 
and optical imaging. We showed that this liposome has a much higher molar 
relaxivities r1 and r2 compared to a more conventional liposome containing 
gadolinium-DTPA-BSA lipid. By incorporating both gadolinium and rhodamine in the 
lipid bilayer as well as biotin on its surface, we used this agent for multimodal 
imaging and targeting of tumors through the strong biotin-streptavidin interaction. 
Since this new liposome is thermosensitive, it can be used for ultrasound-mediated 






Magnetic resonance imaging (MRI) is a routine diagnostic tool with many 
advantages compared to other imaging modalities including its noninvasive 
character, lack of radiation burden and its excellent spatial and temporal resolution1, 
2. Despite its many advantages, there are intrinsic limitations caused by MRI contrast 
agents, such as short vascular half-life circulation, which could lead to potential side 
effects. This drawback can be overcome by using liposomes which can incorporate a 
high payload of gadolinium-containing amphiphilic lipid in their bilayer resulting in a 
spectacular increase in effective longitudinal (r1) relaxivity per particle3-5.  
 
Liposomes are spherical, self-closed structures formed by one or more lipid 
bilayers and contain an aqueous phase inside and between bilayers6. The 
amphiphilic lipids used for the formation of liposomes are usually comprised of a 
hydrophilic head group and two hydrophobic fatty acyl chains. Their amphiphilic 
character results in spontaneous assembly into aggregates in aqueous environment. 
Hydrophilic drugs can be enclosed in the aqueous compartment while hydrophobic 
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drugs can be incorporated in the lipid bilayers core7, 8. These characteristics together 
with their potential to invade the immune system, target cells, and reduce unwanted 
side-effects made them the drug delivery vehicle of choice3, 4, 6, 9. Further, the 
surface of liposomes can be modified and grafted with different targeting moieties 
including antibodies or bioresponsive components like biosensitive lipids or 
polymers8. In addition to drug delivery, the success of liposomes has led to their use 
as carriers for imaging agents since they can either encapsulate a contrast agent, a 
fluorophore for optical imaging, or both within their interior or in their bilayer. This 
characteristic overcomes problems associated with these imaging agents such as 
rapid clearance, non-specific cellular interaction, and toxicity resulting in poor 
contrast and low resolution images3, 8.  
 
Multifunctional liposomes have been developed for image-guided drug 
delivery by incorporating both therapeutic drugs and contrast agents for MRI3, 4. 
Typically, lipid-based contrast agents such as amphiphilic gadolinium(Gd)-DTPA 
derivatives are incorporated within the membrane moiety of the liposome, leaving the 
lumen to encapsulate therapeutic molecules2, 10. The disadvantage of these 
liposomes is that they contain a single Gd-chelate moiety per molecule leading to 
lower MRI detectability. In an attempt to overcome these limitations, macromolecular 
Gd-chelates with several residues in the single molecular chain have been used, 
however, these polychelates could change the liposome structure, affecting its 
surface properties2, 11. Thermosensitive liposomes have been developed for 
ultrasound-mediated drug delivery at specific sites, such as tumors 12-14, and can be 
guided by imaging10, 15, 16. These liposomes typically incorporates the contrast agent 
within their lumen for which relaxivity is low when the liposome is intact and only 
increases during phase transition17.   
 
Given these limitations, an alternative strategy to enhance detectability with 
MRI is to increase the effective longitudinal relaxivity per Gd-chelate moiety. In this 
study, we synthesized and characterized a new liposome, named NLP, which 
contains Gd-DOTA lipid bilayer and is thermosensitive due to the addition of lipids 
with transition temperatures below 45 °C. We compared the activity of this liposome 
to a more conventional liposome (CLP; with a transition temperature of 60 °C) 
containing Gd-DTPA-BSA lipid and showed that NLP has a much higher efficacy as 
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a MRI contrast agent. By embedding the gadolinium imaging agent in the membrane 
of the liposome, this agent exhibits high intrinsic relaxivity when the liposome is 
intact, making it suitable for monitoring the delivery of drug carriers to the target. 
Further, we engineered a targeting multifunctional liposome based on NLP which 
carries both gadolinium and a fluorophore in the lipid bilayer as well as biotin on its 
surface, and demonstrated that it could be used for multimodal molecular imaging 





Synthesis and characterization of the NLP liposome formulation.  We have 
synthesized a thermosensitive liposome with gadolinium containing lipids as a new 
contrast agent for MRI (Fig. 1). We compared the characteristics of this new 
formulation (NLP) to a more conventional DSPC-based Gd-containing liposome 
(CLP, Fig. 1). We first measured the mean average hydrodynamic diameter of the 
NLP liposome and showed it to be 86 nm, which is smaller than the conventional 
CLP liposome having a size of 109 nm (Fig. 2a and Table 1). The mean average 
diameter of the NLP liposome, stored at 4 ºC, was again investigated after 5 weeks. 
We observed that both the size and size distribution of the liposome remained 
constant with an average hydrodynamic diameter of 85 nm (data not shown). The 
consistency of these results indicates a sterically-stabilized liposome preparation 






Figure 1. Schematic overview of CLP, NLP and NLP-biotin-RPE liposomes. 
We synthesized a new DPPC-based liposome (NLP) containing gadolinium-DOTA lipid and 
compared its characteristics to more conventional DSPC-based liposome with gadolinium-
DTPA-BSA (CLP). In order to make NLP multifunctional, a biotin and rhodamine containing 
lipid was added to the formulation so the liposome can be traced both with magnetic 





In order to determine the efficacy of the different liposomes as contrast 
agents, we determined the gadolinium ion concentration in both NLP and CLP. The 
Gd(III) concentration estimated by phosphate determination for CLP and NLP was 
2.790 mM and 1.925 mM respectively (Table 1). The Gd(III) concentration in the 
these liposome were also precisely determined using inductively coupled plasma 
mass spectroscopy (ICP-MS) and found to be 2.920 mM and 2.238 mM, 






Thermosensitivity of NLP liposome. To determine the thermosensitivity of the NLP 
liposome, calcein release during heating was investigated. The fluorescent signal of 
calcein is quenched due to its high concentration (30 mM) inside the aqueous lumen 
of the liposome. During phase transition, the lipids in the liposome rearrange and the 
liposome shell opens resulting in calcein release and hence increased fluorescence 
signal. Upon liposome heating, lipid rearrangement started at 38 °C resulting in 






































































Figure 2. Size distribution and thermosensitivity of NLP and CLP liposomes. (a) The 
size of the liposome was measured with dynamic light scattering. Intensity plots showing the 
average hydrodynamic diameters of NLP and CLP to be 86 nm and 109 nm respectively.  (b) 
NLP-containing calcein was heated at different temperatures. The fluorescent intensity starts 
to increases around 37 - 38 ºC indicating lipid rearrangement and further increases until 
around 39 ºC. No significant further increase is visible upon addition of the lysis reagent 
triton X-100. (c) Differential scanning calorimetry (DSC) showing that NLP has a transition 
temperature of 42 ºC. 
 
 
The fluorescent signal further increased until around 39 ºC at which temperature all 
calcein appeared to be released. No further increase in fluorescence signal was 
visible upon the addition of the lysis reagent Triton X-100, showing that all calcein 
was already released during the 40 minutes heating period. The transition 
temperature of NLP defined as the temperature at the top of transition phase was 
determined with differential scanning calorimetry (DSC) and found to be 42 ºC (Fig. 
2c).  
 
Relaxivity determination of NLP liposome. The measured Gd(III) concentration 
was used to determine the longitudinal (r1) and the transversal (r2) relaxivities of the 
different liposome formulations. Since NLP is thermosensitive (due to the 
incorporation of the DPPC and DMPC lipids), r1 and r2 relaxivities were determined 
at different temperatures to investigate the influence of hyperthermia on the imaging 
efficacy of this liposome. Longitudinal and transversal relaxivities of the liposome 
formulations at different temperatures were obtained from the slope of the linear fit of 
relaxation rates as a function of Gd(III) concentration. At higher temperature, both r1 
and r2 relaxivities of the NLP decreased showing a negative influence of 

















































Figure 3. Longitudinal and transversal relaxivities of the different liposome 
formulations in mM-1s-1. Longitudinal (r1) and transversal (r2) relaxivities were obtained 
from NMR measurements at 60 MHz and 1.41 Tesla. (a) longitudinal and transversal 
relaxivities of NLP liposomes obtained at different temperatures ranging from 22 °C to 67 °C 
with 5 °C intervals. (b,c) Longitudinal and transversal relaxation rates of NLP as compared 





 To determine the efficacy of NLP as a contrast agent, r1 and r2 relaxivities at 
37 °C were compared to the conventional CLP liposome. T1 and T2 measurements 
were performed at 60 MHz corresponding to a magnetic field strength of 1.41 Tesla. 
b c 
e d 
Relaxivities of NLP at different temperatures


















r1 NLP vs CLP 
r1 NLP vs biotin-NLP-RPE 
r2 NLP vs CLP 
r2 NLP vs biotin-NLP-RPE 














The Gd(III)DTPA-BSA-based CLP liposome exhibited a longitudinal r1 relaxivity of 
7.52 mM-1s-1 (Table 2, Fig. 3b), which is similar to values published for the same 
formulation (7.5 mM-1s-1)18. The transversal r2 relaxivity of CLP was found to be 10.6 
mM-1s-1. On the other hand, the Gd(III)DOTA-DSPE based NLP liposome exhibited 
four-fold higher r1 of 29.9 mM-1s-1 and five-fold higher r2 of 49.0 mM-1s-1 as 
compared to CLP (Table 2, Fig. 3b,c). The longitudinal relaxivity of NLP was >2-fold 
higher compared to the published relaxivity for DSPC-based Gd(III)DOTA-DSPE 
containing liposome (12.8 mM-1s-1)18. The reported relaxivities are the average 











Synthesis and characterization of a targeted multimodal NLP liposome. In order 
to increase sensitivity and selectivity of the newly formulated contrast agent, targeted 
NLP was synthesized with a biotin on its surface (biotin-NLP). Further, to make NLP 
suited for multimodal imaging (fluorescence and MRI), rhodamine-PE (RPE) was 
added within the lipid bilayers of the liposome (biotin-NLP-RPE; Fig. 1). The addition 
of biotin and rhodamine to the NLP formulation did not affect its size (93 nm, Table 
1). The gadolinium ion concentration as well as the longitudinal, and transversal 
relaxivities of biotin-NLP-RPE were found to be similar to the non-targeted NLP 
liposome (Table 1,2; Fig. 3d,e).  
 
Targeting of cells with biotin-NLP-RPE in culture. To determine the functionality 
of the newly synthesized biotin-NLP-RPE liposome in targeting tumor cells, viable 
Gli36 human glioma cells overexpressing both the mutant EGFRvIII, a frequent 
genetic alteration in primary brain tumors19 and GFP, or plain Gli36 control cells were 
incubated with a biotinylated antibody against EGFRvIII followed by Streptavidin-
Alexa647 and finally by biotin-NLP-RPE and analyzed by fluorescence microscopy. 




of CLP, NLP and 
biotin-NLP-RPE liposome  
formulations at 37°C obtained from NMR measurements at 60 MHz at 1.5 Tesla. 
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A distinct surface staining of both Alexa647 (indicative of streptavidin binding) and 
rhodamine-PE (liposome) was observed, showing the functionality of this liposome in 
targeting tumor cells (Fig. 4a).  The plain Gli36 cells did not show any surface 
staining (data not shown). 
 To evaluate the usefulness of the biotin-NLP-RPE in targeting tumor cells in a 
different model, Gli36 human glioma cells were engineered by a lentivirus vector to 
express both GFP (marker for transduction efficiency) as well as a fusion protein 
between a biotin acceptor peptide (BAP), preceded by a signal sequence, and the 
transmembrane domain (TM) of the PDGFR receptor (BAP-TM)20. Upon gene 
transfer and expression, the biotin ligase will tag the BAP peptide with a single biotin 
moiety which is presented on the cell surface through TM. These cells as well as 
control cells were then labeled with streptavidin-Alexa647 followed by incubation with 
biotin-NLP-RPE and analyzed by fluorescence microscopy. A distinct cell surface 
staining was found on cells expressing BAP-TM for both Alexa647 and RPE proving 
the specific targeting of biotin-NLP-RPE (Fig. 4b). Control cells did not show any 
















Figure 4. Targeting of cells with biotin-NLP-RPE liposome. (a) Gli36 human glioma cells 
expressing the EGFRvIII receptor and GFP were labeled with a biotinylated-antibody against 
EGFRvIII followed by streaptavidin-Alexa647 and biotin-NLP-RPE, and analyzed by 
fluorescence microscopy for both Alexa647 and RPE.  (b) Gli36 cells were infected with 







lentivirus vector expressing BAP-TM and GFP. These cells were labeled with Streptavidin-
Alexa647 followed by biotin-NLP-RPE and analyzed as in (a).  
 
 
Targeted multimodal in vivo imaging of tumors using biotin-NLP-RPE. To 
confirm the functionality of biotin-NLP-RPE in an in vivo model, Gli36 cells 
engineered by gene transfer to express BAP-TM or plain Gli36 control cells were 
injected subcutaneously in the flanks of nude mice (n=5) at two different locations. 
Two-weeks later, mice were i.v. injected with either biotin-NLP-RPE or a complex 
consisting of biotin-NLP-RPE and streptavidin-Alexa750 (Alexa750-SA-NLP-RPE) 
and imaged first with fluorescence-mediated tomography (FMT; 4 hrs post-injection) 
for Alexa750 confirming streptavidin targeting. Significant accumulation (*p<0.001) of 
Alexa750 signal was observed in tumors expressing biotin on their surfaces as 
compared to control tumors in mice injected with Alexa750-SA-NLP-RPE and not the 
non-targeted biotin-NLP-RPE (without the use of streptavidin), showing efficient 
targeting of this NLP complex to biotin expressing tumors (Fig. 5a,b). The same 
mice were also imaged with T1w MRI at 4 and 24 hrs post-injection. Significantly 
higher accumulation (*p<0.001) of NLP liposome over time was observed in tumors 
expressing biotin on their surfaces as compared to control tumors only in mice 
injected with targeted Alexa750-SA-NLP-RPE complex showing that tumors can be 
targeted and imaged with MR using this liposome complex (Fig. 5c,d). Mice injected 
with non-targeted biotin-NLP-RPE liposome showed similar and lower accumulation 





























Figure 5. Targeting and in vivo imaging of tumors with biotin-NLP-RPE. Gli36 human 
glioma cells or same cells expressing biotin on their surfaces (through BAP-TM) were 
implanted subcutaneously in nude mice (n=5) at 2 different sites. Two-weeks later, mice 
were i.v. injected with either biotin-NLP-RPE or a complex consisting of biotin-NLP-RPE and 
streptavidin-Alexa750 (Alexa750-SA-NLP-RPE) and imaged 4 hrs later with FMT Alexa750. 
(a-b) a representative mouse from each group is shown in (a) and quantitation of fluorescent 
accumulation in each tumor in (b). (c-d) The same mice were also imaged with T1w MRI at 4 
and 24 hrs post-injection (c). T1w intensities at 24 hrs were normalized to 4 hrs for each 















































In this study, we synthesized a new liposome and characterized it by 
comparing its efficacy as a contrast agent to a more conventional liposome. We 
showed that the new liposome NLP exhibited four-fold higher longitudinal and five-
fold higher transversal relaxivity compared to a conventional liposome CLP. Further, 
the longitudinal relaxivity (at 1.41 Tesla) of NLP was >2-fold higher compared to a 
published liposome formulation with the same Gd-DOTA containing lipid (29.9 mM-
1s-1 compared to 12.8 mM-1s-1)18. Since the NLP formulation is thermosensitive, we 
observed a temperature dependency for both longitudinal and transversal relaxivities 
being lower at higher temperature. Recent studies showed that an increase in 
temperature leads to an increase in longitudinal relaxivity for DSPC-based 
Gd(III)DOTA-DSPE containing liposomes (12.8 mM-1s-1 at 37°C compared to over 14 
mM-1s-1 at 67 °C)18. A potential explanation for these differences between typical 
liposomes and NLP could be the increased water exchange across the liposomal 
membrane at higher temperature resulting in larger contribution of Gd(III)DOTA-
DSPE in the inner leaflet of the liposome to the overall longitudinal relaxivity21-24. The 
unique composition of the NLP liposome could possibly positively affect the water 
exchange across the liposomal membrane and explain its high relaxivities compared 
to both CLP and Gd(III)DOTA-DSPE containing liposome. To further increase the 
sensitivity and selectivity of the NLP contrast agent, and to make it useful for 
multimodal imaging, we synthesized the NLP liposome with biotin on its surface and 
rhodamine within the lipid bilayer. The Gd(III) inside the liposome can serve as a 
contrast agent for MRI and the rhodamine can be used for imaging at the single cell 
level with fluorescence.  This biotin-NLP-RPE showed to have three to four-fold 
higher relaxivities compared to CLP18. Further, we showed that streptavidin can 
serve as a bridge between biotin-NLP-RPE and biotinylated antibody to target 
specific receptors overexpressed on tumor cells.   
In vivo optical imaging has limited use due to the problem of light absorption 
by pigmented molecules such as hemoglobin and scattering by mammalian tissues, 
leading to a decrease in the detection limit. The biotin-NLP-RPE was synthesized 
with a rhodamine-containing lipid in the bilayer, which was shown to be useful in 
targeting tumor cells at the single cell level in culture using fluorescence imaging. 
This same complex would be useful for single cell detection in vivo using intravital 
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micoscopy and could be extended for intraoperative fluorescence imaging25. Further, 
the rhodamine can be replaced with any fluorophore emitting in the near infra-red 
region of the spectrum, which can then be used for FMT imaging in deep tissues in 
vivo26. The biotin on the NLP surface makes these liposomes universal targeted 
contrast agents for which practically any peptide/antibody specific to a cell of interest 
can be complexed to it through the strong interaction of biotin with streptavidin. The 
specificity of biotin to streptavidin has been exploited for several medical and 
scientific applications including drug or toxin targeting, in vivo imaging of targeted 
cells, and antibody-guided radioimmunotherapy in humans20, 27, 28.  
 The use of biotin-NLP-RPE liposome can be extended and applied for drug 
delivery. The combination of imaging with drug delivery is very valuable in the search 
for new therapeutic strategies. Further, the thermosensitive characteristic of this 
liposome does not only have a positive effect on the relaxivity, but could also be 
used as a delivery strategy for drugs, for instance to solid tumors.  Our in vitro data 
shows that a temperature of 39 0C can lead to an increase in calcein release from 
NLP liposomes. This thermosensitive feature of NLP has a high clinical impact in 
which NLP liposome can encapsulate a therapeutic drug which can be released 
specifically on the tumor site by ultrasound-induced hyperthermia, similar to 
previously published methods 10, 15, 16. Further, by including Gd(III) in these 
liposomes, MRI can be used for guided drug release at the specific site10.   
In conclusion, we have synthesized a new liposome with higher r1 and r2 
relaxivities as compared to conventional liposome and showed it to be useful for 
targeting and multimodal imaging of tumors. Since this liposome is thermosensitive, 
it can be used for ultrasound-mediated drug delivery at specific sites, such as 
tumors, which can be guided by MRI or catheter based optical imaging 29-32 
 
 
MATERIALS AND METHODS 
 
Materials for liposome preparation. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC), 1,2-ditetradecanoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] 
(PEG2000-DSPE), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[biotinyl(polyethylene glycol)2000] (Biotin-PEG2000-DSPE), 1,2-Dioleoyl-sn-Glycero-
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3-Phosphoethanolamine-N-(Lissamine Rhodamine B Sulfonyl) (Rhodamine PE), 1,2-
distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-
2000] (PEG2000-DSPEmal), 1,2-Distearoyl-sn-glycero-3-phosphocholine (DSPC) 
and cholesterol were purchased from Avanti Polar Lipids (Alabaster, AL). 
Gd(III)DOTA-DSPE and Gd(III)-DTPA-bis(stearylamide) (Gd(III)-DTPA-BSA) were 
obtained from Gateway Chemical Technology (St. Louis, MO).  
Preparation of liposome formulations. Liposomes were prepared according to 
three different formulations: the more conventional liposome DSPC-Gd(III)DTPA-
BSA (CLP), the new formulation DPPC-Gd(III)DOTA (NLP) and the new formulation 
biotinylated and rhodamine-labeled: DPPC-Gd(III)DOTA-biotin (biotin-NLP-RPE). 
NLP liposome was prepared with DPPC, DMPC, Gd(III)DOTA-DSPE and PEG2000-
DSPE at a molar ratio of 50:20:25:5 (Table 3). As a control, CLP liposome were 
used containing DSPC, Gd(III)DTPA-BSA, PEG2000-DSPE, PEG 2000-DSPEmal 
and cholesterol in a molar ratio of 36.7: 25:2.5:2.5:33.3 (Table 3). The biotin-NLP-
RPE liposome was prepared with DPPC, DMPC, Gd (III)DOTA-DSPE,  PEG2000-
DSPE, Biotin-PEG2000-DSPE and Rhodamine PE at a molar ratio of 
50:20:25:2.5:2.5:0.1 (Table 3). These liposomes were prepared by lipid film 
hydration followed by extrusion5. The lipid film was prepared by dissolving the lipid 
mixture (50 mol) in 3:1 v/v CHCl3/MeOH in a 250 ml round-bottomed flask. The 
solution was evaporated using rotation evaporation for 15 minutes at 200 mbar and 
30 ºC and at 150 mbar till dryness. In order to assure complete dryness, rotation 
evaporation was pursued at 0 mbar for 15 more minutes and the film was 
subsequently put under a nitrogen flow for at least one hour. The NLP and biotin-
NLP-RPE films were dried over night. The films were hydrated with 4 ml HEPES 
buffered saline (HBS) (20 mM HEPES and 135 mM NaCl at pH 7.4) at 60 ºC for NLP 
and biotin-NLP-RPE and 65 ºC for the CLP liposomes after heating the film to 65 ºC. 
The films of the NLP and biotin-NLP-RPE liposomes were not heated before addition 
of the HBS. The lipid dispersions were extruded (Lipofast Extruder, Avestin, Ottawa, 
Ontario) at 60 ºC and 65 ºC for the NLP and CLP liposomes respectively. The lipid 
dispersions were extruded through polycarbonate membrane filters (Whatman, 
Maidstone, UK) with a pore diameter of  400 nm (1 time), through filters with a pore 
diameter of 200 nm (6 times) and through filters with a pore diameter of 100 nm (6 



































Liposome characterization. The size and size distribution of liposomes were 
measured using dynamic light scattering (DLS) at 25, 37 or 41 °C on a Malvern 
Zetasizer Nano S apparatus (Malvern, UK) equipped with a 633 nm laser. These 
measurements were performed in sextuple using three different concentrations of 
liposome suspension in 400 ȝl HBS (20 mM HEPES and 135 mM NaCl at pH 7.4).  
Total lipid and gadolinium [Gd(III)] concentrations of liposome suspensions 
were calculated using phosphate determination, performed according to Rouser after 
destruction of the samples with perchloric acid at 180 ºC33. The amount of 
phospholipids in the sample was determined using a calibration curve between 0 and 
80 nmol phosphate. The total amount of lipids and the amount of gadolinium 
containing lipids in the sample was calculated based on the measured amount of 
phospholipids.   
The gadolinium ion concentration was determined for NLP and biotin-NLP-
RPE liposomes using inductively coupled plasma mass spectroscopy (ICP-MS; 
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DRCII Perkin-Elmer, Philips Research Material Analysis, Eindhoven, The 
Netherlands). From each sample, 150 l was taken, weighed and sent in for ICP.  
 
Determination of thermosensitivity 
The thermosensitivity of NLP liposome was determined based on calcein release 
experiment and differential scanning calorimetry. In order to measure calcein 
release, NLP liposome films (25 ȝmol) were hydrated with 2 ml of 30 mM calcein 100 
mM NaCl solution in HBS (pH 6.8). Extrusion was performed according to the same 
protocol as for the NLP liposome. Free calcein was separated from calcein-
containing liposome using PD-10 column (GE-healthcare). Liposome was then 
dissolved in HBS (20 mM HEPES and 135 mM NaCl; pH 7.4). The fluorescent 
intensity of the calcein-containing liposome was measured with a fluorometer 
(excitation wavelength: 494 nm; emission wavelength: 517 nm). As a control, the 
fluorescent intensity of the liposome was measured at room temperature before and 
after addition of 10% triton-X in water. The fluorescent intensity was measured every 
minute for 40 minutes. The first measurement was performed at 25 ºC and the 
temperature of the water bath increased by 1 ºC every minute. The temperature of 
the sample was measured every two minutes. After 40 minutes, 10% triton-X in 
water was added to the sample to determine the maximal fluorescent intensity. The 
phase transition temperature of NLP liposome was measured with differential 
scanning calorimetry (DSC, Universal V4 5A TA Instruments). 
 
Determination of relaxivity. To determine the longitudinal and transversal 
relaxivities of the liposomes, spin-lattice relaxation time (T1) and spin-spin relaxation 
time (T2) measurements were performed on a Bruker (Rheinstetten, Germany) 
Minispec mq60 NMR analyzer (60 MHz) with a magnetic field of 1.41 Tesla. T1 
relaxation times were obtained using the standard inversion recovery method with a 
recycle delay of 20 s, inversion time ranging from 5 ms to 10 seconds, the inversion 
sequence was repeated ten times and four averages. T2 times were measured using 
a Carr-Purcell-Meiboom-Gill (CPMG) sequence with a recycle delay of 20 s, 
interecho time of 0.4 ms, 10,000 echoes and 16 averages.  
The longitudinal r1 and the transversal r2 relaxivities were obtained from the 
slope of the linear fit of relaxation rates as a function of gadolinium ion concentration 
described in equation 1 and 2 respectively (below). The relaxation rates R1 and R2 
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are the inverse of T1 and T2 respectively. The longitudinal and transversal 















    (2)  
 
[CA] is the concentration of the contrast agent, in this case the Gd(III) concentration 
in mM and r1 and r2 the longitudinal and transversal relaxivity respectively34. In order 
to determine the relaxivities of the CLP, NLP and biotin-NLP-RPE liposomes, T1 and 
T2 measurements were performed at 37°C. Since NLP liposome is thermosensitive, 
relaxivities were determined at different temperatures. T1 and T2 measurements 
were performed within a temperature range of 22 °C to 67 °C with 5 °C intervals.  
 
Cell culture.  Gli36 human glioma cells were obtained from Dr. Anthony Capanogni, 
UCLA, CA. Gli36 cells were transduced with a retrovirus vector expressing the 
mutant EGFRvIII and puromycin resistant gene (obtained from Dr. Miguel Sena-
Esteves, Department of Neurology, University of Massachusetts Medical Center, 
Worcester). The cells were selected by culturing the cells in conditioned media with 1 
mg/l puromycin. Gli36 cells were also infected with a lentivirus vector expressing a 
biotin acceptor peptide, preceded by a signal sequence followed by the 
transmembrane domain of PDGFR (BAP-TM) as previously described20. As a 
control, Gli36 cells were infected with similar empty lentivirus vector.  All cells were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% 
fetal bovine serum (Sigma, St. Louis, MO) and 100 U penicillin and 0.1 mg 
streptomycin (Sigma) per milliliter at 37 °C in a 5% CO2 humidified incubator. 
 
In vitro targeting of glioma cells with biotin-NLP-RPE. Seventy five thousand 
cells were plated in 1.5 ml conditioned media on coverslips (Fisher Scientific) in a 24 
well plate. Twenty-four hours later, cells were incubated with 250 ng/ml of 
biotinylated anti-EGFRvIIII antibody for 5 min (in phosphate buffer saline, PBS, a 
kind gift from Dr. Darell D. Bigner, Duke University Medical Center) at room 
temperature. Cells were then washed and incubated with streptavidin-Alexa647 
(1:200; Molecular Probes) for 5 min.  Cells were washed again and incubated with 
biotin-NLP-RPE (70 M) for 5 min. Cells were then washed, fixed with 4% 
paraformaldehyde, mounted on coverslips and analyzed by fluorescence 
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microscopy.  For cells expressing BAP-TM, similar protocol was followed without the 
use of the antibody.   
 
Targeting and Multimodal imaging of tumors with biotin-NLP-RPE in vivo. All 
animal studies were approved by the Subcommittee on Research Animal Care at 
Massachusetts General Hospital and were performed in accordance to their 
guidelines and regulations.  Mice were kept on biotin-deficient diet throughout the 
study. One million Gli36 cells (in 50 l) expressing BAP-TM or control cells were 
mixed with similar volume of Matrigel (Becton Dickinson) and implanted 
subcutaneously in the flanks of nude mice in 2 different locations. Two weeks later, 
mice (n=5) were injected with a complex of streptavidin-Alexa750 (200 g) and 
biotin-NLP-RPE (200 l of 7 mM) pre-incubated for 15 min.  Mice were then imaged 
with fluorescence-mediated tomography and magnetic resonance at different time 
points. 
 
Magnetic resonance imaging. MRI was performed using an animal 4.7 T MRI 
scanner (Bruker, Billerica, MA) consisting of coronal and axial T1w images (rapid 
acquisition with refocused echoes (RARE) sequence, TR=900 ms, TE=14.1 ms, field 
of view=5.4 cm x 4.0 cm, matrix size=256 x 256, slice thickness=1 mm, 16-18 slices) 
obtained before and after intravenous administration of Alexa750-SA-NLP-RPE or 
biotin-NLP-RPE as control as above. Post contrast images were obtained at 4 and 
24 hrs post injection. Image analysis and segmentation was performed using the 
OsiriX™ DICOM viewer. Contrast-to-noise ratios were computed as (ROItumor – 
ROImuscle)/STD(noise), where ROI=region of interest drawn to encompass the tumor 
on the slice where the tumors are the largest or a region of flank muscle, and 
STD=standard deviation. For the 3D MRI image, the tumors were segmented out 
manually in the Amira environment (Visage Imaging, Inc., San Diego, CA). This was 
volume rendered in pseudocolor. The rest of the body was volume rendered in gray 
scale.  
 
Fluorescence-mediated tomography. Quantitative fluorescent tomographic 
imaging was carried out on a commercial imaging system (FMT2500, Perkin Elmer, 
Waltham MA).  Prior to imaging, mice received an intravenous injection of imaging 
agent. Four hours after injection, mice were non-invasively imaged under general 
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isoflurane anesthesia (1-1.5% at 2l/min). Paired absorption and fluorescent data sets 
were collected using a scanning laser, and 3-dimensional reconstructions were 
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Malignant gliomas are one of the most lethal cancers, and despite extensive 
research very little progress has been made in improving prognosis. Multimodality 
treatment combining surgery, radiation, and chemotherapy is the current golden 
standard, but effective treatment remains difficult due to the invasive nature and high 
recurrence of gliomas. Stem cell-based therapy using neural, mesenchymal, or 
hematopoietic stem cells may be an alternative approach because it is tumor 
selective and allows targeted therapy that spares healthy brain tissue. Stem cells 
can be used to establish a long-term antitumor response by stimulating the immune 
system and delivering prodrug, metabolizing genes, or oncolytic viruses. In this 
review, we discuss current trends and the latest developments in stem cell therapy 
against malignant gliomas from both the experimental laboratory and the clinic. 
 
Stem cell-based therapy against gliomas 
Gliomas account for about 60% of all primary central nervous system tumors with a 
very poor prognosis. Glioblastoma (GBM), the most malignant type of glioma, has a 
median survival of approximately 12-18 months 1, 2. The characteristics of this 
malignancy include uncontrolled cellular proliferation, invasiveness with both long 
root-like processes and single invasive cells, areas of necrosis, resistance to 
apoptosis, extensive angiogenesis, and multiple genetic alterations (Figure 1) 3. 
Standard-of-care treatment includes maximal surgical resection of the tumor followed 
by radiation and chemotherapy (temozolomide); however, as the poor survival rate 
indicates, these treatments have not been effective in preventing disease 
progression. Most patients die within a year of diagnosis from a new secondary 
tumor foci forming within 2 cm of the resected area 4, 5. The location of the tumor (the 
brain) and its invasive nature prevent complete surgical removal, while radiotherapy 
cannot be given in a high enough dosage due to inevitable damage to the normal 
brain parenchyma. Since chemotherapeutics cannot efficiently cross the blood brain 
barrier (BBB), and glioma cells have a high tendency to develop resistance against 
these agents, the efficacy of this approach is limited. The heterogeneous nature of 
GBM cells, and the complex interaction between different types of tumor cells, 
stromal cells within the tumor, vasculature, and extracellular matrix (ECM), 
complicates matters even further since no clear target can be identified, and multiple 
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interlinked pathways exist, severely decreasing treatment efficacy. Recently, it has 
been shown that a small population of tumor cells, called cancer stem cells, is 
responsible for tumor/glioma growth, resistance and recurrence. These neural stem-
like cells (also called glioma stem cells; GSC) have the ability of self-renewal and 
differentiation into a diverse population of cells, both tumorigenic and non-
tumorigenic, and display a profound interaction with the endothelial vascular niche. 
Although the working mechanism is not exactly clear, it is thought that GSCs 
promote microvascular angiogenesis through secretion of vascular endothelial 
growth factor (VEGF), while secreted factors from this same vascular niche allow 
them to maintain their undifferentiated state 6. Once implanted in immunogenic mice, 
GSCs have the ability to recapitulate a phenocopy of the original malignancy 7. 
Further, GSCs appear to be more resistant to conventional therapy as compared to 
their non stem-like cells counterpart due to their relative quiescence, and will remain 
at the tumor site, eventually causing a relapse 8, 9. 
 
Over the past decade, stem cells (SC) have become increasingly popular as an 
alternative therapy for treating malignant gliomas. In 2000, Aboody et al. described 
the unique intrinsic capacity of neural stem cells (NSC) to “home” to the tumor site 
and migrate along metastatic/invasive tumor borders far from their initial site of 
transplantation, thereby raising the possibility of using NSCs as a therapeutic 
delivery vehicle in the brain 10. Many research groups followed this example and, as 
of today, a wide variety of stem cell-based therapeutics has been tested. Aside from 
the homing mechanism that selectively targets tumor cells, some stem cells can 
effortlessly cross the BBB, are easily modified to carry therapeutic genes, have 
immunosuppressive properties that prevent a host immunoreaction after 
implantation, and seem capable of shielding therapeutics such as oncolytic viruses 
from the host immune response, thereby ensuring long term reservoirs of therapeutic 






Figure 1. Overview of stem cell-based delivery of different therapeutics to gliomas. Several 
forms of therapy can be delivered by modified stem cells, including antiangiogenic factors 
such as aaTSP or endostatin (A), oncolytic viruses or enzymes capable of processing 
prodrugs such as 5-FC to cytotoxic compounds (B), and immune regulatory factors such as 
interleukin (IL)-12 that can recruit antitumor immune cells (C). Abbreviations: aaTSP, 
antiangiogenic protein thrombospondin; TRAIL, tumor necrosis factor-related apoptosis-
inducing ligand; Th1, T helper 1 cell; Tcx, cytotoxic T cell.    
 
 
NSCs are the stem cell type most commonly used for glioma therapy. They are the 
precursor cells of the central nervous system (CNS) and the only endogenous stem 
cells to the brain. These cells can self-renew and, due to their multipotent nature, 
can differentiate into neurons, astrocytes, and oligodendrites. NSCs have a very 
strong glioma tropism, especially targeting tumor border and hypoxic zones, and can 
cross the BBB, making excellent carriers for therapeutics such as viral particles, 
prodrugs, and cytokines 10. An interesting feature of NSCs is their ability in targeting 
not only the primary tumor mass, but also the invasive GSCs, providing a chance in 
eliminating the driving factor of glioma progression and recurrence. NSCs not only 
target gliomas, but have also shown an equal tropism for breast cancer and 
melanoma brain metastases 11, 12. The mechanism underlying this tumor tropism is 
not yet fully understood, but it is assumed that various chemo attractants and 
cytokines released by the tumor microenvironment are critical. Because NSCs do not 
display major histocompatibility complex type II (MHCII) on their cell surface, no host 
immunoresponse is evoked upon transplantation 13. In addition, the secretion of 
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immunomodulating cytokines such as interleukin 10 (IL-10) further suppresses the 
local immune response, allowing the optimal delivery of a therapeutic payload with 
minimal neuro-inflammation 14. NSCs could potentially be harvested from the adult 
brain, but this process is very complicated and time consuming. As an alternative, 
most studies use stable cell lines of immortalized NSCs originally obtained from 
embryonic cells, which often makes their use controversial due to ethical, regulatory, 
and political concerns.  
 
Mesenchymal stem cells (MSC) are the most often studied alternative to NSCs for 
glioma therapy. These adult stem cells retain their stem cell characteristics, display 
similar tropism to glioma, and can cross the BBB. They can differentiate into any cell 
of the mesenchymal lineage including osteoblasts, chondrocytes, myocytes, and 
adipocytes 15. MSCs are easily obtained from bone marrow, adipose tissue, 
peripheral blood, umbilical cord (UC) blood, or the placenta, and can be isolated by 
their expression of the surface markers CD73, CD90, CD105, CD146, CD271, 
STRO-1, and lack of expression of the hematopoietic markers CD34 and CD45 16. 
As with NSCs, local immunosuppression can be observed upon implantation 17.  
 
Less frequently used cell types include embryonic stem cells (ESCs) and 
hematopoietic stem cells (HSCs). The use of ESCs is heavily disputed due to their 
origin; they can only be obtained from embryonic or fetal tissue 18. Unlike other cell 
types, ESCs can be modified by homologous recombination, not only eliminating the 
use of (often inefficient) viral transduction, but further allowing for vey specific 
genetic alterations yielding lines of cells that are stable and identical, ideal for clinical 
use 19, 20. HSCs on the other hand are adult stem cells that can be easily obtained 
from peripheral blood or bone marrow. HSCs display tropism to brain tumors and 
therefore are becoming of interest for malignant glioma therapy 21. Homing of these 
cells to the tumor site is mediated through attraction to two cytokines, tumor necrosis 
factor beta (TNFȕ) and stromal derived factor alpha (SDF1Į) 22. Furthermore, the 
expression of E-selectin by glioma endothelial cells helps adhere circulating HSCs to 
the tumor tissue. 
 
Currently, a wide range of stem cell-based therapeutic strategies is being 
investigated pre-clinically while a small portion of this research is being transitioned 
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to the clinic (Figure 2; Table 1). In this review, we summarize recent advances in the 




Box 1. Cell types used for glioma stem cell therapy 
NSCs are the only adult stem cells endogenous to the human brain. They can differentiate into 
neurons, astrocytes, and oligodendrites. The subventricular zone (SVZ) of the forebrain is the 
area richest in NSC, but they can also be found in the striatum and the dentate gyrus of the 
hippocampus. NSCs are problematic to isolate and expand because only small numbers are 
available in the mature brain. A wide range of surface markers has been associated with NSCs, 
as well as expression of sox-1 and -2, pax-6 and nestin. A recent study shows selection based on 
expression of the surface markers CD133+/CD184+/CD271-/CD44-/CD24+ allows for highly pure 
cultures of NSCs 23. NSCs tend to grow in neurospheres in vitro and are cultured in specialized 
NSC growth medium containing Dulbecco’s modified Eagle medium (DMEM)/glutamax, B27, 
insulin, glucose, penicillin/streptomycin, bGFG and EGF. Differentiation is promoted by epidermal 
growth factor (EGF) and fibroblast growth factor (FGF) 24.    
 
MSCs are non-hematopoietic bone marrow (BM)-derived adult stem cells with the capacity to 
differentiate into cells of the mesenchymal lineage including osteocytes, chondrocytes, myocytes 
and adipocytes. Compared to NSCs, they are relatively easily isolated from BM, umbilical chord 
(UC) blood, placenta, adipose tissue and peripheral blood. Once cells are aspirated from BM, 
they are cultured in DMEM and fetal bovine serum (FBS) at 37 0C and 5% CO2.  MSCs, in 
contrast to the hematopoietic progenitor cells that are also derived from BM, adhere to tissue 
culture plastic within 24-48h. Isolation and selection occurs based on their adherent growth in 
culture, expression of the surface markers CD73, CD90, CD105, CD146, CD271 and STRO1 and 
lack of expression of CD34 and CD45 and HLA-DR.16  
 
HSCs are bone marrow derived adult stem cells that give rise to blood cells of both the myeloid 
and lymphoid lineage, including thrombocytes, erythrocytes, monocytes, neutrophils, basophils, 
eosinophils, macrophages, dendritic cells (myeloid) and B- and T lymphocytes and Natural Killer 
(NK) cells (lymphoid). Cells can be obtained from the BM, umbilical cord, and peripheral blood. 
Pretreatment with granulocyte colony stimulating factor (GSCF) stimulates migration of HSCs to 
the blood and is often used. Selection takes place based on surface markers and is subject to 
ongoing debate. Currently the markers most widely accepted for human MSCs are 
CD34+/CD59+/Thy-1+/CD38-/c-kit+ combined with a lack of lineage markers25, but for mice MSCs 
different expression markers are used.  
 





Stem cells for cargo delivery 
Genetic manipulation is one of the research strategies most often investigated for 
glioma, because it has an almost unlimited range of potential targets. Therapeutic 
genes stimulating the immune system, inducing tumor cell death, inhibiting 
angiogenesis, and limiting metastatic potential, have been extensively studied, and 
many different approaches and gene combinations have been used.  However, gene 
therapy (and/or viral therapy) alone has not been able to live up to its full potential, 
due to activation and elimination by the host immune system, low transduction 
efficiency and gene expression, and a lack of even distribution throughout the target 
tissue.  Since stem cells are known to display strong tropism to glioma, are capable 
of crossing the blood brain barrier, suppress the host immune system, and are easily 
genetically modified, they make ideal delivery vehicles for therapeutic agents, 
including genes. Most therapeutic strategies for malignant gliomas using stem cells 
involve the delivery of mainly four different types of cargos: cytokines, enzymes or 
prodrugs, oncolytic viruses, and nanoparticles. 
 
potential, which makes them highly attractive for research purposes. However, their use is highly 
disputed due to the source of origin. ESCs are derived from the inner mass of the blastocyst 4 to 
5 days after in vitro fertilization (IVF) by immunosurgery and plated onto a layer of support cells 
consisting of mouse embryonic fibroblast (MEF) in special hESC medium consisting of DMEM 
with 20% KSR, bFGF, glutamine, non essential amino acids, penicillin/streptomycin and ȕ-
mercaptoethanol. This allows the embryonic cells to attach and to expand without the risk of 
differentiation. Differentiation occurs once the embryonic cells are removed from their support 
cells and are allowed to form embryoid bodies. Nanog and Oct4 transcription factors are often 
used to determine the phase of differentiation. As of lately, several protocols using synthetic 
polymers are now available culturing ESC in the absence of feeder cells or serum. However, 
Higuchi et al showed that none of these protocols have been able to prevent differentiation and 
pluripotency of ESCs in the long term, limiting their current value for the stem cell therapy field.26  
 
iPSCs are somatic cells that are reprogrammed to become ESC-like through introduction of 
embryonic genes including Sox 3 and 4, Oct-4, myc and Klf4/LIN28 by viral vectors in a process 
that takes between 15 and 30 days. The infected cells are then cultured in ESC medium, and 
after 10 to 15 days colonies will appear, which can be expanded. These new stem-like cells 
express ESC markers are capable of differentiating into cells of the endoderm, mesoderm, and 
ectoderm and can replicate indefinitely.  
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i. Cytokine-based glioma therapy 
Tumor necrosis factor-related apoptosis-inducing ligand  (TRAIL) is one of the most 
commonly explored cancer therapeutics because it binds to death receptors found 
specifically on tumor cells, causing a widespread apoptotic effect with minimal 
cytotoxic effects on normal tissues (Figure 2); however, some cancer types, 
including GBM, display resistance to TRAIL-mediated apoptosis (Box 2) 27-31. Three 
recent studies have used NSCs as a delivery vehicle for the secreted soluble variant 
of TRAIL (sTRAIL) by fusing the N-terminus of Flt3L (a ligand for Flt3L tyrosine 
kinase receptor) to the extracellular domain of TRAIL. Hingtgen et al designed a 
reporter system to non-invasively monitor the delivery, fate, and therapeutic effect of 
sTRAIL to GBM by fusing a luciferase reporter to sTRAIL 27. NSCs delivered the 
fusion protein to the tumor site, and luciferase bioluminescence imaging allowed 
tracking of both NSCs and the delivery of sTRAIL to glioma tumors. With the 
continuous delivery of sTRAIL by NSCs, a decreased glioma burden was observed 
as soon as six days post-implantation. Given that glioma cells are known to develop 
resistance to TRAIL (Box 2), new ways are being explored to sensitize GBM to this 
therapeutic agent. Balyasnikova et al. explored the possibility of combining sTRAIL 
therapy with the proteasome inhibitor bortezomib and showed that survival 
significantly increases with this dual treatment 32. NSC-mediated delivery of sTRAIL 
has also been combined with the kinase inhibitor PI-103, which inhibits the PI3 
kinase (PI3K)–Akt–mTOR pathway and thus inhibits proliferation and tumor growth 
31. Inhibition of this pathway antagonizes the effect of sTRAIL, resulting in a more 
efficient induction of apoptosis and cell death. Both studies highlight the need for 
therapeutics capable of sensitizing glioma to TRAIL. Recently, Badr et al. 
characterized a family of cardiac glycosides, including lanatoside C, an FDA-
approved compound that sensitizes GBM cells to TRAIL and showed that the 
combination of recombinant TRAIL and lanatoside C yielded an enhanced 
therapeutic effect 33, 34.  Given that this family of compounds is known to penetrate 
the brain, they can be easily applied in combination with the NSC-sTRAIL strategy 
for GBM therapy. Three additional studies used MSCs for sTRAIL delivery. In 2009, 
Sasportas et al. assessed the potential for using MSCs for treating glioma by 
investigating the cell fate, therapeutic efficacy, and genetic engineering of these cells 
28. In a proof of principle study, MSCs were engineered ex vivo to express sTRAIL 35. 
These engineered MSCs migrated towards glioma, retained their stem-like 
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properties, and showed prolonged survival in the tumor surroundings, providing a 
basis to further develop MSC-based therapies for glioma (Figure 2). MSCs 
engineered to secrete sTRAIL also appear to be resistant to its cytotoxic effect, 
whereas a caspase-mediated apoptosis was induced in glioma cells. Shortly after, 
Menon et al. confirmed these finding 29 using MSCs transduced to express both 
sTRAIL and the mCherry fluorescent protein, demonstrating tumor specificity and 
retention in glioma cells both in vitro and in vivo. Moreover, significant survival was 
observed in the treated group as compared to control animals, suggesting that MSCs 
expressing sTRAIL could provide an interesting approach for anti-glioma therapy. 
Choi et al. applied the same strategy using human adipose tissue derived MSCs 
(hAT-MSCs) engineered to express sTRAIL and reported similar results 36.  
 
Genetically modified MSCs can also be used to secrete molecules that do not 
directly target glioma, but which attract innate immune cells to the tumor, as shown 
by Ryu et al. 37. MSCs engineered to express modified interleukin 12 (IL-12M), a 
proinflammatory cytokine that induces T-helper 1 and cytotoxic T cell immunity, 
yielded prolonged survival of glioma-bearing mice when injected intratumorally. 
Remarkably, control mice injected with USB-MSC-IL12M showed resistance to new 
tumorigenesis, suggesting a tumor-specific T cell immunity. 
 
ii. Enzyme/prodrug-based glioma therapy  
As an alternative strategy to the use of active drugs, which have the risk of targeting 
normal tissue, many studies have focused on the use of prodrugs that are activated 
exclusively at the tumor site, thereby increasing tissue selectivity. One of the most 
popular suicide gene therapy approaches relies on the herpes simplex virus type I 
thymidine kinase (HSV-TK) and the prodrug ganciclovir (GCV). Although excellent 
results have been reported in experimental settings, a lack of efficacy was observed 
in clinical trials 38-41. Low transduction efficiency and the absence of a bystander 
effect are thought to be the main causes for this lack of success. To overcome these 
limitations, Ryu et al. designed a protocol using MSCs expressing HSV-TK (MSC-
TK) combined with valproic acid (VPA), which upregulates gap junction proteins 
between MSCs and glioma cells, yielding an enhanced bystander effect 42. This 
combined treatment significantly inhibited tumor growth and prolonged survival 
compared with mice treated with MSC-TK in the absence of VPA. Several studies 
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have tested a rat glioma model with NSCs (HB1.F3) transduced with the gene for 
cytosine deaminase (CD), which converts the prodrug 5-fluorocytosine (5-FC) into 
the active, inhibitory compound 5-fluorouracil (5-FU; Figure 2) 43, 44. In contrast to the 
active drug 5-FU, the prodrug 5-FC can cross the BBB. Two separate studies have 
reported reduced tumor volumes and increased survival in CD/5-FC treated rats with 
glioma. 45 41. Joo et al. demonstrated both migration and homing of the HB1.F3 
NSCs expressing CD to the tumor site as well as reduced tumor volume after breast 
cancer cells were implanted in one hemisphere of the mouse brain and CD-
expressing NSCs were implanted into the contralateral hemisphere, followed by 
injection of the prodrug 5-FC 11. Beyond demonstrating the feasibility of this 
treatment, this experiment showed that NSCs can not only home to primary brain 
tumors, but can also migrate towards metastases. However, the survival of animals 
was not significantly prolonged, suggesting that repeated administration of NSCs 
and prodrug is required. Further, a combination of NSC-encoding different 
therapeutic genes or the addition of conventional anticancer therapies to this 
treatment strategy might be needed. Two other studies reported the use of MSCs to 
deliver CD to brain tumors and showed an increased mice survival upon intratumoral 
injection of MSC-CD cells followed by 5-FC therapy (Table 1) 43, 44.  
 
Lim et al. modified NSCs to express the rabbit carboxylesterase enzyme rCE, which 
converts the prodrug CTP-11 (irinotecan) into the active chemotherapeutic agent 
SN-38 (7-ethyl-10-hydroxycamptothecin), a potent topoisomerase I inhibitor 46. Given 
that intratumoral injection is not favorable when multiple lesions are involved, as in 
the case for glioma, NSCs were administered systemically. After intravenous 
injection, rCE-expressing NSCs efficiently penetrated the brain targeting both the 
primary glioma site as well as infiltrating glioma cells (containing GSCs) that are 
known to be the source of tumor recurrence and patient death. However, the 
accumulation of NSCs in non-brain organs was also observed, but did not lead to 
any tissue damage or tumor formation, although follow-up studies might be needed 
to evaluate these effects on the long term. 46. The authors speculate that the use of 
tumor trophic modulating agents and/or the use of multiple injections could enhance 
NSCs delivery to the tumor site, thereby increasing specificity and therapeutic effect. 
Using the same enzyme/prodrug therapy, Zhao et al. explored the use of NSCs 
engineered to secrete rCE enzyme and showed that this strategy yielded 200-fold 
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higher bystander effect on tumor cells in vitro and enhanced therapeutic effect on 
metastatic breast cancer in vivo47. This strategy should provide an enhanced 
therapeutic effect for malignant gliomas as compared to NSCs expressing 
endogenous rCE. 
 
A hallmark of malignant gliomas is extensive angiogenesis with glioma stem cells 
needing a vascular niche for optimal functioning 6, 8, 48. Yin et al. used MSCs to 
express the anti-angiogenesis factor (endostatin), the prodrug-activating enzyme 
rCE (activates CTP-11 into SN-38), or a combination of both 49. In vivo, MSCs 
expressing endostatin and rCE led to the highest antitumor response, including 
reduced angiogenesis, increased cell death, and a reduced GSCs population. Choi 
et al. evaluated the characteristics and therapeutic potential of human adipose 
tissue-derived MSCs (hAT-MSCs) in a rat brainstem glioma model and found, similar 
to NSCs, that hAT-MCSs modified to express rCE has tumor tropism, drug 
activation, and increased life span 50. In another attempt to target angiogenesis, van 
Eekelen et al. modified NSCs to express antiangiogenic protein thrombospondin 
(aaTSP-1) 51. aaTSP-1 was shown to target glioma vasculature and to significantly 
reduce vessel density in a glioma brain co-culture containing endothelial cells, 
established glioma cells, and glioma stem cells. The decrease in tumor vessel 
density correlated with decrease in tumor progression and increased survival, most 
likely due to the disrupted interaction between endothelial cells and glioma stem 
cells. 
 
iii. Oncolytic virus-based glioma therapy  
Theoretically, oncolytic viruses have a significant potential for glioma therapy due to 
their specificity and high efficiency in killing tumor cells. However, current viral 
therapeutic strategies have not yet reached their full potential due to poor distribution 
at the tumor site, low infectivity of tumor cells, and the host immune response (Box 
2). To overcome these limitations, Ahmed et al. evaluated NSCs as carriers for the 
targeted delivery of CRAD-S-pk7, a glioma restricted oncolytic adenovirus 14. NSCs 
loaded with CRAD-S-pk7 injected intracraniallly inhibited tumor growth and 
increased median survival by 50%, as compared to animals treated with CRAD-S-
pk7 alone, suggesting that NSCs can shield the virus from the host immune system 
before delivery to the tumor. Interestingly, the oncolytic virus seemed to enhance 
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NSCs migration towards the tumor site. In a follow up study by the same group, the 
FDA-approved NSC line HB1.F3-CD was loaded with CRAD-S-pk7 and a thorough 
characterization of this carrier system was performed 52. NSCs loaded with CRAD-S-
pk7 retained tumor tropism,  
continued to replicate CRAD-S-pk7 for over a week after injection, and effectively  
distributed the CRAD-S-pk7 virus among glioma cells in vivo. Nonspecific delivery of 
adenovirus in the brain was drastically reduced and, due to local injection of NSCs, 
no migration of NSCs to distant organs was observed, showing that this oncolytic 
virus carrier system holds a great potential for glioma therapy. 
 
iv. Nanoparticle-based glioma therapy 
Following a different approach, several groups are using MSCs to deliver to gliomas 
nanoparticles, which can carry different therapeutic agents incorporated into the 
particle or attached to the surface. MSCs can circumvent the problem that 
nanoparticles have in crossing the BBB, typically yielding low targeting efficiency to 
brain tumors. In a proof of principle study, Roger et al. used poly-lactic acid 
nanoparticles or lipid nanocapsules loaded with coumarin-6, a lipophilic fluorescent 
dye used to assess the intracellular uptake of nanoparticles by stem cells that was 
successfully delivered to the tumor site 53. In a follow up study, MSCs loaded with 
lipid nanocapsules containing the organometallic complex ferrociphenol (Fc-diOH), a 
drug with demonstrated cytotoxic effect on glioma cells both in vitro and in vivo, were 
shown to have an effective anti-cancer treatment 54. Li et al. designed a high-efficacy 
targeting approach for nanoparticle drug delivery using MSCs expressing silica 
nanorattle doxorubicin (dox) on the cell surface 55. The drug was efficiently delivered 
and resulted in a wider distribution and longer retention of dox at the tumor site, with 
subsequent enhanced glioma apoptosis as compared with free dox and silica-





Figure 2. Examples of stem cell-based therapies against gliomas. Many variations on stem 
cell therapy are possible, and three are depicted here using mesenchymal, neuronal and 
hematopoietic stem cells (MSCs, NSCs, and HSCs, respectively). Abbreviations: TGF ȕ, 
transforming growth factor ȕ; Apt, apoptosis; CD, cytosine deaminase; TRAIL, tumor 
necrosis factor apoptosis-inducing ligand; TȕRIIDN, dominant negative mutant of 
transforming growth factor ȕ receptor II. 
 
 
Routes of administration and enhancement of the stem cell model 
Several studies have focused on developing alternative strategies to increase the 
therapeutic effect of SC-based therapy to brain tumors by enhancing delivery mode, 







i. Routes of administration 
Successful administration of stem cells is crucial for their antitumor efficacy. Both 
intratumoral or intravenous injections can effectively deliver stem cells, and either 
injection route is used in the majority of studies 56. Panciani et al. proposed a 
different delivery route using injections into ventricles or spaces of the brain 
speculating that this injection mode may lead to the formation of a reservoir of 
therapeutic cells 57. This study confirmed that intraventriculary transplanted MSCs do 
create a niche in the subventricular space and can be triggered to migrate to the site 
of tumor formation. A follow up study investigating the life span of implanted MSCs 
and their potential for finding and attacking GSCs and tumor recurrence is planned. 
Meanwhile, Bexell et al. studied long distance tropism and migration of MSCs after 
intratumoral and extratumoral implantations in a rat glioma model 58. No evidence of 
long distance MSC migration to the tumor site through either the corpus callosum to 
the contralateral hemisphere or through the striatum to the ipsilateral hemisphere 
was observed, suggesting the use of MSCs is limited to certain delivery routes. 
Intratumoral injection resulted in a dense and tumor specific distribution, as 
previously reported 59. 
 
Biodegradable synthetic extracellular matrices (sECMs) have been used in various 
rodent models to provide mechanical support that promotes stem cell survival and 
differentiation into neurons 60, 61. Kauer et al. have evaluated the implantation of 
NSCs expressing sTRAIL encapsulated in sECM at the tumor cavity following tumor 
resection and found that the washout of NSCs by cerebrospinal fluid was reduced 
drastically 30. Both migratory stem cells and sTRAIL could leave the ECM 
environment and reach the tumor site, but increased retention at the tumor site and a 
subsequent increase in sTRAIL secretion was observed, suggesting that coating 
stem cells with ECM may be a highly successful strategy for treating GBM 62. 
 
ii. Factors that regulate glioma tropism 
Stem cells are particularly attractive for glioma therapy due to their tropism to the 
tumor site. It is still not clear how this “homing mechanism” works, but growth factors 
and chemokines secreted or expressed by glioma cells are known to be important. 
Park et al. designed MSCs to overexpress the alpha chemokine receptor CXCR4 63, 
a receptor that specifically binds SDF1Į, a key cytokine mediator of glioma tropism 
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64, 65. CXCR4 overexpression enhances the migratory capacity of MSCs to gliomas 
both in vitro and in vivo; inhibition of either SDF1Į or CXCR4 completely blocks 
migration. Kim et al. followed a similar approach and showed that upregulating of 
interleukin 8 (IL-8) secretion by glioma, or overexpression of the IL-8 receptor 
CXCR1 on the MSC surface, enhanced the migration capability of MSCs to the 
tumor. Inhibiting IL-8 significantly reduced migration, suggesting that CXCR1 is a 
major regulator in glioma tropism 66. Velpula et al. showed that multiple cytokines are 
involved in recruiting MSCs to the glioma site, including IL-8, GRO, GROĮ, MCP-1, 
and MCP-2 67, but more research is needed to completely unravel the mechanism of 
tumor site homing.  
 
iii. Improved cellular vehicles 
To date, the experimental use of ESCs for glioma therapy has been limited to the 
delivery of sTRAIL, owing to ethical, regulatory, and political concerns, and no recent 
studies have been published (Table 1) 68. Recently, Lee et al. reported on the use of 
induced pluripotent stem cells (iPSCs) to generate NSCs 69 and showed that in this 
context, iPSCs and ESCs are functionally equivalent, but iPSCs can be relatively 
easy to generate from somatic cells and are not burdened by the ethical concerns. In 
this study, iPSCs cells were generated by transducing primary mouse embryonic 
fibroblasts with four transcription factors, Oct-4, Sox 2, c-Myc and Klf4; by culturing 
iPSCs in monoculture, NSCs were generated. To test the functionality and potential 
use for glioma therapy, these NSCs were transduced with a baculovirus containing 
the HSV-TK gene and injected in the contralateral hemisphere of tumor-bearing 
mice. Prolonged survival and inhibition of tumor growth was observed, indicating that 
iPSC-derived NSCs possess all characteristics required to serve as a cellular carrier 
for glioma therapy. The same research group recently published a new study 
evaluating the use of human embryonic stem cells to generate NSCs 70 in which the 
authors speculate that ESC-derived NSCs have the potential to produce limitless 
amounts of identical NSCs, while at the same time eliminating variability in the 
quality of therapeutic cells, allowing for better comparative analysis of different 
studies. 
 
Endothelial progenitor cells are a subpopulation of hematopoietic stem cells that are 
known to migrate towards the neovasculature of certain cancers and integrate at the 
232 
 
tumor site and have also been studied as gene carries for the treatment of glioma 71. 
Because EPCs can be easily collected from peripheral blood and display the 
appropriate tumor tropism, they make an interesting candidate for glioma stem cell-
based therapy. Accumulation of EPCs at the tumor site has been confirmed by non-
invasive imaging: Tc-99 single photon emission computed tomography (SPECT) and 
magnetic resonance imaging (MRI) imaging of EPCs transformed with the human 
sodium iodide symporter (hNIS) gene or ferumoxides-protamide sulphate (FePro), 
respectively. Using a novel inducible lentivirus expression system under the stress 
controlled HSP70B promoter, Noyan et al. reported a proof of principle study that 
used a HSC-based gene therapy method to treat solid tumors using immunotherapy 
72. Hematopoietic stem and progenitor cells (HSPCs) were genetically modified to 
express the dominant negative mutant of the transforming growth factor-beta 
receptor II (TȕRIIDN), which is known to neutralizes TGF-ȕ signaling in the tumor 
microenvironment and can thereby suppress tumor cell metastasis (Figure 2) 73. 
Mice received a bone marrow (BM) transplant with the modified HSPCs followed by 
subcutaneous injection of glioma cells. A massive antitumor immune response was 




















Table 1. Stem cell therapy against malignant gliomas 
 
Abbreviations: MSC mesenchymal stem cell; NSC neural stem cell; ESC embryonic stem cell; HSC 
hematopoietic stem cell; NP nanoparticle; sTRAIL secretable tumor necrosis factor apoptosis-
inducing ligand; IL-12 interleukin 12; Fc-diOH ferrociphenol; dox doxorubicin; HSV-TK herpes simplex 
virus thymidine kinase; VPA valproic acid; CD cytosine deaminase; rCE rabit carboxylesterase; IL-8 
interleukin 8; aaTSP-1 antiangiogenic protein thrombospondin; sECM synthetic extracellular matrix; 
iPSCs induced pluripotent stem cells; FePro ferumoxides-protamide sulphate; TȕRIIDN Growth factor 
ȕ-receptor II; 5-FC 5-fluorocytosine  




luciferase fusion; NSC 




bortezonib; NSC Glioma sensitization to TRAIL 
32 
sTRAIL plus mTor 
inhibitor; NSC Glioma sensitization to TRAIL 
31 
sTRAIL; MSC Proof of principle MSC-mediated TRAIL therapy 
28,29, 36 




NSC Anti-angiogenesis therapy 
51 
rCE expression; NSC SN-38 mediated therapy 46 




Anti-angiogenesis therapy 49 
CD expression; NSC 5-FC therapy 45,41, 11 
CD expression; MSC 5-FC therapy 43, 44 
HSV-TK and VPA; 
MSC 
Enhanced efficacy of HSV-TK 
mediated therapy 
42 
Oncolytic virus CRAD-S-pk7 expression; NSC 
Proof of principle 14 
Enhanced carrier system 52 
Nanoparticles NPs loaded with coumarin 6; MSC 
Proof of principle NP-mediated 
delivery system 
53 
 NPs loaded with Fc-diOH; MSC NP delivery  
54 
 NPs carrying silicia nanorattle dox; MSC NP delivery  
55 
    
NSC delivery to 
glioma 
Coating with sECM; 
NSC  Improved NSC delivery 
30 
Enhancement of 















overexpression; MSC Enhanced glioma tropism 
63 
IL-8 and/or CXCR 1 





Enhanced glioma tropism 67 
Improved cellular 
vehicles 
IPSCs generated from 
embryonic fibroblasts; 
ESC 
Proof of principle 69 
NSC differentiation; 
ESC Proof of principle 
70 
EPC; hNIS and FePro 












Clinical transition and/or obstacles to translation 
 
i. Glioma stem cell therapy in the clinic 
Although a vast amount of interesting and exciting research is being explored using 
stem cells as a therapeutic strategy for malignant gliomas, most of these studies are 
being performed in the laboratory setting. This indicates that although the bench 
results are promising, translating these therapeutic strategies to the clinic remains 







Box 2. Glioma stem cell therapy in the clinic 
City of Hope Hospital, NCT 01172964 
In July 2010 the very first clinical trial using stem cells as therapeutics for malignant gliomas was 
started at the City of Hope Hospital, California. Patients with histologically confirmed grade III or 
IV glioma, or patients diagnosed with grade II glioma and radiographic findings of grade III/IV 
glioma were enrolled and had their tumor mass removed by craniotomy. At the time of debulking, 
they received intracranial injections with HB1F3.CD genetically modified neural stem cells (day 
zero). In the absence of disease progression or intolerance to the injected cells, patients received 
on day 4–10 oral dosages of 5-FC every six hours. Response to therapy, and adverse effects 
were evaluated by MRI on day 32, 60 and for every 2 months onwards. No results have been 
published yet, and as for now, 30 patients have been enrolled.  
Study details as described on www.clinicaltrials.gov 
x Primary Outcome Measures: determination of the safety and feasibility of intracerebral 
administration of genetically-modified neural stem cells (NSCs) in combination with oral 
5-fluorocytosine. 
x Secondary Outcome Measures: Relationship between intracerebral and systemic 
concentrations of 5-FC and 5-FU with increasing NSC dose level; Presence of 5-FU in 
the brain using 19F-MRS; Assessment of development of immunogenicity against NSCs; 
Obtain preliminary imaging data regarding perfusion permeability parameters and 
imaging characteristics as shown on magnetic resonance imaging (MRI) studies due to 




Box 3. Barriers to glioma therapy 
Blood-brain barrier (BBB): The BBB consists of a lining of tight junctions between the 
endothelial cells of the brain capillaries. These tight junctions restrict the passage of molecules 
from the blood to the brain extra cellular matrix, allowing only certain substances to pass. 
Antibodies, antibiotics, chemotherapeutic agents, and some stem cells are unable to cross, 
severely limiting the potential of systemic therapy for glioma. 
 
Blood-tumor barrier: Angiogenesis with leaky vessel formation, necrosis, and the highly 
heterogeneous character of the glioma cell population makes it vey difficult to establish consistent 
distribution of vectors and other agents. Further, certain areas of the tumor are almost 
inaccessible, resulting in only a very limited effect of the applied therapeutics. 
 
Tumor cells Invasion in the brain: As gliomas progress and invade the brain, an extensive 
modulation of the extracellular matrix occurs. This phenomenon complicates curative surgery and 
radiotherapy considerably and results in tumor recurrence after surgical resection, often leading 
to patient death. 
 
Secretion of local cytokines and growth factors that might induce malignant 
transformation in stem cells: Glioma cells are known to secrete a wide variety of chemokines 
and GF such as matrix metalloproteinases (MMPs), plasminogen tissue inhibitor 1 (PTI1), VEGF, 
EGF, FGF insulin growth factor 2 (IGF2), hepatocyte growth factor (HGF), and IL6 that are 
capable of initiating malignant transformation of nearby stem cells, recruiting them for 
contributement to tumor proliferation and growth. This is of particular concern when one actively 
introduces SC at the tumor site for glioma therapy and therefore extensive research needs to be 
done to address these safety issues.74 
 
Escaping immune surveillance: Glioma surface markers such as MCH surface expression are 
often downregulated allowing glioma cells not only to escape the host immune response, but also 
to protect themselves from newly designed drugs targeted specifically to glioma cells.75   
 
Resistance to therapies such as TRAIL: Malignant gliomas such as glioblastoma are known to 
acquire resistance to therapies. In the case for TRAIL-based therapy, upregulation of the Bcl2 
associated Athanoge (BAG3) genes and multiple other genes have been described to cause 
resistance at various points along the apoptotic pathway. New research is focused at finding 
molecules that sensitize GBM cells to TRAIL.31, 32, 34 
 
Secretion of local immunosuppressants: This problem does not only hinder the efficacy of the 
host immune system against the tumor cells, but also makes it increasingly difficult to use 
immunotherapy for anti-glioma treatment. 
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At the City of Hope (California) by Aboody et al., NSCs (HB1.F3-CD) genetically 
modified to express E. coli cytosine deaminase, which will convert the oral pro-drug 
5-FC into the chemotherapeutic agent 5-FU at the tumor site, are being tested as 
was done in various animal models (Table 1) 11, 41, 43-45. The modified NSCs are 
injected directly at the tumor site after surgical resection of the tumor mass. Oral 5-
FC will be given every six hours between day 4 and day 10. Because NSCs have a 
strong tropism for glioma 10, 76, no toxicity to normal brain cells is expected while 
efficient elimination of GBM cells is expected. The primary aim of this trial is to test 
the safety and feasibility of the NSC-CD system in humans, with secondary objective 
to evaluate immunogenicity and pharmacokinetics.  
 
ii. Improving techniques for clinic/trials 
A major limitation of stem cell therapy in general is safety. Stem cells possess many 
characteristics that make them well suited as cellular transport vehicles but their 
capacity for unlimited self-renewal raises several concerns regarding patient safety. 
Spontaneous tumor formation in longstanding MSC cultures has recently been 
reported, and it was shown that after implantation, a small fraction of immortalized 
NSCs continue to proliferate 10, 77. A 2009 clinical trial by Amariglio et al. for the 
treatment of ataxia telangiectasia with NSC injection reported the formation of 
multiple brain tumors in a patient four years after treatment 78. The standardized use 
of suicide genes such as CD for each stem cell line would theoretically minimize this 
risk.  
Aside from malignant transformation of stem cells, the secretion of growth 
factors and chemokines, and the direct local immunosuppressive effect of stem cells 
may modify the tumor microenvironment in such a way that tumor growth is 
promoted. The latter has been reported in other solid tumors after injection with 
MSCs 74, 79, 80, and MSCs have been shown to enhance the metastatic potential of 
breast cancer cells 81. The tumor promoting role of MSCs, however, remains in 
dispute; several studies report a glioma-suppressing effect of implanted MSCs 82, 83, 
and MSCs used in the clinic to treat neurodegenerative diseases and stroke have 
been well tolerated with limited side effects. The discrepancy between various 
studies is yet another issue that needs to be solved before stem cell-based therapy 
can be successfully applied to glioma treatment in the clinic. For now, it remains very 
difficult to interpret study results and to compare data between various study groups, 
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given the large variability between the stem cells themselves and the methods 
employed by different groups. Better ways of cell selection and preparation are 
absolutely essential to design stable and identical cell lines that can create 
reproducible datasets and optimally functioning cell carrier systems, a characteristic 
that might be attributable to subgroups rather than the stem cell population as a 
whole. Furthermore, systematic comparison of stem cell migratory potential, the 
ability to target GSCs, survival, and efficacy of delivery are needed to identify the 
optimal carrier system and delivery route. Ahmed et al. recently reported that 
effective oncolytic virus delivery by NSCs was clearly superior to MSCs, although 
equivalent migration capacity was displayed 84. However, although many groups 
make use of the enzyme/prodrug combination of CD/5-FC in either NSCs or MSCs, 
no comparative studies have been performed, which is a missed opportunity in the 
quest for an optimal carrier system. Many more examples could be discussed, and 
until these issues are resolved, it seems to be overly optimistic to expect an easy 
transition of stem cell glioma therapy to the clinic. The ability to target glioma stem 
cells rather than glioma cells in general might prove to be a crucial point since these 
cells are thought to be the cause of tumor recurrence and patient death.  
Translation is also slowed by concerns regarding several limitations of current 
glioma models used to test these strategies in the laboratory. Although many 
pathophysiological similarities between the rodent glioma model and human tumors 
are observed, many models are based on xenografts in immunocompromised mice. 
Implanted tumor cells will not mimic the process of de novo tumorigenesis, and 
tumor-associated immunosuppression and immune-modulating events are not likely 
to be accurately reflected, resulting in a slightly different tumor microenvironment. 
Doucette et al. have proposed overcoming this limitation by using an RCAS/Ntv-a 
glioma model in which endogenous glioma develop and acquire tumor and stromal 
features similar to human tumors 85. This may be an improvement over existing 
glioma models, but this study was also performed using immunocompromised mice, 
implying that many variables will remain unknown until clinical testing is completed.  
To resolve some of these issues and obtain a true understanding of the 
working mechanism and antitumor effect of stem cell-based therapy, the 
development of adequate imaging tools is of the utmost importance. Not only do we 
need these tools to increase treatment efficacy, but the ability to track single stem 
cells and determine their fate, tropism, migration, interaction with the tumor 
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environment, and mechanism of action will answer important questions regarding 
safety and efficacy. Several imaging tools capable of tracking stem cells are 
currently available preclinically (e.g., bioluminescence imaging, fluorescence), but 
these techniques are not yet available for use in humans due to several concerns 
including (substrate) toxicity and sensitivity. Recently, Thu et al. developed a method 
to visualize NSCs by magnetic resonance imaging (MRI), using iron labeling 
(ferumoxide-protamine sulfate complex) of NSCs 86, and Menon et al. reported 
similar results after labeling human MSCs with ferumoxide 87; tumor tropism 
remained unaltered. Similar approaches might provide a solution that is easily 
translated to the clinic; however, more research is needed to fine tune these 
techniques for application in humans.  
Whereas new imaging tools are necessary to develop stem cell therapy, the 
availability and efficacy of stem cells and whether they serve as vehicles for therapy 
or have a direct therapeutic effect are issues that also remain to be addressed. 
Malignant gliomas are a rapidly progressing and ever changing cancer, and if too 
much time is needed to obtain a certain number of stem cells, the tumor might have 
acquired resistance to the therapy being explored (e.g., chemotherapeutics, TRAIL, 
etc.).  Furthermore, when stem cells are passaged too many times during expansion, 
differentiation and phenotypic changes may occur that limit their therapeutic 
potential. The use of stem cells might also be disputed due to ethical concerns. 
Limited availability hinders not only research opportunities but also limits the benefit 
of the potential approach, given that a working strategy that is not readily available 
cannot provide a cure. Techniques that allow for the rapid growth and expansion of 
cells while maintaining their characteristics are of extreme importance, as is optimal 
cell delivery to the tumor site. Whereas clinical studies opt for a direct intratumoral 
injection, preclinical experiments are testing intranodal, intradermal, intraventricular, 
or systemic injections in an attempt to enhance delivery success.  
 
iii. Appropriate patient selection - when will this method work? 
Patient selection may play an important role in the efficacy of the chosen therapeutic 
approach. More and more evidence suggest that specific genetic mutations in glioma 
cells respond to different therapies, and therefore genotyping or discovery of new 
biomarkers for personalized medicine could yield to an enhanced treatment success. 
An example would be the status of O6- methylguanine DNA transferrase or MGMT, 
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a DNA repair enzyme that protects cells from damage caused by ionizing radiation 
and alkylating agents. The MGMT promoter is methylated in 40 to 45% of GBMs, 
which means the cells are unable to properly repair DNA damage 88, 89. This group 
might benefit much more from a prodrug/enzyme-based approach as compared to 
patients without a methylated MGMT promoter tumor. Also, it is known that patients 
with an EGFR amplification rarely respond to chemotherapy at all, suggesting that 
the benefit of a CD/5-FC approach in this group will be minimal. This may not only 
potentially downplay the overall efficacy of this therapy, but may also falsely 
disqualify a successful approach by showing that results obtained in experimental 
studies cannot be repeated in the clinic.   
TRAIL plays an important role in the experimental design of stem cell-based 
therapy against gliomas, however, the use of this therapeutic is not (yet) reflected in 
clinical trials. Some clinical studies using TRAIL for treating various cancers can be 
found, but, except for a small subset of patients, the therapeutic results of 
administering TRAIL have been disappointing and do not reflect the results obtained 
in animal models 90, 91. Finding ways to identify the subgroup of patients that are 
responsive to TRAIL therapy or the discovery of adjuvants that help sensitize 
gliomas and other cancer cells to TRAIL might be needed before taking additional 
steps towards the clinic. With the discovery of lanatoside C as a TRAIL sensitizer, 
one of these hurdles has been overcome and since both agents are FDA-approved 
and have been used in the clinic separately, we expect a short transition to the first 
clinical trial. However, a proper comparison between carrier types and injection 





Stem cells provide a highly promising and innovative approach for the treatment of 
malignant gliomas. Provided that some of the discussed issues/limitations can be 
addressed, this therapeutic strategy could become of tremendous value in the 
search for a cure for tumors as heterogeneous and as difficult to reach as 
glioblastoma. Other exciting strategies such as gene therapy and oncolytic viral 
therapy, which by themselves have failed to establish clinically-relevant antitumor 
effects, are now given a second chance to prove their value for the treatment of brain 
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tumors. The combined approach of stem cells and gene/viral therapy has the 
potential to be of great benefit for glioma patients, and in this role, stem cell therapy 
could be used alongside surgery, chemotherapy, and radiation therapy, 





Dr. Tannous is supported by grants from the National Institutes of Health, the 
National Institute of Neurological Disorders and Stroke (1R01NS064983). The 




























1. Johnson DR, Ma DJ, Buckner JC, Hammack JE. (2012). Conditional 
probability of long-term survival in glioblastoma: A population-based analysis. 
Cancer. 
2. Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, et al. 
(2010). Survival of patients with newly diagnosed glioblastoma treated with 
radiation and temozolomide in research studies in the United States. Clin 
Cancer Res.16(8):2443-2449. 
3. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, et al. 
(2007). Malignant astrocytic glioma: genetics, biology, and paths to treatment. 
Genes Dev.21(21):2683-2710. 
4. Hochberg FH, Pruitt A. (1980). Assumptions in the radiotherapy of 
glioblastoma. Neurology.30(9):907-911. 
5. Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al. 
(2004). Population-based study on incidence, survival rates, and genetic 
alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta 
Neuropathol.108(1):49-56. 
6. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, et al. 
(2007). A perivascular niche for brain tumor stem cells. Cancer Cell.11(1):69-
82. 
7. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, et al. 
(2003). Identification of a cancer stem cell in human brain tumors. Cancer 
Res.63(18):5821-5828. 
8. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, et al. (2006). 
Stem cell-like glioma cells promote tumor angiogenesis through vascular 
endothelial growth factor. Cancer Res.66(16):7843-7848. 
9. Chalmers AJ. (2007). Radioresistant glioma stem cells--therapeutic obstacle 
or promising target? DNA Repair (Amst).6(9):1391-1394. 
10. Aboody KS, Brown A, Rainov NG, Bower KA, Liu S, Yang W, et al. (2000). 
Neural stem cells display extensive tropism for pathology in adult brain: 
evidence from intracranial gliomas. Proc Natl Acad Sci U S A.97(23):12846-
12851. 
11. Joo KM, Park IH, Shin JY, Jin J, Kang BG, Kim MH, et al. (2009). Human 
neural stem cells can target and deliver therapeutic genes to breast cancer 
brain metastases. Mol Ther.17(3):570-575. 
12. Aboody KS, Bush RA, Garcia E, Metz MZ, Najbauer J, Justus KA, et al. 
(2006). Development of a tumor-selective approach to treat metastatic cancer. 
PLoS One.1:e23. 
13. Einstein O, Ben-Hur T. (2008). The changing face of neural stem cell therapy 
in neurologic diseases. Arch Neurol.65(4):452-456. 
14. Ahmed AU, Thaci B, Alexiades NG, Han Y, Qian S, Liu F, et al. (2011). Neural 
stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic 
adenovirus in an orthotopic mouse model of human glioblastoma. Mol 
Ther.19(9):1714-1726. 
15. Picinich SC, Mishra PJ, Mishra PJ, Glod J, Banerjee D. (2007). The 
therapeutic potential of mesenchymal stem cells. Cell- & tissue-based 
therapy. Expert Opin Biol Ther.7(7):965-973. 
242 
 
16. Caplan AI. (2009). Why are MSCs therapeutic? New data: new insight. J 
Pathol.217(2):318-324. 
17. Jones BJ, McTaggart SJ. (2008). Immunosuppression by mesenchymal 
stromal cells: from culture to clinic. Exp Hematol.36(6):733-741. 
18. Keller G. (2005). Embryonic stem cell differentiation: emergence of a new era 
in biology and medicine. Genes Dev.19(10):1129-1155. 
19. Germano IM, Uzzaman M, Keller G. (2008). Gene delivery by embryonic stem 
cells for malignant glioma therapy: hype or hope? Cancer Biol Ther.7(9):1341-
1347. 
20. Gerecht-Nir S, Itskovitz-Eldor J. (2004). Human embryonic stem cells: a 
potential source for cellular therapy. Am J Transplant.4 Suppl 6:51-57. 
21. Tabatabai G, Bahr O, Mohle R, Eyupoglu IY, Boehmler AM, Wischhusen J, et 
al. (2005). Lessons from the bone marrow: how malignant glioma cells attract 
adult haematopoietic progenitor cells. Brain.128(Pt 9):2200-2211. 
22. Tabatabai G, Herrmann C, von Kurthy G, Mittelbronn M, Grau S, Frank B, et 
al. (2008). VEGF-dependent induction of CD62E on endothelial cells mediates 
glioma tropism of adult haematopoietic progenitor cells. Brain.131(Pt 
10):2579-2595. 
23. Yuan SH, Martin J, Elia J, Flippin J, Paramban RI, Hefferan MP, et al. (2011). 
Cell-surface marker signatures for the isolation of neural stem cells, glia and 
neurons derived from human pluripotent stem cells. PLoS One.6(3):e17540. 
24. Zhang SC, Wernig M, Duncan ID, Brustle O, Thomson JA. (2001). In vitro 
differentiation of transplantable neural precursors from human embryonic 
stem cells. Nat Biotechnol.19(12):1129-1133. 
25. Miller JS, McCullar V, Punzel M, Lemischka IR, Moore KA. (1999). Single 
adult human CD34(+)/Lin-/CD38(-) progenitors give rise to natural killer cells, 
B-lineage cells, dendritic cells, and myeloid cells. Blood.93(1):96-106. 
26. Higuchi A, Ling QD, Ko YA, Chang Y, Umezawa A. (2011). Biomaterials for 
the feeder-free culture of human embryonic stem cells and induced pluripotent 
stem cells. Chem Rev.111(5):3021-3035. 
27. Hingtgen SD, Kasmieh R, van de Water J, Weissleder R, Shah K. (2010). A 
novel molecule integrating therapeutic and diagnostic activities reveals 
multiple aspects of stem cell-based therapy. Stem Cells.28(4):832-841. 
28. Sasportas LS, Kasmieh R, Wakimoto H, Hingtgen S, van de Water JA, 
Mohapatra G, et al. (2009). Assessment of therapeutic efficacy and fate of 
engineered human mesenchymal stem cells for cancer therapy. Proc Natl 
Acad Sci U S A.106(12):4822-4827. 
29. Menon LG, Kelly K, Yang HW, Kim SK, Black PM, Carroll RS. (2009). Human 
bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a 
cellular delivery vehicle for human glioma therapy. Stem Cells.27(9):2320-
2330. 
30. Kauer TM, Figueiredo JL, Hingtgen S, Shah K. (2012). Encapsulated 
therapeutic stem cells implanted in the tumor resection cavity induce cell 
death in gliomas. Nat Neurosci.15(2):197-204. 
31. Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K. (2011). A 
dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL 
in experimental glioma models. Cancer Res.71(1):154-163. 
32. Balyasnikova IV, Ferguson SD, Han Y, Liu F, Lesniak MS. (2011). 
Therapeutic effect of neural stem cells expressing TRAIL and bortezomib in 
mice with glioma xenografts. Cancer Lett.310(2):148-159. 
243 
 
33. Badr CE, Niers JM, Morse D, Koelen JA, Vandertop P, Noske D, et al. (2011). 
Suicidal gene therapy in an NF-kappaB-controlled tumor environment as 
monitored by a secreted blood reporter. Gene Ther.18(5):445-451. 
34. Badr CE, Wurdinger T, Tannous BA. (2011). Functional drug screening assay 
reveals potential glioma therapeutics. Assay Drug Dev Technol.9(3):281-289. 
35. Shah K, Tung CH, Yang K, Weissleder R, Breakefield XO. (2004). Inducible 
release of TRAIL fusion proteins from a proapoptotic form for tumor therapy. 
Cancer Res.64(9):3236-3242. 
36. Choi SA, Hwang SK, Wang KC, Cho BK, Phi JH, Lee JY, et al. (2011). 
Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-
derived mesenchymal stem cells against experimental brainstem glioma. 
Neuro Oncol.13(1):61-69. 
37. Ryu CH, Park SH, Park SA, Kim SM, Lim JY, Jeong CH, et al. (2011). Gene 
therapy of intracranial glioma using interleukin 12-secreting human umbilical 
cord blood-derived mesenchymal stem cells. Hum Gene Ther.22(6):733-743. 
38. Takamiya Y, Short MP, Ezzeddine ZD, Moolten FL, Breakefield XO, Martuza 
RL. (1992). Gene therapy of malignant brain tumors: a rat glioma line bearing 
the herpes simplex virus type 1-thymidine kinase gene and wild type 
retrovirus kills other tumor cells. J Neurosci Res.33(3):493-503. 
39. Rath P, Shi H, Maruniak JA, Litofsky NS, Maria BL, Kirk MD. (2009). Stem 
cells as vectors to deliver HSV/tk gene therapy for malignant gliomas. Curr 
Stem Cell Res Ther.4(1):44-49. 
40. Ezzeddine ZD, Martuza RL, Platika D, Short MP, Malick A, Choi B, et al. 
(1991). Selective killing of glioma cells in culture and in vivo by retrovirus 
transfer of the herpes simplex virus thymidine kinase gene. New 
Biol.3(6):608-614. 
41. Lee SJ, Kim Y, Jo MY, Kim HS, Jin Y, Kim SU, et al. (2011). Combined 
treatment of tumor-tropic human neural stem cells containing the CD suicide 
gene effectively targets brain tumors provoking a mild immune response. 
Oncol Rep.25(1):63-68. 
42. Ryu CH, Park KY, Kim SM, Jeong CH, Woo JS, Hou Y, et al. (2012). Valproic 
acid enhances anti-tumor effect of mesenchymal stem cell mediated HSV-TK 
gene therapy in intracranial glioma. Biochem Biophys Res 
Commun.421(3):585-590. 
43. Fei S, Qi X, Kedong S, Guangchun J, Jian L, Wei Q. (2012). The antitumor 
effect of mesenchymal stem cells transduced with a lentiviral vector 
expressing cytosine deaminase in a rat glioma model. J Cancer Res Clin 
Oncol.138(2):347-357. 
44. Kosaka H, Ichikawa T, Kurozumi K, Kambara H, Inoue S, Maruo T, et al. 
(2012). Therapeutic effect of suicide gene-transferred mesenchymal stem 
cells in a rat model of glioma. Cancer Gene Ther.19(8):572-578. 
45. Kim JH, Kim JY, Kim SU, Cho KG. (2012). Therapeutic effect of genetically 
modified human neural stem cells encoding cytosine deaminase on 
experimental glioma. Biochem Biophys Res Commun.417(1):534-540. 
46. Lim SH, Choi SA, Lee JY, Wang KC, Phi JH, Lee DH, et al. (2011). 
Therapeutic targeting of subdural medulloblastomas using human neural stem 
cells expressing carboxylesterase. Cancer Gene Ther.18(11):817-824. 
47. Zhao D, Najbauer J, Annala AJ, Garcia E, Metz MZ, Gutova M, et al. (2012). 




48. Folkins C, Shaked Y, Man S, Tang T, Lee CR, Zhu Z, et al. (2009). Glioma 
tumor stem-like cells promote tumor angiogenesis and vasculogenesis via 
vascular endothelial growth factor and stromal-derived factor 1. Cancer 
Res.69(18):7243-7251. 
49. Yin J, Kim JK, Moon JH, Beck S, Piao D, Jin X, et al. (2011). hMSC-mediated 
concurrent delivery of endostatin and carboxylesterase to mouse xenografts 
suppresses glioma initiation and recurrence. Mol Ther.19(6):1161-1169. 
50. Choi SA, Lee JY, Wang KC, Phi JH, Song SH, Song J, et al. (2012). Human 
adipose tissue-derived mesenchymal stem cells: characteristics and 
therapeutic potential as cellular vehicles for prodrug gene therapy against 
brainstem gliomas. Eur J Cancer.48(1):129-137. 
51. van Eekelen M, Sasportas LS, Kasmieh R, Yip S, Figueiredo JL, Louis DN, et 
al. (2010). Human stem cells expressing novel TSP-1 variant have anti-
angiogenic effect on brain tumors. Oncogene.29(22):3185-3195. 
52. Thaci B, Ahmed AU, Ulasov IV, Tobias AL, Han Y, Aboody KS, et al. (2012). 
Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic 
virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain 
tumor model. Cancer Gene Ther.19(6):431-442. 
53. Roger M, Clavreul A, Venier-Julienne MC, Passirani C, Sindji L, Schiller P, et 
al. (2010). Mesenchymal stem cells as cellular vehicles for delivery of 
nanoparticles to brain tumors. Biomaterials.31(32):8393-8401. 
54. Roger M, Clavreul A, Huynh NT, Passirani C, Schiller P, Vessieres A, et al. 
(2012). Ferrociphenol lipid nanocapsule delivery by mesenchymal stromal 
cells in brain tumor therapy. Int J Pharm.423(1):63-68. 
55. Li L, Guan Y, Liu H, Hao N, Liu T, Meng X, et al. (2011). Silica nanorattle-
doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS 
Nano.5(9):7462-7470. 
56. Ahmed AU, Lesniak MS. (2011). Glioblastoma multiforme: can neural stem 
cells deliver the therapeutic payload and fulfill the clinical promise? Expert 
Rev Neurother.11(6):775-777. 
57. Panciani PF, Fontanella M, Tamagno I, Battaglia L, Garbossa D, Inghirami G, 
et al. (2012). Stem cells based therapy in high grade glioma: why the 
intraventricular route should be preferred? J Neurosurg Sci.56(3):221-229. 
58. Bexell D, Gunnarsson S, Svensson A, Tormin A, Henriques-Oliveira C, Siesjo 
P, et al. (2012). Rat multipotent mesenchymal stromal cells lack long-distance 
tropism to 3 different rat glioma models. Neurosurgery.70(3):731-739. 
59. Bexell D, Gunnarsson S, Tormin A, Darabi A, Gisselsson D, Roybon L, et al. 
(2009). Bone marrow multipotent mesenchymal stroma cells act as pericyte-
like migratory vehicles in experimental gliomas. Mol Ther.17(1):183-190. 
60. Pan L, Ren Y, Cui F, Xu Q. (2009). Viability and differentiation of neural 
precursors on hyaluronic acid hydrogel scaffold. J Neurosci Res.87(14):3207-
3220. 
61. Teng YD, Lavik EB, Qu X, Park KI, Ourednik J, Zurakowski D, et al. (2002). 
Functional recovery following traumatic spinal cord injury mediated by a 
unique polymer scaffold seeded with neural stem cells. Proc Natl Acad Sci U 
S A.99(5):3024-3029. 
62. Flight MH. (2012). Drug delivery: Encapsulation improves therapeutic stem 
cell action. Nat Rev Drug Discov.11(2):106. 
245 
 
63. Park SA, Ryu CH, Kim SM, Lim JY, Park SI, Jeong CH, et al. (2011). CXCR4-
transfected human umbilical cord blood-derived mesenchymal stem cells 
exhibit enhanced migratory capacity toward gliomas. Int J Oncol.38(1):97-103. 
64. Luo Y, Cai J, Xue H, Miura T, Rao MS. (2005). Functional SDF1 
alpha/CXCR4 signaling in the developing spinal cord. J 
Neurochem.93(2):452-462. 
65. Bakondi B, Shimada IS, Peterson BM, Spees JL. (2011). SDF-1alpha 
secreted by human CD133-derived multipotent stromal cells promotes neural 
progenitor cell survival through CXCR7. Stem Cells Dev.20(6):1021-1029. 
66. Kim SM, Kim DS, Jeong CH, Kim DH, Kim JH, Jeon HB, et al. (2011). CXC 
chemokine receptor 1 enhances the ability of human umbilical cord blood-
derived mesenchymal stem cells to migrate toward gliomas. Biochem Biophys 
Res Commun.407(4):741-746. 
67. Velpula KK, Dasari VR, Rao JS. (2012). The homing of human cord blood 
stem cells to sites of inflammation: Unfolding mysteries of a novel therapeutic 
paradigm for glioblastoma multiforme. Cell Cycle.11(12):2303-2313. 
68. Germano IM, Uzzaman M, Benveniste RJ, Zaurova M, Keller G. (2006). 
Apoptosis in human glioblastoma cells produced using embryonic stem cell-
derived astrocytes expressing tumor necrosis factor-related apoptosis-
inducing ligand. J Neurosurg.105(1):88-95. 
69. Lee EX, Lam DH, Wu C, Yang J, Tham CK, Ng WH, et al. (2011). Glioma 
gene therapy using induced pluripotent stem cell derived neural stem cells. 
Mol Pharm.8(5):1515-1524. 
70. Zhao Y, Lam DH, Yang J, Lin J, Tham CK, Ng WH, et al. (2012). Targeted 
suicide gene therapy for glioma using human embryonic stem cell-derived 
neural stem cells genetically modified by baculoviral vectors. Gene 
Ther.19(2):189-200. 
71. Varma NR, Janic B, Iskander AS, Shankar A, Bhuiyan MP, Soltanian-Zadeh 
H, et al. (2012). Endothelial progenitor cells (EPCs) as gene carrier system for 
rat model of human glioma. PLoS One.7(1):e30310. 
72. Noyan F, Diez IA, Hapke M, Klein C, Dewey RA. (2012). Induced transgene 
expression for the treatment of solid tumors by hematopoietic stem cell-based 
gene therapy. Cancer Gene Ther.19(5):352-357. 
73. Shah AH, Tabayoyong WB, Kundu SD, Kim SJ, Van Parijs L, Liu VC, et al. 
(2002). Suppression of tumor metastasis by blockade of transforming growth 
factor beta signaling in bone marrow cells through a retroviral-mediated gene 
therapy in mice. Cancer Res.62(24):7135-7138. 
74. Spaeth EL, Dembinski JL, Sasser AK, Watson K, Klopp A, Hall B, et al. 
(2009). Mesenchymal stem cell transition to tumor-associated fibroblasts 
contributes to fibrovascular network expansion and tumor progression. PLoS 
One.4(4):e4992. 
75. Tran CT, Wolz P, Egensperger R, Kosel S, Imai Y, Bise K, et al. (1998). 
Differential expression of MHC class II molecules by microglia and neoplastic 
astroglia: relevance for the escape of astrocytoma cells from immune 
surveillance. Neuropathol Appl Neurobiol.24(4):293-301. 
76. Brown AB, Yang W, Schmidt NO, Carroll R, Leishear KK, Rainov NG, et al. 
(2003). Intravascular delivery of neural stem cell lines to target intracranial 




77. Liu J, Zhang Y, Bai L, Cui X, Zhu J. (2012). Rat bone marrow mesenchymal 
stem cells undergo malignant transformation via indirect co-cultured with 
tumour cells. Cell Biochem Funct. 
78. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, 
Trakhtenbrot L, et al. (2009). Donor-derived brain tumor following neural stem 
cell transplantation in an ataxia telangiectasia patient. PLoS 
Med.6(2):e1000029. 
79. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. (2003). 
Immunosuppressive effect of mesenchymal stem cells favors tumor growth in 
allogeneic animals. Blood.102(10):3837-3844. 
80. Houghton J, Stoicov C, Nomura S, Rogers AB, Carlson J, Li H, et al. (2004). 
Gastric cancer originating from bone marrow-derived cells. 
Science.306(5701):1568-1571. 
81. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. (2007). 
Mesenchymal stem cells within tumour stroma promote breast cancer 
metastasis. Nature.449(7162):557-563. 
82. Kucerova L, Matuskova M, Hlubinova K, Altanerova V, Altaner C. (2010). 
Tumor cell behaviour modulation by mesenchymal stromal cells. Mol 
Cancer.9:129. 
83. Nakamura K, Ito Y, Kawano Y, Kurozumi K, Kobune M, Tsuda H, et al. 
(2004). Antitumor effect of genetically engineered mesenchymal stem cells in 
a rat glioma model. Gene Ther.11(14):1155-1164. 
84. Ahmed AU, Tyler MA, Thaci B, Alexiades NG, Han Y, Ulasov IV, et al. (2011). 
A comparative study of neural and mesenchymal stem cell-based carriers for 
oncolytic adenovirus in a model of malignant glioma. Mol Pharm.8(5):1559-
1572. 
85. Doucette T, Rao G, Yang Y, Gumin J, Shinojima N, Bekele BN, et al. (2011). 
Mesenchymal stem cells display tumor-specific tropism in an RCAS/Ntv-a 
glioma model. Neoplasia.13(8):716-725. 
86. Thu MS, Najbauer J, Kendall SE, Harutyunyan I, Sangalang N, Gutova M, et 
al. (2009). Iron labeling and pre-clinical MRI visualization of therapeutic 
human neural stem cells in a murine glioma model. PLoS One.4(9):e7218. 
87. Menon LG, Pratt J, Yang HW, Black PM, Sorensen GA, Carroll RS. (2012). 
Imaging of human mesenchymal stromal cells: homing to human brain 
tumors. J Neurooncol.107(2):257-267. 
88. Louis DN, Pomeroy SL, Cairncross JG. (2002). Focus on central nervous 
system neoplasia. Cancer Cell.1(2):125-128. 
89. Cairncross G, Macdonald D, Ludwin S, Lee D, Cascino T, Buckner J, et al. 
(1994). Chemotherapy for anaplastic oligodendroglioma. National Cancer 
Institute of Canada Clinical Trials Group. J Clin Oncol.12(10):2013-2021. 
90. Aboody K, Capela A, Niazi N, Stern JH, Temple S. (2011). Translating stem 
cell studies to the clinic for CNS repair: current state of the art and the need 
for a Rosetta Stone. Neuron.70(4):597-613. 
91. Tabatabai G, Wick W, Weller M. (2011). Stem cell-mediated gene therapies 






















































































1Experimental Therapeutics and Molecular Imaging Laboratory, Neuroscience Center, Department of Neurology, 
2Program in Neuroscience, Harvard Medical School, Boston, MA 02114 USA. 3Department of Neurosurgery, 





Glioblastoma (GBM) comprises 51% of all gliomas and is the most malignant form of 
brain tumors with a median survival of 18-21 months. Standard-of-care treatment 
includes maximal surgical resection of the tumor mass in combination with radiation 
and chemotherapy; however, as the poor survival rate indicates, these treatments 
have not been effective in preventing disease progression. Cellular Immunotherapy 
is currently being explored as an adjuvant experimental therapeutic approach to treat 
malignant brain tumors. In this review, we discuss advances in active, passive, and 





Gliomas account for about 60% of all primary central nervous system tumors. 
Glioblastoma (GBM) which comprises 51.2% of all gliomas is the most malignant 
form with a 2 years survival rate of 40% and a median survival of 18-21 months.1, 2 
Current standard of care includes surgical debulking of the tumor mass, followed by 
radiation and chemotherapy (temozolomide);3 however, as the poor survival rate 
indicates, these treatments have not been effective in preventing disease 
progression. The location of malignant gliomas (the brain) and their invasive 
properties cause complete surgical resection of the tumor mass nearly impossible, 
while high doses of radiotherapy cannot be delivered due to potential damage to the 
normal brain. Chemotherapeutics often cannot cross the blood-brain barrier 
efficiently and gliomas are known to develop resistance along these treatment 
regimen.4-8  
 
Cellular therapy is based on the idea of introducing a specific cell type into a 
particular tissue to treat the disease. Its earliest application can be dated back into 
the fifties where it was used in the bone marrow transplantation field.9, 10 Currently, a 
broader spectrum of cellular therapy application is pursued.  Different cell types are 
used in replacement therapies, taking over the function of diseased cells in the target 
organ, as can be seen in diabetes where insulin producing cells are injected in order 





which ex vivo whole organs are recreated out of cells is in its early phase but holds a 
tremendous potential for the future.13 An example that found its way to the clinic is 
artificial skin grown from collagen scaffolds seeded with the patient’s own epidermal 
skin cells.14 This technique is FDA-approved and has shown to drastically improve 
the life of patients with burn injuries. While both replacement therapy and tissue 
engineering focus on the use of cells for their inherent function (e.g. myoblast for the 
generation of muscle tissue), other research is focusing on the application of cells for 
tasks outside of their preprogrammed function profile. For instance, stem cells or 
immune cells can be used for immunotherapy or as carriers of therapeutic genes or 
pro-drugs that gets activated at a specific location in the body. This cell-based 
therapy provides a new and interesting strategy for the treatment of cancer including 
brain tumors. Cellular Immunotherapy in particular has the potential to both 
specifically target brain tumor cells (and thereby limiting brain damage), and to 
establish a long term antitumor response by stimulating the immune system, and 
thus is being explored as an alternative therapy for gliomas. Currently, a wide range 
of strategies is investigated at the bench, while slowly but steadily a small portion of 
this research is transitioned to the clinic. In this review, we cover recent advances in 
the field of Immuno-cellular therapy for malignant gliomas both in the early 
experimental phase as well as in the clinical setting. 
 
EXPERIMENTAL IMMUNO-CELL THERAPY 
 
Over the last decade, extensive studies have been performed evaluating the use of 
modified immune cells as a potential therapeutic approach for gliomas. In vivo 
glioma xenografts of intracranial or subcutaneously-injected cells as well as 
spontaneously-induced gliomas are widely used and commonly accepted models 
that depict an accurate and reproducible tumor environment in rodents. 
Histopathological changes as pseudopallisade necrosis, glomeruloid vascular 
hyperplasia, and infiltrating cells mimic those found in human gliomas.15 In this 
section, we discuss experimental approaches using a variety of cells to boost the 





Overview of immuno-cell therapy. Cellular immunotherapy is based on the use of 
cells from the innate and adaptive immune system to elicit an antitumor response. 
Either passive or active immunotherapy can be pursued. Passive immunotherapy 
involves the ex vivo activation of immune cells, which are subsequently injected back 
into the patient to attack the tumor directly. Often, these cells are not only activated, 
but also genetically modified to have enhanced antitumor properties. This approach 
has proven to be successful, but has the limitation of lacking prolonged or 
continuous antitumor response. Recent studies are focusing towards active 
immunotherapy or a combination of both. Active immunotherapy relies on the 
activation of the endogenous immune system either by vaccines or ex vivo activated 
cells. This approach allows for long-term antitumor effect, which not only enhances 
the likelihood of the tumor being eradicated, but also decreases the risk of tumor 
recurrence. T-cells, dendritic cells, and macrophages are the cells of choice for this 




Table 1 Overview of experimental immuno-cell therapy against gliomas 
Abbreviations: HER2, human epidermal growth factor receptor 2; CAR, chimeric antigen receptor; 
IL13Ra2, interleukin-13 zetakine 2; Ad-Flt3L/Ad-TK, adenovirus expressing Flt3L/TK; CSCs, cancer 
stem cells; NS, nanoshell 
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Box 1 Cells used for immune-cellular therapy 
T Cells or T-lymphocytes are part of the white blood cell compartment and play an important role 
in the cell-mediated immunity. Hallmark of these cells is expression of the T Cell Receptor (TCR) 
on their surface. Several subtypes of T Cells do exist, all with a different role in the adaptive 
immune response. CD4 lymphocytes, or T helper lymphocytes are the mediators of the immune 
system. Once activated by encounter of antigen presenting cells (APCs) expressing antigens in 
the MHC class II, they start secreting cytokines that in turn activate cytotoxic T lymphocytes 
(CTL) and macrophages, helping differentiation of B cells into plasma cells, initiating a humoral 
immune response. CLTs, or CD8 T Lymphocytes are responsible for direct cell mediated killing. 
They recognize their target by binding to antigens expressed by MCH class I complex, found on 
the surface of virtually every cell in the body. Their main targets are cells infected with virus, 
transplants, and tumor cells. The last group of T lymphocytes are the Natural Killer T Cells  
(NKTs). These cells are very similar to NK cells (natural killer cells) of the innate immune system. 
Their job is to recognize glycolipid antigen expressed by CD1d. Once activated, they can 
differentiate into either T helper lymphocytes or cytotoxic T lymphocytes, initiating both a cytokine 
mediated and direct cytolytic immune response. 
Macrophages play an important role in the immune response. They can be recognized by 
surface expression of CD14, CD40, CD11b, lysozyme M, Mac1/3 and CD68. They originate from 
monocytes, which, once activated through local inflammatory factors, starts differentiating. 
Macrophages play a role in both in innate and adaptive immune system, in which they have three 
distinct roles. They phagocytose pathogens and cellular debris, cleaning the inflammation site; 
these cells present the digested pathogens in MHC class II, thereby stimulating CD4 
lymphocytes, and they secrete various local monokines and interleukins, creating a strong 
chemotactic environment for T cells. 
Dendritic Cells function as APCs, just like macrophages. Their hallmark is expression of the toll 
like receptor (TLR). They are present in skin, respiratory and gastro-intestinal tract, patrolling all 
tissues in contact with the external environment. Once a pathogen is encountered, migration 
towards the lymph nodes occurs, where they present their pathogen to B and T lymphocytes. 
DCs are the only APCs capable of presenting antigens both through the MHC class I and class II 
pathways, thereby stimulating B cells, CD4 T lymphocytes and CD8 lymphocytes. Additionally, 
these cells are capable of secreting cytokines that further enhance differentiation of surrounding 
immune cells.  
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T cell-based immunotherapy. T cells are often used as cellular vehicles for the 
treatment of different types of cancer, typically resistant to conventional therapy. 
These cells can be easily modified with tumor-specific antigens to target tumor cells. 
An interesting strategy in T cell-based immunotherapy is the use of chimeric antigen 
receptors (CARs). CARs combine the antigen-binding domain of antibodies with the 
ȗ chain of T cell receptors, creating an increased binding between the T cell and the 
tumor antigen. In a proof-of-concept study, Wang et al.,16 showed that CD8+ T cells 
can become tumor-specific when directed towards a tumor epitope such as the 
human epidermal growth factor receptor 2 (HER2), overexpressed in tumors versus 
normal tissues. Gene-engineered T-cells to express anti-HER2 chimeric receptor 
were intravenously transferred in combination with lymph ablation and interleukin-2 
(IL-2). The autoimmune effect had no significant toxicity on normal mammary and 
brain tissues expressing HER2, while antitumor effect could be demonstrated, 
indicating that the modified T cells were specific to the tumor. Nakazawa et al.,17 
similarly combined HER2 and CARs to modify a T cell population, creating a 
functional HER2 chimeric antigen receptor (HER2-CAR). Although HER2 is 
overexpressed by many different tumors, including malignant gliomas, the 
expression is often too low to be recognized by T cells. Intratumoral injection of 
CARs demonstrated efficient killing of tumor cells in vivo, including the CD133-
positive glioma stem-like cells (GSC; also known as tumor initiating cells-resistant to 
chemo- and radiotherapy), and increased survival rate.23 The challenge of this 
therapeutic strategy is to establish stable expression of the activated antigen while 
achieving enough expansion with nonspecific activated T cells (ATC; known to be 
intolerant to transfection) as well as persistent antitumor effect. To overcome these 
limitations, the same group used Epstein-Bar virus (EBV) to stimulate T cells (EBV-
CTLs), a method known to elicit an enhanced immune response.24 EBV-CTLs 
outperformed the ATCs in both expansion and antitumor persistence.25-27  Further, 
the nonviral piggybac (PB) transposon system was evaluated for HER2-CAR gene 
delivery to T cells. While this model has been successfully applied in mouse primary 
cells, human cell lines, and inducible pluripotent stem cells (iPSC), PB has not been 
evaluated for in vivo immunotherapeutic model. No preferential integration near or 
into oncogenes was observed, as typically the case with retrovirus and lentivirus-
based transduction method. PB gene transfer was highly effective and the 





transgene expression and T cell properties. Since transposons are less expensive 
than viral vectors, and easier to produce, this method provides an interesting new 
approach for gene delivery.  
 
Dendritic cell and macrophage-based therapy. Dendritic Cells (DCs) are the most 
potent antigen-presenting cells (APCs) of the human body, sensitizing T cells to all 
acquired antigens. In contrast to activation of T cells ex vivo, dendritic cells activation 
and stimulation induce a long-term immune response and is therefore considered 
active immunotherapy. Dendritic cells can be loaded with tumor antigens ex vivo that 
can subsequently activate the endogenous immune system upon injection. Although 
this technique is safe, clinical efficiency is still to be improved to achieve high 
expression of the antitumor antigen at the major histocompatibility complex (MHC) 
on the dendritic cell surface and to expand the subgroup of these cells that primes 
naïve T cells. Saka et al.,19 designed a DC vaccine-based strategy aimed at 
targeting the interleukin-13 zetakine (IL13Ra2), overexpressed in gliomas. Since 
proper expression of this antitumor antigen at the DC MHC was problematic, a late 
endosomal/lysosomal sorting signal was added to the IL13ra2 plasmid. DCs were 
transduced with this plasmid and injected intraperitoneally in glioma-bearing mice on 
day 3 and 10 post-tumor implantation. A significant increase in the number of CD4+ 
and CD8+ T lymphocytes in the IL13ra2-DC-treated tumor environment was 
observed, resulting in an increased survival rate.19 In a model in which gene therapy 
is effective but dendritic cell vaccination is not-effective, Mineharu et al.,20 
demonstrated that combining in situ Ad-Flt3L/Ad-TK–mediated gene therapy (an 
FDA-approved adenoviral vector expressing either fms-like tyrosine kinase 3 ligand 
or thymidine kinase) with dendritic cell vaccination increases therapeutic efficacy and 
antitumor immunity as compared to in situ Ad-Flt3L/Ad-TK–mediated gene therapy 
alone. Ad-Flt3L and Ad-TK were intratumorally injected, followed by systemic 
administration of the prodrug ganciclovir (GCV). Flt3L causes dendritic cells to 
migrate, differentiate, and expand within the tumor microenvironment of mice and 
rats. TK at the tumor site converts GCV into a highly toxic phosphorylated drug 
causing the death of dividing tumor cells. Further, tumor treated with GCV releases 
high mobility group 1 protein (HMGB1), which serves as an adjuvant of the innate 
immune system by stimulating Toll like receptor 2 in signaling bone marrow-derived 
DCs (BMCDs) confirming previous studies.28, 29 To achieve enhanced proliferation 
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and antitumor effect, the dendritic cells were conditioned ex vivo with Fl3t and 
interleukin-6 (IL-6).20   
As an alternative of loading DCs with regular tumor antigens, Xu et al.,21 
explored the use of cancer stem cells (CSC) antigens as a source for DC anti-glioma 
vaccination. CSCs are thought to play an important role in the onset, progression, 
and recurrence of malignant gliomas and are known to express high levels of MHCs 
and tumor associated antigens (TAA). A sufficient T cell response against CSCs and 
an increase in survival of mice bearing 9L gliosarcoma CSCs tumors was observed 
as compared to DCs loaded with daughter or conventionally cultured 9L cells after 
intradermal injection of the vaccine. Albeit conventional loading and CSCs antigen 
loading of DCs require further comparison in DC maturation and memory T cell 
generation in vivo, the authors speculate that CSC antigens might indeed be more 
suited for DCs loading as compared to conventional tumor antigens. A clinical trial 
evaluating DCs vaccines using CSCs is being considered and will start shortly.21  
 
Another antigen-presenting cells used for immuno-cell therapy are macrophages. 
The advantage of these cells is their ability to easily travel across the blood-brain 
barrier, which often remains a great limitation for effective brain tumors therapy. 
Tumor-associated macrophages are often observed in glioma microenvironment, 
and intravenously injected macrophages targets the brain tumor site.30 In a recent 
study, Baek et al.,22 used macrophages loaded with gold-coated nanoshells for the 
treatment of human multicellular glioma spheroids, an in vitro model with similar 
characteristics in both resistance to radio- and chemotherapy, and in growth and 
metabolic rates of glioma tumors in vivo, while simulating the tumor before 
vascularization. Nanoshells are spherical nanoparticles consisting of a di-electric 
core (called the silica), and an outer layer coated with a thin metallic shell (often 
made of gold) that converts the absorbed light to heat with great efficiency. 
Nanoshells are relatively small and can thereby easily be taken up by macrophages. 
In this study, using the glioma spheroids model, the authors compared macrophages 
loaded with empty nanoshells to macrophages with gold-coated nanoshells and 
found that the latter were able to inhibit tumor growth by photo-thermal therapy, while 







IMMUNO-CELL THERAPY IN THE CLINIC 
 
Despite an abundance of experimental research, only a small number of clinical trials 
is currently in progress focusing on the safety, efficacy, and feasibility of immuno-
cellular therapeutic approach in a phase I/II setting. While experimental therapies 
show a wide variety of strategic approaches, the clinic reflects a somewhat more 
conservative approach with dendritic cell vaccines and modified T lymphocytes 
dominating the picture (Table 2). Recently, two clinical trials showed the potential of 
immuno-cell therapy for the treatment of cancer. A study led by Professor Carl June 
at the University of Pennsylvania showed the success of adoptive CAR T cell 
therapy in treating chronic lymphocytic leukemia (CLL), where 2 out of 3 patients 
underwent complete remission after CAR-CD19 therapy and are remaining so for >1 
year after treatment.31, 32 Another trial led by Drs. Renier Brentjens and Michel 
Sadelain at the Memorial Sloan Kettering Cancer Institute showed that the same 
CAR strategy can successfully treat patients with CLL and B cell acute lymphoblastic 
leukemia (ALL), two forms of blood cancer.33, 34 These successful trials prove the 
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Abbreviations: BTIC, brain tumor initiating cell; CTL, cytotoxic T lymphocyte; DCIK, dendritic cell 
(DC) activated cytokine induced killer cell (CIK); 06BG, 06-Benzylguanine; EGFR, epidermal growth 
factor receptor; CAR, chimeric antigen receptor; HER2, human epidermal growth factor receptor 2; 
TUMAP, tumor-associated peptides; ILGFR1, Insulin-like Growth Factor Receptor-1 
 
T cell immunotherapy in the clinic. With malignant gliomas being known for their 
immune evasive strategies, barely any immune response is provoked. However, the 
immune cells could be of tremendous value in the fight against brain tumors; they 
could provide a very efficient elimination mechanism of the tumor bulk and 
metastatic/invasive cells, without the need to undergo quality of life impairing as in 
the case for chemo- or radiotherapeutic paradigms. Many of the current strategies 
are exploring methods to overcome the lack of immune response to glioma cells by 
artificially stimulating the immune system either by passive or active immunization. 
The use of T cells is one of the most popular strategies in the clinic, often used in 
combination with dendritic cell vaccines. Two clinical trials focus on ex vivo-
stimulation of T cells to boost a passive immune response are currently in progress.   
In one trial by Forsman et al., at the City of Hope Medical Center, autologous 
peripheral blood mononuclear cells (PBMC) are collected and genetically modified to 
express the membrane-tethered IL13 cytokine chimeric T cell receptor (TCR) 
targeting the IL13 receptor Į2 (IL13RĮ2) present in over 80% of malignant gliomas. 
This IL13 zetakine has an E13Y mutation, which enhances its specificity for the 
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the healthy brain tissue.18, 35 in addition to the IL13 zetakine, the cytotoxic T 
lymphocytes (CTL) were further modified to express the thymidine kinase suicide 
gene (Hy/TK) under the control of the constitutively active cytomegalovirus (CMV) 
promoter in case immediate ablation of CTL activity is required. Repeated CTL 
infusion was performed over 2 weeks (3 times/week) followed by an injection every 3 
weeks in the absence of disease progression and signs of autoimmunity. Recently, 
an experimental study from the same group was published discussing the use of the 
IL13 zetakine in an orthotopic mouse tumor model.18, 35 The authors showed that 
IL13RĮ2 is expressed by both glioma stem cells and the more differentiated tumor 
cell population, and that IL13RĮ2 zetakine therapy ablates the tumor initiating activity 
of IL13RĮ2 positive GSCs. At time of writing, the pilot study has been completed, 
however, the results have not been published yet.  
Rosenberg et al., at the National Institutes of Health Clinical Centre takes on a 
similar approach by genetically modifying peripheral blood lymphocytes to express 
the anti-EGFRvIII chimeric antigen receptor. As in the case for IL13RĮ2, the mutant 
EGFRvIII receptor is overexpressed in 30-70% of glioblastoma, while no expression 
is seen in the normal brain.55 After ex vivo preparation, the autologous modified cells 
will be intravenously injected and safety, feasibility, and progression-free interval will 
be monitored. 
 
Vaccine therapy in the clinic. With 9 clinical trials either in progress or recently 
completed, vaccine therapy is the most popular clinical immuno-cellular therapeutic 
approach for malignant gliomas. Vaccine therapy is based on active immunization of 
the body against glioma, resulting in a permanent and sustained attack of the tumor 
by the immune system. In five out of the nine trials, autologous dendritic cells are 
used to stimulate the patient immune system to evoke an antitumor immune 
response. Dendritic cells are the most potent antigen-presenting cells with the 
capability of presenting antigenic material not only by the MHC II pathway 
(stimulating CD4+ T lymphocytes), but also by MHC I pathway (stimulating a CD8+ 
Lymphocyte response) through a process called ‘cross presenting’, which results in a 
diversification of the immune response.39, 56  ImmunoCellular therapeutics, LTD., 
recently initiated a phase II study using the immunotherapeutic vaccine ICT-107 
composed of synthetically purified antitumor antigens corresponding to epitopes 





injected intradermally upon completion of tumor removal and 6 weeks of 
temozolomide therapy. An earlier Phase I study demonstrated safety and efficacy of 
this therapeutic strategy. Earlier this year, Odumsi et al., at the Roswell Park Cancer 
Institute initiated a large phase I study evaluating the safety and feasibility of a new 
vaccine aimed at NY-ESO-1 expressing solid tumors in combination with Sirolimus, 
an mTOR inhibitor.40 Autologous dendritic cells are ex vivo pulsed with the 205-NY-
ESO-1 fusion protein and intranodally injected. The investigators hope that this 
strategy will elicit a stronger immune response yielding to enhanced tumor killing. At 
the same time, Berneman et al., at the University Hospital (Antwerp, Belgium) are 
evaluating immunogenicity and efficacy of intradermal vaccination with autologous 
dendritic cells genetically modified to express WT1 protein, overexpressed in a 
variety of solid tumors. A previous phase I study in patients with acute myeloid 
leukemia demonstrated the vaccine is well tolerated and elicits a CD8+ T lymphocyte 
response.42, 43 In China, Zhou et al., at the Huashan Hospital initiated a Phase II 
study evaluating the overall survival of patients with primary and/or secondary GBM 
after treatment with autologous dendritic cells loaded with autogenic glioma stem 
cells (A2B5+). A study investigating the adverse and therapeutic effect of post-
operative dendritic cells-derived tumor vaccine was recently published by Chang et 
al.,45 in the Journal of Clinical Neuroscience reporting an increase in the median 
survival to 525 days and a 5 year survival rate to 18.8% as compared to the 
historical control group (380 days and 0%). Patients underwent surgery to debulk the 
tumor mass and the vaccine was prepared using cells from the surgical specimen. 
Autologous dendritic cells were administered using a 6 months-10 injections course. 
The authors report that 47% of the enrolled patients developed a transient elevation 
in alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels, which 
correlated with the vaccination schedule and high doses of dendritic cells vaccine. At 
lower levels of dendritic cells vaccine, no increase in serum ALT/AST was observed 
suggesting the safe upper limit of 2x107 dendritic cells/dose. 
Another recently completed study by Fadul et al.,46 was reported in the 
Journal of Immunotherapy focusing on the immune response, progression free 
survival (PFS), and overall survival (OS) of GBM patients treated with intranodal 
autologous tumor lysate dendritic cells vaccination. CTL tumor specific activation 
was measured and correlated with both PFS and OS. All patients were still alive 6 
months after diagnosis and a PFS of 9.5 months was reported. Median OS was 28 
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months, which is significantly higher than the OS of 18-21 months in GBM patients 
receiving standard therapy.2 
As an alternative to the standard dendritic cells approach, Andrews et al., at 
the Thomas Jefferson University (Philadelphia) initiated a pilot study evaluating the 
possibility of stimulating the dendritic cells population in vivo. In vivo stimulation is 
thought to be more effective and is expected to elicit a stronger and longer immune 
response as compared to ex vivo stimulation.57 Diffusion chambers containing 
autologous tumor cells treated ex vivo with insulin-like growth factor receptor-1 
(IGFR-1) antisense oligodeoxynucleotide were re-implanted in the rectus sheet to 
stimulate the native immune system. Loss of IGFR-1 is expected to result in 
apoptosis with subsequent release of tumor antigen containing exosomes 
(microvesicles), which will allow the diffusion chamber to act as a slow-release 
antigen depot.50 Since a wound containing a foreign body is created upon 
implantation of the diffusion chamber, high levels of dendritic cells are expected to 
be present in the immediate surroundings, enhancing the efficacy of antitumor 
activation of the immune system.  
Three studies demonstrated that the use of dendritic cells for vaccine therapy 
is not the only way to go.  A pilot study by Moertel et al., at the Masonic Cancer 
Centre (University of Minessota) developed a cell-based cancer vaccine composed 
of glioma stem-like associated antigens found in the brain tumor initiating cell line 
GBM6 (BTICs).58, 59 Upon administration, the BTIC vaccine is thought to stimulate an 
antitumor CTL response against both GSCs and the more proliferated tumor bulk. 
Since GSCs have the ability of self-renewal and seem to drive tumor growth and 
initiation, elimination of this specific group of glioma cells would be of tremendous 
benefit. Vaccine administration will start following radiation therapy and will be given 
every 2 weeks for 4 weeks in combination with the drug imiquimod, which acts as an 
immune response modifier.  
Two separate groups are conducting a phase I study to test the safety and 
feasibility of IMA 950, a therapeutic multi-peptide vaccine containing 11 tumor-
associated peptides (TUMAPs) found in a majority of GBMs designed to activate 
TUMAP-specific T cells. Rumpling et al., (Cancer Research UK) are testing the 
vaccine in combination with granulocyte-macrophage colony-stimulating factor (GM-
CSF) and radiation and chemotherapy (temozolomide) for patients with newly 





with the National Cancer Institute) follow a similar approach to test IMA 950 with GM-
CSF and locally-applied imiquimod, 20 min after each vaccination. Patients will 
further be treated with one dose of cyclophosphamide prior to the first vaccination.  
 
Vaccine and cellular therapy combined. Two clinical trials using the combined 
approach of vaccine and immunotherapy are being performed by Ahmed et al., at 
the Baylor College of Medicine. In the first trial, autologous CTLs are ex vivo 
stimulated with human ȕ herpes cytomegalovirus (h-CMV) presenting dendritic cells. 
CMV-specific antigens can be detected in 70-90% of malignant glioma cells, but not 
the normal brain.61, 62 The CMV-specific CTLs are then cultured in the presence of 
EBV-infected cells, to boost a stronger immune response upon intravenous 
administration.24 The second trial goes a step further and genetically modifies the 
CMV-specific CTLs to express the chimeric antigen receptor targeting HER2, which 
is associated with 70% of GBM malignancies.63 Both trials are still in their initial 
phase I stage; however, a recently published pilot study by the same group 
evaluated the use of CMV-specific T cells and demonstrated that autologous T cells 
could successfully be activated and expanded, are able to recognize the CMV 
antigens pp65 and IEI, and are capable of killing CMV-infected autologous GBM 
cells.53 In the meantime, Wood et al., (TVAX Biomedical) are testing in a phase II 
trial (supported by positive safety and efficacy study in a phase I trial) a brain cancer 
vaccine called TVI-Brain I, consisting of neutralized autologous tumor cells. Upon 
vaccination, an immune response of killer T cells is expected yielding a highly 
effective antitumor activity. Yao et al., at Quindao University use a somewhat similar 
approach in a phase I/II trial combining intranodal dendritic cells vaccination with 
subsequent ex vivo expansion of activated T cells in patients with recurrent glioma. 
The study is specifically aimed at a group of T cells, called cytokine-induced killer 
cells (CIK), which are known to express a very potent antitumor activity.52, 64 Cells 
will be selected by expression of the cell markers CD3 and CD56.  
  
 
LIMITATIONS AND FUTURE PROSPECTS OF IMMUNO-CELL THERAPY 
 
Although a wide range of potential targets and immuno-cellular therapeutic strategies 
are investigated experimentally, only the most successful are transitioned to the 
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clinic. The translation from the laboratory to the clinic remains a difficult phase, with 
dendritic cells vaccine strategy being the most successful example. Dendritic cell 
therapy has proven safe with some therapeutic success; however, no breakthrough 
has been achieved using this therapeutic strategy for gliomas. The clinical outcome 
did not reflect the expected results on the bench, showing perhaps a limitation in the 
existing glioma models. For dendritic cell therapy to be effective in animal models, 
vaccination is mostly given before tumor implantation. This of course is impossible in 
human patients. While many pathophysiological similarities between the rodent 
glioma models and the human tumors can be observed, many models are performed 
in immunocompromised mice. Therefore, tumor-associated immunosuppression and 
immune modulating events are not likely to be reflected accurately and their 
usefulness as models for evaluating immuno-cellular therapy might be limited. 
Further, tumor xenografts will not mimic the process of tumorigenesis de novo, 
resulting in a slightly different tumor microenvironment. The use of rodents with intact 
immune system, and the development of genetically-induced glioma models could 
help optimizing preclinical studies, leading to a more predictable transition to the 
clinic. 
Another difficulty in assessing the efficacy and success of dendritic cells 
vaccination (or any other strategy) in the clinic is the relatively low number of glioma 
patients per trial group often leading to a weak statistical significance. Further, it is 
difficult to compare study outcomes from different trials, since inclusion criteria and 
injection route differ from one group to another, which can have a substantial effect 
on patient survival. The use of corticosteroids and other co-medication, as often 
seen in malignant glioma patients such as GBM, impairs objective assessment even 
further as efficacy of treatment might be limited, side effects might get masked, and 
differentiation of immune cells is halted. In the case of vaccination, improvements 
have only been seen when compared to historical controls, which are improper 
controls to use for glioma studies. When compared to standard of care, no clinical 
significant benefits have been reported. Furthermore, caution has to be exerted 
when interpreting effects on immune function following vaccination. In most if not all 
clinical trials of vaccination, brain inflammation has never been detected. Although 
this is usually (wrongly) interpreted as the vaccines being safe, the absence of any 
adverse effects in hundreds of immunized patients, most likely speaks of the 





absence of side effects as a result of non-effective vaccination, or, actual safety. So 
far, only a single study combining gene/vaccine therapy in dogs showed 
physiologically effective immune activation associated with brain inflammation, which 
resulted in clinical benefits.65 This study is the only objective description supporting 
the idea that under the right conditions, it is possible to stimulate a systemic immune 
response that can attack the brain and brain tumors.  
To undermine some of these problems, and to get a true understanding of the 
working mechanism and antitumor effect of immuno-cellular therapies, the 
development of adequate imaging tools is of uttermost important. The ability to track 
immune cells and to determine their fate, tropism, migration, interaction with the 
surroundings, and mechanism of action will answer important questions regarding 
safety and efficacy. Several imaging tools are currently available in the preclinical 
setting (e.g. bioluminescence and fluorescence); however, these techniques are not 
(yet) translatable for use in humans due to several concerns including (substrate) 
toxicity and sensitivity. Labeling of stem cells with femuroxide, which allows them to 
be tracked in vivo by magnetic resonance imaging (MRI) has been successfully 
reported to monitor in real-time migration and distribution of these cells at the tumor 
site.66  Similar approaches might be translated to the clinic to track immune cells, 
however, additional studies are required to fine tune this technique and increase its 
sensitivity to make it suited for in human use. While new imaging tools are a 
necessity to further develop the immuno-cell therapy field, another issue that needs 
to be addressed is the availability and efficacy of the cells themselves. High passage 
number of effector cells in vitro, in order to reach adequate levels, could lead to 
differentiation and change of phenotype, limiting their therapeutic potential. New 
techniques that allow rapid growth and expansion of these cells while maintaining 
their characteristics will be of extreme importance for the cellular Immunotherapy 
field. Similar problems can be seen in the clinic where lack of in vivo expansion and 
inability to maintain high expression levels over a sufficient period of time could limit 
treatment efficacy. This may result not only in unsuccessful clinical trials, but also in 
the abandonment of a potentially successful strategy.  The success of the CAR-
CD19 adoptive T cell therapy study for CLL and ALL shows that once the immune 
cells are manipulated, extensive in vivo expansion and high levels of gene 
expression could be maintained over time, therefore, immunotherapy can indeed be 
an effective strategy in the battle against cancer. In order to stimulate cell survival 
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and proliferation, a 4-1 BB co-stimulatory domain was added to the CAR construct, 
resulting in >1000-fold higher proliferation rate of T cells once injected in vivo, with 
each T cell killing approximately 1000 CLL cells. Three out of three CLL patients 
showed clinical activity lasting for over 6 months, with 2 out of 3 patients reaching 
complete remission.31, 32 Kloss et al., demonstrated a similar successful approach in 
a prostate cancer model using a chimeric co-stimulator receptor (CCR) together with 
CARs, with increased selectivity of the modified T cells for prostate cancer cells.67  
Although still at the experimental level, this strategy may greatly increase efficacy 
and safety of T cell adaptive immunotherapy. Both approaches could easily be 
adapted to T cells glioma therapy (similar to the Nakazawa17 and Wang16 studies), 
potentially in combination with EBV-CLT.   
Several studies are exploring different strategies to deliver immune cells to 
the tumor. While many choose a direct injection route, others are exploring 
intranodal, intradermal, or systemic injection, in an attempt to enhance the delivery 
success. Direct comparison of these delivery strategies should be performed in order 
to reach the optimal injection route for effective glioma therapy. Other research 
groups argue that ex vivo cell manipulation is time consuming and may result in 
cellular differentiation and an increased risk of infection. Thus, the focus should not 
be on “how to deliver the manipulated cells”, but on “how to manipulate the cells in 
vivo”.  The studies being performed by Andrews et al., at the Thomas Jefferson 
University will shed new light on these possibilities.  
Finally, when discussing treatment efficacy and success of new clinical 
strategies, it is important to bear in mind the current prognosis and treatment options 
available for glioma patients. While the results of CAR-CD19 trial showed that 2 out 
of the 3 CLL patients are in remission for over a year, which is extraordinary, one 
must realizes that with a median survival of 8 to 10 years, the CLL population is not 
comparable to glioma patients. We advocate that in a patient population where the 2 
years survival rate is only 40%, and in the past 25 years, the median survival rate 
has only increased by 3 months, our expectation on efficacy should be as equally 
moderate.1, 2 Further, the gain of months rather than years should be valued as well 
as the decrease in side effects and/or increase in patient’s well-being. The aim of 
trials should therefore not only be directed against increased survival, but also for 
better “quality of life”. Hopefully, optimizing some of the strategies discussed here 





For now, it is difficult to conclude the role and effect of immuno-cellular therapy on 
malignant gliomas. If some of the discussed issues can be addressed, and current 
clinical trials show promising results, this therapeutic strategy has the potential to 
give a tremendous value in the search for a cure for tumors as heterogeneous as 






Box 2 Cell isolation and preparation for immunotherapy 
T lymphocytes can be obtained from several sources, including thymus, lymphnodes, spleen 
and peripheral blood, the latter being the most accessible. Cells are separated from the whole 
blood samples by Ficol isopaque-based density gradient separation. Since lymphocytes are less 
dense than erythrocytes, they can easily be extracted after centrifugation. Distinction between B 
and T lymphocytes can then be made based on differences in growth patterns, with T 
lymphocytes forming rosettes in the presence of sheep erythrocytes and B lymphocytes being 
non rosette forming. Nylon fiber column separation is an alternative approach, allowing to 
specifically select for adherent T lymphocytes. Several commercial kits are available to 
specifically purify T lymphocyte subtypes (CD4, CD8, NKT) based on monoclonal antibody 
reactions. To generate CLTs against specific antigens  (for instance expressed on tumor cell 
surface), the CTLs can be cultured in the presence of APCs loaded with the desired antigen. 
Cells are cultured in basal medium containing RPMI 1640, 10% fetal calf serum, 
penicillin/streptomycin, L-glutamate, phytohaemagglutin and a buffer solution. New studies are 
focusing on the development of serum free medium, in order to standardize T cell populations 
and eliminate confounders. 
Macrophages can be isolated from various tissues. One strategy involves isolation of these cells 
from peripheral blood. Blood-derived macrophages are isolated based on the very same Ficol-
gradient centrifugation protocol described for T lymphocytes. Antibody-based cell separation kits 
selecting the CD14 monocyte fraction are available. Subsequent culture of these cells in the 
presence of macrophage colony stimulating factor 1 (M-CSF-1) will result in macrophage 
differentiation. The same RPMI culture media is used as described for T lymphocytes. 
Dendritic cells can be generated through various protocols. One technique involves DCs 
separation from the whole blood samples by Ficol gradient centrifugation. B-lymphocytes and 
monocytes are then subtracted from the cell suspension using monoclonal antibodies directed 
towards CD19 and CD14. Dendritic cells are then isolated from the remaining (B and monocyte 
depleted) mixture by CD304, CD141 andCD1c directed antibodies. Selected cells are cultured in 
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Part 1: Discussion by Sarah Bovenberg 
 
I. CREATING THE IDEAL ANTI GLIOMA AGENT 
 
As has been highlighted throughout this thesis, brain tumors, and GBM in particular, 
are very difficult types of cancer to treat. A quick search on PubMed will reveal a 
wide range of strategic approaches that are currently being explored, ranging from 
new chemotherapeutic agents and/or dose schemes, drugs, surgical techniques, 
antibodies, to cell- and gene therapy. Even though it is beyond the scope of this 
thesis to discus all of these approaches, it can be concluded that many exciting 
research is being done, based on ideas that theoretically should be able to destroy 
the tumor mass completely. However, what works on paper does not necessarily 
work in the lab, let alone in clinical settings. Other strategies seem to work just fine – 
without anyone fully understanding what causes their success. When thinking about 
the ideal anti-glioma agent, the following characteristics should be present: 
 
1) The agent is highly selective to glioma cells, while causing minimal damage to 
the normal brain tissue 
2) The agent has the ability to track down single invasive cells 
3) The agent should attack the glioma cells through a range of pathways, 
thereby blocking tumor escape mechanisms and accounting for the 
heterogeneous nature of the glioma cell population 
4) Its action should be continuous, until the eradication of all tumor cells is 
completed 
5) The agent should contain a biological marker that allows for monitoring of the 
effect of treatment over time 
6) The agent should be able to cross the blood-brain barrier 
7) The agent is tailored to the individual patient 
 
Objectively, stem cell therapy seems to hold all the right cards. However, as can be 
concluded from our reviews in Chapter XI and XII, we still have a long way to go 
before all issues are resolved. This raises the following questions: 
Ǧ What is needed to improve treatment efficacy? 





The primary aim of this thesis was to gain better understanding of both glioma 
biology and anticancer mechanisms by visualizing what happens at cellular and 
molecular level. Imaging tools will be of the utter most importance to get a true 
understanding of the working mechanisms and antitumor effect of cellular therapies. 
The ability to track single cells, to monitor cell differentiation, tropism, migration, 
interactions with the environment and mechanisms of action will allow us to answer 
important questions regarding safety and efficacy. 
 
To create this ideal anti-glioma agent, in this thesis we have developed several tools. 
First, we focused on secreted blood reporters, since they allow for sensitive, fast 
detection, quantification and non invasive, ex vivo monitoring of in vivo processes, 
with the generation of multiple data sets without the need to sacrifice the animal. 
Therefore, we developed an enhanced Gluc blood assay (Chapter III), in which Gluc 
is captured from the blood by an antibody-mediated reaction before bioluminescence 
reaction takes place. This procedure prevented signal quenching by pigmented 
molecules like hemoglobin, and resulted in an over one order in magnitude increase 
in sensitivity, allowing the detection of few circulating cells and early tumor 
metastases by the simple measurement of a few drops of blood.  
 
Second, we selected an agent that is highly specific to glioma cells, while leaving 
healthy brain tissue unaffected. Through an extensive drug screen the Tannous lab 
recently discovered how the cardiac glycoside lanatoside C seems to sensitize 
glioma cells to anti cancer agent TRAIL. In Chapter V we describe how the 
combined treatment of sTRAIL and lanatoside C is highly effective in eradicating 
glioma cells and avoiding resistance and/or recurrence in vivo. Since TRAIL cannot 
cross the blood brain barrier, we decided to circumvent this problem by delivering 
sTRAIL directly to brain tumor environment by AAV-mediated gene delivery. By 
engineering the normal brain to synthesize and secrete sTRAIL, we created a zone 
of resistance against newly developed glioma, which can be treated with lanatoside 
C therapy.  While treatment with sTRAIL by itself resulted in an initial decrease in 
tumor progression, followed by regrowth through resistant cells, no regrowth took 
place in the presence of lanatoside C. Further, since sTRAIL binds selectively to 
death receptors found only on tumor cells, no additional damage to healthy brain 
tissue was observed.  
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Third, to measure the effect of combined lanatoside C and TRAIL treatment, we 
developed the first triple luciferase bioluminescence imaging system for in vivo use 
(Chapter V). The reporter system allowed us to sequentially monitor the changes at 
cellular level once therapy was initiated, with Vargula luciferase being used as a 
marker of efficient gene transfer of sTRAIL to healthy brain tissue, Gaussia 
luciferase as marker of TRAIL binding to the death receptor on Glioma cells and 
firefly luciferase as a marker of tumor volume and therefore therapeutic response.  
 
Fourth, since tumorigenesis is an intricate and dynamic process and GBM cells in 
particular are known for their ability to escape cell death and change characteristics, 
we developed the first multiplex blood reporter based on secreted alkaline 
phosphatase (SEAP), Gaussia and Vargula luciferases (Chapter IV). This multiplex 
system differs from the triple imaging system as described in Chapter V in that here 
all reporters are secreted. As a result, tumor changes can be followed in real time 
(by simply taking an aliquot of blood), whereas the reporter from chapter V does not 
allow for real time imaging. Since Vargulla has not been previously used as a blood 
reporter we first characterized it as a secreted blood reporter. As a proof of concept 
we monitored the response of three different subsets of glioma cells to the 
chemotherapeutic agent Temozolomide (TMZ) in the same animal. U87 glioma 
parent cells (sensitive to TMZ) were engineered by a lentivirus vector to express 
Gluc (U87-Gluc), while U87R1 (resistant to TMZ) were engineered to express Vluc 
(U87R1-Vluc) and U87R2 (resistant to TMZ) were engineered to express both SEAP 
and Fluc (U87-SEAP/Fluc). All cell lines were mixed equally and intracranially 
implanted. One week later mice were either injected with TMZ or DMSO (control) 
and blood was collected at different time points. As expected, a continuous decrease 
in Gluc signal was observed over time in the TMZ group, while an increase in signal 
was observed in the control group. Both Vluc and SEAP levels increased over time 
in both treatment and control group, showing that U87R1 and U87R2 cells are 
indeed resistant to TMZ. No signal bleeding or substrate cross reaction was 
observed, proving that these 3 reporters can be used simultaneously in the same 
animal. This new multiplex reporter system can be extended and applied to many 







II. FUTURE APPLICATION 
 
All together, these systems create the tools to develop a highly effective 
therapeutic/diagnostic anti-glioma agent. Since viral therapy is known to have its 
limitations in terms of distribution and delivery (as discussed throughout this thesis), 
and stem cells intrinsically posses quite some of the characteristics needed for the 
ideal glioma agent (tropism, penetrating the blood brain barrier, ability to track 
metastasis), stem cells would be the ideal carrier for our toolbox. In this case, the 
combined sTRAIL/lanatoside C therapy approach could be applied to stem cell 
carrier system, in which stem cells will be modified to express sTRAIL. These cells 
can either be injected in the tumor cavity after surgery or even be given systemically. 
The genetically modified stem cells can be tracked using the enhanced Gluc blood 
assay, visualizing patterns of migration and tropism over time. Since the assay is 
sensitive enough to pick up signals from as little as 10 cells, the ability of the 
modified stem cells to invade the healthy brain parenchyma to capture single 
invasive glioma cells can be evaluated, as well as the specificity of the stem cells to 
glioma. Simultaneously, Vargula luciferase under the control of NFțB responsive 
elements, which can be detected either in the blood or by means of BLI, can be used 
to monitor delivery and binding of sTRAIL to the death receptors on glioma cells, 
while Fluc imaging (or the SEAP blood assay) can be used to evaluate the tumor 
response to TRAIL and lanatoside C. This approach will for the first time allow 
monitoring of several biological processes in response to therapy, giving new insight 
in the complex interactions of therapeutics to cancer cells. Obviously, other 
parameters can be chosen, since this system is applicable to any biological process 
of interest. Further, since lanatoside C, AAV vectors, stem cells and TRAIL have 
been previously used in the clinic separately, this combined therapeutic approach 
should be easily adaptive to the clinical setting.  
 
III. CREATING THE IDEAL LUCIFERASE 
 
Once working on optimizing BLI reporters to monitor several tumor processes 
simultaneously, a second issue came to mind. While Gaussia Luciferase possesses 
many favorable characteristics needed in a reporter, including high signal intensity, 
favorable enzyme stability and a secretion signal, and is thereby the luciferase of 
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choice for many BLI applications, its use for in vivo imaging is limited due to its 
emission of blue light which is absorbed by pigmented molecules such as 
hemoglobin and scattered by mammalian tissues.  Furthermore, its flash type 
bioluminescence reaction, which makes the signal decrease in intensity shortly after 
the substrate is added, makes it unsuited for high-throughput applications such as 
drug screens. Therefore, in Chapter VI, we started a directed evolution mediated 
screen for Gluc mutants with more favorable characteristics, which resulted in the 
generation of multiple clones with higher signal intensity, glow-like kinetics (suited for 
high-throughput applications) and a shift in the emission towards the red region of 
the spectrum (suited for in vivo applications). Although more work needs to be done 
to further optimize these clones, the first step towards a red-shifted Gaussia 
Luciferase has been made. This is not only interesting for laboratory work, but in a 
time where optical guided surgery is on the verge of break through, a luciferase with 
good tissue penetration can become of tremendous value.  
 
IV. FUTURE APPLICATIONS  
Stable Gaussia 
Since the ‘discovery’ of the alkylating agent temozolomide no real improvement has 
been made in the development of anti-glioma drugs. One approach to solve this 
problem is the screening of small molecule libraries for potential anti-glioma hits.  
This process is a time-consuming and costly as thousands of molecules must be 
screened. Gaussia luciferase is commonly used as cell viability marker as it is 
secreted, allowing functional analysis of drug kinetics over time by sampling of the 
conditioned media. As described above, its flash like luminescence, requiring each 
well to be injected with substrate before the read – instead of reading complete 
plates at a time – severely limited the amount of data that could be obtained in a 
certain time. The new Gluc clones with glow type BLI will be able to simplify and 
speed up the current process, allowing more clones to be screened and thereby 
increasing the chance of finding a hit. One could also imagine the benefit of using 
multiple luciferase reporters at the same time (e.g., the multiplex reporter systems as 
developed in this thesis), in order to develop a multi-parameter high throughput 
screening. This would provide valuable information with regards to drug working 
mechanisms and gene/pathway activation -  thereby eventually allowing mapping of 






Optical guided surgery, which hypothetically allows for real time visualization of 
tumor borders, metastatic cells and nearby vulnerable structures, could potentially 
create a revolution in oncologic surgery. As for now, it comprises various modalities, 
including PET, CT, MRI and near infrared (NIR) fluorescence. While PET, MRI and 
CT are great diagnostic tools, they are less suitable to translate their findings to mark 
sharp borders of “sick” and “healthy” tissue in the operation field. Further, they are 
costly and not always available in OR setting. Fluorescence imaging is based on a 
fluorescent probe that has the ability to absorb light at a particular wavelength and 
subsequently emits light at a longer wavelength. Where the original fluorescent 
markers were not quite suitable for in vivo use, due to poor tissue penetration and 
high signal to noise ratio’s (SNR), near infra red (NIR) fluorescence (with an 
emission spectrum of 650-900nm) has overcome these problems. A recent pilot 
study in the Netherlands using the fluorescent probe fluorescein isothiocyanate 
(FITC) in patients with ovarian cancer was highly successful in identifying the tumor 
mass and metastasis < 0.5 mm, while no benign masses were colored (Van Dam 
GM, Themelis G, Crane LM, et al. Intraoperative tumor-specific fluorescence imaging 
in ovarian cancer by folate receptor-alpha targeting: first in-human results. Nat Med. 
2011;17:1315-9). NIR fluorescence is both cost efficient and easy to use and 
therefore makes a good candidate for optical-guided surgery. If instead of 
fluorescence probes, a red-shifted Gaussia Luciferase could be developed, it would 
have the additional advantage that no external light source is needed, resulting in a 
further reduction of the SNR and the generation of even higher sensitivity. In animal 
settings, BLI is preferred over fluorescence due to this higher sensitivity. However, 
since Gaussia needs its substrate coelenterazine in order to emit light, toxicity 
concerns related to the substrate and immunogenicity of the Gaussia protein should 
be evaluated before the step to the clinic is made. 
 
V. ENHANCING TISSUE CULTURE RELIABILITY 
 
Tissue culture is the foundation for glioma research. Human glioma cell lines are 
differentiated, expanded, and manipulated in order to develop reliable glioma models 
that will increase our insight in tumor biology and give us the opportunity to test 
various strategies. The more reliable the tumor model, the more reliable the outcome 
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of the experiment and the more likely the obtained results will be reproducible in 
clinical setting. However, when cells are passaged over a long period of time, 
differentiation and phenotypic changes may occur, as well as contamination with 
bacteria, funghi and/or other organisms.  Whereas some types of contamination are 
easily detected and therefore solved, others go unnoticed and severely compromise 
results. The latter can be said for Mycoplasma, the smallest type of free-living 
organism known.  In order to enhance tissue culture reliability we developed a 
Gaussia-luciferase based mycoplasma detection assay, in which the rate of Gluc 
degeneration corresponds with the amount of Mycoplasma in the tissue culture 
media.  
 
VI. FUTURE APPLICATION 
 
Our current assay is more sensitive and cheaper than currently available commercial 
assays and will help researchers to work more efficient and accurate. 
 
VII. CURRENT LIMITATIONS AND FUTURE DIRECTIVES: THE BIG PICTURE 
 
In the beginning of this chapter two questions were raised: 
 
Ǧ What is needed to improve treatment efficacy? 
Ǧ What is needed to bridge the gap to the clinic? 
 
Chapter-wise we discussed what actions were taken to overcome some of the 
limitations faced in our specific field of glioma research, in order to increase both 
efficacy and the likelihood of the approach being successful in clinical settings. Now 
it’s time to look at the big picture. When looking at the glioma research field an sich 
one can’t help but notice that very little research is able to – successfully - cross the 
gap between experimental setting and the clinic. Considering the amount of time 
(and results) that is required to ‘prepare’ a strategy for FDA approved clinical testing, 
this is remarkable.  
 
One important limitation slowing the translation from experimental setting to clinic 





similarities between the rodent glioma model and human tumors are observed, many 
models are based on xenografts in immunocompromised mice. Implanted tumor 
cells will not mimic the process of de novo tumorigenesis, and tumor-associated 
immunosuppression and immune-modulating events are not likely to be accurately 
reflected, resulting in a slightly different tumor microenvironment. Especially when 
testing immunotherapeutic approaches that require activation of the body’s immune 
system to attack the tumor cells, this situation is les than optimal and might confound 
results severely. The use of rodents with an intact immune system and genetic 
induction of the tumorigenesis might circumvent these problems.  
 
A second limitation arises at the level of the clinical trial itself. Since glioblastoma is a 
relatively ‘rare’ disease and since survival is poor, there’s only a limited number of 
patients that can be enrolled. This results in trials with less than optimal numbers for 
statistical analysis. Further, since inclusion criteria differ between study groups, 
substantially influencing survival rates and outcome, it is hard to compare results. 
Also, patients often use of co-medication including corticosteroids, which impairs 
objective assessment even further, as efficacy of the treatment may be limited, side 
effects may be masked and tumor differentiation may be halted.  
 
A third limitation is caused by difficulties related to acquiring proper expression levels 
of the to be tested therapy. Viral gene transduction levels tend to be low or decline 
steadily over a sufficient period of time. In both scenarios treatment efficacy is 
limited. This may result not only in unsuccessful clinical trials, but also in the 
abandonment of a potentially successful strategy. Targeting healthy brain tissue 
instead of the tumor itself has shown to result in more effective gene expression and 
might be an alternative to the current approach. In experimental setting stem- and 
immuno-cell carriers have shown impressive results with regards to tracking tumor 
cells and delivering oncolytic viruses, enzymes, cytokines, activated immune cells 
and other lethal substances directly to the tumor cells. However, this has yet to be 
demonstrated on larger scale in the clinic. 
 
A fourth issue, closely related to the third, is appropriate patient selection. As 
discussed extensively throughout this thesis, GBM is a highly heterogeneous tumor 
on both molecular and genetic level. More and more evidence suggest that specific 
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genetic mutations in glioma cells respond to different therapies, and therefore 
genotyping or discovery of new biomarkers for personalized medicine could yield to 
an enhanced treatment success. Patient selection will not only increase patient 
quality of life (QoL) - withholding chemotherapy when genetic profiling will predicted 
the tumor is not responsive to this type of therapy - but will also give new therapeutic 
approaches a fair shot. Including patients with a EGFRIII mutation –which is often 
unresponsive to chemotherapy- for a clinical trial to test a new alkylating agent may 
not only potentially downplay the overall efficacy of this therapy, but may also falsely 
disqualify a successful approach by showing that results obtained in experimental 
studies cannot be repeated in the clinic.   
 
A fifth issue is safety. The use of stem and/or immuno-cells, with the capacity of 
unlimited self-renewal, raises concerns with regards to malignant transformation. 
Further, the secretion of cytokines and growth factors and the local immuno-
suppressive effects of stem cells could hypothetically promote tumor growth. The 
standard inclusion of a suicide gene in the DNA of each stem cell might help creating 
a safer experience. Besides safety matters, ethical issues need to be addressed. 
These questions do not only concern the glioma research field, but are applicable to 
the research community as a whole.  
 
From the above one conclusion can be drawn: to undermine these problems and to 
get a true grip on a tumor as diverse as GBM a multi angle approach is needed. It is 
highly unlikely that – for a tumor this diverse - a single agent approach will yield the 
desired results. An integrated therapy based on genetic profiling that blocks several 
tumor escape mechanisms at once, has much more chances of succeeding.  
 
The same can be said for the approach towards glioma research in general. A 
multidisciplinary, multi-angle approach is much more likely to yield results than 
isolated, singular attempts. To stimulate this process, the National Brain Tumor 
Society recently launched the DREAM Cancer Prediction Challenge, a campaign in 
which researchers from all backgrounds are asked to work together to attack Glioma. 
A virtual database, containing all available preclinical data from research groups over 
the world, will be generated and made accessible to participating researchers. The 





libraries against glioma, and can predict tumor response to the selected agent. If 
such a program can be developed, the benefit will be enormous. Not only will we be 
able to screen millions of compounds in a time- and cost-effective manner, it will also 
drastically reduce the amount of animal sacrifices needed.  The data obtained by 
multiplex reporter systems to map the various pathways activated by certain drugs or 
involved in tumor escape mechanisms might play a crucial role in this project.  
 
image obtained from the National Brain Tumor Society.  
 
 
VII. IN CONCLUSION 
 
In conclusion, in this thesis we have developed several tools for the road towards a 
better understanding of glioma biology and more effective therapy. In order to justify 
the importance of this work, in Chapter XI and XII we give an overview of the 
research being done in the neuro-oncology community and the difficulties 
encountered.  The tools we developed (including a therapeutic agent specifically 
selective for glioma cells, two new multiplex imaging modalities and more sensitive 
assays and luciferase imaging agents) will eventually help us to translate 
experimental setups to the clinic, since a better understanding of the ‘what’ at 
molecular level, will result in a ‘how’ in a broader setting. The triple BLI and blood 
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assays will be of enormous value in this understanding, since they will allow us to 
study interactions – of tumor cells, growth factors, intrinsic pathways and 
therapeutics – in vivo; mimicking the ‘real’ situation as close as possible, and giving 
us new clues on how to increase efficacy, select new targets, prevent safety issues 





























Part 2: Discussion by Hannah Degeling 
 
In The Netherlands, cancer is the leading cause of death and surpassed 
cardiovascular diseases in 2008. Of the 136.058 people that died in 2010, 32% of all 
the deaths were caused by cancer. 2 Even though great achievements are made in 
the battle against cancer, with a cure rate of 90% for testicular cancer as a good 
example, numerous cancer types are still difficult to treat:6patients diagnosed with 
glioblastoma multiforme will have a  life expectancy of around 1 year.  7 The 
treatment of cancer remains a critical issue in our society.   
The battle against cancer continues and we carry on developing new molecular 
imaging modalities to diagnose and monitor cancer growth. We screen for new drugs 
to improve chemotherapy 8, we use radio-isotopes in the field of nuclear medicine, 
and we even isolate the DNA gene sequence coding for the light emission in the 
copepod Gaussia princeps. We know the ‘light proteins’ better as luciferases and 
use them for bioluminescence imaging.    
Bioluminescence imaging (BLI) has greatly contributed to developments in cancer 
research. BLI allows for monitoring of real-time tumor processes in animal models 
without disturbing the natural dynamics. This led to the use of BLI in xenogeneic, 
orthotopic, and genetically engineered animals and provided for great insight in 
tumor processes.9 Even more, BLI is not only used to evaluate the characteristics of 
an already existing tumor, it can also provide us of more information about the onset 
of cancer. 10 Evidently, BLI has conquered an indispensable place in experimental 
research for cancer.  
Nevertheless, the different luciferases used for BLI each have their disadvantages. 
Gaussia luciferase (Gluc) has a high light output, an enzymatic half-life of around 5 
days, and is secreted out of the cells into the blood stream, making ex vivo 
applications possible. 11 However, Gluc has a light emission in the blue spectrum, 
which is, during in vivo imaging, mostly absorbed by pigmented molecules such as 
hemoglobin and is scattered by mammalian tissues before even reaching the 
camera.12 Further, Gluc has a flash light emission, which can on one hand be useful 
for real-time monitoring, on the other hand, it makes high-throughput screening for 
drugs impossible. Hence, we screened for a Gluc with better characteristics in 
chapter VI and found mutants with a peak shift towards the red region of the 
spectrum, opening the path for further screen.  The shift in wavelength is not enough 
288 
 
for more sensitivity during in vivo experiments. However, it does provide information 
about which part of Gluc is associated with the wavelength of the light emission, 
which will be useful for future attempts in Gluc wavelength engineering. Moreover, 
we found a Gluc mutant which yields stable light output without the need of a 
detergent such as of Triton-X 10013, suited for high-throughput screening. High-
throughput screening requires a stable signal of the luciferase in order to compare 
the signal of the first reading with the last one. Gluc is of great advantage for such 
drug-screens since it is naturally secreted out of the cells and simply measuring 
signal in the media is sufficient. Until now Gluc needed the addition of Triton-X 10013 
to provide a stable signal, while obviously no additional supplements to screening 
media are preferred. A downside of the stable mutant is its low signal intensity, 
making the luciferase less sensitive. Finally, we observed that all Gluc mutants 
contained mutations in a specific region and thereby we revealed the active site of 
Gluc. Once more, a better understanding of the structure of Gluc protein is very 
important for future Gluc engineering. 
 
When measuring Gluc signal in the blood ex vivo, instead of searching for a red-
spectrum Gluc, another approach to overcome Gluc signal quenching in the blood is 
to optimize the actual assay. In Chapter III, by capturing Gluc from blood using 
specific antibody, we developed a Gluc blood assay that showed a ten-fold higher 
sensitivity compared to assaying Gluc signal directly in the blood.12 In the case of 
tumor, the Gluc signal in the blood can be detected at a much earlier time point and 
requires less tumor load.4  
However, the antibody assay does have certain limitations. First of all the 
preparations and the actual assay are time consuming compared to simply assaying 
Gluc directly in the blood. Further, Gluc antibody has certain costs; this could be a 
limitation when many animals need to be monitored on a regular basis.  
Nevertheless, Gluc signal in the blood is often at the low side and a more sensitive 
assay will be of great value. This high sensitivity will give us the opportunity to 
monitor very small or slow growing tumors and to detect only a few circulating tumor 
cells, as in the case of metastasis, which was until now difficult to achieve with Gluc. 
Hence, the Gluc antibody assay makes it possible to obtain more accurate 
information about apoptosis and the actual tumor growth. 12, 14, 15  Perhaps, this 





applications. On the other hand, the assay could also serve as a temporarily tool for 
more sensitivity until research found the red Gluc. 
 
Different secreted reporters can be multiplexed together to monitor several 
processes in the blood at the same time ex vivo, given that each reporter utilizes a 
different substrate. 16 Chapter IV evaluates the potential to multiplex three different 
blood reporters, Gluc, secreted embryonic alkaline phosphatase (SEAP), and 
Vargulla luciferase (Vluc), and explores the possibility of a triple blood system for 
future research applications. Experimental research will benefit from these novel 
blood reporter combinations, especially when there is no need to sacrifice the 
animal. A downside of the reporter system is that it will take some effort to  achieve a 
high transduction efficiency of the tumor cells and to read each time point with the 
three different reporters requiring three different assay procedures. . 
Theoretically, an ex vivo blood reporter assay would have the potential for future 
clinical application, nonetheless, the genes coding for the blood reporters will still 
have to be incorporated into the DNA of our tumor cells.  
 
As for blood reporters, research has also focused on discovering and constructing 
different variants for different luciferases. Not only to optimize the specific 
characteristics of each luciferase, but also to expand the diversity of luciferases for 
imaging multiple processes simultaneously. In the case of the Italian firefly luciferase 
(liFluc) from luciola italica, a green and a red light emission variant was 
characterized as described in chapter VII. 17 Since Fluc is due to its benefital 
characteristics a popular luciferase in experimental research, it will be of great use to 
have different variants. Nevertheless, Fluc is partly popular due to its red light 






The clinical application of luciferases is still far from being established. Even though 
BLI appears to be of great use in experimental animal models, a gap between these 
models and humans remains. What milestones should be conquered? 
First of all, the human genome does not encode for the luciferases as used in 
experimental setting. This means that our immune system will try to eliminate the 
luciferase protein once expressed. Besides a potential immuno-reaction, we have 
not determined yet whether these foreign proteins are safe to our body, and, most 
importantly, what the long term effect is of expressing these foreign molecules. 
Secondly, luciferases require a substrate to emit light. Even if it would be safe to 
have cells in human expressing Gaussia luciferase, the necessity remains to deliver 
a substrate to those cells. One delivery option would be an injection into the 
bloodstream. However, since this substrate would bypass all our body tissues, we 
should be absolutely certain that no side-effects will occur.  
To generate an experimental animal model orthotropic tumor cells are first 
transduced with the gene encoding for the luciferase, afterwards injected into the 
animals, and once the tumor has grown we try to eliminate it again. Obviously, in a 
clinical setting the tumor is already present and our main purpose is only to remove 
the tumor cells: the opposite principle. First of all, in contrast to experimental 
research, in humans we are not able to decide on the type of Glioblastoma; with a 





biopsy we are merely able to observe the specific type. Secondly, when a biopsy of 
the tumor mass of the patient is taken and the treatment is started, we can’t be sure 
whether the entire tumor, including the microsatellites, of the patient remains 
genetically identical. 18 Besides, high grade gliomas differ genetically for different 
individuals, limiting the possibility of finding a common molecular treatment for 
multiple patients. 19 20Thirdly, it is relatively simple to manipulate the tumor cells in 
vitro before injecting them in vivo, while in humans the manipulation would be 
performed in vivo, with for example viral vectors, which is much more difficult to 
perform successfully.  Further, in public opinion, manipulation of the human genome 
is still controversial.  
To circumvent the problems mentioned above is to use luciferases for cellular 
therapy against cancer, as described in the experimental part of the review of 
chapter XI. Since these stem cells are first modified ex vivo to carry i.a. certain 
drugs, theoretically it should be possible to image the migration and the production of 
these cells and their drugs in a clinical setting with bioluminescence. Perhaps, one 
day through cellular therapy, BLI can be introduced into humans. 
Whereas bioluminescence imaging is nowadays restricted to experimental use, 
fluorescence imaging is already applied in clinical setting. Fluorescence is used for 
endoscopic diagnostics, for example the exploration of gastric and colonic mucosae, 
and can even be used during surgeries.21  During surgery, fluorescence can provide 
information about the tumor edge and the distinction between normal tissue and 
tumor tissue. An example is 5-aminolevulinic acid, an optical dye that specifically 
adheres to brain tumor cells and thereby serves as a useful tool during malignant 
glioma resection.22 One limitation for clinical use of fluorescence is a limited tissue 
penetration. Radioisotopes provide much greater depth tissue penetration. However, 
for surface diagnostics, such as endoscopic diagnostics, less penetration is 
necessary and fluorescence appears to be very useful. 22  Another limitation is the 
exact quantification of the signal, since different tissues absorb the light in different 
quantities and different tissues show different background fluorescence, resulting in 
a bias of the measured fluorescence signal.21 Bioluminescence, on the contrary, is 
only measured when the luciferase and the substrate are actually present, which 
would provide more accurate results compared to fluorescence. Certainly, 
bioluminescence is not introduced into humans yet. Even so, with fluorescence each 
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dye also needs to be proven safe separately for clinical application, which definitely 
slows down the progress of fluorescence for clinical purposes.21 
 
Another approach for the treatment of cancer, which is widely used in experimental 
setting and also useful for clinical purposes, is the use of liposomes. Liposomes 
provide for selective target delivery and can carry a sufficient amount of drugs. Since 
they are currently widely used in pharmaceutical setting, and thus approved for 
clinical purposes, they are of great interest.23 An example of a successful liposomal 
drug is a target specific liposome containing doxorubicin to treat breast cancer 
metastasis. 24 However, also in the field of liposomes certain drawbacks remain, 
such as the quick elimination of liposomes from the blood. In the last decade, 
liposomes have been a popular topic in research resulting in the creation of many 
different variants, including long-circulating liposomes and immuno-specific 
liposomes.23 One can theorize that the combination of an optimized liposome that is 
target specific, that can cross the blood-brain-barrier, and only releases the effective 
drug at the site of tumor, would be ideal for the treatment of the glioblastoma. And if 
we continue to speculate about future possibilities, we might even be able to 
incorporate the gene sequence for Gluc combined with an effective drug or an 
apoptotic gene sequence into a cationic liposome, and we will be able to monitor the 
tumor of the patient weekly by BLI. 
Nonetheless, even in experimental research it would be difficult to create a liposome 
with all the structures mentioned above incorporated in its body. Moreover, a 
liposome is not like a viral vector, it doesn’t incorporate into the human genome for 
stable expression, which means that a liposome carrying solely the gene sequence 
of Gluc wouldn’t be of any use. The liposome would have to carry a viral vector with 
the Gluc sequence for Gluc expression.  
Further, it would be important that the liposome has optimal MRI contrast to 
determine the correct location before releasing its viral vector. Still, once 
experimental research will have a solid and relatively simple protocol for the creation 
of such liposomes, they will be of great use for pre-clinical research.  
Since we can find liposomes in many different shapes and formats, it is reasonable 
to speculate about all the different treatment possibilities with liposomes. Liposomes 
are not only drug carriers or DNA delivery vehicles for cancer treatment; on the 





neurodegenerative diseases, such as Duchenne muscular dystrophy. And liposomes 
have already been investigated for the delivery of a variety of agents, including 
nucleic acids and prednisolone, in the fight against this disease. 25 ʹ͸ Ideally in 
numerous of diseases, liposomes would adhere at the location of preference and 
locally produce our enzyme of interest. And most remarkably, research did already 
develop liposomes that are able to produce proteins themselves, resulting in a 
combined delivery and production system.27Therefore, what remains is the necessity 
of finding a perfect liposome that is very sensitive for camera detection to follow its 
track, it adheres specifically to the tissue of preference, and it will solely at that 
location release the drugs or secrete the produced protein. Conceivably, progress 
will be made with liposomes as protein producing vehicles and we will improve the 
use of essential cellular elements within a liposome. 
In chapter X, we developed a liposome that is very well detectable with MRI; the 
liposome is target specific due to the presence of biotin at its surface and thermo-
sensitive for the release of its contents.  This liposome will be very suitable for the 
delivery of drugs to tumor cells. And hopefully, due to the possibility of tracking its 
faith accurately by MRI and its target specificity, this liposome will be able to serve 
as a promising model for a combined delivery and production system.   
 
Many roads lead to Rome and liposomes are not the only drug delivery vehicles that 
can be modified for target specifity. In chapter XI, the use of stem cells for the 
treatment against brain cancer has been reviewed. Even though only one clinical trial 
so far is making use of these vehicles, the experimental data provide an interesting 
perspective.  Besides serving as drug vehicles, stem cells can also deliver gene and 
oncolytic viral therapy at the tumor site. A prospect for experimental research would 
be a luciferase coupled to a virus and carried by stem cells. And theoretically, 
oncolytic viruses have a significant potential for glioma therapy due to their specificity 
and high efficiency in killing tumor cells. However, current viral therapeutic strategies 
have not yet reached their full potential due to poor distribution at the tumor site, low 
infectivity of tumor cells, and the host immune response. Therefore the strategy of 
hiding the virus within a stem cell has great potential. 28 Moreover, in experimental 
research a luciferase was coupled to TRAIL and delivered by neural stem cells.29
Aside from stem cells, immune cells are useful as well as described in chapter XII. 
Glioma tumor cells are clever in evading the innate immune system; immune cell 
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therapy can trigger an immune response instead. And since dendritic cells are potent 
antigen presenting cells, they emerge as promising vaccine cells in clinical trials.30,31 
For both stem and immune cell therapy, experimental research widely explores the 
possibilities while the clinical application advances more gradually. The translation 
from experimental to clinical application remains a difficult phase. The use of rodents 
with intact immune system, and the development of genetically-induced glioma 
models could help optimizing preclinical studies, leading to a more predictable 
transition to the clinic. 
 
Since this thesis is about Cancer and Luciferases, the luciferases are mainly 
evaluated for the use in cancer research and the revelation of tumor processes. 
However, their value in experimental research is much broader than that and even to 
the extent that a disturbing Mycoplasma contamination can be revealed by Gluc. 
Gluc protein in cell culture is degraded in the presence of Mycoplasma and in such a 
stable manner that we created a Gluc Mycoplasma assay as described in chapter 
VIII and IX.3 
The assay is more sensitive and less expensive than other often used Mycoplasma 
assays. A limitation is that most research doesn’t make use of transduction 
techniques with viral vectors, and definitely not a Gluc vector, which means that Gluc 
media will either have to be ordered from other laboratories or a great number of 
cells need to be transformed with Gluc protein for a sufficient stock.  
Even so, once a solid Gluc containing media stock is acquired, the assay is simple to 
perform and in sensitivity and expenses it is superior to a popular mycoplasma 
assay.3 Therefore, it might just be a matter of time before this assay becomes the 
standard Mycoplasma detection assay at most cell culture laboratories. 
   
Notably, Mycoplasma sp. do not only occur in cell culture; on the contrary, they are 
known to give for example pneumonia in humans.32 With this knowledge, one can 
speculate that Gluc in clinical setting would be degraded by Mycoplasma as well. 
Even more, if Mycoplasma contamination has such a significant effect on Gluc, 
wouldn’t we be able to construct a Gluc sensitive to a particular biological substance 
of interest? This would be of great value for future experimental research. We did 
speculate the possibility of this idea and constructed a Gluc protein which contains a 





proteins produced by almost every cell. The constructed Gluc was expected to show 
a greatly reduced half-life in the presence of MMPs; however, no decrease in half-life 
was observed in the presence of MMPs. An explanation for this can be sought in the 
folding structure of Gluc, which would conceal the sensitive cleavage spot from the 
MMPs. 
 
Bioluminescence and cancer: experimental perspectives 
 
Long ago, in the nineteenth century, seamen and fishermen saw lights on the water 
and realized that these lights were from organisms in the water emitting them: this 
was called bioluminescence. Only about 45 years ago, various luciferases began to 
be characterized.333435 Nowadaysbioluminescence is widely used in experimental 
research. 
Novel luciferase variants are still discovered and created, which gives rise to even 
more imaging possibilities, such as dual/triple/quadruple imaging.  Research reveals 
the structure of luciferases and provides thereby a manual for future luciferase 
engineering, resulting in optimal luciferase variants. In the last decades luciferases 
became important tools in experimental research.  
What is it that makes luciferases valuable?  
First of all, molecular cancer research needs solid tools that reveal tumor processes 
and monitor treatment effects. Luciferases serve as these tools; they can be 
attached to many different vehicles for numerous of research applications. Secondly, 
the variety in different kinds of luciferases creates the opportunity to use them for a 
wide spectrum of services; they can, for example, be used for the monitoring of gene 
expression, but also for tracking stem cell therapy.29 Thirdly, certain luciferases can 
serve as secreted blood reporters and the in vivo tumor biologics can be measured 
ex vivo by these reporters. This is very useful for experimental in vivo research, 
since the animals don’t need to be sacrificed for every single time point. Obviously, 
not all diagnostic agents require the animal to be sacrificed for the desired 
information and the tumor can, for example, be made visible under a camera. 
However, if the animals receive anesthetics before imaging it will definitely take a 
considerate amount of time to image all the animals for every single time point and 
simply withdrawing some blood will have an advantage. Besides, one of the great 
utilities of blood reporters is that they can provide detailed information about the 
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different biological processes of the tumor. Moreover, since multiple blood reporters 
exists, we are able to monitor the tumor response to therapy of different kinds of 
tumor cells at the same time, as shown in chapter IV. And, since blood reporters can 
be coupled to different genes expressed by the same tumor, our triple reporter 
system will make it possible to monitor noninvasively three different biological 
processes of the same tumor. Further, since luciferases can be expressed by all 
kinds of tumor cells, their value is not restricted to brain cancer research. And lastly, 
the lack of signal background makes them very specific compared to other imaging 
modalities. 
Even so, luciferases could be applied in research to a much greater extent. Why the 
hesitation? 
In the last decades molecular research has had a high focus on discovering and 
developing novel reporters, resulting in the availability of different reporters suited for 
the same purposes. Fluorescence, for example, can mark tumor cells and with the 
use of a laser it can easily be seen by eye. Or, for example liposomes with MRI 
contrast in their bilayer, they can be tracked by MRI and don’t need a luciferase for 
monitoring. Besides, the contrast doesn’t require a substrate to light up under the 
camera. Since current glioblastoma diagnostics and follow-up are MRI-guided, 
research has a relatively high focus at optimizing and developing new MRI 
applications. This brings us to the understanding that if bioluminescence would be 
introduced into humans, luciferases would not only serve as optimal tools for basic 
experimental research but their value would also be extended to preclinical 
experiments.  .   
Another practical limitation of bioluminescence is that a sensitive and quick reading 
luminometer needs to be acquired, which doesn’t belong to standard laboratory 
equipment. However, once a luminometer is purchased it doesn’t require much 
expertise and since the bioluminescence readings are often quick a single machine 
would serve for a couple of laboratories. Further, for monitoring gene expression in 
mammalian cells, viral vectors are needed to transduce the BLI genes, which is also 
not a technique every laboratory is familiar with. However, luciferases can be 
purchased as purified protein, they can be expressed by bacteria, and mammalian 
cells can easily be transformed with the protein. And even if stable transduction of 
the mammalian cells is required, BLI expressing cells can be provided by other 





Regarding the limitations, for the expansion of luciferases in experimental research 
we need to continue the work of optimizing the existing variants and the creation of 
novel reporter systems. Further, it will be essential to have simple protocols for the 
usage of different BLI constructs for different applications. Luciferases do require 
special handling; however, with the correct equipment and techniques, they definitely 
have the potential of becoming valuable tools for every day laboratory use. 
In conclusion, molecular research is indispensable for the understanding of cancer 
and luciferases play an important role in revealing these tumor processes. Therefore, 
in this thesis, we contributed to a better understanding of luciferases and their 
applicability in experimental cancer research. For (pre-) clinical purposes we 
expanded our field to the creation of a liposome that is susceptible for a biotin-
streptavidin complex by biotin on its surface and highly sensitive for MRI. Moreover, 
we evaluated cellular vehicles to efficiently reach and treat the tumor target. 
Hopefully, in the battle against cancer, luciferases will continue to contribute to a 
better understanding of cancer and serve as useful guidance tools in the 
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Glioblastoma multiforme (GBM) is the most malignant variant of glioma. This tumor 
does not only display an extremely aggressive, invasive growth pattern, but is also 
very difficult to treat. With a two-year survival rate of 40% and a median survival of 
12-18 months after treatment, prognosis is poor. Factors contributing to this outcome 
can be divided in two groups. First, current treatment options are not successful in 
halting tumor progression. The current standard of care includes surgical debulking 
of the tumor mass, followed by radiation and chemotherapy (temozolomide). 
However, the location of the tumor (the brain) and its invasive, root like growth 
pattern limit the results that can be achieved by surgery. The same limitations apply 
to radiotherapeutic treatment, with the nature of the surrounding tissue not allowing 
high enough doses of radiation to be delivered. Chemotherapeutics cannot cross the 
blood brain barrier efficiently and often resistance develops before the tumor is 
eradicated. While treatment has prolonged lifespan from 4-6 months to 12-18 
months, we seem to book less progression than seen in other cancer fields.   
 
The second complicating factor, which is closely related to minimal improvements in 
treatment modalities, is the highly complex and aggressive behavior of GBM tumor 
cells. GBM tumors are highly heterogeneous, display all kinds of anti-apoptotic 
escape routes, suppress the immune system, invade the surrounding parenchyma 
with unmatched aggressiveness and possess a whole array of tools to rearrange the 
extra tumoral environment to their advantage. Glioma stem cells (GSC) seem to 
drive this process, and, as recent research has shown, can reestablish a copy of the 
original tumor when transplanted into immunocompromised mice. Studies 
investigating the genetic profile of GBM have demonstrated further that the 
heterogeneity has a strong genetic component. Several genetic alterations can 
occur, each predisposing its bearer to a certain growth pattern and level of 
invasiveness and, most importantly, response to therapy. The complexity and 
crosstalk of intracellular pathways contribute even more to the difficulty of finding an 
effective treatment. 
 
Whereas for example patients with a loss of chromosome 1p respond to a 





temozolomide, GBMs with EGFR-III amplification rarely respond to chemotherapy at 
all. O6- methylguanine DNA transferrase or MGMT, a DNA repair enzyme that 
protects cells from damage caused by ionizing radiation and alkylating agents, is 
currently the most powerful molecular predictor of outcome and benefit of 
temozolomide treatment. If MGMT methylation is present, the cells are unable to 
properly repair DNA damage, resulting in a relatively good response to treatment.  
 
Based on current state of matter it can be concluded that new interventions are 
needed. Gene therapy was long thought to be the magical approach to cure all kind 
of diseases, including cancer. However, clinical trials have shown this approach has 
yet to overcome some major limitations in order to make a difference in the medical 
field. Some mayor successes have been reported, however, many attempts still fail 
to make a clinically relevant impact. Lack of efficient gene delivery and transfer, and 
the inability to achieve high enough levels of gene expression are some of the major 
limitations of this approach. The patient’s own immune response against the 
allogeneic gene and its viral vector is partly responsible for this. Since inadequate 
expression will confound results, it is hard to judge on the efficacy of certain 
therapeutic gene strategies and this may partly explain the inconsistency that exists 




In order to get a better understanding of glioma tumor biology, and to develop a 
more successful therapeutic approach, it is important to be able to visualize the 
processes taking place on cellular, molecular, and even genetic level. 
Bioluminescence imaging (BLI) is a technique that uses the enzymatic activity of 
luciferases to visualize all kind of intra- and extracellular processes. In order to emit 
light, a chemical conversion of the luciferase by its substrate is needed. American 
Firefly luciferase (Fluc), Gaussia Princeps (Gluc), Renilla reniformis (Rluc) and 
Vargulla hilgendorfi (Vluc) have all successfully been used as mammalian cell 
reporters.   
 
BLI is extensively used in cancer. Due to the high complexity, the interactions 
between cells and their environment, intracellular crosstalk and the invasive nature 
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of GBM tumors, it is highly desirable to be able to label tumor cells and detect cancer 
pathways. BLI can help understanding these complex processes by visualizing “what 
happens” during tumorigenesis, by assessing gene activation, cell growth and 
behavior, tracking of cancer stem cells (CSC) and metastasis and recurrence 
following chemotherapy. Further, it can potentially visualize tumor cell response to 
certain therapeutic compounds, allowing us to see which pathways and escape 
mechanisms are activated and where intervention is needed. Since BLI can be used 
both in vitro and in vivo, it can help identifying new cancer treatments by validating 





In this thesis we developed reporters, diagnostics and a 'curative strategy' for 
Glioma, based on the joint forces of BLI and gene therapy. 
In Chapter III we describe the development of a new antibody based Gaussia 
luciferase blood assay. Gaussia luciferase differs from other luciferases in that it is 
secreted from the cell and can be detected in the circulation. The advantages of this 
characteristic are huge. Instead of having to measure BLI signal by either using a 
CCD camera (which is time consuming and static) or by sacrificing the animal, one 
can simply take an aliquot of blood and measure the Gluc signal. This allows for the 
ex vivo monitoring of in vivo processes in real time, which is extremely valuable 
when studying tumorigenesis. However, Gluc emits blue light, which is partly 
absorbed by pigmented molecules as hemoglobin. This limits the sensitivity of the 
assay, as a part of the signal is lost. To overcome this problem, we developed an 
alternative assay in which Gluc is captured from the blood in an antibody-mediated 
reaction before the signal is acquired. By elimination of the signal quenching 
molecules the assay showed to be over one order of magnitude more sensitive in 
detecting the Gluc signal. The new sensitivity standard will allow us to detect small 
numbers of circulating cells, early tumor metastasis and apoptosis. 
 
In Chapter IV the development of a multiplex ex vivo blood reporter system based 
on the secreted alkanine phosphatase (SEAP), Gaussia luciferase and a secreted 





reporter and multiplexed it with Gluc and SEAP to develop a triple blood reporter 
system to monitor three distinct biological processes. As a proof of concept, we 
successfully monitored the response of three different subsets of glioma cells to the 
chemotherapeutic agent temozolomide in the same animal. This multiplex system 
can be extended and applied to many different fields for simultaneous monitoring of 
multiple biological parameters in the same biological system. 
 
In Chapter V the development of an in vivo triple reporter system based on Vargula, 
Gaussia and Firefly luciferases for sequential imaging of three different biological 
processes is described. We applied this system to monitor the effect of the 
apoptosis-inducing ligand sTRAIL (soluble Tumor necrosis factor-Related Apoptosis-
Inducing Ligand) on GBM tumor cells using an adeno-associated viral AAV vector. 
TRAIL is only toxic to cancer cell since only these cells overexpress TRAIL death 
receptors. However, there also appears to be a group of tumors, including GBM, that 
is resistant to TRAIL-mediated apoptosis. To overcome this limitation, we identified a 
molecule that sensitized GBM cells for TRAIL, called lanatoside C, which is a known 
cardiac glycoside. Since TRAIL cannot cross the blood brain barrier, we engineered 
the normal brain to synthesize and secrete sTRAIL. Thereby,  we created a zone of 
resistance against newly developed glioma, which can be treated with lanatoside C 
therapy. We used Vluc to monitor AAV gene delivery of sTRAIL to the healthy brain 
parenchyma, Gluc to monitor the binding of sTRAIL to the glioma death receptor on 
the tumor cells and the consequential activation of downstream events, and Fluc to 
measure tumor response to combined sTRAIL and lanatoside C treatment. Binding 
of sTRAIL on tumor cells activated downstream events leading to an initial decrease 
in glioma proliferation.  However, this was followed by tumor re-growth through 
resistant cells. Co-treatment with lanatoside C sensitized the resistant subpopulation 
of glioma to sTRAIL-induced apoptosis as monitored by the triple reporter system. 
Since AAV vectors, TRAIL, and cardiac glycosides have already been used in a 
clinical setting, though in uncombined administration strategies, this therapeutic 
strategy could be easily adapted for use in humans. This work is the first 
demonstration of triple in vivo bioluminescence imaging and will have broad 




In Chapter VI the development of better variants of Gaussia luciferase, that can be 
used in the multiplex reporter systems of Chapter III, IV and V, or by themselves, 
are described. Gaussia luciferase has many advantageous properties over other 
luciferases, including high signal intensity, favorable enzyme stability and a secretion 
signal, which allows for signal detection in the blood. However, current limitations of 
Gluc as a reported include signal quenching and absorption by pigmented molecules 
(as discussed in Chapter IV) and its flash type light emission, which results in rapid 
light decay and makes Gluc less suitable as cell viability marker in drug screens. 
When thousands of compounds need to be tested, stable light emission is required. 
To overcome these limitations, a library of Gluc variants was generated using 
directed molecular evolution and screened for relative light output, a shift in emission 
spectrum, and glow-type (stable) emission kinetics. Several variants with a 10-15nm 
shifts in emission spectrum were identified, as well as a Gluc variant yielding over 10 
minutes of stable light output that can be used in high throughput applications.   
 
Different variants of the same luciferase can be used simultaneously as long as 
there is enough difference in their range of light emission. In chapter VII we 
characterized a codon-optimized variant of Italian firefly luciferase (liFluc) for 
mammalian gene expression and used the green and red light emission variants for 
in vivo tumor imaging. The red shifted variant showed to be a useful marker for in 
vivo tumor growth over time. 
 
In Chapter VIII and IX a simple and sensitive assay to monitor mycoplasma 
contamination is described.  Mycoplasma contamination in mammalian cell culture is 
often overlooked, yet is a serious issue that can induce a myriad of cellular changes 
and thereby confound results. Since glioma research heavily relies on cell culture 
and the effects of mycoplasma can set research projects back for years, we 
developed a mycoplasma detection assay based on the degradation of Gluc in the 
conditioned medium of contaminated cells.  Whereas Gluc has a half life of > 7 days 
in the conditioned media of mycoplasma free cells, the half life of Gluc is 
tremendously decreased in the presence of mycoplasma contaminations, with the 
level of decline correlating to the mycoplasma infection rate. Our Gluc based 
mycoplasma assay proved to be more sensitive as compared to commercially 





In chapter X we took a different approach for the treatment of brain cancer: we 
developed a liposome as a contrast agent for MRI with a higher efficiency than the 
conventional liposome. Liposomes are spherical, self-closed structures formed by 
one or several concentric lipid bilayers with an aqueous phase inside and between 
the lipid bilayers. They are proven effective for the delivery of drugs and imaging 
agents to the tumor site. Our liposome can target cells by its biotin inclusion, it can 
be monitored by MRI, and the therapeutic agent can be released by ultra sound, due 
to its thermo-sensitivity.  
 
In Chapter XI and XII we provided an overview of the Glioma research field, placing 
the work developed in this thesis in a broader setting. We reviewed current research 
strategies, both in experimental setting and in the clinic, discussed the translational 
gap that exists between those two worlds and reflected on possible future directions. 
Cellular therapeutic strategies (including stem cells and immuno cells) seem to 
provide a solution for the problems that currently halt the advances in gene therapy. 
Stem cells have the ability to specifically target glioma cells, both invasive and 
located in the tumor. Aside from the homing mechanism that selectively targets 
tumor cells, stem cells can effortlessly cross the BBB, are easily modified to carry 
therapeutic genes, have immunosuppressive properties that prevent a host 
immunoreaction after implantation, and seem capable of shielding therapeutics such 
as oncolytic viruses from the host immune response, thereby ensuring long term 
reservoirs of therapeutic virus at the tumor site. 
Immunocells are used as vaccines to stimulate an antitumor response by the 
patient's own immune system. The advantage of this approach is the establishment 
of a sustainable tumor attack, theoretically not only eradicating the tumor, but also 
protecting the patient against the development of recurrences. Both stem- and 
immuno cell therapies are now carefully introduced in the clinic, and first results 
seem to indicate they are well tolerable and safe. The efficacy of these approaches 
is not yet optimal, but examples in other fields show that when optimization steps are 
taken, current limitations can be overcome. Suggestions for improvement of the field 











































































Glioblastoma multiforme (GBM) is de meest maligne variant van de glioom tumoren. 
Deze tumor staat niet alleen bekend om zijn extreem aggressieve, invasieve 
groeipatroon, maar is daarnaast zeer moeilijk te behandelen. Met een 2-jaars 
overleving van 40% en een mediane overleving van 12 tot 18 maanden is de 
prognose somber. Factoren die hieraan bijdragen zijn onder te verdelen in twee 
groepen. Ten eerste zijn de huidige behandelopties niet in staat tumor progressie 
een halt toe te roepen. Het standaard behandelplan voor GBM tumoren bestaat uit 
chirurgische resectie van de tumor, gevolgd door bestraling en temozolomide 
chemotherapie. De locatie van de tumor (het brein) en zijn invasieve, grillige 
groeipatroon maken het echter praktisch onmogelijk de tumor in zijn totaliteit te 
verwijderen, terwijl radiotherapie niet in optimale dosering kan worden toegediend 
door mogelijke schade aan het omliggende weefsel.  Verder is de waarde van 
chemotherapeutica  beperkt, doordat de bloed-hersenbarrière efficiënte opname 
verhindert. Hoewel bestaande behandelingen de levensverwachting van patienten 
met GBM hebben verlengd van 4-6 maanden naar 12-18 maanden, lijken de 
ontwikkelingen en ziektewinst achter te blijven bij de progressie die op andere 
terreinen van kankeronderzoek geboekt wordt.  
 
De tweede complicerende factor in het GBM onderzoek, die nauw gerelateerd  is 
aan de minieme ontwikkelingen op therapeutisch gebied, is de biologische 
complexiteit van de GBM tumor formatie. GBM tumoren zijn bijzonder heterogeen, 
brengen verschillende anti-apoptose mechanismen tot expressie, onderdrukken het 
immuunsysteem, groeien volgens een zeer invasief patroon diep in het omringende 
weefsel, en bezitten daarnaast een hele gereedschapskist aan mogelijkheden om 
het extratumorale weefsel naar hun voordeel te moduleren. Glioma stam cellen 
(GSC) lijken de drijvende kracht in dit proces. Recent onderzoek heeft aangetoond 
dat deze cellen in staat zijn een exacte kopie van de originele tumor te genereren, 
wanneer ze getransplanteerd worden in immuungecompromitteerde muizen. Verder 
kunnen verschillende genetische veranderingen worden aangetoond, die 
corresponderen met een specifiek groeipatroon, de mate van invasiviteit en, 






Waar patiënten met verlies van chromosoom 1p goed reageren op een 
chemotherapie schema van temozolomide en PVC (procarbazine, CCNU en 
vincristine), heeft dezelfde behandeling bij patiënten met een EGFR-III mutatie geen 
enkel effect. O6-methylguanine DNA transferase (MGMT) status is momenteel de 
meest accurate voorspeller van een goede reactie op temozolomide behandeling. 
MGTM is een DNA herstel eiwit dat cellen beschermt tegen schade ten gevolge van 
straling en alkaliserende middelen. In een bepaald percentage GBM tumoren is 
MGMT gemethyliseerd, wat leidt tot een onvermogen temozolomide geïnduceerde 
DNA schade te herstellen, resulterend in celdood.  
 
Nieuw interventies zijn gezien de huidige stand van zaken meer dan gewenst. Gen 
therapie werd lange tijd beschouwd als de magische oplossing voor de genezing van 
velerlei ziekten, waaronder kanker. In klinische studies is echter naar voren 
gekomen dat deze strategie nog flink wat hindernissen te overwinnen heeft, voordat 
we kunnen spreken van een doorbraak in de geneeskunde. Hoewel enkele grote 
successen zijn gerapporteerd, is het percentage studies dat een klinisch relevant 
resultaat behaalt, nog altijd laag. Een gebrek aan adequate gen overdracht en 
distributie, en het onvermogen om hoge expressie waarden te bewerkstelligen, zijn 
enkele van de problemen die overwonnen moeten worden. Het immuunsysteem van 
de patiënt, dat het gen en bijbehorende virus vector als lichaamsvreemd beschouwd, 
speelt hierin een belangrijke rol. Aangezien inadequate gen expressie confounding 
van studie resultaten kan opleveren, waarbij men onterecht aanneemt dat de 
gekozen therapie niet werkt, is het lastig oordelen over de daadwerkelijke effectiviteit 
van gen therapie. Dit biedt mogelijk ook een verklaring voor de inconsistentie tussen 




Om een beter inzicht te krijgen in de processen die een rol spelen bij de GBM 
tumorformatie en om een aanknopingspunt te vinden voor een succesvolle 
therapeutisch benadering, is het van groot belang om de gebeurtenissen die op 
cellulair, moleculair en genetisch niveau plaats vinden, te begrijpen. 
Bioluminescence imaging (BLI) is een techniek die de enzymatische activiteit van 
luciferases gebruikt om intra- en extracellulaire processen- letterlijk- zichtbaar te 
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maken. Wanneer een luciferase in contact komt met zijn substraat, wordt licht 
uitgezonden. Koppeling van het luciferase gen aan het gen dat men wil onderzoeken 
(gene of interest, GOI), leidt tot het ontstaan van een Bioluminescence signaal op 
het moment dat het GOI actief wordt (bijvoorbeeld in respons op een bepaald 
medicijn), terwijl geen signaal gedetecteerd kan worden wanneer activatie niet plaats 
vindt. American Firefly luciferase (Fluc), Gaussia princeps (Gluc), Renilla reniformis 
(Rluc) en Vargulla hilgendorfi (Vluc) zijn voorbeelden van luciferases die met succes 
gebruikt zijn als reporters in verscheidene cel systemen.  
 
BLI is een techniek die meer en meer gebruikt wordt in het kankeronderzoek. Door 
de hoge mate van complexiteit van GBM tumoren, de vele interacties tussen 
tumorcellen en het omringend weefsel, de intracellulaire crosstalk en het invasieve 
groeipatroon, is het bijzonder waardevol om cellen te kunnen labelen en vervolgen. 
Ook de identificatie van de  intracellulaire pathways die dit gedrag bewerkstellingen 
is een cruciaal onderdeel van de zoektocht naar een therapeutische interventie. BLI 
kan ons helpen deze complexe processen te begrijpen door zichtbaar te maken ‘wat 
er nou precies gebeurt’ tijdens de tumorigenese. De activatie van specifieke genen, 
de groei en gedragsveranderingen van cellen, de effecten van Kanker Stam Cellen 
(cancer stem cells, CSC) en hun patroon van metastase en recidief formatie na 
chemotherapie kan theoretisch allemaal gevolgd worden via BLI. Ook de tumor cel 
respons op bepaalde middelen, met activatie van bepaalde pathways en escape 
routes, zou via BLI in beeld gebracht moeten kunnen worden, met een ‘map’ van 
mogelijke interventiepunten als resultaat. Aangezien BLI zowel in vitro als in vivo 
toepasbaar is, kan het tevens een belangrijke ‘tool’ worden voor de validatie van 
experimentele anti kanker medicijnen in diermodellen, daarmee een brug slaand 
tussen cel modellen en de kliniek. 
 
In dit proefschrift hebben we de krachten van gentherapie en Bioluminescence 
imaging gecombineerd voor de ontwikkeling van nieuwe reporters, diagnostische 











In dit proefschrift hebben we reporters, diagnostische tools en een “curatieve 
strategie” ontwikkeld voor de behandeling van Glioom tumoren, op basis van gen 
therapie en BLI.  
 
In Hoofdstuk III beschrijven we de ontwikkeling van een nieuwe assay voor de 
detectie van Gluc in het bloed, gebaseerd op een antilichaam reactie. Gaussia 
luciferase verschilt van andere luciferases in feit dat het gesecreteerd wordt door de 
cellen die het Gluc gen tot expressie brengen en in de circulatie terecht komt. De 
voordelen van deze eigenschap zijn enorm. In plaats van meting van het BLI signaal 
door middel van een CCD camera (wat een tijdrovend en statisch proces is) of door 
opoffering van het proefdier, kan worden volstaan met het afnemen van enkele 
druppels bloed waaruit vervolgens het Gluc signaal bepaald kan worden. Dit stelt 
men in staat om ex vivo in vivo processen te vervolgen op het moment dat deze ook 
daadwerkelijk plaatsvinden (en niet pas minuten, uren of dagen later). Voor het 
ontrafelen van tumorgenese is dat van onvoorstelbaar belang. Een limiterende factor 
in deze strategie werd gevormd door het feit dat Gluc blauw licht uitstraalt. Blauw 
licht wordt geabsorbeerd door gepigmenteerde moleculen als hemoglobine, wat de 
sensitiviteit van de assay sterk doet afnemen, aangezien een deel van het signaal 
verdwijnt. Om dit probleem te omzeilen hebben we een alternatieve assay 
ontwikkeld, waarin Gluc wordt ‘gevangen’ uit het bloed door een antilichaam, voordat 
de Bioluminescence reactie plaatsvindt. Doordat de reactie nu plaats kan vinden in 
de afwezigheid van  signaal absorberende moleculen, is de sensitiviteit van het 
bloed assay met meer dan een orde van grootte toegenomen en zijn we in staat om 
een tiental circulerende cellen en beginnende metastasen te detecteren. 
 
In Hoofdstuk IV beschrijven we de ontwikkeling van een multiplex reporter in het 
bloed gebaseerd op secreted alkanine phosphatase (SEAP), Gaussia luciferase en 
Vargula hilgendorfi, voor het ex vivo analyseren van gebeurtenissen in vivo. Vluc 
was nog niet eerder gebruikt als reporter in het bloed en moest daarom eerst 
gekarakteriseerd worden. Vervolgens zijn Vluc, Gluc en SEAP gebruikt voor de 
ontwikkeling van een reporter die gebruikt kan worden voor het gelijktijdig meten van 
drie verschillende biologische parameters in het bloed. Waar in de praktijk de CCD 
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camera gebruikt wordt om de activiteit van luciferases te monitoren, volstaat voor 
deze nieuwe reporter het afnemen van enkele druppels bloed op de door de 
onderzoeker gewenste tijdstippen. Dit heeft niet alleen het voordeel dat de 
procedure zo een stuk minder tijd in beslag neemt, maar daarnaast stelt het de 
onderzoeker in staat in real time cellulaire processen te vervolgen, zonder rekening 
te hoeven houden met de halfwaarde van een eventueel eerder gemeten signaal. 
Om de reporter te testen werd de reactie van 3 verschillende glioma cel lijnen op het 
chemotherapeuticum temozolomide gelijktijdig gemeten in hetzelfde proefdier. De 
drie verschillende signalen waren goed van elkaar te onderscheiden en leken niet 
met elkaar te reageren. Dit systeem kan op heel veel verschillende gebieden worden 
toegepast. 
 
In Hoofdstuk V beschrijven we de ontwikkeling van een drievoudig reporter 
systeem, gebaseerd op Vargula, Gaussia en Firefly luciferase, voor het gelijktijdig 
vervolgen van drie verschillende biologische processen in vivo. Dit systeem is 
vervolgens gebruikt om het effect van soluble tumor necrosis factor-related 
apoptosis-inducing ligand (sTRAIL, verpakt in een AAV vector) gecombineerd met 
de cardiac glycoside Lanatoside C in verschillende glioom modellen te evalueren. De 
TRAIL death-receptor  wordt alleen tot expressie gebracht door tumor cellen, 
waardoor gezonde cellen geen schade ondervinden van de toediening van TRAIL. 
Er lijkt echter ook een groep tumoren te bestaan, die niet gevoelig is voor  door 
TRAIL gemedieerde celdood. Gliomen behoren helaas tot deze groep. In een poging 
deze resistentie te overwinnen, hebben we een screen gedaan naar moleculen die 
glioomcellen gevoelig maken voor TRAIL, leidend tot de identificatie van Lanatoside 
C.  
Aangezien TRAIL niet instaat is de bloed hersen barriere te passeren, hebben we 
eerst het gezonde hersenweefsel gemodificeerd om sTRAIL tot expressie te 
brengen. Dit resulteerde in de formatie van een ‘zone of resistance’ rondom de 
tumor cellen. Lanatoside C werd vervolgens gebruikt als therapeuticum. Om een 
inzicht te krijgen in het precieze werkingsmechanisme van ons systeem  is Vluc 
expressie gekoppeld aan het AAV-sTRAIL gen, waardoor gen-transfer en expressie 
gekwantificeerd kon worden. Daarnaast is Gluc expressie gekoppeld aan activatie 
van de glioma death receptor en de daaropvolgende activatie van intracellulaire 





gecombineerde behandeling van sTRAIL en Lanatoside C. Hierdoor konden we zien 
dat de binding van TRAIL aan de tumorcellen  (Vluc) leidde tot de activatie van 
verschillende intracellulaire pathways (Gluc) en een initiële afname van de glioom 
cel proliferatie (Fluc). Dit werd echter gevold door een fase van hergroei door 
therapie resistente cellen (Fluc). Wanneer we echter sTRAIL tegelijk met Lanatoside 
C toedienden, bleek dat ook de subpopulatie van resistente cellen werd 
geëlimineerd. Aangezien AAV-vectoren, TRAIL en Lanatoside C allen onafhankelijk 
van elkaar al enkele jaren met goedkeuring van de FDA in de kliniek gebruikt 
worden, zou het relatief eenvoudig moeten zijn om deze combinatietherapie voor 
GBM voor patiënten beschikbaar te maken. Het drievoudige in vivo BLI reporter 
systeem dat wij ontwikkeld hebben voor deze studie is het eerste in zijn soort, en 
heeft een brede toepasbaarheid in vele onderzoeksgebieden. 
 
In Hoofdstuk VI beschrijven we de ontwikkeling van nieuwe en betere varianten van 
Gaussia luciferase, die zowel gebruikt kunnen worden in de boven beschreven 
reportersystemen (Hoofdstuk 3, 4 en 5) als op zichzelf. Gaussia luciferase heeft vele 
eigenschappen die het de luciferase van keuze maakt voor velerlei toepassingen, 
zoals een hoge signaal intensiteit, gunstige enzym stabiliteit  en een secretie 
sequentie, die detectie in het bloed mogelijk maakt. Echter, de emissie van licht in de 
blauwe zone van het spectrum (zoals besproken in hoofdstuk III) en een flash-type 
bioluminescence reactie, maken dat Gluc niet voor alle toepassingen even geschikt 
is. De flash-type bioluminescence, waarbij snelle afname van het signaal volgt na 
contact met het substraat, is vooral onhandig wanneer grote hoeveelheden data 
geanalyseerd dienen te worden, zoals bij een high throughput drug screen. De 
waarde van Gluc als cell viability marker is in die situatie beperkt, aangezien er, puur 
door de tijd die het kost het signaal te lezen, afname van de signaal intensiteit 
ontstaat, en  het begin en einde van de screen daardoor niet goed met elkaar 
vergeleken kunnen worden. In een poging deze eigenschap te veranderen, hebben 
wij een middels ‘directed molecular evolution’ een library van  > 5000 Gluc varianten 
gegenereerd. Al deze varianten zijn gescreend voor signaal intensiteit, een shift in 
emissiespectrum, en glow-type (stabiele) licht emissie. De screen heeft verschillende 
varianten met een 10 tot 15nm shift in emissie spectrum opgeleverd en een Gluc 
variant met een licht output die stabiel bleef gedurende 10 minuten. Deze laatste 




Het is ook mogelijk verschillende varianten van dezelfde luciferase tegelijk toe te 
passen, zolang ze maar verschillen in lichtemissie. In hoofdstuk VII hebben we een 
codon geoptimaliseerde variant van de Italian Firefly luciferase (liFluc) 
gekarakteriseerd voor genexpressie in zoogdiercellen. Bovendien hebben we de 
rood-lichtemissie variant toegepast in in vivo tumor beeldvorming.  De rode variant 
bleek een succesvolle marker voor het in tijd volgen van tumorgroei. 
 
In Hoofdstuk VIII en IX beschrijven we het ontstaan van een eenvoudige en 
sensitieve assay voor het detecteren van mycoplasma contaminatie. Mycoplasma 
contaminatie in celkweek wordt vaak niet opgemerkt, maar is een ernstig probleem 
dat een scala aan cellulaire veranderingen veroorzaakt en daarmee 
onderzoeksresultaten in sterke mate kan beïnvloeden. Aangezien celkweek de 
fundatie vormt voor glioomonderzoek en mycoplasmacontaminatie kan leiden tot het 
weggooien van jaren van onderzoek, hebben we een mycoplasma detectie assay 
ontwikkeld gebaseerd op de degradatie van Gluc in het medium van 
gecontamineerde cellen. Onder normale omstandigheden heeft Gluc een 
halfwaardetijd van > 7 dagen. Echter, in de aanwezigheid van Mycoplasma wordt 
Gluc afgebroken met een snelheid die direct correspondeert met de hoeveelheid 
mycoplasma contaminatie. Ons op Gluc gebaseerde mycoplasma detectie assay is 
daarmee sensitiever dan de detectie kits die momenteel commercieel verkrijgbaar 
zijn.  
 
Ons onderzoek naar de therapie en diagnostiek naar hersentumoren neemt een 
andere wending in hoofdstuk X: we hebben een liposoom ontworpen die over een 
hogere contrastintensiteit voor MRI onderzoek beschikt dan de conventionele 
liposoom. Liposomen zijn sferische, afgesloten structuren die uit een dubbele lipide 
buitenlaag bestaan met daartussen en in het centrum van de liposoom een 
waterachtige substantie. Ze zijn bewezen effectief voor het vervoer van drugs en 
beeldvormende stoffen naar de tumorcellen. Onze liposoom kan vanwege zijn biotin 
doelgericht specifieke cellen bereiken, zijn baan kan worden gevolgd met MRI, en 
vanwege zijn thermossensitiviteit kan de therapeutische inhoud op de gewenste 






In Hoofdstuk XI en XII geven we tot slot een overzicht van de huidige stand van 
zaken in het glioom onderzoek, waardoor het werk van dit proefschrift in een breder 
kader geplaatst kan worden. We bespreken verschillende onderzoeksstrategieën, 
zowel in experimentele setting als in de kliniek, en evalueren het gat dat tussen 
beide werelden bestaat. Verder gaan we in op stappen die ons in ziens ondernomen 
moeten worden om het onderzoeksveld op een hoger plan te tillen. Cel therapie 
(zowel stam cel therapie als immunocell therapie) lijkt een oplossing te bieden voor 
veel van de problemen die de effectiviteit en progressie van het gentherapie 
onderzoek momenteel belemmeren. Stam cellen kunnen gebruikt worden als 
transport middel voor therapeutische genen en zijn in staat specifiek glioom cellen 
op te sporen, zelfs wanneer het metastasen betreft, bestaande uit slechts enkele 
cellen. Ze passeren zonder moeite de bloed –hersenbarrière en hebben een lokaal 
immunosuppressieve werking, wat voorkomt dat er een immuunreactie volgt na 
transplantatie. Ook schermen ze het therapeutische gen af van het immuunsysteem, 
wat leidt tot een vele male effectievere gen-transfer en een langdurige antitumor 
respons. Immuun cellen daarentegen worden vaak gebruik als cel vaccins en maken 
juist gebruikt van het immuunsysteem van de patiënt. Het voordeel van deze aanpak 
is dat het eigen immuunsysteem van de patiënt wordt gestimuleerd om de tumor aan 
te vallen, wat niet alleen leidt tot eradicatie van de tumor, maar de patiënt in theorie 
ook zou moeten beschermen tegen het ontstaan van recidieven. Zowel stamcel- als 
immunotherapie vindt langzaam de weg naar de kliniek, waar de eerste trials laten 
zien dat ze  (in ieder geval op korte termijn) veilig zijn  en goed getolereerd worden. 
De resultaten uit experimentele studies heeft men nog niet kunnen evenaren, maar 
voorbeelden uit andere onderzoeksgebieden laten zien dat met de nodige 
optimalisatie veel van de huidige problematiek overwonnen kan worden. Suggesties 
voor verbeteringen, en de potentiele rol van BLI hierin, worden besproken in 
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